{
  "oid": "1228",
  "task": "I was reviewing the annual report of an organization. One of their area of contribution is vaccination, for example, this organization is behind the distribution of more than 50% of vaccines for a deadly viral disease. In a specific year, 20XX, their revenue increased between 1600-2000 million inclusive, and two years ago, in 20(XX-2), their total revenue rose by between 13-19%(inclusive) compared to the previous year. In 20XX, their spending was between 7000-10000 million USD. Around 353-365(inclusive) million of their budget was spent on management costs in that year. In that year, they supported around 95-150(inclusive) countries in delivering vaccines for a disease that caused a pandemic.  Could you help me identify where this organization's headquarters is located and determine its revenue in 20XX and 20(XX-2)(in million USD)?",
  "messages": [
    {
      "content": "I was reviewing the annual report of an organization. One of their area of contribution is vaccination, for example, this organization is behind the distribution of more than 50% of vaccines for a deadly viral disease. In a specific year, 20XX, their revenue increased between 1600-2000 million inclusive, and two years ago, in 20(XX-2), their total revenue rose by between 13-19%(inclusive) compared to the previous year. In 20XX, their spending was between 7000-10000 million USD. Around 353-365(inclusive) million of their budget was spent on management costs in that year. In that year, they supported around 95-150(inclusive) countries in delivering vaccines for a disease that caused a pandemic.  Could you help me identify where this organization's headquarters is located and determine its revenue in 20XX and 20(XX-2)(in million USD)?\n\nYour response should be in the following format:\nExplanation: {your explanation for your final answer}\nExact Answer: {your succinct, final answer}\nConfidence: {your confidence score between 0% and 100% for your answer}",
      "role": "user"
    },
    {
      "content": "",
      "reasoning_content": "\nWe need to identify an organization with contributions in vaccination, behind distribution of >50% of vaccines for a deadly viral disease. Likely this is Gavi, the Vaccine Alliance? Or the Bill & Melinda Gates Foundation? Or WHO? Let's think.\n\nThe organization distributes >50% of vaccines for a deadly viral disease. Which disease? Could be polio? Or measles? Or COVID-19? However \"deadly viral disease\" that caused a pandemic suggests maybe COVID-19 pandemic. Many organizations contributed to distribution of vaccines for COVID-19: COVAX (co-led by Gavi, WHO, CEPI). The organization could be \"Gavi, the Vaccine Alliance\". Gavi is a public-private global health partnership focused on increasing access to immunization in poor countries. It co-leads COVAX. It also has contributed to distribution of more than 50% of the vaccines for a deadly viral disease (maybe for the Ebola? Not sure). Or it's about \"Meningitis\"? Or \"Polio\"? Polio vaccination is heavily done by UNICEF, WHO, Rotary International. But distribution of more than 50% of vaccines for a deadly viral disease - for polio? Actually polio is a viral disease, but vaccine distribution is largely supported by WHO and UNICEF; but Gavi may have contributed heavily to measles vaccines? The phrase \"deadly viral disease that caused a pandemic\" could be \"COVID-19\". So maybe it's \"Gavi\". However Gavi's revenue: in 2021 they had $6.2bn? I'm not sure. They receive contributions from donors, not exactly revenue like a corporation. Also they have \"management costs\" around 353-365 million USD. Could be the \"Bill & Melinda Gates Foundation\"? They have large revenue and budget; they spend money on management costs etc. But the Gates Foundation is a charitable organization. Their annual revenue (donations) in 2022 might be $7.5bn? Actually Gates Foundation's assets > $50bn, but its revenue (donations and investment returns) is like $5bn per year. Management cost of around $360 million seems plausible for Gates Foundation? They might spend about $5bn on grants, and overhead around $150 million? Not sure.\n\nAlternatively, \"UNICEF\" is an organization that provides vaccines for children worldwide. They might have >50% distribution for measles? But they are UN agency, not exactly revenue.\n\nAlternatively, \"World Health Organization\" (WHO) has a budget of $6bn? Actually WHO's regular budget is about $2bn. But they have many contributions. Management costs around $360m? Possibly.\n\nBut the numbers given: revenue in 20XX increased between 1600-2000 million inclusive (i.e., revenue increase was between $1.6bn and $2bn?). The phrase \"their revenue increased between 1600-2000 million inclusive\" could be interpreted as the revenue itself is in that range (i.e., revenue is between 1.6bn and 2bn). Or the increase in revenue is that amount. It says: \"In a specific year, 20XX, their revenue increased between 1600-2000 million inclusive\". The phrasing ambiguous. Could be \"their revenue increased by ...\", meaning the increase amount is between 1.6-2.0bn. Or could be \"their revenue increased ... (i.e., was between 1.6-2.0bn)\". Usually phrasing: \"their revenue increased to ... between X and Y\" would indicate final revenue. Or \"their revenue increased between ... inclusive\" is weird. Could be \"their revenue increased by ... inclusive\". But given the data points we have: spending in that year was between 7000-10000 million USD (i.e., $7-10bn). Management costs were about 353-365 million USD. So if revenue increased by $1.6-2bn and total revenue is unknown? Or revenue itself is $1.6-2bn? But spending is $7-10bn, so revenue would need to be larger than spending? Actually organization may have other funding sources besides revenue, but generally they'd operate within budget. The question asks: \"determine its revenue in 20XX and 20(XX-2) (in million USD)\". So we need to provide revenue for both years. So likely revenue is a known figure for a specific year.\n\nThe organization contributed to vaccines for a disease that caused a pandemic. They supported around 95-150 countries delivering vaccines for that disease. That's huge; perhaps for COVID-19 vaccine distribution globally across nearly all countries. Which organization had such reach? COVAX delivered vaccines to ~145 countries? Actually COVAX aimed to deliver to lower-income economies. The co-leaders: Gavi (the Vaccine Alliance), WHO, CEPI (Coalition for Epidemic Preparedness Innovations). CEPI funded development of vaccines. Gavi handles procurement and delivery. Gavi's support to \"over 150 countries\" for vaccine delivery? Gavi works with 73 low- and lower-middle-income countries for routine immunization. For COVAX they may have delivered to more.\n\nAlternatively, \"UNICEF\" delivered COVID-19 vaccines to over 150 countries? UNICEF is the main distributor for COVAX, indeed UNICEF helped deliver vaccine doses to over 140 countries. UNICEF's total budget is around $7-10bn? Actually UNICEF's total expenditures are around $6-7bn per year. Management costs? Not sure. Revenue? UNICEF receives voluntary contributions and government support.\n\nAlternatively, \"World Bank\" financed vaccine procurement for many countries? Not exactly.\n\nBetter: \"The Global Fund\" fights AIDS, TB, malaria; they do vaccine? Not exactly.\n\nCould be \"Clinton Health Access Initiative (CHAI)\"? Probably not.\n\nThe organization may be \"The Global Alliance for Vaccines and Immunisation (Gavi)\". Let's check Gavi's financials. In 2021, Gavi's total income (contributions) was $5.3bn? Actually let's look up. We'll search.",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"query\":\"Gavi revenue 2022 million\"}",
            "name": "search"
          },
          "id": "call_2c3b214cdad04552a739acd5",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "【0† Annual Progress Report 2022†https://www.gavi.org/progress-report-2022】\nThe Alliance maintains a relentless focus on reaching the 10.2 million \"zero-dose\" children who did not receive a single shot of basic vaccines in 2022. As the ...\n\n【1† Gavi Annual Progress Report 2022 - World†https://reliefweb.int/report/world/gavi-annual-progress-report-2022】\nAlongside the record US$162 million in co-financing contributions in 2022 (see above), the number of vaccine programmes originally introduced ...\n\n【2† Gavi's Annual Progress Report highlights rebound in†https://iffim.org/news/gavis-annual-progress-report-highlights-rebound-routine-immunisation-underpinned-record】\nGavi reveals that basic childhood immunisation rebounded in 2022 as lower-income countries collectively contributed US$ 162 million to co-finance ...\n\n【3† The U.S. Government and Gavi, the Vaccine Alliance†https://www.kff.org/global-health-policy/the-u-s-government-gavi-the-vaccine-alliance】\nGavi reports it has helped to immunize more than 1 billion children in supported countries, including more than 68 million in 2022 alone, and ...\n\n【4† Gavi's impact on the world in 2022: 7 key statistics†https://www.gavi.org/vaccineswork/gavis-impact-world-2022-7-key-statistics】\nUS$ 162 million was committed to co-finance Gavi-supported vaccines in 2022. While Gavi provides financial support to lower-income countries ...\n\n【5† Gavi Grant Cut by USAID†https://www.npr.org/sections/goats-and-soda/2025/03/28/g-s1-56881/vaccines-gavi-usaid-rubio】\nOf that amount $880 million has so far been dispersed. On the list of canceled programs. But this week, according to a 281-page document ...\n\n【6† GAVI†https://en.wikipedia.org/wiki/GAVI】\nAs a result, GAVI announced it would fall almost $3 billion short of its budget aim of $11.9 billion with a total budget of $9 billion.\n\n【7† Replenishment of Gavi, The Vaccine Alliance (2025)†https://focus2030.org/Replenishment-of-Gavi-the-Vaccine-Alliance-Vaccinating-half-of-the-world-s-children】\nBetween 2021 and 2022, Gavi invested over $1.3 billion in health systems strengthening. In response to climate change, which contributes to the spread of ...\n\n【8† Annual Progress Report 2022†https://www.developmentaid.org/api/frontend/cms/file/2023/10/Gavi-Progress-Report-2022.pdf】\n2022 progress: In 2022, Gavi-supported countries reported 17.2 million ... in lower-income countries.From April to May 2022, the Gavi CSO. Constituency, in ...\n\n【9† Danish Organisation Strategy 2023-2026 for Gavi†https://um.dk/en/-/media/websites/umen/danida/about-danida/danida-transparency/public-consultations/draft-organisation-strategy-for-gavi-the-vaccine-alliance-gavi-2023-2026.ashx】\nGavi's total annual income in 2022 was DKK 13,984 million. (USD 2,055 million) ... Investments and other income. 125. (54)2. Other revenue. 434. 634. Total. 1,639.\n\n",
      "name": "search",
      "role": "tool",
      "tool_call_id": "call_2c3b214cdad04552a739acd5"
    },
    {
      "content": "",
      "reasoning_content": "\nResult 9 shows Gavi's total annual income in 2022 was DKK 13,984 million (~USD 2,055 million). That's within the 1600-2000 million range. Could be that. Let's open.",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"url\":\"https://um.dk/en/-/media/websites/umen/danida/about-danida/danida-transparency/public-consultations/draft-organisation-strategy-for-gavi-the-vaccine-alliance-gavi-2023-2026.ashx\"}",
            "name": "open"
          },
          "id": "call_d19cd5410a1948d8ad0481e1",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "Title: \n\nURL Source: https://um.dk/en/-/media/websites/umen/danida/about-danida/danida-transparency/public-consultations/draft-organisation-strategy-for-gavi-the-vaccine-alliance-gavi-2023-2026.ashx\n\nPublished Time: Mon, 21 Aug 2023 13:21:07 GMT\n\nMarkdown Content:\nDanish Organisation Strategy 2023 -2026 \n\n# for Gavi, the Vaccine Alliance (GAVI )\n\nIntroduction :\n\nGAVI ’s key results :\n\n1. Introduc e and scal e-up coverage of high -impact vaccines for disease \n\nprevention \n\n2. Strengthen health systems to increase equity in immunisation \n\n3. Improve sustainability of immunisation programmes \n\n4. Ensure healthy markets for vaccines and related products \n\nJustification for support: \n\nGavi’s mandate and work is highly relevant for key Danish priorities and \n\ninterests on global health – sustainable develop ment through immunization \n\nand promotion of healthy populations and communities . By improving \n\nhealth thorough immunization Gavi’s work support s the Danish goals on \n\nstronger pandemic prevention and response through stronger health \n\nsystems. \n\n- Gavi meets the requirements of an effective multilateral organisation \n\nand is considered fit for purpose. The organisation works together \n\nwith national governments, private sector and civil society to leverage \n\neach stakeholder’s comparative advantage to fund im munisation and \n\nto shape the vaccine market. \n\n- Gavi demonstrates transparency and accountability in its operations, \n\nand its compliance with fiduciary and social requirements and \n\nsafeguards is strong. \n\nFrom 2000 to 2021, Gavi’s programmes helped vaccinate mor e than 1 \n\nmillion children. Gavi currently operates in 57 countries, covering \n\napproximately 50 percent of the global birth cohort. 19 countries have \n\ntransitioned out of Gavi -support. \n\nHow we will ensure results and monitor progress :\n\n Monitoring of progress w ithin prioritised areas will be done through \n\nannual reports, participation in Gavi briefings and meetings. \n\n Denmark will seek to influence Gavi through participation in the \n\nNordic+ Constituency .\n\nRisk and challenges :\n\n Competing priorities and lack of capacity and capability among \n\npartner countries. \n\n Insufficient demand and vaccine hesitancy \n\n Investments in health system strengthening does not materially \n\nimprove programmatic outcomes \n\n Global supply shortage of vaccines \n\n Insufficient donor support \n\n Misuse of funds and fraud \n\nFile No.  2023 -28069 \n\nResponsible \n\nUnit \n\nMNS \n\nMill.  DKK  2023  2024  2025  2026  total \n\nCommitment  25  25  25  25  100 \n\nProjected Disb.  25  25  25  25  100 \n\nDuration  of \n\nstrategy \n\n2023 -202 6\n\nFinance Act \n\ncode. \n\n§ 06.36.03.17 \n\nDesk  officer  Marie My  Warborg Larsen \n\nFinancial \n\nofficer \n\nAntonio Ugaz -Simonsen \n\nSDGs relevant for Programme   \n\n> No\n> Poverty No\n> Hunger\n> Good\n> Health ,\n> Wellbeing\n> Quality\n> Education\n> Gender\n> Equality\n> Clean Water,\n> Sanitation\n> Affordable\n> Clean\n> Energy\n> Decent\n> Jobs, Econ.\n> Growth\n> Industry,\n> Innovation,\n> Infrastruct\n> ure\n> Reduced\n> Inequalities\n> Sustainable\n> Cities,\n> Communities\n> Responsible\n> Consumption\n> & Production\n> Climate\n> Action\n> Life below\n> Water\n> Life on\n> Land\n> Peace &\n> Justice ,\n> strong Inst.\n> Partnerships\n> for Goals\n\nBudget \n\nAnnual budget 202 2 from Gavi’s externally audited \n\nconsolidated financial statements :\n\nTotal : 2,054  mio. USD \n\nStrat. objectives  Priority results  Core information \n\nTo save lives and protect \n\npeople’s health by \n\nincreasing equitable and \n\nsustainable use of \n\nvaccines \n\n1.  Health security, \n\npandemic preparedness \n\nand health system \n\nstrengthening \n\n2.  Addressing the effects \n\nof climate change on \n\nhealth \n\n3.  Equity, access and \n\ngender equality \n\nEstablished : 2000 \n\nHeadquarters : Geneva \n\nBoard member:  Eighteen members  are representative board \n\nmembers and nine members are unaffiliated/independent board \n\nmembers \n\nReach:  Gavi currently operates in 57 countries \n\nDanish involvement in governance structure \n\n1. Denmark vil become member of the Nordic+ \n\nConstituenc yOrganisation Strategy \n\n# Gavi  │2023 -202 6 \n\n> DRAFT August 2023\n\n2\n\nCONTENT \n\n1. Objective ................................ ................................ ................................ ................ 3\n\n2. The organisations ................................ ................................ ................................ .... 3\n\n2.1 Mana gement ................................ ................................ ................................ ..... 5\n\n2.2 Governance and accountability ................................ ................................ ............ 5\n\n2.3 Financial resources ................................ ................................ ............................ 6\n\n3.  Lessons learnt, key strategic challenges and opportunities ................................ ............  7\n\n3.1 Present and new challenges ................................ ................................ .................... 7\n\n3.2 The relevance and effectiveness of Gavi in relation to the i nternational development and \n\nhumanitarian agenda ................................ ................................ ................................ .. 9\n\n4. Justification for support and priority areas ................................ ................................ .. 9\n\n5. Monitoring and reporting ................................ ................................ ........................ 11 \n\n6. Risk and assumptions ................................ ................................ ............................ 12 \n\n7. Annex ................................ ................................ ................................ .................. 14 \n\n2.4 Annex 1 ................................ ................................ ................................ ......... 14 \n\n2.5 Annex 2 ................................ ................................ ................................ ......... 14 \n\n2.6 Annex 3 ................................ ................................ ................................ ......... 14 3\n\n1. Objective \n\nThis organisation strategy for the cooperation between Denmark and Gavi, the Vaccine Alliance (Gavi) \n\nforms the basis for the Danish support to Gavi and is the foundation for Denmark’s partnership and \n\ndialogue with Gavi. It sets out Danish priorities for Ga vi’s performance within the overall framework \n\nestablished by Gavi’s own strategy 2020 -2025 (cf. annex 1). This stra tegy covers the period 2023 -2026 .\n\nIn 2023 , Gavi has conducted a Midterm Review as a basis for discussions on the development of the \n\nnext stra tegic framework 2025 -2029. \n\nEvidence show s that immuni sation program me s are one of the most successful and cost -effective public \n\nhealth interventions. Immunis ed communities are healthier and better educated, their household \n\neconomics are bolstered, and the next generation will grow up and be more productive members of \n\nsocieties (refer to section 3. 2). Gavi’s partnership model and strategic priorities to strengthen health \n\nsystems and ensure healthy markets for vaccines and related products are aligned with D enmark’s \n\npartnership approach, which brings together government, private partners , and civil society organisations \n\nas well as innovative instruments to make development assistance more sustainable and effective. \n\nThe overall objective of Denmark’s engagement with Gavi is – in line with Denmark’s strategy for \n\ndevelopment cooperation – to contribute to the achievement of the United Nation’s Sustainable \n\nDevelopment Goals (SDGs). There is a particular focus on SGDs prioritis ed by Denmark in co untries \n\nand areas that are hit the hardest by poverty, conflict , and climate change, namely 1 (no poverty), 3 (good \n\nhealth and well -being), 5 (gender equality), 6 (clean water and sanitation), 13 (climate action), and 17 \n\n(partnerships in a changing world). The Danish development cooperation is rooted in a human rights -\n\nbased approach and the principle s of ‘leave no one behind’ , non -discrimination, participation, \n\ntransparency , and accountability across the development cycle. \n\nThis strategy builds on ‘the organisation s trategy for Denmark’s Support to Gavi 2018 -2022 ’ and \n\nidentifies key strategic priorities for the partnership and dialogue between the Danish Ministry of Foreign \n\nAffairs (MFA) and Gavi . It outlines specific goals and results that Denmark will pursue in cooperation \n\nwith G avi and like -minded partners. \n\n2. The organisations \n\nBackground: Gavi is an international alliance established in 2000 to improve access to and affordability \n\nof new and underused vaccines for children living in the poorest countries in the world. The backdrop \n\nof establishing Gavi was a stalling in the progress in international immunis ation in the late 1990s . The \n\nGavi partnership model is designed to leverage finan cial resources and technical expertise to shape a \n\nhealthy market mechanism and make vaccines more affordable , available and the supply more reliable .\n\nBy increasing equitable uptake and coverage of vaccines in lower -income countries , the partnership \n\ndeliver s on the mission to save children’s lives and protect people’s health. \n\nDenmark is one of the six original donors in the alliance. Other partners include civil society \n\norgani sations, developing country governments, developing country pharmaceutical industry, \n\nindustriali sed country pharmaceutical industry, and research and technical institutes. 4\n\nVision and mission: In June 2019, the Gavi Board approved a new five -year strategy with the vision of \n\n‘Leaving no one behind with immunisation ’ and a mission to save lives and protect people’s health by \n\nincreasing equitable and sustainable use of vaccines. \n\nFrom 2000 to 2021, Gavi ’s program me s helped vaccinate more than 1 million children. Gavi currently \n\noperates in 57 countries , covering approximately 50 percent of the global birth cohort . 19 countries have \n\ntransitioned out of Gavi -support. \n\nFundamental for the Gavi business model is that support includes an exit strategy for implementing \n\ncountries to take over their national im munis ation program me s. Count ries receiving support have to co -\n\nfinance program me s and work towards sustainable national budget allocation for national immuni sation \n\nprogram me s. The business model and the theory of change is illustrated below in figure 2.1  \n\n> FIGURE 1: THE GAVI BUSINESS M ODEL AND THEORY OF CHANGE\n\nGavi strategy 2020 -2025 \n\nGavi’s current strate gy Phase V is supported by four goals: \n\nGoal 1 – the vaccine goal , to be achieved through three strategic objectives : (1) st rengthening countries’ \n\nprioritis ation of vaccines; (2) support countries to introduce and scale up coverage of vaccines for \n\nprevention of endemic and epidemic disease s; and (3) enhance outbreak response through availability \n\nand strategic allocation of vaccine stockpiles. \n\nGoal 2 – the equity goal , to be achieved by : (1) helping countries extend immunis ation services to zero -\n\ndose children , defined as children who failed to receive any routine vaccination, and under -immunis ed \n\nby building stronge r primary health care platforms; (2) supporting countries to en sure that immuni sation \n\nservices harness innovation and are well -managed and sustainable ; and (3) work with countries and \n\ncommunities to build resilient demand and to address ge nder -related barriers to immunis ation. \n\nGoal 3 – the sustainability goal , to be a chieved by: (1) strengthening political and social commitment to \n\nimmunis ation; (2) promoting domestic public resources for immuni sation and primary health care to \n\nimprove allocative efficiency; and (3) preparing and engaging self -financing countries to mai ntain/ \n\nincrease performance. 5\n\nGoal 4 – the health markets goal , to be achieved by: (1) ensuring sustainable, healthy market dynamics \n\nfor vaccines and immuni sation -related products at a ffordable prices; (2) incentivis ing innovation for the \n\ndevelopment of suitable vaccines, and ( 3) scaling up innovati on in immunis ation -related products. \n\nIn the light of the impact of the COVID -19 -pandemic on global health in general and the set -back in \n\nroutine -vaccination in particular, the Gavi strategy 2021 -2025 was update d with the Board ’s adoption of \n\nthe Gavi 5.1 strategy . Gavi 5.1 builds on the lessons of the pandemic and acknowledge new challenges \n\nin global health security posed by the increasing number of outbreaks and their profound societal, \n\neconomic , and technologic al impact of the environment in which Gavi operates . The 5.1 strategy will \n\nserve as a bridge to Gavi 6.0 (for the period 2026 -2030) by reflecting the changing context of recent years. \n\n2.1 Management \n\nGavi is a Swiss foundation with international institution status in Switzerland. The Gavi secretariat is \n\nbased in Gavi ’s headquarters in Geneva, with support from a n office in Washington DC. The secretariat \n\nis led by the chief executive officer. \n\nThe Gavi secretariat is responsible and accountable for the day -to -day operations of the Gavi alliance as \n\nthey are set forth in the operations procedures determined by the Board. Main r esponsibilities include \n\nmobilis ation of resources to fund program me s; coordinat ion of program me approval s and \n\ndisbursement s; policy develop ment and strategic initiative implementa tion ; monitoring and evaluation; \n\nlegal and financial management; and administration for the Gavi Board. \n\n2.2 Governance and accountability \n\nGavi is governed by a B oard, which is the highest decision -making body of the alliance. T he B oard is \n\ncompr ised of 18 “representative seats”, 9 seats for independent or “ unaffiliated ” individuals and one seat \n\nfor the Gavi Chief executive officer. Donor countries have five seats, shared in constituencies. Denmark \n\nis currently not member of a constituency , but in dialogue with the Nordic+ Constituency about joining. \n\nThe Nordic+ currently comprises of Norway, Sweden, Finland and Switzerland with Norway \n\nrepresenting the constituency on the B oard until the end o f 2023. The Nordic+ Constituency is \n\nconsensus driven and positions are developed in collaboration prior to the two annual board meetings .\n\nThe Danish priorities are in line with the priorities of the Nordic+ Constituency. \n\n> FIGURE 2 : GAVI BOARD COMPOSITION 6\n\nThe Gavi Board is responsible for strategic direction and policy -making. Key tasks of the board include; \n\nadopti ng strategies and procedures necessary for the administration and management of Gavi, overseeing \n\nthe operation of the vaccine a lliance ; and monitoring program me implementation. \n\nAn independent internal audit function (named “Audit and Investigations”) was established in 2009 to \n\neva luate and strengthen risk management, internal control , and governance. The work of Audit and \n\nInvestigations extends not only to the secretariat, but also program me s and activities of Gavi’s in -country \n\nprogram me s, including grant recipients. The accountability framework of Gavi compr ises of the \n\nfollowing :\n\n1. Internal audit, responsible for evaluating and improving t he effectiveness of the organis ation’s risk \n\nmanagement, control, and governance processes. \n\n2. Program me audit, evaluating program me s in -country to assess whether Gavi support, including \n\ncash, vaccines and related supplies, has been used as intended. Audits take into account both \n\nfinancial and programmatic aspects. \n\n3. Investigations and counter -fraud, responsible for mak ing evidence -based investigations of possible \n\nmisuse or other misconduct with G avi and Gavi -supported program me s in -country. \n\n4. Whistleblower (con fidential) reporting, receiving reports from internal and external sources on potential \n\nmisuse or misconduct of Gavi resources .\n\n2.3 Financial resources \n\nDenmark has since 2000 contributed a total of DKK 310 million in core contribution s to Gavi , which \n\ninclude an extraordinary contribution of DKK 10 million to support preparation for the launch of the \n\nhuman papilloma virus (HPV ) vaccine . In addition to the core contribution to Gavi, Denmark \n\ncontributed an extraordinary DKK 190 million in 2021 -202 2 to the Gavi COVAX Advance Market \n\nCommitment (COVAX AMC), a financial mechanism within COVAX that supports low - and middle -\n\nincome countries to COVID -19 -vaccines through procurement, and support to delivery and logistics \n\nrelated to COVID -19 vaccines.          \n\n> TABLE 1: DENMARK’S PLANNED CONTRIBUTION TO SUPPORT TO GAVI 2023 -202 6IN\n> MILLION DK*\n> 2023 2024 2025 2026\n> 25 25 25 25\n\n7\n\n*Subject to annual parliamentary approval of the Danish Finance Act \n\nAt the last replenishment conference in 2020, hosted by UK in London, world leaders pledged USD 8.8 \n\nbillion for Gavi’s 5.0 strategy, 2021 -2025. Gavi’ s total annual income in 2022 was D KK 13,984 m illion \n\n(USD 2,055 mi llion). Table 2 present a breakdown of the revenue by source during the current strategy \n\nperiod 1. This only includes core Gavi programmes and not COVAX. \n\nTABLE 2: GAVI INCOME BY SOURCE, IN MILLIONS USD \n\nYear  2021  2022 \n\nGovernments and private donors  1,080  1,474 \n\nInvestments and other income  125  (54) 2\n\nOther revenue  434  634 \n\nTotal  1,639  2,054 \n\nMajor donors include United States, United Kingdom, Norway, Germany, Canada, Sweden and the \n\nNetherlands. In total , government contributions constitute approximately three quarters of the total \n\nfunding to Gavi. The rest consists of private contributions from foundations (e.g. the Bill & Melinda \n\nGates Foundation) and others. \n\n3.  Lessons learnt, key strategic challenges and opportunities \n\nSince its inception in 2000 , Gavi has contributed to the immunis ation of 1 billion children and supported \n\ncountries in adverting more than 16 -17 million deaths. From 2000 -2017 vaccin ation program me s has \n\ncontributed to a 70 percent reduction in vaccine -preventable child deaths and a 5 0 percent reduction in \n\nunder -5 mortality rate in the countries where Gavi operates . When the alliance was founded, it supported \n\nvaccines against three diseases. Today , Gavi support s vaccines against 19 diseases, cf. figure 3 below on \n\nthe expansion of the G avi vaccine portfolio from 2000 till today. \n\nFIGURE 3 : THE EXPANSION OF GAVI’S VACCINE PORTFOLIO FROM 2000 -2023         \n\n> 1The figures in table 2 are from Gavi’s externally audited consolidated financial statements, which are prepared in conformity with\n> accounting principles generally accepted in the United States. Governments’ and private donors contributions are reported as revenues\n> in the year in which payments are received or unconditional promises are made. So depending on when a grant agreement is sign ed,\n> the level of contributions in the grant agreement and/ or when payment is received –this affects the timing in which the amount can be\n> recognis ed as revenue.\n> 2Negative interest on money in the bank, placements of IFFIm contributions .8\n\nIn the current strategy period 130 mi llion children have been immunis ed, which indicates that Gavi is on \n\ntrack to de liver the 2025 target of immunis ing an additional 300 million children, preventing 7-8 million \n\ndeaths .\n\n3.1 Present and new challenges \n\nDespite significant progress overall and in the Gavi 2020 -20 25 strategic period, challenges and risks \n\nremain in terms of meeting the strategic goals . The pandemic magnified global inequalities in access to \n\nvaccines and other countermeasures and took a disproportionate tol l on the most vulnerable countries \n\nand communities. \n\nComing out of the pandemic, the wor ld is facing multiple cris es. Increasing debts and rising inflation has \n\nleft countries with fiscal constraints. The impact of climate change, rising level s of conflict and insecurity, \n\nincluding food insecurity, and health systems that are strained after the pandemic all amount to a\n\nchallenging environment for the Alliance, partners , and not least implementing countries and \n\ncommunities. \n\nThe COVID -19 pandemic demonstrated that countries with strong health s ystems - including strong \n\nimmunis ation program me s - and swift access to countermeasures and vaccines were best placed to \n\nrespond to the pandemic. Moving forward there is a need to learn from the pandemic and integrate \n\nexperiences and lessons -learned in a stronger and more robust g lobal health security infrastructure. There \n\nis a need to define Gavi’s role in the global architecture for pandemic preparedness, prevention and \n\nresponse. Furthermore, Gavi’s country -programmes has an important role to play in building stronger \n\nhealth syst em capacity to prepare, prevent and respond to disease outbreaks with pandemic potential. \n\nClimate change causes vector -borne diseases carried by mosquitos , such as malaria, yellow fewer , and \n\ndengue to spread to new areas and regions. At the same time , extreme weather caused by climate change \n\ndamages local health infrastructure and disrupts health delivery services. Increasing climate change in \n\nconnection with urbani sation also increases the risk of the emergence of new diseases capable of \n\nspreading fro m wild animals to humans. 9\n\nThe World Health Organis ation (WHO) has estimated that the number of un - or under -vaccinated \n\nchildren grew from 17 million in 2019 to 25 million in 2021. At the same time , outbreaks of vaccine -\n\npreventable diseases have increased. In 2022 , Gavi supported 40 campaigns in response to outbreaks - a\n\n75 percent increase compared to 2021 . T his upwards trend is continuing in 2023. In terms of extendin g\n\nthe power of increased immuni sation there is a need to resume the targeted focus on reaching zero -dose \n\nchildren to preven t further backsliding of immunis ation and recover from set -backs during the pandemic. \n\nDelays to key vaccine rollouts, e.g. HPV vaccine , as countries have been f orced to prioritis e during the \n\npandemic, also needs attention. \n\nThe Gavi business model is based on partner countries taking incr eased ownership of their immunis ation \n\nprogram me s by contributing more domestic resources over time. Six countries are expected to transition \n\nout of Gavi support from 2020 -2025, falling short of the goal of 10 countries. Also, countries are expected \n\nto fall USD 200 million short of the USD 3.6 billion t arget for self -financing and co -financing by 2025. \n\nAt the same time , newer vaccines with increased prices and higher than expected prices for existing \n\nprogram me s are challenging the sustainability of Gavi’s co -financing model. Recognis ing these issues, \n\nthe Gavi Board has updated the transition policy. As an alliance , Gavi will work closely with transitioning \n\ncountries to establish the strong political commitment necessary to lay the foundation for sustainable \n\nnational immuni sation program me s. \n\nInequalities in immunisation program me s persist and United Nations Gender Development Index shows \n\nthat immuni sation coverage is better in more equal countries. Structural barriers, in particular gender, can \n\nalso prevent children from being immunised . W hile there is no significant difference in immunisation \n\ncoverage rates for girls and boys, the status of women in a society impact s her ability to access health \n\nservices and therefore also her children ’s likel ihood of being immunised regardless of their sex . The \n\nchallenges are numerous : women’s lack of household financial resourc es to pay for indirect cost, limited \n\neducation and health literacy, as well as security and mobility issues. For all children to have access to \n\nvaccines, gender barriers need to be addressed. Women and girls’ lack of access to health services is also \n\na challenge in relation to cervical cancer. Every year 266,000 women die from cervical cancer, 80% of the \n\ncases are in developing countries. If the current trend continues, cervical cancer deaths can out pace \n\nmaternal mortality. It is estimated that HPV -vaccines can prevent up to 90% of all cervical cancer cases, \n\nwhich means that today , women die from cervical cancer that is preventable. \n\nTo address the gender barriers , Gavi has an extensive gender polic y in place . With the gender policy Gavi \n\nhas committed to increasing immunisation coverage by supporting countries to overcome gender -related \n\nbarriers to accessing immunisation services and promoting equity of access for all genders to \n\nimmunisation and related health services that respond to their different needs. \n\n3. 2 The relevance and effectiveness of Gavi in relation to the international development and \n\nhumanitarian agenda \n\nImmunisation is a global public good and remains one of the most effective way s to save lives. Our \n\nresponse to th e COVID -19 pandemic demonstrated the power of vaccinations, but it also served as a \n\nreminder that no one is safe until everyone is safe. The Gavi mandate to save lives and protect against 10 \n\nfuture disease outbreaks, epidemi cs , and pandemics remains important to secure progress on achieving \n\nthe sustainable development goal s, in particular poverty reduction (SDG 1), good and health and well -\n\nbeing (SDG 3), equality in education (SDG 4), decent work and economic growth (SDG 8), peace and \n\nstrong institutions (SDG 16) , and partnerships for goals (SDG 17). \n\nStrong health systems and better public health support long -term stability and create jobs and contribute \n\nto reduced inequality. Gavi’s public -private partnership model drives pro gress in immunisation by \n\nsupporting healthy markets, reduc ing prices, promot ing innovation and sustain ing supply and demand. \n\nVaccinations build resilience to mitigate disaster in humanitarian settings , whether from conflict, \n\ninstability, climate change , or natural disasters , and have a positive impact on the health and well -being \n\nof communities . Gavi adopted a Fragility, Emergency and Refugees Policy (FER policy) in 2017 with the \n\naim of: 1) articulating criteria for identifying a subset of Gavi countries that are affected by fragility, as \n\nper international standards; 2) providing guidance on adapting certain Gavi policies to tailor them to the \n\nlocal context; and 3) detailing flexibilities that can be extended in the case of an emergency and for Gavi \n\ncount ries hosting refugees. An evaluation of the FER policy in 2021 concluded that the FER policy is \n\nrobust enough to allow flexibility in Gavi policies and operations in countries facing fragility, emergencies, \n\nor refugee situations. The policy would benefit f rom a revised application mechanism enabling prompt \n\ndecision -making where immediate action is required .\n\n4. Justification for support and p riority areas \n\nThe overall mission of Gavi to promote sustainable development through immunisation and promotion \n\nof healthy populations and communities are in line with the Danish priorities for global health .\n\nDenmark’s priorities in global health are defined in the Danish development strategy “The World We \n\nShare” and in the How -to note for Social sectors and social Saf ety nets. The objectives in “The World \n\nWe Share” is to contribute to the fulfilment of the UN Sustainable Development Goals (SDGs). The \n\nmain goal on health in “The World We Share” is supporting access to healthcare services in fragile \n\ncountries and regions , with particular focus on marginalised groups, women, children and young people. \n\nBased mainly on SDG 3 Denmark’s priorities in global health include strengthening local, regional and \n\nglobal health and health security, including pandemic prevention, prepar edness and response, stronger \n\nhealth systems , and access to primary care. Denmark’s priorities in global health also recognis e the effect \n\nof climate change. P ressure on nature and population growth ha s a negative effect on public health .\n\nTherefore, the i nt egration of climate mitigation and adaptation in global health initiatives is crucial. Gavi’s \n\nfocus on gender eq uality and empowerment of women is in line with the Danish priority for gender \n\nequality as a crosscutting issue in Danish development cooperatio n.\n\nThe priority areas and results to be achieved are based on the link between Denmark’s strategic priorities \n\nfor sustainable global development , Gavi’s strategic priorities and the challenge and opportunities \n\ndescribed in section 3.1 above. \n\nHealth security, pandemic preparedness and health system strengthening \n\nStrong institutions, robust health systems and resilient supply chains are critical for health global ly ,\n\nregional ly and local ly and for countries to be able to develop and maintain immu nis ation program me s. \n\nThis includes technical capacity to administer and deliver vaccines, operational capacity to plan and \n\nexecute program me s and an open dialogue on priorities and needs to designing and operating well -11 \n\nfunctioning health systems. Denmark i s committed to take part in efforts to strengthen health security \n\nand pandemic preparedness at the local, national and global level alongside likeminded and multilateral \n\npartners . Likewise, Gavi ’s goal is to explore new ways to partner with others to build resilience at country \n\nlevel and contribute to the overall global pandemic prevention . This includes addressing the inadequate \n\nmanufacturing capacity and lack of diversification of supply chains. \n\nDenmark will continue to support Gavi’s promotion of health system strengthening and the \n\nintegration of lessons learned from the pandemic to build stronger and more robust country \n\ncapacity to address disease outbreaks and prevent pandemics. Denmark will a lso support Gavi’s \n\nwork on contributing to a higher level of global health security by building stronger production \n\ncapacity and more resilient supply chains to ensure equal and timely access to vaccines and \n\nother countermeasures. \n\nAddressing the effects of climate change on health \n\nClimate change is creating conditions for preventable diseases to spread , and climate emergencies damage \n\nlocal infrastructure and disrupt essential health services. Furthermore, climate change exacerbates the risk \n\nof antimicrobial -resistant bacteria (AMR) by spreading resistant bacteria to new areas and creating \n\nconditions for development of new resistant bacteria and fungi. Six of Gavi ’s vaccines protect against \n\nAMR diseases by reducing transmission of se nsitive and resistant strains and preventing people from \n\ncatching hard -to -treat infections. Vaccines also contribute to the battle against AMR by reducing the \n\nunnecessary antibiotic use. \n\nGlobally, the health sector is responsible for around 5 percent of t he total greenhouse gas emissions. \n\nGavi – together with partners, including UNICEF, is focused on mitigat ing emissions related to \n\nimmunis ation program me s. This is for example done by introducing sustainable energy solutions in the \n\ncold chain or levering ne w and more energy -efficient technology in delivering vaccines, e.g. the use of \n\ndrones to reach remote areas instead of using trucks and vans. \n\nDenmark will support Gavi initiatives to address the effects of climate change and climate \n\nemergencies on health and health systems in its mission. D enmark will work to ensure that the \n\nupdated Gavi strategy for 2026 -2030 includes ambitious goals on addressing climate change and \n\nits effects on Gavi’s core mission and program me . This includes goals on how to further mitigate \n\nemissions related to immuni sation program me s, including e.g. more sustainable waste \n\nmanagement. \n\nEquity, Access and Gender Equality \n\nEquity, equal access to health services , and gender equality are values underpinning the Danish \n\ndevelopment strateg y on global heal th. The Danish approach emphasis es a human rights based approach \n\nto development as the basis for the development of sustainable and equal societies. Denmark places \n\nstrong emphasis on gender equality and the right s of women and girls, including sexual and reproductive \n\nhealth and rights. This includes access to vaccines such as H PV. The revitali sation of the HPV vaccin ation \n\nprogram me is based on a tailored approach for reaching women and young girls. In June 2020, a revised \n\ngender policy was a pproved by the Gavi Board, which includes initiatives to encourage and advocate for 12 \n\nwomen’s and girls’ full and equal participation in decision -ma king related to health program me s and \n\nwellbeing. Furthermore , Gavi has established a new gender -responsive funding system as part of the \n\noverall gender policy .\n\nDenmark will closely follow Gavi ’s work with develop ment and strengthen ing of the gender \n\npolic y and the ability to identify and address actual gender barriers for accessing immuni sation. \n\nDenmark will furthermore work to ensure that the newly established gender -responsive funding \n\nsystem is implemented and evaluated to ensure the overall effectiveness of the program me .\n\n5. Monitoring and reporting \n\nGavi is an international alliance between multiple private partners (including the funding partners; WHO, \n\nWorld Bank, Unicef and Bill & Melinda Gates Foundation), donor governments, partner countries , and \n\ncivil soci ety organi sations. Denmark’s ability to influence the strategy and operating model of Gavi is \n\nthrough its participation in the Nordic+ Constituency . Each constituency ha s a seat at the Board. .\n\nMFA will seek to influence the development of the Gavi strategy 6.0 for the period 2025 -2030 by \n\nemphasis ing the priority areas in collaboration with the Nordic+ C onstituency. The influence of the \n\nconstituency is relatively high as it is a homogeneous group that is able to leverage each other strengths \n\nto influ ence the overall strategic direction and decision making. \n\nTo monitor performance and progress of Gavi strategy 2020 -2025 there is specific goals and objectives \n\nfor each strategic goal . The results are based on Gavi’s results framework and progress monitor ing \n\nsystems. Overall, the Gavi goals and indicators contribute to the achievement of the SDGs and the \n\nDanish priorities. The secretariat monitors progress based on Gavi’s indicators, and reports to the Board \n\non the progress. \n\n6. Risk and assumptions \n\nThe Gavi Alliance recogni ses that risks must be taken into consideration and managed carefully. To \n\nmanage risks, the Gavi Board has adopted a risk policy in 2014 . A yearly report provide s an update on \n\nrisk management across the alliance, including an analysis of trends affecting Gavi’s risk profile and \n\nchanges in top risks compared to previous years. \n\nWhile not an immediate health emergency, the COVID -19 pandemic continuously influence s the \n\nenvironment in which Gavi operates with a significant impact on the risks facing the Alliance. \n\nCompeting priorities and lack of capacity and capability . The Alliance is based on collaboration and \n\ninvolvement of partner countries. However, many partner countries continue to have insuffici ent capacity \n\nand capabilities to develop, maintain , restore , and strengthen immunis ation program me s. For countries \n\nthat have transitioned out of Gavi -supported program me s there is a risk tha t they fail to sustain progress. \n\nOf the 19 countries that have transitioned out of Gavi support as of 2022, 13 have not yet introduced at \n\nleast one of pneumococcal conjugate vaccine (PCV), rotavirus vaccine, or HPV vaccine. Competing 13 \n\npriorities in a time of multiple crisis is the reality for Governments in implement ing countries around the \n\nworld . This makes continued commitment and capacity to collaboration an area of attention. \n\nInsufficient demand and vaccine hesitancy . High levels of demand are critical to reach every child and \n\nevery community and to achieve high levels of vaccine uptake. Demand can be affected by v accine \n\nhesitancy, due to immunis ation not being actively prioriti sed by parents and caretakers , and by lack of \n\ndata on zero -dose/under -immuni sed children. Vaccine confidence depends on trust on the safety and \n\nefficiency of vaccines and the systems and health workers delivering them. The experience of roll -out of \n\ncovid -19 vaccines have in some countries and communities led to increased vaccine hesi tancy, which \n\nneeds to be actively addressed as a drop in demand for vaccines would negatively affect Gavi’s ability to \n\nachieve its overall mission. \n\nHealth systems strengthening. During the current Gavi strategy 2020 -2025, Gavi is expected to invest \n\napprox imately 2 billion USD in the strengthening health systems in partner countries to reach zero -dose \n\nchildren, improve cold -chain equipment , and other optimi sation platforms, including digital platforms. \n\nThere is a risk that the investments in health system s trengthening does not materially improve \n\nprogrammatic outcomes due to systematic and programmatic bottlenecks, such as gaps in workforce, \n\ndesign of the overall health system, grants and program me s duplicate other program me s, or if grants are \n\nnot big enough to have a significant impact. \n\nGlobal supply of vaccines . Gavi tries to mitigate supply shortages by its market -shaping strategy to help \n\nbuild and support a healthy global vaccine market . The strategy enables manufacturers to produce \n\nvaccines in quantitie s, and at prices, that are sustainable for lower -income countries. However, some \n\nmarkets continue to be of low health, due to lack of supplier diversity as well as limited capacity for \n\nmanufacturing expansion. S ustained supply security continues to be depe ndent on factors and \n\nassumptions outside the scope and influence of Gavi, such as global production capacity, (lack) of \n\nsupplier diversity , and lack of introduction of new technologies, that may influence manufacturers \n\ncapacity. A stronger global diversification of supply chains and vaccine manufacturer will help secure \n\nglobal supplies. \n\nContinued d onor support . The continued support from donors is crucial to sustain Gavi’ s program me s\n\nand keep up with a growing birth -cohort. Global economic setbacks and uncertainty, a changing \n\ngeopolitical environment, and competing priorities in development (such as climate change, migration, \n\nsecurity, education) as well as a general domestic strain on resources in most countries, poses a risk to \n\ncontinued donor support. Reduced donor support and access to financing, will undermine achievements \n\nand risk further backsliding leading to increased risk of a re -emergence of covid -19 as well as the risk of \n\nnew pandemics caused by vaccine -preventable diseases. \n\nMisuse of funds and fraud . The risk of deliberate misuse of Gavi support and Gavi funds remains high \n\nin time of economic uncertainty, low morale after years struggling with the pandemic, and financial \n\npressure. At the same time, countries and implementing partners were under pressure to spend faster to \n\ndeliver progress during the immediate health emergency setting aside some of the usual processes for \n\nprocurement, oversight and assurance. Gavi acknowled ges that during the duration of a health 14 \n\nemergency, risks may increasingly materiali se despite efforts to mitigate them. In case of actual misuse, \n\nhowever, Gavi will always require reimbursement as a condition for continued support. It is the \n\nresponsibilit y of the internal auditor, under the supervision of the Board, to conduct investigations and \n\ncounter -fraud, which conducts an evidence -based examination of possible misuse and other misconduct \n\nwithin G avi, in Gavi -supported program me s in countries , or whic h otherwise impact upon the \n\norgani sation .15 \n\n7. Annex \n\n2.4 Annex 1\n\nGAVI, THE VACCILANCE ALLIANCE STRATEGY 2020 -2025 \n\nPhase 5 (2021 –2025) (gavi.org) \n\n2.5 Annex 2\n\nGAVI RISK POLICY (2014) \n\nTravel and Non -travel Business Related Expense Policy and Reference Manual (gavi.org) \n\n2.6 Annex 3\n\nGAVI RISK APPETITE STATEMENT VERSION 3.0 \n\nBoard Document Template (gavi.org)\n",
      "name": "open",
      "role": "tool",
      "tool_call_id": "call_d19cd5410a1948d8ad0481e1"
    },
    {
      "content": "",
      "reasoning_content": "\nThe document gives details: total annual income in 2022 was DKK 13,984 million (USD 2,054 million). It also says revenue increased between 1600-2000 million inclusive. The increase from previous year: 2021 total income? Table 2 shows total 2021: 1,639 million USD. So increase from 2021 to 2022: 2,054 - 1,639 = 415 million. That's not 1.6-2bn. But maybe they refer to revenue increase for the year of 2021 relative to prior year? Let's see. The table shows 2021 total: 1639. If we go back to 2020 maybe it was lower. Could be that the revenue increased by around 1.6-2bn between 2019 and 2020? Not sure.\n\nBut the question mentions \"In a specific year, 20XX, their revenue increased between 1600-2000 million inclusive, and two years ago, in 20(XX-2), their total revenue rose by between 13-19%(inclusive) compared to the previous year.\" So there is an organization where revenue increased between 1.6bn-2bn in year 20XX, and two years earlier revenue grew by 13-19% YoY.\n\nAlso \"In 20XX, their spending was between 7000-10000 million USD. Around 353-365(inclusive) million of their budget was spent on management costs in that year.\" So in that same year (20XX), they spent between $7-10bn and management costs were $353-365m. That matches Gavi? Actually Gavi's total expenditure is about $7-8bn? Let's check Gavi's financial statements. Maybe Gavi's spending is roughly $8bn, and management costs maybe $300m? Possibly.\n\nAlternatively, the organization might be \"UNICEF\". UNICEF's total expenditure (income) is about $6-7bn per year. Management costs (administrative costs) around $300m? They might be lower. Let's see UNICEF's financials.",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"query\":\"UNICEF total expenditure 2022 management costs 350 million\"}",
            "name": "search"
          },
          "id": "call_0e7f393cde254e06b38ba5d3",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "【11† FUNDING COMPENDIUM 2022†https://www.unicef.org/sites/default/files/2023-07/UNICEF_FundingCompendium2022_FINAL_WEB.pdf】\nIn 2022, UNICEF`s total income increased to $9,326 million, from $8,122 million in 2021, representing an increase of 15 per cent or $1,205 million. Of this ...\n\n【12† FUNDING COMPENDIUM 2023†https://www.unicef.org/media/159111/file/UNICEF_FundingCompendium2023_R3.pdf】\nIn 2023, UNICEF's total income decreased to $8,920 million, from $9,326 million in 2022, representing a decrease of 4 per cent or $406 million. Of this income, ...\n\n【13† Financial report and audited financial statements†https://www.unicef.org/executiveboard/media/19346/file/A-78-5-Add-3-Financial-report-UNBOA-2022-EN-ODS.pdf】\nIn 2022, total licensing revenue was $4.89 million (2021: $2.21 million). Note 22. Investment revenue. (Thousands of United States dollars).\n\n【14† E/ICEF/2023/10 - Economic and Social Council†https://docs.un.org/en/E/ICEF/2023/10】\nUNICEF worked on Goal Area 1 in 155 countries in 2022. The total Goal Area. 1 expense was $3.3 billion, including $2.1 billion for humanitarian ...\n\n【15† UNICEF Annual Report 2022†https://www.unicef.org/reports/unicef-annual-report-2022】\nIn 2022, UNICEF procured a record $7.4 billion in goods and services for children in 162 countries and areas, representing a 93 per cent ...\n\n【16† 2022 UNICEF financial report and audited†https://www.unicef.org/executiveboard/media/20091/file/2024-FRS-Informal-Item-10-UNICEF-financial-report-BOA-and-MR-Thomas-Asare-EN-PPT-2024-01-15.pdf】\nTotal expenses increased by 20% to $8.54 billion (2021: $7.14 b) ... management expenses decreased slightly to $0.46 billion (2021: $0.47 billion).\n\n【17† E/ICEF/2025/AB/L.6 Economic and Social Council†https://www.unicef.org/executiveboard/media/32581/file/2025-ABL6-Integrated-budget-2026-2029-EN-ODS.PDF】\nA total of $30.0 million is requested for capital expenditure linked to premises maintenance and management and the pursuit of the broader ...\n\n【18† A/79/494 General Assembly†https://unsceb.org/sites/default/files/2024-10/A.79.494%20Budgetary%20and%20Financial%20Situation%20of%20UN%20system%20organizations.pdf】\n(j) UNICEF total expenses for 2021 and 2022 were restated in its financial statements and are reflected in the present report. (k) WFP expenses ...\n\n【19† financial-report-2022-2023-outlook-2024-2026-†https://tdr.who.int/docs/librariesprovider10/meeting-reports/financial-report-2022-2023-outlook-2024-2026-web.pdf?sfvrsn=63eae283_5&download=true】\n3.2 Expenses. • Staff costs. US$ 6.2 million in 2023 (US$ 7.0 million in 2022) reflects the total cost of employing staff, including charges ...\n\n【20† 🗣️ Voices of Specialists Reviewing the 2026 National†https://www.facebook.com/unicefzambia/posts/%EF%B8%8F-voices-of-specialists-reviewing-the-2026-national-budget-budgets-are-moral-doc/1225111576317232】\nDive into UNICEF Zambia's 2026 Social Sector Budget Analysis Report for more details: https://www.unicef.\n\n",
      "name": "search",
      "role": "tool",
      "tool_call_id": "call_0e7f393cde254e06b38ba5d3"
    },
    {
      "content": "",
      "reasoning_content": "\nLet's open result 11.",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"url\":\"https://www.unicef.org/sites/default/files/2023-07/UNICEF_FundingCompendium2022_FINAL_WEB.pdf\"}",
            "name": "open"
          },
          "id": "call_3d5cd16e56b44f21b029592a",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "Title: \n\nURL Source: https://www.unicef.org/sites/default/files/2023-07/UNICEF_FundingCompendium2022_FINAL_WEB.pdf\n\nPublished Time: Fri, 28 Jul 2023 14:32:26 GMT\n\nMarkdown Content:\n# FUNDING COMPENDIUM 2022 WHO IS UNICEF? We are the world’s largest children’s organization and an agency of the United Nations (UN). Mandated by the Convention on the Rights of the Child, we ensure that children and adolescents are protected, healthy, and educated. We have a presence in over 190 countries and territories, and work during times of peace and stability and when emergency strikes. We partner with national governments and local communities, other UN agencies and non-governmental organizations, and the public and private sectors to achieve our mission to create a better future for children and adolescents. UNICEF’s work is 100 per cent voluntarily funded. We depend on quality and predictable resources from our partners to accelerate the implementation of the Sustainable Development Goals and to maximize our collective impact in results for every child. Cover photo: © UNICEF/UN0669306/Korta Sisters Ewelina (5) and Yelezaveta (7) from Lviv left Ukraine in March and travelled to Poland with their mother and grandmother. Page 3 photo: © UNICEF/UN0632758/Gilbertson VII Photo On 15 April 2022 in Ukraine, Olena (43) holds her son Mikhailo (9), in a tight embrace, and kisses him, in front of their damaged home in Novoselivka, outside of Chernihiv. Page 8 photo: © UNICEF/UN0730511/Bashir On 3 November 2022 in Jacobabad, Sindh province, Pakistan, 6-year-old Benazir goes to school for the first time since UNICEF established a temporary learning centre in her area, which was one of the worst hit by the recent floods. Page 14-15 photo: © UNICEF/UN0632066/Vockel On 15 March 2022, a small child plays at the Blue Dot hub in Sighetu Marma ției, Romania. Page 18 photo: © UNICEF/UN0765149/Pedro UNICEF , with the support of the Global Programme to end Child Marriage (GPECM), produced and painted a graffiti on the walls of a secondary school in Monapo district (Nampula province) to sensitize the community on the negative impact of child marriage and on the appropriate reporting channel to follow (Child Helpline 116). Page 20 photo: © UNICEF/UN0616786/Dejongh Children attending class, in a school made out of recycled plastic bricks, in Sakassou, in the center of Côte d’Ivoire. Page 41 photo: © UNICEF/UNI76260/Holmes Portraits of children from rural areas in the Lao People’s Democratic Republic. 1\n\n# CONTENTS Note of thanks  ........................................................................................ 2 Executive summary  ............................................................................... 3 Resources by type of funding  ................................................................ 4 Resources by type of resource partner  .................................................. 5 Top 30 resource partners, 2022.............................................................. 6 Top 20 public sector resource partners, 2022  ........................................ 7 Top 20 private sector resource partners, 2022  ....................................... 8 Core resources for results  ...................................................................... 9 Rental of premises: in-kind regular resources  ...................................... 10 Other Resources  ...................................................................................11 Thematic funding .................................................................................. 12 Results achieved in 2022  ...................................................................... 14 Other Resources (regular)  .................................................................... 16 Other Resources (emergency)  ............................................................. 17 Private sector partnerships  .................................................................. 19 Multi-year resources ............................................................................. 21 UNICEF’s Transparency Journey  ........................................................... 22 UN Interagency Arrangements  ............................................................. 23 Government partners contributing through joint programmes and UN to UN agreements.......................................................................... 24 UN pooled funds  .................................................................................. 24 Global Programme Partnerships  ........................................................... 25 International Financial Institutions  ........................................................ 25 Development Assistance Committee (DAC) member governments, total contributions received to UNICEF compared to ODA, ODA per capita and GNI per capita, 2022  ........................................................... 26 Development Assistance Committee (DAC) Regular Resources by contributions received to UNDP , UNFPA, UNICEF and UN Women, 2022  ................................................................................. 27 UNICEF contributions received by resource partner, 2022  .................. 28 Financial information/donor listing  ........................................................ 33 Glossary  ............................................................................................... 40 Abbreviations ........................................................................................ 41 2\n\n# NOTE OF THANKS In 2022, the world’s children continued to face an unprecedent array of crises. From conflict and climate change to soaring rates of malnutrition and the persistent socioeconomic consequences of a global pandemic, these multiple, simultaneous, and strongly interdependent shocks and stressors – also called ‘polycrisis’ – risk the achievement of the Sustainable Development Goals for children as we approach 2030. Throughout the year, we again had to be at our best while more children were in need than at any time in UNICEF’s 75 years of history. With the support and commitment of our public and private sector partners, we have been on the ground responding to the ongoing and new humanitarian crises; we have been working with governments, communities, and families to offset the consequences of the COVID-19 pandemic, while continuing to provide critically needed medical supplies and vaccines; and we have been relentlessly advocating for keeping the survival and development of children a priority of international and national agendas. UNICEF is working to achieve lasting systemic change for the world’s children. To do this, UNICEF must be fit for purpose, and deliver on the promise and ambition of its 2022-2025 Strategic Plan and Agenda 2030 for children. To do so, we are focusing on longer-term results to make sure we make more progress on quality, reliability, and resilience of services rather than mere access to those services. This shift to longer-term results, however, is only possible with the support of our partners. At the same time, shifting funding trends are reshaping the role of UNICEF . With flexible funding shrinking every year and increased earmarking rising, UNICEF faces a fundamental risk of having to convert from a mandate-based to a project-based organisation. As ever, UNICEF and our implementing partners on the ground need the right support to deliver programmes for children where they are needed most. Timely, predictable, and flexible funding are indispensable if we are to seize the opportunities provided -- and called for -- by Agenda 2030. To step up progress for children over the coming years, we must be able to respond quickly, to anticipate future risks, and to provide countries and communities with support that contributes to their long-term resilience and future development. We are grateful to all our partners with whom we share the achievements for the year 2022, detailed on the following pages. As we look to 2023, we know that the lives of children and adolescents will continue to be impacted and shaped by multiple and growing challenges, with far-reaching effects. This calls on us to work ever closer with our partners to bring humanitarian and development work together with a focus on children and populations in need. This is a time of urgency and opportunity. Just like fragility can spread, so can resilience. So can solidarity. So can progress. Over the last several decades, the world has made enormous progress for children, spanning every sector. We can do it again – and we must. Carla Haddad Mardini Director, Private Fundraising and Partnerships Geneva, July 2023 \n\nJune Kunugi \n\nDirector, Public Partnerships New York, July 2023 3Funding Compendium 2022 | UNICEF \n\n# EXECUTIVE SUMMARY This Funding Compendium comprises information on income and contributions received provided by public and private sector resource partners to UNICEF in 2022. 1 While the Funding Compendium is not an official UNICEF financial document, it draws on official financial data. The Funding Compendium is intended to serve as a practical and illustrative report to demonstrate the results of extensive policy and programme partnerships between UNICEF and its resource partners. The UNICEF Strategic Plan for 2022-2025, Integrated Budget and Financial Estimates Update documents use a concept of ‘income’ which represents contributions received in a given year from public sector partners (governments, the European Commission, inter-organizational arrangements, global programme partnerships and international financial institutions) and revenue from private sector partners. In order to ensure alignment and comparability with key strategic documents, the Funding Compendium shows income for resources by type of funding and partner, and contributions received for top resource partners. In 2022, UNICEF`s total income increased to $9,326 million, from $8,122 million in 2021, representing an increase of 15 per cent or $1,205 million. Of this income, unearmarked core resources or Regular Resources (RR) amounted to $1,326 million. This represents a decrease of $83 million in core resources compared to $1,408 million in 2021. Public Sector RR decreased by seven per cent, from $533 million in 2021 to $494 million in 2022. This is largely due to delayed payments of several RR contributions and negative impact of foreign exchange losses. Private sector RR decreased by six per cent, from $754 million in 2021 to $709 million in 2022. Core resources as a proportion of UNICEF’s overall income decreased from 17 per cent in 2021 to 14 per cent in 2022. Earmarked Other Resources increased by 19 per cent from 2021, to a total of $8,001 million in 2022. Of this, $4,164million or 52 per cent, came in the form of Other Resources (regular), and $3,837 million or 48 per cent in the form of Other Resources (emergency). Public sector income constituted 70 per cent or $6,539 million of UNICEF’s total income in 2022. This was composed mostly of contributions received from 138 government partners, including the European Commission. The three largest public sector partners were the United States of America, Germany, and the World Bank. Private sector income, generated by UNICEF National Committees, PSFR and non-PSFR country offices from individuals, foundations, philanthropists, businesses, and membership and faith-based organizations, constituted 29 per cent or $2,665 million of UNICEF’s total income. The three largest private sector partners were United States Fund for UNICEF , German Committee for UNICEF and Japan Committee for UNICEF . Other income, classified as RR, includes income from interest, procurement services and other sources, totaled $123 million or one per cent of overall income. With the support of our partners, we made a remarkable difference to the situation of children worldwide in 2022. UNICEF will continue to accelerate its resource mobilization efforts and to strengthen public and private sector partnerships as a key strategy for delivering results for children and adolescents, especially the most vulnerable. 1 All figures in this report have been rounded and may not add up to the totals. \n\nINCOME, REVENUE AND CONTRIBUTIONS RECEIVED Income: Income includes contributions received in a given year from public sector partners (governments, the European Commission, inter-organizational arrangements, global programme partnerships and international financial institutions) and revenue from private sector partners. UNICEF uses income for the preparation of the financial framework, which forms a part of the UNICEF Strategic Plan. Income is not part of the audited UNICEF financial statements. \n\nRevenue: UNICEF recognizes revenue for the full contribution agreement value when the partner agreement is signed in line with requirements of International Public Sector Accounting Standards (IPSAS). This includes multi-year contribution agreements reflecting the full commitment of our partners for current and future years. \n\nContributions received: Cash and contributions in kind received from resource partners within a calendar year. 4\n\n# RESOURCES BY TYPE OF FUNDING In 2022, the total income 1 for UNICEF was $9,326 million. This represents an increase of 15 per cent or $1,205 million compared to 2021. Regular Resources (RR) decreased by six per cent or $83 million, from $1,408 million in 2021 to $1,326 million in 2022. Other Resources increased by 19 per cent or $1,288 million, from $6,713 million in 2021 to $8,001 million in 2022. Unrestricted Regular Resources are the ‘life-blood’ for UNICEF to fulfill its mandate for children. In 2022, these core resources accounted for 14 per cent of total income − a decrease from 17 per cent in 2021. UN Member States have committed, through the UN Funding Compact, to providing 30 per cent of UNICEF income as core resources. To reach this goal for children, UNICEF encourages partners to channel more contributions to these core funds. 1 Figures are based on ‘income’ which here represents contributions received from public sector, revenue from private sector and other income. See ‘Revenue, Contributions and Income’ on page 3. Income by type of funding, 2022 1Income by type of funding, 2014-2022 1\n\n1,000 02,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 \n\n2014      \n\n> Share RR/OR 26% / 74% 23% / 77% 27% / 73% 22% / 78% 20% / 80%\n\n2015 2016 2020 \n\n> 17% / 83%\n\n2021 \n\n> 14% / 86%\n\n2022 \n\n> 21% / 79%\n\n2019 \n\n> 23% / 77%\n\n2018 2017 \n\n5,169 5,010 4,884 6,027 6,400 7,219 8,122 6,060 2,264 1,579 1,326 2,055 1,933 1,780 1,174 1,639 1,312 2,591 2,732 2,995 3,559 3,731 1,973 2,046 1,422 1,322 2,034 2,189 2,982 1,371 1,470 1,408 9,326 3,837 4,164 1,326 \n\n> Regular Resources Other Resources (emergencies) Other Resources (regular) Total US$ MILLIONS\n\nRegular Resources (RR) are unearmarked funds that are foundational to deliver results across the Strategic Plan. \n\nOther Resources (OR) are earmarked contributions for programmes; these are supplementary to the contributions in unearmarked RR and are made for a specific purpose such as an emergency response or a specific programme in a country/region. \n\nOther Resources (regular) are funds for specific, non-emergency programme purpose in general and strategic priorities. \n\nOther Resources (emergency) are earmarked funds for specific humanitarian action and post-crisis recovery activities. \n\nRegular Resources, $1,326 M \n\n14% \n\nOther Resources (emergency), $3,837 M \n\n41% \n\nOther Resources (regular), $4,164 M \n\n45% $9,326 M Total 5Funding Compendium 2022 | UNICEF \n\n# RESOURCES BY TYPE OF RESOURCE PARTNER UNICEF total income 1 reached $9,326 in 2022. Of this income, public sector income broke a record of $6,539 million, and constituted 70 per cent of UNICEF’s total income. This represents an increase of 10 per cent compared to public sector income in 2021. Most of the public sector income was contributed by government partners of the Development Assistance Committee of the Organisation for Economic Co-operation and Development (OECD/DAC), including the European Commission. Private sector income likewise reached a record high in 2022, at $2,665 million. This represents an increase of 28 per cent or $588 million compared to 2021, mainly driven by digital fundraising and humanitarian crises. This income was primarily generated by UNICEF National Committees and Country Offices with structured private sector fundraising operations. Other income, including income from interest, procurement services and other sources, amounted to $123 million or one per cent of total UNICEF income. Income by type of resource partner, 2022 1Income by type of resource partner, 2014-2022 11 Figures are based on ‘income’ which here represents contributions received from public sector, revenue from private sector and other income. See ‘Revenue, Contributions and Income’ on page 3. 2 Public sector includes governments, the European Commission, Inter-Organizational Arrangements, Global Programme Partnerships, and International Financial Institutions. 3 Private sector includes income from foundations, individuals, Non-Governmental Organizations, UNICEF National Committees and UNICEF Country Offices. 4 Other income includes income from interest, procurement services and other sources. \n\nPublic sector Private sector Other Total 01,000 2,000 3,000 4,000 5,000 6,000 7,000 8,000 9,000 10,000 2014 2015 2016 2017 2018 2020 US$ MILLIONS  5,169 5,010 4,884 6,027 6,060 7,219 1,444 1,465 1,453 1,606 94 97 121 139 172 3,456 3,318 4,423 4,434 5,451 \n\n2021 2022 \n\n8,122 2,077 5,924 \n\n2019 \n\n6,400 1,457 203 4,740 3,679 1,396 1,457 162 121 9,326 2,665 6,539 123 \n\nPublic sector 2$6,539 M \n\n70% \n\nPrivate sector 3$2,665 M \n\n29% \n\nOther income 4$123 M \n\n1% \n\n$6.4M $9,326 M 6\n\n# TOP 30 RESOURCE PARTNERS, 2022 In 2022, the top 30 resource partners provided $7 ,738 million or 84 per cent of the total contributions received by UNICEF . These partners provided 76 per cent of total Regular Resources and 85 per cent of the total Other Resources contributions. Top 30 resource partners, 2022, by contributions received 1\n\n0 300 600 900 1200 1500 Regular Resources Other Resources (regular) Other Resources (emergency) USD MILLIONS United States Germany United States Fund for UNICEF World Bank Group European Commission Gavi, The Vaccine Alliance Canada German Committee for UNICEF Japan Committee for UNICEF United Kingdom Office for the Coordination of Humanitarian Affairs (OCHA) 2Sweden Japan Global Partnership for Education Netherlands United Kingdom Committee for UNICEF Norway United Nations Multi-Partner Trust Fund Office (UN MPTFO) Swedish Committee for UNICEF Korean Committee for UNICEF French Committee for UNICEF Spanish Committee for UNICEF Committee for UNICEF Switzerland and Liechtenstein Asian Development Bank Dutch Committee for UNICEF Education Cannot Wait Fund Democratic Republic of the Congo 3Italian Committee for UNICEF Foundation Denmark United Nations Joint Programmes 1,286 1,047 680 542 524 339 263 234 233 228 224 222 199 177 173 166 133 110 108 106 97 95 92 83 70 67 63 60 58 57  \n\n> 1\n\nContributions received in cash and in kind. Please refer to pages 28-32 for all UNICEF contributions received by resource partner. In addition to direct contributions, UNICEF received additional funds through UN Joint Programmes and UN to UN agreements. Please refer to page 24. Excluding UNICEF Country Office Private Sector Fundraising. The United Kingdom’s core contribution for 2022 was intended for disbursement in the calendar year of 2022, however, due to unforeseen circumstances, the core contribution was paid in full in March 2023. 2 Contributions received from the Office for the Coordination of Humanitarian Affairs include $197 million related to the Central Emergency Response Fund, and $27 million related to humanitarian country-based pooled funds. 3 Contributions received from the Democratic Republic of the Congo include $49 million related to the World Bank Group, $12 million related to Gavi, the Vaccine Alliance, and $2 million related to the Global Fund. 7Funding Compendium 2022 | UNICEF \n\n# TOP 20 PUBLIC SECTOR RESOURCE PARTNERS, 2022 The top 20 public sector resource partners provided $5,851 million or 63 per cent of total UNICEF contributions in 2022. These partners provided 32 per cent of the total Regular Resources, and 69 per cent of the total Other Resources contributions. In 2022, a total of 138 government partners, including the European Commission, contributed to UNICEF resources. Top 20 public sector resource partners, 2022, by contributions received 11 Contributions received in cash and in kind. Please refer to pages 28-32 for all UNICEF contributions received by resource partner. In addition to direct contributions, UNICEF received additional funds through UN Joint Programmes and UN to UN agreements. Please refer to page 24. Excluding UNICEF Country Office Private Sector Fundraising. The United Kingdom’s core contribution for 2022 was intended for disbursement in the calendar year of 2022, however, due to unforeseen circumstances, the core contribution was paid in full in March 2023. 2 Contributions received from the Office for the Coordination of Humanitarian Affairs include $197 million related to the Central Emergency Response Fund, and $27 million related to humanitarian country-based pooled funds. 3 Contributions received from the Democratic Republic of the Congo include $49 million related to the World Bank Group, $12 million related to Gavi, the Vaccine Alliance, and $2 million related to the Global Fund. \n\n0 300 600 900 1200 1500 Regular Resources Other Resources (regular) Other Resources (emergency) United States Germany World Bank Group European Commission Gavi, The Vaccine Alliance Canada United Kingdom Office for the Coordination of Humanitarian Affairs (OCHA) 2Sweden Japan Global Partnership for Education Netherlands Norway United Nations Multi-Partner Trust Fund Office (UN MPTFO) Asian Development Bank Education Cannot Wait Fund Democratic Republic of the Congo 3Denmark United Nations Joint Programmes Republic of Korea USD MILLIONS 1,286 1,047 542 339 263 228 224 222 199 177 173 133 110 83 67 63 58 57 55 524 8\n\n# TOP 20 PRIVATE SECTOR RESOURCE PARTNERS, 2022 UNICEF National Committees (legally independent non-governmental organizations) in 33 countries, and 53 UNICEF Country Offices were instrumental in mobilizing private sector resources from individuals, foundations, philanthropists, businesses, and membership and faith-based organizations, for UNICEF’s work in 2022. The top 20 private sector resource partners contributed $2,313 million or 25 per cent of total UNICEF contributions. These partners provided 51 per cent of the total Regular Resources, and 21 per cent of total Other Resources contributions. Top 20 private sector partners, 2022, by contributions received 11 Contributions received in cash and in kind. Please refer to pages 28-32 for all UNICEF contributions received by resource partner. Please refer to pages 33-39 for detailed listings of partners contributing $100,000 or more to UNICEF .\n\n0 100 200 300 400 500 600 700 800 Regular Resources Other Resources (regular) Other Resources (emergency) United States Fund for UNICEF German Committee for UNICEF Japan Committee for UNICEF United Kingdom Committee for UNICEF China PSFR Swedish Committee for UNICEF Korean Committee for UNICEF French Committee for UNICEF Spanish Committee for UNICEF Committee for UNICEF Switzerland and Liechtenstein Dutch Committee for UNICEF Italian Committee for UNICEF Foundation Danish Committee for UNICEF Finnish Committee for UNICEF Canadian UNICEF Committee Belgian Committee for UNICEF Australian Committee for UNICEF Limited United Arab Emirates PSFR One-off donations PSFR Malaysia PSFR USD MILLIONS 680 234 233 118 108 106 97 95 92 70 60 54 42 29 29 26 26 23 23 166 9Funding Compendium 2022 | UNICEF \n\n# CORE RESOURCES FOR RESULTS Core Resources for Results (RR), or Regular Resources, is unrestricted funds to be used flexibly for children. RR is the highest quality funding that provide UNICEF with three critical tools: (a) the predictability to plan and implement long-term programmes for children; (b) the flexibility to address challenging and often rapidly changing contexts so as to achieve real, lasting results; and (c) the efficiency that comes from reducing transaction costs and thereby maximizing the resources that can go directly to children. The predictability, flexibility, and efficiency allow UNICEF to achieve the greatest possible impact: transforming children’s lives, solving complex challenges, and preventing suffering. RR allows UNICEF a more calculated, coherent approach by investing in strategic action, and oversight and management functions, while building organisational resilience to sustain shocks. UNICEF’s total RR income was $1,326 million in 2022. This represents a decrease of six per cent, or $83 million, from $1,408 million in 2021. This is largely due to delayed payments of several RR contributions and negative impact of foreign exchange losses. Of this total income, $494 million or 37 per cent was contributed by public sector partners, and $709 million or approximately 54 per cent was contributed by private sector partners. The remaining $123 million or 9 per cent included income from interest, procurement services and other sources. The ratio of RR to UNICEF’s total overall income decreased by three per cent, from 17 per cent in 2021 to 14 per cent in 2022. This downward trend, driven by more rapid growth especially in earmarked Other Resources, coupled with volatile exchange rates negatively impacting non-USD income, indicates a concerning trend away from the Member States’ Funding Compact commitment target of core resources representing 30 per cent of overall income. In 2022, UNICEF’s top 20 Regular Resource partners contributed $1,043 million or 78 per cent of the total RR income. For details on the role and impact of this core funding in UNICEF’s programme results in 2022, see the 2022 Core Resources for Results Report at www.unicef.org/reports/core-resources-results-2022. Regular Resources income by type of resource partner, 2022 11 Figures are based on ‘income’ which here represents contributions received from the public sector, revenue from the private sector and other income. See ‘Revenue, Contributions and Income’ on page 3. 2 Public sector includes governments, the European Commission, Inter-Organizational Arrangements, Global Programme Partnerships, and International Financial Institutions. 3 Private sector includes foundations, individuals, Non-Governmental Organizations, UNICEF National Committees and UNICEF Country Offices. 4 Other income includes income from interest, procurement services, and other sources. 5 Contributions received in cash and in kind. Please refer to pages 28-32 for all UNICEF contributions received by resource partner. The United Kingdom’s core contribution for 2022 was intended for disbursement in the calendar year of 2022, however, due to unforeseen circumstances, the core contribution was paid in full in March 2023. 6 Excluding UNICEF Country Office Private Sector Fundraising. Top 20 Partners to Regular Resources by Contributions Received 5 , 2022 (Millions of United States dollars) \n\nRank Resource partner 6 Regular Resources \n\n1 United States 134 2 Japan Committee for UNICEF 133 3 Germany 98 4 Korean Committee for UNICEF 86 5 German Committee for UNICEF 79 6 Sweden 63 7 Spanish Committee for UNICEF 61 8 French Committee for UNICEF 51 9 Italian Committee for UNICEF Foundation 44 10 Norway 44 \n\nRank Resource partner 6 Regular Resources \n\n11 United States Fund for UNICEF 41 12 Swedish Committee for UNICEF 38 13 Netherlands 34 14 Dutch Committee for UNICEF 28 15 Switzerland 23 16 Japan 19 17 United Kingdom Committee for UNICEF 19 18 Belgian Committee for UNICEF 17 19 Belgium 15 20 Finnish Committee for UNICEF 14 \n\nPublic sector 2$494 M \n\n37% Other income 4$123 M \n\n9% \n\nPrivate sector 3$709 M \n\n54% $1,326 M Total 10 \n\n# RENTAL OF PREMISES: IN-KIND REGULAR RESOURCES In 2022, in addition to the cash contributions towards Regular Resources, UNICEF received $28 million of in-kind contributions as rental of premises from 84 government partners. This support enabled UNICEF to channel cash received towards programmes for children. \n\nEast Asia and Pacific \n\nChina $561,000 Democratic People’s Republic of Korea $130,070 Fiji $71,169 Indonesia $144,970 Mongolia $90,408 Thailand $280,000 Timor-Leste $100,000 Viet nam $14,254 \n\nEastern and Southern Africa \n\nAngola $180,000 Comoros $70,000 Ethiopia $386,000 Kenya $150,000 Lesotho $120,000 Madagascar $6,000 Mozambique $7 ,500 Namibia $120,000 Somalia $435,700 Sudan $121,400 South Sudan $141,900 Uganda $459,000 Zambia $279,282 \n\nEurope and Central Asia \n\nArmenia $114,790 Bulgaria $57 ,500 Croatia $26,125 Georgia $155,000 Kazakhstan  $217 ,160 Kyrgyzstan  $55,000 Montenegro $18,912 Republic of Moldova $54,000 Romania $50,000 Poland $10,550 Serbia $51,000 Tajikistan $32,400 Türkiye $54,835 Turkmenistan $62,746 Uzbekistan $310,000 \n\nHQ Outside New York \n\nDenmark $5,303,640 Finland $ 74,180 Hungary $3,728,231 Italy $17 ,385 Republic of Korea $80,975 Sweden $127 ,820 \n\nLatin America and Caribbean \n\nBarbados $195,575 Bolivia (Plurinational State of) $40,000 Brazil $1,846,515 Dominican Republic $88,000 Guyana $31,672 Jamaica $87 ,828 Mexico $35,480 Panama $740,000 Peru $25,785 Uruguay $72,450 \n\nMiddle East and North Africa \n\nIraq $48,785 Jordan $802,963 Lebanon $2,500 Oman $397 ,400 Saudi Arabia $139,184 United Arab Emirates $2,208,264 \n\nSouth Asia \n\nAfghanistan $67 ,853 Bangladesh $106,235 Bhutan $13,118 India $101,500 Pakistan $7 ,931 Sri Lanka $130 \n\nWest and Central Africa \n\nBenin $24,124 Cabo Verde $350,000 Central African Republic $44,000 Chad $112,884 Congo $747 ,250 Côte d’Ivoire $12,600 Democratic Republic of the Congo $698,370 Equatorial Guinea $102,672 Gabon $89,452 Ghana $190,512 Guinea $350,000 Guinea-Bissau $621,000 Mali $33,500 Mauritania $20,610 Niger $4,000 Nigeria $2,258,911 Sao Tome and Principe $19,500 Senegal $398,500 Sierra Leone $384,000 Togo $26,000 This map is stylized and not to scale. It does not reflect a position by UNICEF on the legal status of any country or area or the delimitation of any frontiers. The dotted line represents approximately the Line of Control agreed upon by India and Pakistan. The final status of Jammu and Kashmir has not yet been agreed upon by the Parties. The final boundary between the Republic of the Sudan and the Republic of South Sudan has not yet been determined. \n\nEurope and Central Asia \n\nTotal $1.3 M \n\nEast Asia and Pacific \n\nTotal $1.4 M \n\nEastern and Southern Africa \n\nTotal $2.5 M \n\nSouth Asia \n\nTotal $0.3 M \n\nWest and Central Africa \n\nTotal $6.5 M \n\nLatin America and the Caribbean \n\nTotal $3.2 M \n\n# Grand Total \n\n# $28 M HQ outside New York \n\nTotal $9.3 M \n\nMiddle East and North Africa \n\nTotal $3.6 M 11 Funding Compendium 2022 | UNICEF \n\nOther Resources contributions received by region, 2022 1 (Millions of United States dollars) OTHER RESOURCES Other Resources are earmarked contributions for UNICEF programmes, supplementary to the Regular Resources or core resources contributions. Other Resources range from softly earmarked thematic funds to tightly earmarked funds for a specific purpose such as emergency response or a specific programme in a country or region. Other Resources income grew by 19 per cent to $8,001 million in 2022. Of this funding, 76 per cent or $6,045 million came from the public sector and 24 percent or $1,956 million from the private sector. Top 15 recipient countries of Other Resources by contributions received, 2022 1 The map does not reflect $1,638 million of Other Resources earmarked for Headquarters. 2 Contributions received by ECARO include UNICEF’s response to the war in Ukraine. \n\n$1,179 M \n\nMiddle East and North Africa \n\n> ORR 58% | ORE 42%\n\n$1,158 M \n\nEastern and Southern Africa \n\n> ORR 64% | ORE 36%\n\n$1,346 M \n\nEurope and Central Asia \n\n> ORR 14% | ORE 86%\n\n$1,129 M \n\nSouth Asia \n\n> ORR 65% | ORE 35%\n\n$840 M \n\nWest and Central Africa \n\n> ORR 62% | ORE 38%\n\n$322 M \n\nEast Asia and Pacific \n\n> ORR 68% | ORE 32%\n\n$274 M \n\nLatin America and Caribbean  \n\n> ORR 41% | ORE 59% ORR = Other Resources (regular) ORE = Other Resources (emergency)\n\nOther Resources (emergency) Other Resources (regular) \n\n> US$ MILLIONS\n\n0100 200 300 400 500 600 700 800 \n\n> Afghanistan Europe and Central Asia Reional Office (ECARO) 2Lebanon Sudan Somalia Democratic Republic of Congo South Sudan Yemen Ukraine Bangladesh Nigeria Pakistan Syria Niger Ethiopia\n\n499 6240 727 100 299 302 55 149 96 117 70 66 68 54 80 72 24 84 46 57 83 78 103 106 98 123 98 197 72 12 \n\n# THEMATIC FUNDING Thematic contributions are softly earmarked pooled funds categorized as Other Resources designed to support the UNICEF Strategic Plan 2022-2025. They are the most flexible funding after core funding and support high-level results at the country, regional, and global levels. The flexibility of thematic funding allows UNICEF to respond more effectively by strengthening systems across sectors, promoting sustainability, and reducing transaction costs, serving as an ideal complement to Regular Resources. They are aligned with the principles of good multilateral resource partnerships and good humanitarian donorship, as well as the Grand Bargain and the Funding Compact. Thematic funding hit record levels in 2022, due to a 126 per cent increase in humanitarian thematic funding, largely from the private sector. Eighty-three donors (15 Governments, 33 National Committees and 35 Country Offices) contributed a total of $1,201 million in thematic funding to UNICEF in 2022, up from $756 million in 2021, an increase of 59 per cent. The private sector contributed $917 million of total thematic funding in 2022 which represents an increase of 137 per cent compared to 2021. The increase in overall thematic funds, together with increasing ratio of thematic funding as a per cent of total income, is an encouraging development. This is in line with the Funding Compact commitments between Governments and the United Nations Sustainable Development Group, in which UN Member States have committed to doubling the share of non-core contributions provided through single agency thematic funds, such as UNICEF’s thematic funding pools. In alignment with this Funding Compact commitment, the UNICEF’s Strategic Plan 2022-2025 includes the goal to double thematic funding as a share of all Other Resources from Member States by 2025. To reach this goal and to strengthen impact for children, UNICEF encourages partners to channel more contributions through these softly earmarked funds. Thematic Contributions by Sector, 2022 \n\nGENDER EQUALITY US$3 million <1% HUMANITARIAN ACTION US$928 million 77% HIV AND AIDS US$6 million <1% HEALTH US$19 million 2% CHILD PROTECTION US$23 million 2% NUTRITION US$77 million 6% WASH US$51 million 4% SOCIAL PROTECTION, INCLUSION AND GOVERNANCE US$1 million <1% EDUCATION US$59 million 5% SAFE AND CLEAN ENVIRONMENT US$18 million 1% CROSS-CUTTING REGIONAL AND COUNTRY 1US$19 million 2% \n\n$1,201 M Total  \n\n> 1Cross-cutting regional and country include a flexible CPD window, giving the flexibility for countries to receive funds and to programme in areas that are not covered by the thematic windows.\n\n13 Funding Compendium 2022 | UNICEF \n\nFor partners, contributions to UNICEF’s 10 thematic funding pools offer a modality to champion the principles of good multilateral resource partnerships. Thematic funds yield a higher return on investment for results for children, as lower indirect cost recovery allows for more funding to go towards programming as compared to more tightly earmarked contributions. In 2022, the top 10 thematic funding resource partners contributed $916 million or 76 per cent of the total thematic contributions to UNICEF . These partners provided 78 per cent of the total thematic funding for UNICEF’s non-humanitarian thematic pools, and 76 per cent of the total humanitarian thematic funding. The top three thematic funding partners were United States Fund for UNICEF , Germany, and German Committee for UNICEF . These three partners contributed 44 per cent or $523 million of UNICEF’s total thematic funding in 2022. Top 10 Resource Partners to Thematic Funding by Contributions Received, 2022 Other Resources contributions received 2014-2022: Thematic vs Non-thematic \n\n> 020% 40% 60% 80% 100%\n\n2014 $3,798 M 2015 $3,857 M 2016 $3,938 M 2019 $4,945 M 2020 $5,600 M 2021 $6,558 M 2022 $7,886 M 2017 $4,677 M 2018 $4,583 M \n\nThematic Other Resources (regular) Thematic Other Resources (emergency) Non-Thematic \n\n91% 90% 92% 92% 93% 6% 4% 4% 4% 4% 4% 4% 3% 92% 4% 4% 88% 5% 6% 85% 3% 12% 92% 5% 3% 5% 5% \n\nThematic Other Resources (emergency) Thematic Other Resources (regular) United States Fund for UNICEF Germany Sweden French Committee for UNICEF Denmark Swedish Committee for UNICEF German Committee for UNICEF Japan Committee for UNICEF United Kingdom Committee for UNICEF Committee for UNICEF Switzerland and Liechtenstein US$ MILLIONS  \n\n> 050 100 150 200 250 300\n\n287.8 130.2 105.4 81.6 76.3 60.1 59.0 51.4 32.4 31.3 15.7 272.0 20.7 8.2 97.2 72.8 8.8 75.2 1.1 59.7 0.5 47.3 1.9 15.3 3.1 28.2 17.1 49.5 11.7 109.5 14 \n\n# RESULTS ACHIEVED \n\n# IN 2022 \n\nFor children across the globe, 2022 was a year fraught with difficult challenges and intractable crises. UNICEF continued to deliver lifesaving and life-changing results, with a focus on reaching the most vulnerable. Please see the below highlights of some of the key results UNICEF and partners achieved for children in 2022, across more than 190 countries and territories. For more details, please see the 2022 UNICEF Global Annual Results Reports. These reports provide a detailed account of UNICEF’s results at the global, regional and country levels in 2022, based on the goals and cross-cutting priorities of the UNICEF Strategic Plan for 2022–2025. \n\n356.3 million children under 5 – more than ever before – benefited from programmes to prevent malnutrition \n\nin all its forms and a remarkable 182.4 million benefited from programmes for the early detection and treatment of wasting. \n\n77.9 million children were vaccinated \n\nagainst measles, over 27 million in countries affected by humanitarian crises. UNICEF also continued to lead COVAX, the largest vaccine operation in history, delivering 977.8 million COVID-19 vaccine doses and supporting COVID-19 vaccination in 143 countries. 37.9 million out-of-school children and adolescents (49 per cent girls) accessed \n\neducation in 2022, including 3.1 million children on the move and 18.6 million children in humanitarian settings. 15 Funding Compendium 2022 | UNICEF \n\nThe number of children, adolescents and caregivers provided with community-based mental health and psychosocial support services (MHPSS) more than doubled, from 12 million in 2021 to 25.2 million in 2022. UNICEF scaled up programming to prevent violence, exploitation and harmful practices , including through parenting support programmes reaching 11.8 million caregivers in 2022, up from 3 million in 2021. 26 million people gained access to at least basic sanitation services, 30.6 million to basic water, and 23.6 million to basic hygiene and 39 million people provided with water, sanitation or hygiene \n\nservices in humanitarian emergencies. At COP27, UNICEF advocacy in partnership with the Children’s Environmental Rights Initiative led to the formal recognition of the role of children and youth as agents of change in climate action .With UNICEF support, governments reached over 129 million children with \n\ncash transfer programming. Disability-inclusive programmes reached over 4.5 million children with disabilities in 142 countries. UNICEF engaged 7.4 million children, adolescents, and youth in advocacy, nearly 6.6 million in communication and 27.1 million in online platforms. 16 \n\n# OTHER RESOURCES (REGULAR) Other Resources (regular) are funds for non-emergency programme purposes in general and strategic priorities. In 2022, the Other Resources (regular) income to UNICEF amounted to $4,164 million. This represents an increase of 12 per cent, or $433 million, from $3,731 million in 2021. Of this, 80 per cent, or $3,318 million, was provided by public sector partners, and 20 per cent, or $846 million, was provided by private sector partners. In 2022, the top 20 resource partners to this funding category contributed $3,297 million, or 81 per cent, of the total contributions received as Other Resources (regular). 1 Figures are based on ‘income’ which here represents contributions received from public sector, revenue from private sector and other income. See ‘Revenue, Contributions and Income’ on page 3. Contributions received in cash and in kind. Please refer to pages 28-32 for all UNICEF contributions received by resource partner. Contributions received from the Democratic Republic of the Congo include $49 million related to the World Bank Group, $5 million related to Gavi, the Vaccine Alliance, and $2 million related to the Global Fund. Excluding UNICEF Country Office Private Sector Fundraising. 2 Public sector includes governments, the European Commission, Inter-Organizational Arrangements, Global Programme Partnerships and International Financial Institutions. 3 Private sector includes income from foundations, individuals, Non-Governmental Organizations, UNICEF National Committees and UNICEF Country Offices. \n\nNo. Resource Partner Other Resources (regular) \n\n1 Germany 690 2 World Bank Group 542 3 United States Fund for UNICEF 328 4 European Commission 317 5 Canada 196 6 Global Partnership for Education 177 7 United States 167 8 Gavi, The Vaccine Alliance 111 9 Netherlands 94 10 Sweden 87 Top 20 resource partners for Other Resources (regular), 2022, by contributions received (Millions of United States dollars) \n\nNo. Resource Partner Other Resources (regular) \n\n11 Asian Development Bank 81 12 United Nations Multi-Partner Trust Fund Office (UN MPTFO) 68 13 United Kingdom 68 14 Education Cannot Wait Fund 67 15 United Kingdom Committee for UNICEF 62 16 Norway 57 17 Democratic Republic of the Congo 56 18 United Nations Joint Programmes 49 19 Global Fund 45 20 Japan 33 Other Resources (regular) income by type of resource partner, 2022 1\n\nPrivate sector 3$846 M \n\n20% \n\nPublic sector 2$3,318 M \n\n80% $4,164 M Total 17 Funding Compendium 2022 | UNICEF  \n\n> 1\n\nFigures are based on ‘income’ which here represents contributions received from public sector, revenue from private sector and other income . See ‘Revenue, Contributions and Income’ on page 3. 2 Public sector includes governments, the European Commission, Inter-Organizational Arrangements, Global Programme Partnerships and International Financial Institutions. 3 Private sector includes income from foundations, individuals, Non-Governmental Organizations, UNICEF National Committees and UNICEF Country Offices. 4 Contributions received in cash and in kind. Please refer to pages 28-32 for all UNICEF contributions received by resource partner. 5 Contributions received from the Office for the Coordination of Humanitarian Affairs include $197 million related to the Central Emergency Response Fund, and $27 million related to humanitarian country-based pooled funds. OTHER RESOURCES (EMERGENCY) Other Resources (emergency) are earmarked funds for humanitarian action and post-crisis recovery activities. In 2022, Other Resources (emergency) income to UNICEF totaled $3,837 million. This represents an increase of 29 percent, or $855 million, from $2,982 million in 2021. Of the total Other Resources (emergency) income, $2,728 million, or 71 per cent, was provided by public sector partners, while the remaining $1,110 million, or 29 per cent, was provided by private sector partners. The top 20 resource partners to this funding category contributed $3,262 million, or 85 per cent, of the total contributions received as Other Resources (emergency). Other Resources (emergency) income by type of resource partner, 2022 1\n\nPublic sector 2US$2,728 M \n\n71% \n\nPrivate sector 3US$1,110 M \n\n29% $3,837 M Total \n\nTop 20 resource partners for Other Resources (emergency), by contributions received, 2022 4(Millions of United States dollars) \n\nNo. Resource Partner Other Resources (emergency) \n\n1 United States 985 2 United States Fund for UNICEF 311 3 Germany 259 4 Gavi, The Vaccine Alliance 229 5 Office for the Coordination of Humanitarian Affairs (OCHA) 5 224 6 European Commission 207 7 United Kingdom 160 8 Japan 146 9 German Committee for UNICEF 128 10 United Kingdom Committee for UNICEF 85 \n\nNo. Resource Partner Other Resources (emergency) \n\n11 Japan Committee for UNICEF 79 12 Sweden 72 13 Committee for UNICEF Switzerland and Liechtenstein 68 14 Swedish Committee for UNICEF 62 15 Canada 55 16 Netherlands 45 17 United Nations Multi-Partner Trust Fund Office (UN MPTFO) 42 18 Dutch Committee for UNICEF 38 19 Italy 35 20 French Committee for UNICEF 34 18 \n\nFUNDING SHORTFALL: \n\nAs of 31 December 2022, $4.25 billion 1 had been received in humanitarian funding for the 2022 appeal, 43 per cent more than the $2.96 billion received for the 2021 appeal. A point of concern is that the majority of contributions – both public and private – were earmarked, largely for a small number of emergency appeals. 64 per cent of the $4.25 billion received in 2022 was earmarked for appeals for four crises: Ukraine and Refugee Outflow, Access to COVID-19 Tools Accelerator (ACT-A), Afghanistan, and Syrian Refugee hosting countries. In fact, the Ukraine and Refugee Outflow appeal accounted for 25 per cent of all humanitarian funds the organization received in 2022, making it the top recipient of funding and the most well-funded Humanitarian Action for Children appeal. Global humanitarian thematic funding (GHTF) is the most flexible type of resource after core resources. GHTF more than tripled in 2022, reaching $119.8 million. Global humanitarian thematic funding contributed to the UNICEF response in the Horn of Africa and Sahel countries; ensured timely response to a cholera outbreak in the Syrian Arab Republic and to Ebola disease in Uganda; and helped to scale up responses to natural disasters in the East Asia and Pacific and Latin America and Caribbean regions and in Pakistan, providing timely funding to cover critical gaps. Despite the record level of funding received in 2022 for humanitarian action, the requirements continued to grow, which meant that most humanitarian responses remained severely underfunded. It is in this environment that an increase in quality funding – multi-year and flexible funding – is critical for addressing emergencies, including those driven by climate change.  \n\n> 1Humanitarian funding includes other resources – emergency along with other types of funding that support UNICEF humanitarian response from public sector resource partners. In 2022, UNICEF implemented a system to record funds dedicated to humanitarian response from non-emergency partners’ budgets resulting in $433.2 million in other resources – regular dedicated to humanitarian responses. This contributed to the funds available against the appeals for Afghanistan, the Bolivarian Republic of Venezuela, West and Central Africa and the Refugee and Migrant Crisis in Europe and to the global appeal for ACT-A. Resource partners who provided such funding are as follows, starting from the largest contribution: the World Bank, Canada, Asian Development Bank, the European Commission, Norway, the United States Agency for International Development, Iceland, the Development Bank of Latin America and the United Nations Multi-Partner Trust Fund Office.\n\n19 Funding Compendium 2022 | UNICEF \n\n# PRIVATE SECTOR PARTNERSHIPS The private sector plays a crucial role in the ability of UNICEF to deliver results for children. In 2022, through extraordinary collaborations and fundraising efforts UNICEF raised a record high $2.67 billion from the private sector – 29 per cent of UNICEF’s total income. UNICEF is extremely grateful for all the support received from its broad range of private sector partners, comprising 10.5 million individual donors who give cash, pledge and legacy gifts; over 7 ,700 philanthropists, foundations, membership, and faith-based organizations; and 41,000 businesses. Beyond income, 2022 witnessed exponential growth in the UNICEF advocacy and child rights agenda, and the role of the private sector in using its influence to positively impact children’s rights. The partnerships outlined below, and detailed in the accompanying listings for partners contributing $100,000 or more, on pages 33-39, are a testament to the strength and the breadth of our relationships with the private sector in support of work to help shape a better world for every child, everywhere in the world. CORPORATE PARTNERSHIPS 2022 was a record-breaking year for UNICEF and its corporate partners. • UNICEF’s global corporate partner portfolio comprised 430 partnerships of over $100,000, with 80 partners giving more than $1 million annually – representing 55 per cent of corporate revenue. • Leading global partnerships drove significant growth, including the LEGO Foundation ($20.5 million), Kimberly Clark ($9.9 million), UNILEVER ($7 million), and Z Zurich Foundation ($4.9 million). • Corporate partners provided $44.4 million in new multi-year partnerships above the value of $1 million. This includes partners such as Eli Lilly ($14.4 million) and Siemens Healthineers ($5.6 million) supporting health systems strengthening. • Corporate partners provided 46 critical one-off emergency grants in the value of above $1 million. These included Epic Games ($26.6 million) for the Ukraine crisis, and Tetra Laval \n\n($10 million) for COVAX. FOUNDATION PARTNERSHIPS Foundation partnerships continue to bring their investment, influence and expertise to support UNICEF across a range of thematic areas and geographies. UNICEF engages with some of the world’s most catalytic foundations and in 2022 grew the number of active foundations partners by 44 per cent. In total 72 institutional foundation partners gave over 100,000, and 23 partners gave over $1 million in 2022. UNICEF and foundation partners were also instrumental in leveraging an additional $500 million in funding for the SDGs and delivery of outcomes for children. UNICEF’s longstanding partnership with the Bill & Melinda Gates Foundation continued to grow, representing $273 million in investments in 2022. This critical relationship helps drive innovative and inclusive programme delivery and the procurement of lifesaving products that accelerate progress in health, nutrition, education, WASH, and other critical areas for children. The partnership with Education Above All Foundation’s \n\nglobal Educate A Child programme also grew, with the signing of four new partnership agreements in The Gambia, Paraguay, Somalia and Tanzania with a total EAA-UNICEF joint contribution of $90.8 million, aiming to enroll 496,768 out-of-school children. PHILANTHROPISTS In 2022, UNICEF partnered with more than 4,000 individuals and family foundations to protect the rights of every child, including commitments to core resources designed to equitably reach the most vulnerable children around the world, bringing us closer to achieving the Sustainable Development Goals (SDGs) for children. The UNICEF International Council \n\n(UIC) – a community of the world’s leading philanthropic families – welcomed 24 new members, bringing the total to 136 members from 19 countries. Lastly, UNICEF launched the NextGen Global Principals community —a small group of influential young philanthropists using their influence and resources to protect child rights, with 11 inaugural members representing over 11 countries. \n\nOther \n\n1% \n\nPhilanthropy \n\n17% Individual giving \n\n50% \n\nFoundations \n\n12% \n\nBusiness \n\n20% \n\n$6.4M \n\nProportion of income by private sector income streams, 2022 20 \n\nMEMBERSHIP AND FAITH-BASED ORGANIZATIONS In 2022, membership and faith-based organizations continued mobilizing their influence, reach and resources for children. This year, Rotary International , who has worked with UNICEF since 1988, contributed more than $150 million to the Global Polio Eradication Initiative that UNICEF is a partner in. Zonta celebrated 50 years of partnership with UNICEF ,providing more than US$13 million since 1972 to empower women and girls. The Church of Jesus Christ of Latter-day Saints continued their support with over $16 million given for nutrition, health and emergency education. Organizations also responded generously to emergencies - over $20 million was raised for the Ukraine emergency, including a $10 million gift from Buddhist Tzu Chi Foundation . And the Interfaith Movement to End the Pandemic completed its campaign raising $2.5 million for COVAX.. The UNICEF Multifaith Giving Circle , representing Buddhist, Christian, Jewish, Muslim and interfaith organizations, grew to 11 members and collectively raised over $32 million. MULTI-STAKEHOLDER PARTNERSHIPS Multi-stakeholder platform engagement expanded to further drive income and influence: • With the World Economic Forum , UNICEF is steering seven global public-private initiatives on areas including resilience, health equity, education, digital inclusion, and more – shaping the outputs including policy guidance and actions needed, and advanced global advocacy and partnerships through engagement in the Annual Meeting. • Two memorandums of understanding were signed, with the \n\nInternational Chamber of Commerce and with the Global Alliance for Trade Facilitation . These were instrumental in localizing global engagement. • The Global Coalition for Youth Mental Health positioned youth mental health on the global agenda and helped grow partnerships and collective action with Jo Malone London, Spotify, Zurich Insurance Group and Z Zurich Foundation. CHILD RIGHTS AND BUSINESS • Together with UN Global Compact and Save the Children ,UNICEF hosted a high-level anniversary event to mark the 10th anniversary of the Children’s Rights and Business Principles, and many offices convened national events. • The Responsible Innovation in Technology for Children (RITEC) project, initiated by UNICEF and the LEGO Group \n\nand funded by the LEGO Foundation , continued to advance the agenda of child well-being through digital design. • In partnership with Norges Bank Investment Management , the Network on Nutrition and Children’s Rights in the Food Retail Sector was established to explore approaches to manage sustainability risks and make progress in nutrition and health. 21 Funding Compendium 2022 | UNICEF \n\n# MULTI-YEAR RESOURCES As part of all UNICEF contributions, multi-year commitments are efficient and effective investments that improve the predictability of funding streams for results. Multi-year commitments enable faster and more efficient response, and longer-term programme planning and implementation. In 2022, UNICEF received 42 per cent of its total contributions from partners as multi-year commitments. This represents an increase of four per cent as compared to multi-year commitments in 2021. In terms of Regular Resources, UNICEF received 10 per cent of these contributions as part of partners’ multi-year core funding agreements. This represents a decrease of one per cent in multi-year core funding from 2021. Of Other Resources (regular) contributed in 2022, 63 per cent was part of multi-year grants. This is four per cent less than in 2021. Of Other Resources (emergency) funding, 30 per cent were multi-year contributions in 2022. This represents an increase of 16 per cent from multi-year emergency contributions in 2021. As we continue to deliver results for children under UNICEF’s Strategic Plan 2022-2025, UNICEF encourages partners to increase multi-year core and other contributions to a target of at least 50 per cent. This will enable UNICEF to fulfil its mandate in the most effective, impactful way. 1 Revenue is recognized, for the most part, in the year the agreement is signed and amounts in other years represent revaluation due to exchange rate fluctuations. Revenue data excludes write-downs. 2 Agreements with a lifetime of two years or more are defined as multi-year agreements. These include any amendments. Other Resources (regular) include contributions to specific management activities. Proportion of total contributions received as part of multi-year agreement, 2 2016-2022 \n\n2017 2021 2022 2019 2018 2020 \n\nContributors to Multi-Year 1 Regular Resources Revenue Recognized 2018-2022 \n\n2023 2024 2025 2026 \n\n> Regular Resources\n> Other Resources (regular) Other Resources (emergency)\n\n010 20 30 40 50 60 70 80 2016 2017 2018 2019 2021 2022 2020 Percentage (%) 15% 19% 27% 26% 18% 7% 8% 18% 19% 18% 66% 66% 71% 78% 64% 14% 63% 67% \n\n11% \n\n30% \n\n10% \n\nSwitzerland: $150 M Australia: $78 M Netherlands: $112 M Denmark: $37 M New Zealand: $24 M Luxembourg: $22 M Qatar: $16 M Canada: $49 M Sweden: $529 M United Kingdom: $154 M Belgium: $64 M 22 \n\n# UNICEF’S TRANSPARENCY JOURNEY Transparency is important to UNICEF . It is foundational to UNICEF’s role as a trusted partner of choice, accountable for how we use our resources for the cause of children. Furthermore, transparency means leveraging data to accelerate progress on the Sustainable Development Goals and delivering results for children in an increasingly complex world. In 2022, UNICEF confirmed its position as a globally trusted development and humanitarian partner that achieves results for children and maintains high transparency standards by becoming the best-performing UN agency in the 2022 Aid Transparency Index (ATI), 1 the only independent measure of aid transparency among the world’s major development agencies. UNICEF signed onto the International Aid Transparency Initiative (IATI) 2 in 2012. Since then, UNICEF has committed itself to a journey of advancing transparency globally and across the organization. In true UNICEF spirit, we have pioneered and innovated our way to scale up the quality and depth of data. In the Aid Transparency Index in 2016, UNICEF was recognized as making the most progress and ranked as third out 46 organizations (“Very Good” category). In the 2018 Index, UNICEF dropped to the “Good” category, largely due to an evaluation methodology change aimed at significant data improvements in the long term. Since 2020, UNICEF has restored and maintained its performance ranking as one of the few organizations worldwide in the ‘Very Good’ category on transparency. On the IATI dashboard, UNICEF consistently ranks as one of the top performers for providing timely, forward-looking, and comprehensive data to the public. 3 Keeping our commitments to the Grand Bargain, UNICEF is among the top performers for indicators related to Humanitarian Reporting. 4However, we need to keep exceeding expectations beyond compliance to the IATI open data standard or ranking. UNICEF has continued to improve the quality and richness of its data published to the public. In 2022, to meet the conditionality of the European Union, UNICEF added details on Cash transfer amounts to Implementing partners to its IATI publications. A new section on Implementing Partners was furthermore added to the UNICEF transparency portal at open.unicef.org. As a member of the IATI Governing Board (representing multilateral organizations) 5, UNICEF has continued to support the strengthening of IATI communications and institutional arrangements. UNICEF and UNDP co-led a revitalized UN Transparency Task Team to support the uptake of the IATI standard across UN Entities. Driving results for every child requires us all to use resources as effectively and efficiently as possible. Transparency and open data are a critical part of this. As a globally trusted development and humanitarian partner, UNICEF will continuously adapt and strengthen transparency in our own working culture and help lead worldwide initiatives. 1 Aid Transparency Index: https://www.publishwhatyoufund.org/the-index/  \n\n> 2\n\nInternational Aid Transparency Initiative (IATI) is a global multi-stakeholder initiative to make it easier for all stakeholders to find, use and compare aid information: https://iatistandard.org/en/ 3 To see the top-ranking organizations on the IATI Standard and Humanitarian data, visit the IATI dashboard: http://publishingstats.iatistandard.org/summary_stats.html 4 IATI Humanitarian Reporting Dashboard: http://publishingstats.iatistandard.org/humanitarian.html 5 IATI Governing Board: https://iatistandard.org/en/governance/who-runs-iati/ UNICEF’s transparency milestones and progress on IATI UNICEF’s Transparency Milestones and Progress on IATI \n\nGlobal Aid Transparency Index (ATI) Ranking  \n\n> UNICEF became an IATI signatory Published in the IATI Registry for the first time\n> Began regular quarterly updates of IATI datasets\n\n2015 2012 2014 2013 2016 2017 2018    \n\n> BEST IMPROVER\n> UNICEF recognized as the organization that made the\n> “most significant progress”\n> since 2013 Published data of better quality & depth; became leading organization globally on\n> humanitarian reporting in IATI Prepared an ‘ambitious ’ IATI implementation schedule\n> Became a full member of IATI’s Governing Board\n> Became one of only 10 organizations\n> that have fulfilled their commitment to aid transparency by end of 2015 Began monthly\n> updates of IATI datasets\n> GOAL:\n> Transparency integrated as part of UNICEF’s working culture; UNICEF as a trusted partner; frontrunner and innovator in Transparency\n\n2020 2021 2019          \n\n> Launched the Transparency Portal OPEN.UNICEF.ORG\n> Became one of the few organizations publishing SDG information\n> continuous improvement in data quality & comprehensive-ness Maintained a leading position in the\n> IATI Common Standard and Humanitarian reporting dashboards\n> Very Good Good Fair Poor\n> 2012 : Ranked 63 rd out of 72 organizations surveyed\n> 2013 : Ranked 21 st out of 67 organizations surveyed\n> 2014 : Ranked 14 th out of 68 organizations surveyed\n> 2016 : Ranked 3rd out of 46 organizations surveyed\n> Good\n> 2018 : Ranked 9th out of 45 organizations surveyed\n> 2020: Ranked 6th out of 47 organizations\n> Very Good No Rating No Rating\n> 2015 : No Index 2019 : No Index\n\n2022   \n\n> UNICEF becomes the BEST performing UN agency\n> Very Good\n> 2022: Ranked 6th out of 50 organizations\n\n23 Funding Compendium 2022 | UNICEF \n\n# UN INTERAGENCY ARRANGEMENTS UNICEF welcomes an upward trend on Member States contributing through UN interagency modalities to deliver on its Strategic Plan priorities. These arrangements enhance UN system coherence towards achievement of the Sustainable Development Goals. UN interagency modalities drive integrated and multisectoral responses to development challenges in a streamlined manner across UN agencies and other stakeholders. In 2022, UNICEF received $471 million through UN inter-organizational arrangements for both development and humanitarian interventions. This amount represents nine per cent of total Other Resources contributions provided by public sector partners. The partnerships modalities used include pooled funds, joint programmes, UN to UN agreements, Central Response Emergency Funds (CERF), and Country Based Pooled Funds (CBPFs). Annually, UNICEF manages funds for joint programmes on behalf of various government partners. These funds are passed through UNICEF to several UN agencies across various regions. Over the past few years, funds administered by UNICEF have increased. Contributions received through UN inter-organizational arrangements 1 by type of funding, 2014-2022 \n\nOther Resources (regular) Other Resources (emergency) Total \n\n0$200M $300M $400M $500M $600M 2014 2015 2016 2017 2018 2019 2020 422 285 202 171 174 350 315 246 137 176 124 123 146 233 277 378 295 296 496 548 523 2021 2022 192 289 187 284 481 471  \n\n> 1\n\nContributions received excluding refunds. Please refer to pages 28-32 for contributions received through inter-organizational arrangements, by resource partner. 2 Country-Based Pooled Funds (CBPFs): CBPFs are multi-donor humanitarian financing instruments established by the Emergency Relief Coordinator. They are managed by OCHA at the country-level under the leadership of the Humanitarian Coordinator. Donor contributions to each CBPF are un-earmarked and allocated by the Humanitarian Coordinator through an in-country consultative process. UN Partnerships Modalities and Arrangements, 2022 \n\nUN to UN Agreements, $73 M, \n\n15% \n\nCBPFs 2through OCHA, $27 M, \n\n6% \n\nPooled Funds, $117 M, \n\n25% \n\nJoint Programmes, $57 M, \n\n12% \n\nCERF through OCHA, $197 M, \n\n42% $471 M Total \n\nUNICEF as Administrative Agent, 2014-2022 \n\n> US$ MILLIONS\n> 020 40 60 80 100 120 140\n\n2014 2015 2016 2017 2018 2019 2020 2021 2022 $54 M $58 M $81 M $101 M $115 M $117 M $131 M $120 M $90 M 24 \n\n# GOVERNMENT PARTNERS CONTRIBUTING THROUGH JOINT PROGRAMMES AND UN TO UN AGREEMENTS Total contributions to UNICEF through Joint Programmes and UN to UN agreements totaled $130 million in 2022. UN POOLED FUNDS UNICEF received $117 million through UN pooled funds in 2022. Of this, $110 million was contributed by United Nations Multi-Partner Trust Fund Office (MPTFO), $6 million was from United Nations Programme on HIV/AIDS, and $0.5 million was from United Nations Trust Fund for Human Security. \n\nIn addition, the European Commission contributed $11 million, the United Kingdom contributed $9 million, and Canada contributed 4 million through UN Joint Programme. \n\nGovernment partners contributing through UN to UN agreements by contributions received 1MPTF Office funds to UNICEF Contributions received from UN MPTF Office, 2018 - 2022 1 European Commission contributed $11 million through UN Joint Programme, in addition to $11.5 million via UN to UN agreement. Please refer to pages 28-32 for all UNICEF contributions received by resource partner. Abbreviations: CBPFs - Country Based Pooled Funds, CERF - Central Emergency Response Fund, MPTF - Multi Partner Trust Fund, OCHA - Office for the Coordination of Humanitarian Affairs. Source: Multi-Partner Trust Fund Office – Participating Organization Factsheet, June 2022. \n\n0 2 4 6 8 10 12 Other Resources (regular) Other Resources (emergency) USD MILLIONS Sweden United Kingdom Canada Netherlands United States Republic of Korea Switzerland 11.5 5.6 5.2 5.2 2.2 .35 .33 .06 .03 Korea International Cooperation Agency European Commission \n\nJoint SDG Fund \n\n7% \n\nOther funds \n\n20% \n\nPeacebuilding Fund \n\n10% \n\nSpotlight Initiative Fund \n\n20% \n\nAfghanistan Humanitarian Fund \n\n22% \n\nSomalia Multi-Window Trust Fund \n\n5% \n\nDRC Humanitarian Fund \n\n4% \n\nMalawi SDG Acceleration Fund \n\n4% \n\nUN Sri Lanka SDG Multi-Partner Trust Fund \n\n9%  2018 2019 2021 2022 2020 020 40 60 80 100 120 140 \n\n> US$ MILLIONS\n\n25 100 19 66 18 25 42 14 68 100 \n\nOther Resources (regular) Other Resources (emergency) 25 Funding Compendium 2022 | UNICEF \n\nInternational Financial Institutions International Financial Institutions, 2016-2022 GLOBAL PROGRAMME PARTNERSHIPS For Global Programme Partnerships (GPPs), contributions are received directly and through agreements in collaboration with programme country governments, which request UNICEF to assist in the implementation of parts of their GPP funding. Indirectly, funds are received either when governments transfer GPP funding directly to UNICEF , or via tripartite agreements between UNICEF , the government, and the GPP .Contributions received from GPPs to UNICEF have more than doubled since 2016. In 2022, UNICEF received $655 million from GPPs in direct funding and $102 million through tripartite agreements with governments. Gavi, the Vaccine Alliance was the top GPP donor, providing $339.4 million in direct funding and $81 million in indirect funding. INTERNATIONAL FINANCIAL INSTITUTIONS UNICEF is increasingly partnering with International Financial Institutions (IFIs) to help countries pursue a resilient and inclusive pandemic recovery and achieve the Sustainable Development Goals. Recognizing that IFIs are not donors but rather critical partners that provide large-scale financing to governments to support their development activities, UNICEF works with IFIs to help mainstream child-sensitive planning, budgeting and programming. UNICEF can both leverage and influence IFI investments in areas that are critical for the well-being of children. In certain cases, UNICEF can be selected as an implementing partner for an IFI-financed programme. In 2022, the World Bank Group provided the greatest overall IFI contribution of $542 million in direct funding to UNICEF . In addition, the World Bank Group provided $98 million via tripartite agreements with governments. IFIs are a key growth partner for UNICEF for delivering results under its Strategic Plan 2022-2025. \n\n2016 2017 2018 2020 2021 2022 2019 Bilateral (direct) Tripartite (indirect) US$ MILLIONS 0100 200 300 400 500 600 700 800 \n\n34 353 50 98 88 401 155 125 113 461 135 626 21 0.3 \n\nGlobal Programme Partnerships, 2016-2022 1 Funding through agreements in collaboration with programme country governments. Global Programme Partnerships \n\nResource Partners US$ Millions Bilateral (Direct) Tripartite 1(indirect) \n\nEducation Cannot Wait Fund 67 .3 End Violence Fund 7.0 Gavi, The Vaccine Alliance 339.4 81.0 Global Partnership for Education 177 .0 Nutrition International 13.0 Global Financing Facility 6.0 Global Fund 44.9 20.8 \n\nBilateral (direct) 654.6 101.8 Resource Partners US$ Millions Bilateral (Direct) Tripartite 1(indirect) \n\nAfrican Development Bank 7.1 Asian Development Bank 83.3 8.4 Development Bank of Latin America 0.4 0.1 Inter-American Development Bank 0.1 3.5 Islamic Development Bank 0.3 18.2 World Bank Group 542.3 97 .8 \n\nBilateral (direct) 626.5 135.1 \n\n2016 2017 2018 2020 2021 2022 2019 \n\nBilateral (direct) Tripartite (indirect) \n\n0100 200 300 400 500 600 700 800 \n\n58 169 68 253 87 214 80 275 150 104 457 102 655 550 \n\n> US$ MILLIONS\n\n26 \n\n# DEVELOPMENT ASSISTANCE COMMITTEE (DAC) MEMBER GOVERNMENTS, TOTAL CONTRIBUTIONS RECEIVED TO UNICEF COMPARED TO ODA, ODA PER CAPITA AND GNI PER CAPITA, 2022 This table ranks resource partner countries’ total contribution to UNICEF per capita. The contributions featured here include Government and National Committee sources for any given country. In 2022, Luxembourg ranked first with a $41.79 per capita contribution. Sweden ranked second with a $31.13 per capita contribution, followed by Norway with a $27 .65 per capita contribution. \n\nResource Partner countries Govt US$ NatCom US$ Total US$ Total ODA US$ millions ODA per capita US$ GNI per capita US$ ODA as % of GNI \n\nLuxembourg 16.92 24.87 41.79 530 757 76,061 1.00 \n\nSweden 20.98 10.14 31.13 5456 515 57 ,418 0.90 \n\nNorway 24.13 3.52 27 .65 5161 938 108,675 0.86 \n\nIceland 13.17 12.48 25.64 93 233 68,195 0.34 \n\nDenmark 9.83 9.22 19.04 2850 483 69,405 0.70 \n\nSwitzerland 5.85 10.50 16.35 4476 509 90,732 0.56 \n\nGermany 12.57 2.81 15.38 35302 424 50,485 0.83 \n\nNetherlands 9.83 3.98 13.81 6471 368 55,026 0.67 \n\nFinland 4.10 7.55 11.64 1614 293 50,924 0.58 \n\nIreland 4.62 3.43 8.05 2452 481 74,948 0.64 \n\nCanada 6.77 0.75 7.51 9286 239 54,593 0.37 \n\nUnited Kingdom 3.37 2.46 5.83 15716 232 45,624 0.51 \n\nUnited States 3.78 2.00 5.78 55000 162 74,896 0.22 \n\nBelgium 2.23 2.47 4.70 2691 230 50,166 0.45 \n\nJapan 1.61 1.89 3.50 16723 136 36,514 0.39 \n\nRepublic of Korea 1.07 2.05 3.12 2883 56 32,572 0.17 \n\nNew Zealand 1.65 1.04 2.69 538 103 45,599 0.23 \n\nAustralia 1.59 1.00 2.59 3040 115 61,570 0.19 \n\nSpain 0.18 2.00 2.17 3978 84 29,734 0.30 \n\nFrance 0.66 1.50 2.15 17353 268 44,027 0.56 \n\nItaly 0.80 1.03 1.83 6520 111 34,595 0.32 \n\nAustria 0.96 0.84 1.80 1842 205 52,731 0.39 \n\nPortugal 0.01 1.76 1.76 422 41 21,845 0.23 \n\nSlovenia 0.52 1.06 1.58 164 78 29,118 0.27 \n\nCzechia 0.23 0.49 0.72 987 94 26,262 0.36 \n\nHungary 0.39 0.13 0.52 396 39 14,050 0.28 \n\nPoland 0.00 0.41 0.42 3363 82 16,024 0.51 \n\nSlovakia 0.02 0.06 0.09 171 29 19,259 0.15 \n\nGreece 0.04 0.00 0.04 305 30 21,174 0.14 \n\nLithuania 0.01 0.02 0.02 197 73 25,101 0.29 \n\nAverage 4.93 3.72 8.64 6866 247 47,911 0.45 \n\nContributions Per Capita to UNICEF , 2022 Gross National Income Per Capita, 2022 Source: OECD Development finance data – ODA in 2022, June 2023 The population figures are taken from the UNFPA State of the World Report 2023. \n\n76,061 57,418 108,675 68,195 69,405 90,732 50,485 55,026 50,924 74,948 54,593 45,624 74,896 50,166 36,514 35,572 45,599 61,570 29,734 44,027 41.79 31.13 27.65 25.64 19.04 16.35 15.38 13.81 11.64 8.05 7.51 5.83 5.78 4.70 3.50 3.12 2.69 2.59 2.17 2.15 US$ 0510 0 20,000 40,000 60,000 120,000 100,000 30 45 15 20 25 35 40 80,000 \n\n> Luxembourg Sweden Norway Iceland Denmark Switzerland Germany Netherlands Finland Ireland Canada United Kingdom United States Belgium Japan Republic of Korea New Zealand Australia Spain France\n\n27 Funding Compendium 2022 | UNICEF \n\n(Millions of United States dollars) DEVELOPMENT ASSISTANCE COMMITTEE (DAC) REGULAR RESOURCES BY CONTRIBUTIONS RECEIVED TO UNDP ,UNFPA, UNICEF AND UN WOMEN, 2022 \n\nResource Partners UNDP USD Millions UNFPA USD Millions UNICEF USD Millions UN Women USD Millions Total USD Millions Overall Rank \n\nUnited States of America 100.3 50.6 134.0 10.0 294.9 1Germany 74.4 60.1 98.5 18.7 251.7 2Sweden 70.7 70.1 62.9 15.4 219.2 3Norway 39.8 60.2 43.5 10.2 153.8 4Switzerland 62.9 16.7 23.5 16.7 119.7 5Japan 65.7 16.5 19.3 4.5 106.0 6Netherlands 30.9 36.2 34.1 4.1 105.3 7Denmark 22.5 34.3 11.4 11.0 79.3 8Finland 2.1 34.4 5.9 19.7 62.2 9Canada 30.1 11.7 12.0 4.8 58.6 10 Belgium 10.0 10.2 15.0 4.3 39.6 11 Ireland 8.1 4.6 7.6 2.2 22.5 12 Australia 8.7 6.7 5.6 21.0 13 France 10.3 1.1 5.3 4.1 20.8 14 Italy 6.3 3.3 5.3 3.0 18.0 15 Luxembourg 4.7 5.5 3.5 2.6 16.4 16 New Zealand 7.1 3.8 3.8 1.6 16.2 17 Republic of Korea 8.5 0.2 3.6 2.4 14.6 18 United Kingdom 2 10.0 10.0 19 Hungary 3.8 3.8 20 Iceland 0.2 0.9 1.1 1.1 3.4 21 Austria 1.0 0.2 1.2 0.3 2.7 22 Spain 0.7 0.3 0.2 0.8 1.9 23 Portugal 0.1 0.3 0.0 0.0 0.4 24 Czechia 0.1 0.0 0.1 25 Slovenia 0.0 0.0 0.0 0.1 26 Poland 0.0 0.0 27 Slovakia 0.0 0.0 28 \n\nTotal DAC 1 contributions 565.3 437.9 495.6 143.2 1,642.0 Total Non-DAC contributions 25.9 4.6 27.3 8.0 65.9 \n\nTotal Contributions 591.2 442.5 522.9 151.2 1,707.9 \n\nComparative Regular Resources Funding from DAC countries, 2022 Comparative Regular Resources Funding from Non-DAC countries, 2022 1 DAC members: Australia, Austria, Belgium, Canada, Czech Republic, Denmark, European Union, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Japan, Korea, Lithuania, Luxembourg, The Netherlands, new Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, United Kingdom, United States. 2 The United Kingdom’s core contribution for 2022 was intended for disbursement in the calendar year of 2022, however, due to unforeseen circumstances, the core contribution was paid in full in March 2023. \n\nUNFPA \n\n27% \n\nUN Women \n\n9% \n\nUNICEF \n\n30% \n\nUNDP \n\n34% \n\nUNFPA \n\n7% \n\nUNDP \n\n39% \n\nUN Women \n\n12% \n\nUNICEF \n\n42% 28 \n\n# Resource Partner Regular Resources 2Other Resources (regular) Other Resources (emergency) Total \n\nGovernments including European Commission 1 Afghanistan 67 ,853 2,442,798 2,510,651 2 Angola 180,000 180,000 3 Armenia 120,790 120,790 4 Australia 20,069,334 21,968,921 42,038,256 5 Austria 1,168,452 902,703 6,571,742 8,642,896 6 Bangladesh 3 216,235 17 ,131,378 17 ,347 ,613 7 Barbados 195,575 195,575 8 Belgium 15,030,060 4,517 ,624 6,576,137 26,123,821 9 Belize 122,250 122,250 10 Benin 24,124 958,292 982,416 11 Bhutan 13,118 13,118 12 Bolivia (Plurinational State of) 40,000 40,000 13 Brazil 1,846,515 395,016 2,241,531 14 Bulgaria 78,500 36,774 104,483 219,757 15 Burkina Faso 1,078,520 203,950 1,282,470 16 Burundi 8,486,033 8,486,033 17 Cabo Verde 350,000 350,000 18 Cambodia 207 ,492 352,485 559,977 19 Canada 11,964,549 195,650,651 54,913,881 262,529,081 20 Central African Republic 44,000 1,402,981 1,446,981 21 Chad 112,884 3,025,578 3,138,462 22 Chile 84,000 561,167 645,167 23 China 2,250,120 1,909,694 800,000 4,959,815 24 Colombia 303,366 303,366 25 Comoros 70,000 410,280 480,280 26 Congo 747 ,250 2,522,525 3,269,775 27 Costa Rica 14,404 14,404 28 Côte d’Ivoire 12,600 3,453,104 3,465,704 29 Croatia 26,125 247 ,376 273,501 30 Cyprus 31,983 63,966 95,949 31 Czechia 2,460,476 2,460,476 32 Democratic People’s Republic of Korea 130,070 130,070 33 Democratic Republic of the Congo 698,370 56,111,914 6,451,456 63,261,739 34 Denmark 11,429,214 23,905,588 22,636,016 57 ,970,818 35 Dominican Republic 88,000 1,926,693 2,014,693 36 Equatorial Guinea 102,672 102,672 37 Estonia 36,765 36,765 38 Ethiopia 386,000 924,979 1,310,979 39 European Commission 317 ,070,112 206,802,456 523,872,568 40 Fiji 71,169 554,243 625,412 41 Finland 5,937 ,719 15,087 ,373 1,506,024 22,531,117 42 France 5,279,831 12,408,112 24,788,328 42,476,271 43 Gabon 89,452 89,452 44 Gambia 34,520 34,520 45 Georgia 155,000 155,000 46 Germany 98,472,918 690,114,451 258,595,866 1,047 ,183,236 47 Ghana 190,512 190,512 48 Greece 31,949 344,980 376,929 49 Guinea 4 350,000 -34,449 84,930 400,481 50 Guinea-Bissau 621,000 1,992,748 2,613,748 51 Guyana 31,672 31,672 52 Haiti 5,704,572 5,704,572 53 Hungary 3,799,574 150,000 3,949,574 54 Iceland 1,144,689 3,292,054 829,581 5,266,324 55 India 847 ,769 5,074,992 5,922,761 UNICEF CONTRIBUTIONS RECEIVED BY RESOURCE PARTNER, 2022 129 Funding Compendium 2022 | UNICEF \n\n# Resource Partner Regular Resources 2Other Resources (regular) Other Resources (emergency) Total \n\n56 Indonesia 144,970 1,120,554 1,265,524 57 Iraq 48,785 48,785 58 Ireland 7,563,025 7,451,718 8,555,321 23,570,064 59 Israel 200,548 200,548 60 Italy 5,297 ,216 7,007 ,532 34,992,930 47 ,297 ,678 61 Jamaica 87 ,828 87 ,828 62 Japan 19,324,490 32,885,475 146,433,374 198,643,339 63 Jordan 802,963 802,963 64 Kazakhstan 217 ,160 150,000 367 ,160 65 Kenya 150,000 743,513 893,513 66 Kuwait 200,000 940,000 4,035,000 5,175,000 67 Kyrgyzstan 55,000 2,557 ,757 413,208 3,025,965 68 Latvia 31,024 21,322 122,768 175,114 69 Lebanon 2,500 2,500 70 Lesotho 120,000 70,728 190,728 71 Liechtenstein 318,976 318,976 72 Lithuania 20,683 20,683 73 Luxembourg 3,530,752 5,905,486 2,404,390 11,840,628 74 Madagascar 6,000 7,688,992 400,000 8,094,992 75 Malawi 5,058,611 5,058,611 76 Mali 33,500 5,867 ,140 3,501,222 9,401,862 77 Malta 20,080 20,080 78 Mauritania 20,610 20,610 79 Mexico 35,480 529,091 564,571 80 Monaco 28,474 256,878 53,752 339,104 81 Mongolia 101,390 101,390 82 Montenegro 23,912 23,912 83 Morocco 96,949 334,858 431,806 84 Mozambique 7,500 2,770,412 3,826,515 6,604,427 85 Namibia 120,000 120,000 86 Netherlands 34,126,163 94,383,980 44,570,174 173,080,318 87 New Zealand 3,771,213 339,436 4,469,911 8,580,560 88 Nicaragua 2,500 2,500 89 Niger 4,000 21,977 ,607 21,981,607 90 Nigeria 2,258,911 24,117 ,942 13,070,166 39,447 ,019 91 Norway 43,549,046 57 ,453,190 31,688,019 132,690,255 92 Oman 397 ,400 1,000,000 1,397 ,400 93 Pakistan 7,931 7,931 94 Panama 1,125,000 449,000 1,574,000 95 Peru 25,785 25,785 96 Philippines 52,975 52,975 97 Poland 10,550 53,881 119,000 183,431 98 Portugal 46,652 26,652 73,305 99 Qatar 3,825,606 1,635,214 5,460,821 100 Republic of Korea 3,584,514 25,199,677 26,580,000 55,364,191 101 Republic of Moldova 54,000 54,000 102 Romania 50,000 281,908 331,908 103 Russian Federation 1,000,000 1,000,000 104 Sao Tome and Principe 19,500 710,746 730,246 105 Saudi Arabia 139,184 341,485 12,757 ,893 13,238,562 106 Senegal 398,500 398,500 107 Serbia 51,000 975,700 1,554,404 2,581,104 108 Sierra Leone 384,000 207 ,601 4,420,980 5,012,581 109 Singapore 50,000 50,000 110 Slovakia 135,699 135,699 111 Slovenia 30,400 1,055,966 1,086,366 112 Somalia 435,700 2,193,398 2,629,098 113 South Sudan 141,900 7,140,780 7,282,680 114 Spain 159,915 8,352,147 8,512,062 115 Sri Lanka 130 130 116 Sudan 121,400 9,454,263 9,575,663 30 \n\n# Resource Partner Regular Resources 2Other Resources (regular) Other Resources (emergency) Total \n\n117 Sweden 62,929,753 87 ,102,231 72,393,551 222,425,535 118 Switzerland 23,467 ,973 12,779,849 15,235,550 51,483,372 119 Syrian Arab Republic 2,937 ,511 2,937 ,511 120 Tajikistan 32,400 1,694,379 1,726,779 121 Thailand 514,507 230,000 63,726 808,234 122 Timor-Leste 100,000 100,000 123 Togo 26,000 26,000 124 Tonga 3,722,464 3,722,464 125 Trinidad and Tobago 15,000 25,000 40,000 126 Türkiye 54,835 54,835 127 Turkmenistan 62,746 62,746 128 Tuvalu 1,118,637 1,118,637 129 Uganda 459,000 459,000 130 United Arab Emirates 2,208,264 653,595 7,436,790 10,298,648 131 United Kingdom 68,335,250 159,985,941 228,321,190 132 United States 134,000,000 166,676,240 984,914,091 1,285,590,332 133 Uruguay 72,450 72,450 134 Uzbekistan 310,000 310,000 135 Vanuatu 3,028,620 3,028,620 136 Viet Nam 34,254 100,000 134,254 137 Zambia 279,282 601,969 881,251 138 Zimbabwe 1,142,841 1,142,841 Global Programme Partnerships 1 Education Cannot Wait Fund 67 ,294,797 67 ,294,797 2 End Violence Fund 7,028,175 7,028,175 3 Gavi, The Vaccine Alliance 110,606,853 228,788,808 339,395,661 4 Global Financing Facility 6,000,000 6,000,000 5 Global Fund 44,905,224 44,905,224 6 Global Partnership for Education 177 ,015,550 177 ,015,550 7 Nutrition International 12,967 ,746 12,967 ,746 International Financial Institutions 1 Asian Development Bank 81,448,661 1,887 ,500 83,336,161 2 Development Bank of Latin America 441,091 441,091 3 Inter-American Development Bank 80,000 80,000 4 Islamic Development Bank 34,449 285,452 319,901 5 World Bank Group 542,315,559 542,315,559 UN Inter-Organisational Arrangements 1 Food and Agriculture Organization of the United Nations (FAO) 5,106,622 87 ,314 5,193,936 2 International Labour Organization (ILO) 2,991,215 2,991,215 3 International Organization for Migration (IOM) 1,404,765 104,135 1,508,899 4 Office for the Coordination of Humanitarian Affairs (OCHA) 223,926,297 223,926,297 5 Office of the High Commissioner for Human Rights (OHCHR) 16,038 16,038 6 The United Nations Educational, Scientific and Cultural Organization (UNESCO) 3,938,879 3,938,879 7 United Nations Assistance Mission for Iraq (UNAMI) 1,159,110 1,159,110 8 United Nations Assistance Mission in Somalia (UNSOM) 84,248 84,248 9 United Nations Development Programme (UNDP) 4,282,180 712,567 4,994,746 10 United Nations Entity for Gender Equality and the Empowerment of Women (UN Women) 337 ,169 337 ,169 11 United Nations Framework Convention on Climate Change (UNFCCC) 49,140 49,140 12 United Nations High Commissioner for Refugees (UNHCR) 120,000 2,470,001 2,590,001 13 United Nations Joint Programmes (UNJP) 49,387 ,279 7,245,251 56,632,530 14 United Nations Multi-Partner Trust Fund Office (UN MPTFO) 68,389,281 41,776,887 110,166,168 15 United Nations Office for Project Services (UNOPS) 5,017 ,854 4,234,074 9,251,927 16 United Nations Population Fund (UNFPA) 17 ,032,235 17 ,032,235 17 United Nations Programme on HIV/AIDS 6,089,150 6,089,150 18 United Nations Relief and Works Agency (UNRWA) 12,932 12,932 31 Funding Compendium 2022 | UNICEF \n\n# Resource Partner Regular Resources 2Other Resources (regular) Other Resources (emergency) Total \n\n19 United Nations Resident Coordinator's Office (UNRCO) 138,780 33,251 172,030 20 United Nations Trust Fund for Human Security (UNTFHS) 235,425 277 ,987 513,412 21 World Food Programme (WFP) 7,172,718 751,403 7,924,121 22 World Health Organization (WHO) 14,162,246 2,026,252 16,188,498 Academic and Research Institutions 1 International Development Research Centre (Canada) 2,036,664 2,036,664 UNICEF National Committees (NC) 1 Andorran Committee for UNICEF 131,068 201,655 86,368 419,091 2 Australian Committee for UNICEF Limited 2,880,674 7,814,003 15,718,213 26,412,890 3 Austrian Committee for UNICEF 4,230,205 170,609 3,172,544 7,573,358 4 Belgian Committee for UNICEF 17 ,302,823 1,308,847 10,266,476 28,878,146 5 Canadian UNICEF Committee 8,308,648 5,056,329 15,573,789 28,938,766 6 Czech Committee for UNICEF 3,282,218 708,243 1,119,036 5,109,497 7 Danish Committee for UNICEF 5,138,816 19,121,675 30,118,439 54,378,930 8 Finnish Committee for UNICEF 13,855,907 3,203,405 24,456,869 41,516,181 9 French Committee for UNICEF 51,396,407 11,456,776 34,307 ,797 97 ,160,980 10 German Committee for UNICEF 79,080,960 27 ,245,350 128,044,540 234,370,850 11 Hong Kong Committee for UNICEF 10,138,334 2,438,841 604,513 13,181,688 12 UNICEF Hungarian Committee 707 ,254 5,239 601,611 1,314,104 13 Icelandic National Committee for UNICEF 3,578,969 61,111 1,350,117 4,990,197 14 UNICEF Ireland 1,309,448 2,086,476 14,106,707 17 ,502,631 15 Italian Committee for UNICEF Foundation 44,398,932 3,033,928 13,049,985 60,482,845 16 Japan Committee for UNICEF 133,193,146 21,171,006 79,067 ,143 233,431,295 17 Korean Committee for UNICEF 86,126,694 13,109,366 6,827 ,351 106,063,411 18 Lithuanian National Committee for UNICEF 29,784 16,697 46,480 19 Luxembourg Committee for UNICEF 2,254,547 703,683 14,453,055 17 ,411,286 20 Dutch Committee for UNICEF 27 ,544,419 4,868,290 37 ,580,035 69,992,744 21 The New Zealand National Committee for UNICEF 337 ,036 2,068,725 2,985,518 5,391,278 22 Norwegian Committee for UNICEF 4,762,140 2,607 ,850 12,001,348 19,371,337 23 Polish National Committee for UNICEF 10,759,911 551,220 5,625,095 16,936,227 24 Portuguese Committee for UNICEF 11,298,261 1,138,906 5,490,387 17 ,927 ,554 25 Slovak Foundation for UNICEF 37 ,572 40,240 285,408 363,220 26 Slovenia Foundation for UNICEF 1,219,266 266,560 750,642 2,236,469 27 Spanish Committee for UNICEF 61,058,426 9,906,382 23,832,232 94,797 ,040 28 Swedish Committee for UNICEF 37 ,855,483 8,167 ,869 61,508,610 107 ,531,962 29 Committee for UNICEF Switzerland and Liechtenstein 7,480,797 17 ,223,832 67 ,723,349 92,427 ,978 30 Turkish National Committee for UNICEF 1,254,951 228,293 231,415 1,714,658 31 United Kingdom Committee for UNICEF 19,269,269 62,235,514 84,947 ,182 166,451,965 32 United States Fund for UNICEF 41,498,979 327 ,991,851 310,555,294 680,046,125 33 Other 124,631 124,631 UNICEF Country Office Private Sector Fundraising (PSFR) 1 Angola PSFR 1,161,277 1,161,277 2 Argentina PSFR 7,215,344 10,431,295 2,575,483 20,222,122 3 Bahrain PSFR 8,452 8,452 4 Bangladesh PSFR 252,038 16,130 268,168 5 Belarus PSFR 17 ,691 61,138 235,461 314,290 6 Bolivia PSFR 765,826 765,826 7 Botswana PSFR 30,881 30,881 8 Brazil PSFR 5,520,566 8,123,809 2,896,121 16,540,495 9 Bulgaria PSFR 183,843 853,497 357 ,465 1,394,804 10 Chile PSFR 13,551,931 3,350,336 162,936 17 ,065,203 11 China PSFR 24,989,590 76,134,670 16,900,469 118,024,728 12 Colombia PSFR 4,165,143 6,711,101 135,090 11,011,333 13 Costa Rica PSFR 75,372 75,372 14 Cote d'Ivoire PSFR 49,200 49,200 15 Croatia PSFR 1,043,080 2,801,188 835,477 4,679,745 16 Dominican Republic PSFR 877 ,066 1,354 878,420 17 Ecuador PSFR 2,976,298 4,495,100 63,574 7,534,972 18 Egypt PSFR 336,989 43,051 380,040 19 Greece PSFR 18,097 283,718 188,068 489,883 32 \n\n# Resource Partner Regular Resources 2Other Resources (regular) Other Resources (emergency) Total \n\n20 Guatemala PSFR 37 ,464 37 ,464 21 Guyana PSFR 1,158 1,158 22 Haiti PSFR 57 ,264 57 ,264 23 India PSFR 8,392,492 7,754,269 4,275,005 20,421,767 24 Indonesia PSFR 2,990,449 5,467 ,535 315,508 8,773,493 25 International On-line Donations 583,713 2,452,906 3,036,620 26 Iran PSFR 35,169 35,169 27 Kazakhstan PSFR 9,764 253,848 263,612 28 Kenya PSFR 60,241 60,241 29 Kuwait PSFR 125,809 125,809 30 Libya PSFR 10,874 10,874 31 Macedonia PSFR 32,711 32,711 32 Malaysia PSFR 17 ,141,180 5,377 ,342 192,626 22,711,148 33 Mexico PSFR 4,410,982 6,630,676 2,371,414 13,413,072 34 Mongolia PSFR 21,629 21,629 35 Montenegro PSFR 83,528 83,528 36 Nicaragua PSFR 89 89 37 Nigeria PSFR 1,218,238 34,155 1,252,393 38 One-off donations PSFR 18 23,200,000 23,200,018 39 Pakistan PSFR 21,558 21,558 40 Panama PSFR 125,452 2,934 128,386 41 Paraguay PSFR 89,003 89,003 42 Peru PSFR 2,607 ,023 2,493,078 1,018,998 6,119,099 43 Philippines PSFR 3,008,612 3,202,015 854,257 7,064,884 44 Qatar PSFR 12,006,543 140,168 12,146,711 45 Romania PSFR 1,229,508 1,527 ,615 3,001,902 5,759,026 46 Rwanda PSFR 120,960 120,960 47 Saudi Arabia PSFR 459,445 4,151,071 5,154,975 9,765,491 48 Serbia PSFR 537 ,249 995,447 183,714 1,716,410 49 Singapore PSFR 477 ,669 1,248,217 1,725,887 50 South Africa PSFR 200,000 2,699,204 94,056 2,993,260 51 Sri Lanka PSFR 15,748 15,748 52 Thailand PSFR 6,333,128 8,387 ,494 608,827 15,329,450 53 Tunisia PSFR 38,646 38,646 54 Ukraine PSFR 748,174 748,174 55 United Arab Emirates PSFR 212,954 15,208,777 10,799,799 26,221,530 56 Uruguay PSFR 5,897 ,780 2,896,327 87 ,136 8,881,243 57 Venezuela PSFR 150 150 58 Viet Nam PSFR 411,984 29,500 441,484 Other 1 Other 741,455 741,455 1 Contributions received in cash and in kind. 2 Regular resources include contributions for specific management activities. 3 Bangladesh`s core contribution for 2021 was intended for disbursement in the calendar year of 2021, however, due to unforeseen circumstances, the core contribution was paid in 2022. 4 The negative amount is due to reprogramming. 33 Funding Compendium 2022 | UNICEF \n\nAlane Adams \n\nAgencia Asturiana de Cooperación (Spain) \n\nAgencia Extremeña de Cooperación (Spain) Agencia Vasca de Cooperación (Spain) \n\nAggreko Eva Ahlström Foundation \n\nAhmad Al Abdulla \n\nAJA Foundation \n\nAlumbra Innovations Foundation \n\nAl Waleed Philanthropies \n\nA musical expression dedicated to the children of Ukraine AnenA Fonds \n\nArigatou International Micky and Madeleine Arison Family Foundation \n\nArt Be a Part [Medha Nanda] \n\nScott Asen \n\nAtwater James Family Fund \n\nAvery Dennison Foundation \n\nAvra Foundation Ayuntamiento de Bilbao (Spain) Ayuntamiento de Madrid (Spain) Bainum Family Foundation \n\nBrenda and Stéphane Bancel \n\nMary Jan and Paul Bancroft \n\nPaula H. Barbour and Thomas Barbour \n\nBeedie Foundation \n\nEric and Kirsty Bendahan \n\nBezos Family Foundation \n\nPooja Bhandari and Caesar Sengupta \n\nBill & Melinda Gates Foundation \n\nThomas C. Bishop \n\nBlackstone Charitable Foundation \n\nPeter and Charlotte Bolland \n\nRobert Brinker and Hilary Brinker \n\nAnthony and L. Britt Giuffre Family Fund \n\nBuddha's Light International Association USA \n\nBuddhist Tzu Chi Foundation USA \n\nBuilder’s Initiative Mary Catherine Bunting \n\nCabildo de Gran Canaria (Spain) FINANCIAL INFORMATION/DONOR LISTING \n\nPrivate foundations, major donors, partnerships with subregional governments, and membership and faith-based organizations contributing $100,000 or more to UNICEF programmes in 2022 \n\nCDC Foundation Children's Investment Fund Foundation Chin Family Foundation \n\nCity of Helsinki Clariant Foundation Tim Clark \n\nClay and Vi Riddell Fund for Children \n\nClé De Peau Beauté \n\nCMA Foundation COFRA Foundation \n\nColleges Ontario Comunidad de Madrid (Spain) Congregation of the Sisters of Charity of the Incarnate Word \n\nConrad N. Hilton Foundation COPE Disaster Champions \n\nJim Craigie and Sally Brophy Crespo Foundation Crimson Lion/Lavine Family Foundation \n\nHugh Culverhouse Jr. \n\nDamrongsak Arunprasertkul \n\nDASRA David T. Heath and Amy L. Dunn \n\nDiputación de Alicante (Spain) Diputación de Castellón (Spain) Diputación de Valladolid (Spain) Diputación Foral de Bizkaia (Spain) Diputación Foral de Gipuzkoa (Spain) Educate A Child The Edwards Family \n\nStanley Eisenberg \n\nMs. and Mr. Michael R. Eisenson \n\nElof Hansson Holding Giovanni & Paola Ferrero \n\nFIA Foundation Susan Cummings-Findel and Mr. Stefan Findel \n\nFM Global Foundation \n\nFondation Botnar Fondation Marcelle et Jean Coutu \n\nFondation Primart Fondo Nacional Armenia de Argentina Fondo Unido Chihuahua Ford Foundation Henrietta H. Fore \n\nFred Hollows Foundation Fundacion Carlos Slim Fundación Santo Domingo \n\nFundación Sertull \n\nGeneralitat Valenciana (Spain) GHR Foundation \n\nGinsburg Family Foundation \n\nGlobal Ministries & UMCOR \n\nGloria Principe and John O'Farrell \n\nGobierno de Aragón (Spain) Gobierno de Baleares (Spain) Gobierno de Canarias (Spain) Gobierno de Cantabria (Spain) Gobierno de Castilla La Mancha (Spain) Gobierno de Navarra (Spain) Lisa and Douglas Goldman Fund \n\nKaia Miller Goldstein and Jonathan Goldstein \n\nDeborah Hart and Bill Goodykoontz \n\nSuzan Gordon \n\nGrodman Family Foundation \n\nBarrett M. Guthrie \n\nMohamed Hafez \n\nHallie Beth Davey & George Byron Macready \n\nCarol J. Hamilton \n\nCast of 'Hang Out With Yoo' \n\nHappel Foundation Hawk Foundation \n\nHD Smith Foundation \n\nHelp, Hope and Healing: Children's Healthcare Canada and Pediatric Chairs of Canada Support Ukrainian Children Hobson/Lucas Family Foundation \n\nHwa Soo Choi \n\nIF Foundation Iger Bay Foundation \n\nIKEA Foundation Inamori Foundation In Sook Huh 34 \n\nInternational Owl Center \n\nIslamic Relief Australia Isle of Man Government Mike Jacobellis \n\nJacobs Foundation Japan Committee, Vaccines for the World's Children Japanese Communist Party Japanese Trade Union Confederation Joe Jarvis \n\nJersey Overseas Aid Jeunesse Global \n\nJi Min Han \n\nMr. and Ms. Alan Johnson \n\nAlistair and Christina Johnston \n\nPasi Joronen \n\nJ.T. Tai & Co. Foundation, Inc. \n\nAbram and Ray Kaplan Foundation \n\nKhachaturian Foundation \n\nDr. Sippi Khurana and Mr. Ajay K.  Khurana \n\nJoseph R. Kirsch \n\nKiwanis International \n\nKlaus Tschira Stiftung gGmbH Klaus und Gertrud Conrad Stiftung \n\nFaye Kolhonen \n\nAmy Kuehner \n\nKwok Foundation \n\nG. Barrie Landry, Landry Family Foundation \n\nTea Leoni \n\nHenrik Lind \n\nBill Losch & Susanne Losch \n\nLove My Neighbour Lund Trust Connie Lurie & Bob Lurie \n\nMahon Family Foundation \n\nMail Force Margaret A. Cargill Foundation Martini Family Foundation \n\nMasonic Charitable Foundation Maßvoll Stiftung, under the aegis of the Fondation de Luxembourg MasterCard Foundation McCusker Charitable Foundation \n\nAditya and Megha Mittal \n\nMERI Foundation William D. Morgan Jr. \n\nMurphy Family Fund \n\nNational Philanthropic Trust Nova Ukraine \n\nMark Nygard & Linda Nygard \n\nOak Foundation OneFamily Foundation \n\nOpen Society Foundations Otto Haas Charitable Trust \n\nPurvi Padia & Harsh Padia \n\nAndrea, Luisa and Annagreta Panconesi, LuisaViaRoma \n\nMr. Poitevin & Ms. Juliana V. Ruecker \n\nNatasha Poonawalla \n\nPopulation Action International PORTICUS Prudential Foundation \n\nRandom Character Collective \n\nReynolds Family Foundation \n\nDanny and Manizeh Rimer \n\nRissho Kosei-kai RNLI Eleanor Robbins \n\nDr. Robert I. Tepper and Dr. M. Lynn Buttolph \n\nStephen Robertson \n\nMr. Bruce & Ms. Lori Laitman Rosenblum \n\nRuth Lilly Philanthropic Foundation \n\nMs. Crystal & Mr. Chris Sacca \n\nAlvin Sandefur \n\nJennie K. Scaife Charitable Foundation \n\nSeok Soo Kim \n\nSeon Jeong Choi \n\nMr. Bruce & Ms. Cynthia Sewell \n\nSamer Shaja \n\nBarbara Shapiro & Edward Shapiro \n\nShareGift His Highness Sheikh Mohamed bin Zayed Al Nahyan \n\nRusy and Purviz Shroff Charitable Foundation Siemer Family Foundation \n\nSisters of the Sacred Heart of Mary \n\nSeph Skerritt \n\nGreg Sobiech \n\nMr. John A. & Ms. Susan Sobrato \n\nSobrato Philanthropies \n\nMs. Lisa & Mr. Matthew Sonsini \n\nSoon Wok Kim \n\nMr. and Mrs. Cyrus W. Spurlino \n\nSquarepoint Foundation Stanley Black & Decker \n\nMr. and Mrs. Ewout Steenbergen \n\nStichting de Lichtboei \n\nBernhard Waldinger Stiftung \n\nStiftung Elena und Heinz Hasselberger \n\nStiftung für Natur und Kinder – Klaus Habermaass \n\nKlaus-Friedrich-Stiftung \n\nReinhold und Heike Fleckenstein Stiftung \n\nSusan Littlefield and Martin F . Roper \n\nMr. Kerry & Ms. Brendan Swords \n\nWahei Takeda \n\nTanoto Foundation Mr. and Mrs. Kirill Tatarinov \n\nJulie Taymor \n\nTDR Capital \n\nThe 72 Fund \n\nThe Ajram Family Foundation \n\nThe Association for the Promotion of UNICEF Child Friendly Cities The Autry Foundation/Mrs. Gene Autry \n\nThe Band Aid Charitable Trust The Charles Engelhard Foundation \n\nThe Chellaram Foundation The Church of Jesus Christ of Latter-day Saints \n\nThe Colin and Belle MacDonald Charitable Foundation \n\nThe Constance Travis Charitable The Derek A.T. Drummond Fund \n\nThe Dietz Family Fund \n\nThe Eleanor Crook Foundation \n\nThe ELMA Foundation \n\nThe Elma Philanthropies The Fairmount Foundation \n\nThe FirstLine Foundation \n\nThe Fund for Second Nature \n\nThe Garrett Family Foundation \n\nThe Goodman Foundation \n\nThe Jerome Avenue Fund \n\nThe Leukemia & Lymphoma Society \n\nThe Mendelsohn Family Fund \n\nThe Power of Nutrition The Rauch Family Foundation \n\nThe Ravi and Naina Patel Foundation \n\nThe Rockefeller Foundation The Rotary Foundation of Rotary International \n\nThe Scottish Government The Slaight Family Foundation 35 Funding Compendium 2022 | UNICEF \n\nThe Task Force for Global Health \n\nThe Tom Mikuni and Minnie Obe Hirayama Charitable Fund \n\nHoward and Ann Thorne \n\nTisBest Philanthropy \n\nTrott Family Philanthropies \n\nUBS Optimus Foundation UN Foundation \n\nUNFCU Foundation \n\nUnited Methodist Church of the Resurrection \n\nBruce and Jina Veaco Foundation \n\nViiV Healthcare W Buehler Family Foundation \n\nWaldrop Family Charitable Fund \n\nWellspring Philanthropic Fund Robert J. Weltman \n\nMelody Wilder Wilson and David Wilson \n\nPeter and Jan Winslow \n\nWon Sun Yang \n\nXunta de Galicia (Spain) Yarbrough Family Foundation \n\nYork Bötzow, Menschen in Not-Stiftung Zegar Family Foundation \n\nZonta International \n\nMarcin Zukowski \n\nMel Zwissler \n\nINTERNATIONAL PARTNERSHIPS \n\nAccenture Airtel Africa Amadeus IT Group Apple Inc. Arm Ltd. Baxter International Foundation Bighit Music BNP Paribas Cardif BT Group Capgemini Change for Good [Aer Lingus (Ireland), American Airlines (United States), Asiana Airlines (Republic of Korea), Cathay Pacific (Hong Kong, China), Cebu Pacific Air (Philippines), easyJet (United Kingdom), Japan Airlines (Japan), Qantas Airways Ltd. (Australia)] Chloé Clarios Foundation Clé de Peau Beauté Dell Technologies DSM Eli Lilly and Company Epic Games Inc Ericsson AB Ethical Tea Partnership Flexport Formula 1 Formula E Fundación Abertis Fundación FC Barcelona Gardena GmbH Gina Tricot \n\nCorporate sector partnerships contributing $100,000 or more to UNICEF programmes in 2022 \n\nH&M Foundation H&M Hennes & Mauritz AB Hempel Foundation Hydro ASA Iberdrola Johnson & Johnson, Inc. Kimberly-Clark Corporation LEGO Foundation LEGO Group Les Mills International LIXIL Corporation L'OCCITANE en Provence and la Fondation L'OCCITANE Louis Vuitton Malletier Marriott International Inc Meta Microsoft Corp. Moncler MSC Foundation Novo Nordisk A/S Novo Nordisk Foundation P&G – PAMPERS Pandora A/S Poul Due Jensen Foundation Primark PwC SAP SE SEF (Saudi Esport Federation) - Gamers Without Borders Sony Corporation of America Spotify AB Takeda Pharmaceutical Company Limited Tata Consultancy Services (TCS) Telenor Group Teleperformance SE Toyota Tsusho Unilever Group Valentino Vitality Volvic Wemade World Gold Council Xylem Inc. Z Zurich Foundation Zurich Insurance Group \n\nNATIONAL PARTNERSHIPS Argentina \n\nPrisma Medios de Pago \n\nAustria \n\nAMEX Export-Import GmbH Plaion GmbH Voestalpine AG TroGroup \n\nAustralia \n\nCharter Hall Group Commonwealth Bank of Australia EBOS GROUP LIMITED GILBERT & TOBIN LAWYERS Goodman Group KPMG Macquarie Group Foundation National Australia Bank Rio Tinto Limited - Global HQ 36 \n\nSims Ltd Westpac \n\nBrazil \n\nAccenture Alpargatas Americanas ADM do Brasil B3 Social BRK Ambiental Instituto BRF Fundação Vale Hydro Grupo Profarma Instituto Claro Itaú Social Klabin Ministério Público do Trabalho (MPT) Nivea Pfizer Raia Drogasil Roche Sanofi Takeda Yara YouTube \n\nBulgaria \n\nFANTASTICO GROUP \n\nCanada \n\nBenevity Inc. IKEA Canada Maple Leaf Foods Inc. New Gold Inc. Pan American Silver Corporation Scotiabank Teck Resources Ltd. \n\nDenmark \n\nArtist Ole Aakjær Augustinus Foundation Bagger-Sørensen & Co.A/S Danske Commodities Danske Lions Klubbers Katastrofehjælp Færchfonden GN Store Nord A/S Haldor Topsøe A/S Heartland A/S Hofmann og Husmans Fond K.W. Bruun & Co. A/S Knud Højgaards Fond Krogagerfonden LB Foreningens Fond Lind Invest ApS Nets Denmark A/S NREP A/S Ørsted Saxo William Demant Foundation \n\nFinland \n\nAhlström Collective Impact Berner Fazer Group Finnair Oyj Fiskars Group Greenstep Kesko Kouvolan Lakritsi Oy Kuusakoski Lindström Oy Lumene Oy Metso Corporation Nokia Nokian Renkaat Oyj Nordea Normet Oma Säästöpankki Outokumpu Oyj Rettig Group Rovio Entertainment Smartly.io 3 Step IT Group Oy Wolt \n\nFrance \n\nAnimoca Arkema AXA BUT International Clarins Eleva Capital Exante Fédération Française de Football Fondation CMA CGM Fondation Crédit Agricole Solidarités Fondation Groupe EDF Fondation S Fonds de Dotation Biomerieux Fonds de Dotation Eurazeo Garance Gémo Groupe Editor Ivoire Le Fonds L ’Oréal pour les Femmes Michelin Naos Sucden The Sandbox Vinci Energies Webhelp \n\nGermany \n\nALDI Nord Stiftungs GmbH Allianz SE Amazon Smile BASF Foundation / BASF SE Bauer Media Group Bechtle AG bpa - Bundesverband privater Anbieter Brenntag SE BRITA SE Budnianer Hilfe e.V. BMW Group C.H. Boehringer Sohn AG & Co. Coroplast Fritz Müller GmbH & Co. KG Cosnova GmbH CYBEX GmbH Daimler Truck AG Eppendorf SE Geschwister Oetker Beteiligung Hapag-Lloyd AG Hello Fresh SE ING DiBa AG Knorr Bremse AG MEWA Textil-Service AG + Co. Pricewaterhouse Coopers GmbH Ravensburger Verlag GmbH Rohloff AG Salzgitter AG Siemens Caring Hands e.V. Siemens Healthineers Swiss Eye International GmbH Symrise AG United Internet for UNICEF Foundation Viessmann Foundation GmbH Würth Group 37 Funding Compendium 2022 | UNICEF \n\nHong Kong, China \n\nDoo Group \n\nIndia \n\nAmazon India Aricent Louis Vuitton India Retail Pvt Oracle India Pvt. Ltd. \n\nIndonesia \n\nPrudence Foundation \n\nIreland \n\nAn Post Applegreen plc Avolon Bank of Ireland Brown Thomas | Arnotts Cairn Homes Canada Life and Irish Life CRH DCC Limited ESW Glenveagh Kingspan Group Plc KPMG Ireland Microsoft Ireland Musgrave Group PayPal Giving Fund Permanent TSB Playrix Uniphar Group PLC \n\nItaly \n\nAmazon Barilla Cassa Depositi e Prestiti Chiesi Farmaceutici CNH Industrial Deliveroo Epta Fondazione Generali – The Human Safety Net Jefferies Lavazza Loro Piana EssilorLuxottica \n\nJapan \n\nAEON 1% Club Foundation AEON Co., Ltd. Amway Japan G.K. Consumers Co-operative CO-OP Aichi Consumers' Co-operative CO-OP GUNMA Consumers' Co-operative CO-OP MIRAI Consumers' Co-operative CO-OP NAGANO Consumers' Co-operative Co-op Shiga Consumers' Co-operative CO-OPDELI NIIGATA CONSUMERS CO-OPERATIVE KOBE Consumers’ Co-operative Lala Co-op Consumers’ Co-operative Nara Co-op Consumers’ Co-operative Oita Co-opdeli Consumers' Co-operative Union COOP SAPPORO Cosmo Energy Holdings Co., Ltd. DAIICHI SANKYO COMPANY, LIMITED Daiwabo Information System Co., Ltd EIKEN CHEMICAL CO.,LTD. FCO•OP consumer cooperative FUJI ELECTRIC CO., LTD. Fuji Television Network, Inc. (FNS Charity Campaign) FUJIFILM Holdings Corporation HEIWADO CO., LTD. Hiroshima Consumers’ Co-operative Society Hitachi, Ltd. HOYA CORPORATION IBARAKI CO-OP Consumers' Co-operative IDOM Inc. ITOHAM FOODS INC. Iwate Consumers’ Co-operative Society Japanese Consumers' Co-operative Union Japanet Holdings Co.,Ltd. Kao Corporation KDDI CORPORATION KYOCERA Corporation MARUI GROUP MEDICOM TOY CORPORATION Mitsubishi HC Capital Inc. Mitsui O.S.K. Lines, Ltd. Miyagi Consumers' Co-operative Society NIHON KOHDEN CORPORATION NIKON CORPORATION Nippon Life Insurance Company Nippon Yusen Kabushiki Kaisha NTT Group ONO PHARMACEUTICAL CO., LTD Osaka Izumi Co-operative Society Palsystem Consumers' Co-operative Union POLA ORBIS HOLDINGS INC. RECRUIT HOLDINGS CO.,LTD. Saraya Co., Ltd. Sawai Group Holdings Co., Ltd. Seiko Group Corporation SL Creations Co., Ltd. Sompo Holdings, Inc. Sumitomo Mitsui Card Company, Ltd. TOCHIGI CO-OP Consumers' Co-operative U CO-OP Consumer Co-operative Society Yamaha Corporation YAOKO Co.,Ltd. \n\nLuxembourg \n\nAermont Capital ArcelorMittal Arendt&Medernach Binance Charity Foundation Cactus SA Cargolux Airlines International S.A Letterone Vega Wealth Management \n\nMalaysia \n\nJohor Darul Ta'zim Football Club \n\nMexico \n\nBanco Santander Mexico Essity Kimberly-Clark Mexico Liomont Signal \n\nThe Netherlands \n\nAction Arcadis N.V. ASML Foundation CataWiki Elsevier B.V. ING Nationale Postcode Loterij Randstad TUi Care Foundation \n\nNew Zealand \n\nBybit Fintech Limited Jefferies LLC \n\nNorway \n\nDNB ASA Equinor ASA Ferd AS 38 \n\nKiwi Norge AS Møller Mobility Nordic Choice Hotels AS Norwegian Air Shuttle ASA Pecuina AS Pictura Gruppen AS Stokke AS SpareBank1 Visma AS Yara International \n\nPeru \n\nBanco de Crédito del Perú BBVA Diners Club Tide Foundation \n\nPoland \n\n4kraft Sp. z o.o. Le Fonds L ’Oréal pour les Femmes Fundacja ING Dzieciom Fundacja Santander Bank Polska S.A. im. Ignacego Jana Paderewskiego Heidrick and Struggles International Konimpex Sp. z o.o. Mattel Poland Sp. z o.o. PayU S.A. Polen Zement Beteiligungsgesellschaft mbH SK hi-tech battery materials Poland Sp. z o.o. STADA Poland Sp. z o.o. Triumph International Polska Sp. z o.o. XTB S.A. \n\nRepublic of Korea \n\nBGF Retail Daewoo E&C Samsung Electronics \n\nRomania \n\nBamesa JYSK România; OMV Petrom; Yardi. \n\nSpain \n\nBBVA Caixabank El Corte Inglés Eroski Forletter Fundación La Caixa Fundación Profesor Uría Goldberg Ediciones Hoteles Amigos Iberia ICT Foxy ING España Mayoral Pymes Amigas Supermercados Gadis We are Water Foundation \n\nSweden \n\nABG Sundal Collier AcadeMedia AFRY AB Akelius Foundation Altor Equity Partners AB C'est Normal Productions COOP Sverige AB Depona AB Elof Hansson Holding AB Husqvarna Aktiebolag INGKA HOLDING B.V. (IKEA) Inter IKEA Systems B.V. Largus Aviation AB Lindéngruppen Pandox AB Pictura Polestar Automotive Sweden AB Sandvik Coromant Securitas AB Swedish Postcode Lottery Tetra Laval AB The Greta Thunberg and Beata Ernman Foundation Triton Volvo Personvagnar AB \n\nSwitzerland \n\nAcronis International GmbH ALDI SUISSE Capri Sun CFC Comet Holding AG Ferring International Fondation Trafigura Fondation Lombard Odier HUGO BOSS LGT Capital Partner OC Oerlikon Pictet Group Foundation Sportradar AG Tetra Laval Valora Management AG Viseca Payment Services SA Würth Gruppe \n\nThailand \n\nCentral Group Prudence Foundation and Prudential Thailand \n\nUnited Kingdom \n\n3i Aberdeen Standard Investments Amazon Arup & Partners Asda AstraZeneca Aveva BP Bupa Burberry Checkout.com Clarks Eight Roads EY UK HSBC Holdings PLC IHS Towers Jo Malone London Keller Group KPMG Intl KPMG UK Lloyds Register Manchester United Marks & Spencer Mercedes-Benz Grand Prix Ltd National Grid NatWest Group NEXT NIVEA Nord Anglia Education People’s Postcode Lottery Petroleum Experts Pladis Global Oracle Red Bull Racing Rentokil Initial RSM UK 39 Funding Compendium 2022 | UNICEF \n\nRX SafetyKleen Scottish Football Association Sky Standard Chartered Stewart Investors The McClay Foundation Thrifty Car & Van Rental Wickes \n\nUnited States \n\nAmazon.com Services LLC American Airlines American Express Foundation Applied Medical Becton, Dickinson and Company Bloomberg, L.P .Cognizant Technology Solutions Global Impact GlobalFoundries Google, Inc. GP Cellulose Greg Dixon of Calmoseptine, Inc. Hallmark Cards, Inc Hubbell Incorporated IKEA U.S. Retail Jazz Pharmaceuticals, Inc. JPMorgan Chase Foundation Lenovo Foundation L'Oreal USA -- Giorgio Armani Fragrances Louis Vuitton Americas Merck Micron Technology Foundation, Inc. MSC Cruises (USA) Nike, Inc. PayPal Giving Fund Pfizer, Inc. Salesforce Target Corporation The Procter & Gamble Company The UPS Foundation The VF Foundation The Walt Disney Company TikTok Inc. Twilio Uber Technologies, Inc. VISA Foundation Wolverine World Wide, Inc. Zappos.com LLC 40 \n\n# GLOSSARY \n\nCentral Emergency Response Fund (United Nations) \n\nAn emergency fund administered by the United Nations Office for the Coordination of Humanitarian Affairs (UNOCHA), from which UN agencies can receive advances for financing emergency operations. \n\nCountry-Based Pooled Funds (CBPFs) \n\nMulti-donor humanitarian financing instruments established by the Emergency Relief Coordinator. These instruments are managed by OCHA at country-level, under the leadership of the Humanitarian Coordinator. Donor contributions to each CBPF are un-earmarked and allocated by the Humanitarian Coordinator through an in-country consultative process. \n\nInter-organizational Arrangements \n\nArrangements that include, among others, contributions received through UNAIDS, UNDG, UNDP , UNESCO, UNFPA, UNOCHA, UNTFHS, WHO, and the World Bank Group. Funding from these sources is mostly directed to humanitarian response and include, among others, income from various pooled funding mechanisms, such as grants from the UNOCHA managed Central Emergency Response Fund (see above) and multi-partner trust fund contributions. \n\nOther Resources \n\nEarmarked contributions for programmes. These are supplementary to the contributions in unrestricted Regular Resources and are made for a specific purpose such as an emergency response or a specific programme in a country or region. \n\nOther Resources (Emergency) (ORE) \n\nFunds specifically provided for UNICEF’s humanitarian action and post crisis recovery activities. In addition to UNICEF’s traditional resource partners, important sources of ORE funding are the inter-organizational arrangements including the Central Emergency Response Fund and the Multi Donor Trust Funds. Funding for ORE is raised through the UNICEF Humanitarian Action for Children (HAC) appeal, Flash Appeals, the UN consolidated Humanitarian Needs Overview, and the UN Strategic Response Plan. \n\nOther Resources (Regular) (ORR) \n\nFunds for specific, non-emergency programme purposes, and strategic priorities. ORR funding allows UNICEF to implement specific projects at global, regional, and country levels. The most strategic and effective ORR contributions are those that are flexible both in their purpose and duration, given as thematic funding towards country programmes. \n\nPrivate Sector \n\nFunding received from a grouping of resource partners that include UNICEF’s National Committees, UNICEF Country Office private sector fundraising, Non-Governmental Organizations, foundations, corporations, and individuals. \n\nPublic Sector \n\nFunding received from a grouping of resource partners that include governments, the European Commission, Inter-Organizational Arrangements, Global Programme Partnerships, and International Financial Institutions. \n\nRegular Resources (RR) \n\nUnrestricted funds that are foundational to delivering results across the UNICEF Strategic Plan. Regular Resources mainly include revenue from the voluntary annual core funding contributions of governments, and un-earmarked funds contributed by UNICEF National Committees, raised through fundraising appeals and ongoing relationships with individuals, civil society groups, companies, and foundations. \n\nStrategic Plan (SP) \n\nUNICEF’s Strategic Plan 2022–2025 provides a global framework for UNICEF country programmes and National Committees, outlining key programmatic goals and a related set of result areas, change strategies and enablers, including approaches on topics like climate action, mental health and social protection. The Strategic Plan guides synchronized action towards an inclusive recovery from COVID-19, acceleration towards the achievement of the Sustainable Development Goals and the attainment of a society in which every child is included, without discrimination, and has agency, opportunity and their rights fulfilled. The Plan was informed by voices of children, communities, governments, UN sister agencies, private sector, civil society and other partners. \n\nThematic Funding \n\nThematic Funding contributions are pooled funds designed to directly support the achievement of outcomes or results in the UNICEF Strategic Plan 2022-2025 through flexible multi-year funding windows and achieve UNICEF’s mandate to advocate for the protection of children’s rights, to help meet their basic needs and to expand their opportunities to reach their full potential. \n\nUNICEF National Committee \n\nRegistered non-profit structures in support of UNICEF’s global mandate. UNICEF National Committees are mostly categorized as non-governmental entities established according to national laws. They play a key role in mobilizing resources for UNICEF’s work through partners in the private sector, civil society, and individual donors worldwide. 41 Funding Compendium 2022 | UNICEF \n\n# ABBREVIATIONS \n\nAIMs  Aid Management Systems \n\nCBPFs  Country-Based Pooled Funds \n\nCERF  Central Emergency Response Fund \n\nDAC  Development Assistance Committee \n\nEAPRO  East Asia and Pacific Regional Office \n\nEC  European Commission \n\nGlobal Fund  the Global Fund to Fight AIDS, Tuberculosis and Malaria \n\nGNI  Gross National Income \n\nGPP  Global Programme Partnerships \n\nHAC  Humanitarian Action for Children \n\nIATI  International Aid Transparency Initiative \n\nIDA  International Development Association \n\nIFI  International Financial Institutions \n\nMPTF  Multi-Partner Trust Funds \n\nNGO  Non-Governmental Organization \n\nOCHA  see UNOCHA \n\nODA  Official Development Assistance \n\nOECD  Organization for Economic Co-operation and Development \n\nPSFR  UNICEF Country Office Private Sector Fundraising \n\nRR  Regular Resources \n\nUN  United Nations \n\nUNDP  United Nations Development Programme \n\nUNICEF  United Nations Children’s Fund \n\nUNOCHA  United Nations Office for the Coordination of Humanitarian Affairs \n\nWASH  Water, Sanitation, and Hygiene Published by UNICEF 3 United Nations Plaza New York, NY 10017 www.unicef.org July 2023 \n\n#ForEveryChild\n",
      "name": "open",
      "role": "tool",
      "tool_call_id": "call_3d5cd16e56b44f21b029592a"
    },
    {
      "content": "",
      "reasoning_content": "\nThis PDF is huge and contains a lot of information. However, the key numbers we need: revenue increase between 1600-2000 million inclusive; two years earlier revenue rose by 13-19% YoY. Spending in year between $7-10bn. Management costs 353-365 million. Supported 95-150 countries delivering vaccines for a disease that caused a pandemic.\n\nThese numbers seem to match Gavi's financials? Let's check Gavi's revenue (total income) 2022: $2,054 million (as per Table 2). That is within 1.6-2bn range. Also management costs might be around $350 million? Let's search Gavi management cost.",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"query\":\"Gavi management costs 2022 USD\"}",
            "name": "search"
          },
          "id": "call_2a3cd711b2bd4baa86861040",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "【22† 02b - PEF and Secretariat Budget 2021-2022.†https://www.gavi.org/sites/default/files/board/minutes/2020/15-dec/02b%20-%20PEF%20and%20Secretariat%20Budget%202021-2022.pdf】\n3.4 The Secretariat budget request is for US$ 128.5 million for 2021 and US$ 132.7 million in 2022, compared to US$ 110.3 million for 2020. The increase in ...\n\n【23† The Immunization Delivery Cost Catalogue†https://immunizationeconomics.org/wp-content/uploads/2024/11/1.-IDCC-presentation.pdf】\nEconomic and financial cost per dose (2022 USD). Facility-based ... How can you use the Immunization Delivery. Cost Catalogue? Immunization ...\n\n【24† How Gavi 6.0 Can Take a Bigger Leap†https://www.cgdev.org/publication/how-gavi-60-can-take-bigger-leap】\nBeyond vaccine support, budgets for cash-grant support and other expenses have ballooned almost threefold, from $1.8 billion for Gavi 3.0 to a ...\n\n【25† Gavi, the Vaccine Alliance, has its billion-dollar grant cut by†https://www.npr.org/sections/goats-and-soda/2025/03/28/g-s1-56881/vaccines-gavi-usaid-rubio】\n... Administration a grant of $2.53 billion starting in September 2022 through the year 2030. Of that amount $880 million has so far been ...\n\n【26† Gavi 6.0 'Strategic Cost Estimate'†https://www.gavi.org/sites/default/files/board/minutes/2024/6-7-june05%20-%20Annex%20D%20-%20Gavi%206%200%20Strategic%20Cost%20Estimate.pdf】\nThe final cost of Gavi 6.0 will be driven by the resources mobilised through the replenishment process and a detailed forecasting will take place in H1 of 2025.\n\n【27† Gavi, WHO experience major funding cuts in U.S. federal†https://philanthropynewsdigest.org/news/gavi-who-experience-major-funding-cuts-in-u.s.-federal-funding】\nSimilarly, a $2.53 billion grant issued to Gavi by the Biden administration in 2022 that was supposed to run through 2030 has been eliminated, ...\n\n【28† Financial risk protection from vaccines in 52 Gavi-eligible low†https://pmc.ncbi.nlm.nih.gov/articles/PMC12585062】\nVaccines have the potential to provide financial risk protection (FRP) by preventing illnesses and associated healthcare costs. We estimate the ...\n\n【29† Annual Progress Report 2022†https://www.developmentaid.org/api/frontend/cms/file/2023/10/Gavi-Progress-Report-2022.pdf】\nGavi-supported immunisations. Amount in US dollars of the direct and indirect benefits of immunisation supported by Gavi, derived as the costs of illness.\n\n【30† GAVI, THE VACCINE ALLIANCE†https://docs.publicnow.com/viewDoc.aspx?filename=125665%5CEXT%5C24F3DB2A4E4D74841E017EF142E1E873A9779E2B_9C771451465E9C4EF9182A105DC7F67F61BE5379.PDF】\nGavi – Core's percentage operating expenses decreased slightly from 7.61% in 2022 to 6.83% in 2023. This decrease in the Gavi – Core's.\n\n【31† THE COST OF DELIVERING COVID-19 VACCINES IN THE†https://thinkwell.global/wp-content/uploads/2024/04/DRC-C19-costing-study-report_final.pdf】\nAll costs are presented in 2022 US dollars (USD, $) . Costs were converted from Congolese Francs (CDF) to US. Dollars (USD) using a conversion of 1 USD = 1,996 ...\n\n",
      "name": "search",
      "role": "tool",
      "tool_call_id": "call_2a3cd711b2bd4baa86861040"
    },
    {
      "content": "",
      "reasoning_content": "\nLet's open result 30.",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"url\":\"https://docs.publicnow.com/viewDoc.aspx?filename=125665%5CEXT%5C24F3DB2A4E4D74841E017EF142E1E873A9779E2B_9C771451465E9C4EF9182A105DC7F67F61BE5379.PDF\"}",
            "name": "open"
          },
          "id": "call_29dc71ed5ad94c6792154fcb",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "Title: Just a moment...\n\nURL Source: https://docs.publicnow.com/viewDoc.aspx\n\nWarning: Target URL returned error 403: Forbidden\nWarning: This page maybe requiring CAPTCHA, please make sure you are authorized to access this page.\n\nMarkdown Content:\ndocs.publicnow.com\n------------------\n\nVerify you are human by completing the action below.\n\ndocs.publicnow.com needs to review the security of your connection before proceeding.\n",
      "name": "open",
      "role": "tool",
      "tool_call_id": "call_29dc71ed5ad94c6792154fcb"
    },
    {
      "content": "",
      "reasoning_content": "\nLet's open result 29.",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"url\":\"https://www.developmentaid.org/api/frontend/cms/file/2023/10/Gavi-Progress-Report-2022.pdf\"}",
            "name": "open"
          },
          "id": "call_96eadf4a4e0d40588368bbeb",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "Title: \n\nURL Source: https://www.developmentaid.org/api/frontend/cms/file/2023/10/Gavi-Progress-Report-2022.pdf\n\nPublished Time: Fri, 29 Sep 2023 11:14:11 GMT\n\nMarkdown Content:\n# Annual Progress Report 2022 \n\nchildren immunised since 2000 \n\nin economic benefits since 2000 \n\n## >US$ 220.5 bn >1bn S P E C I A L F O C U S\n\n# >17.3 m\n\ndeaths averted since 2000 \n\nResponding to the climate crisis Country stories from VaccinesWork Preparing for the next pandemic Gavi prepares an Annual Financial Report for each calendar year, which includes the audited consolidated financial statements of the Gavi Alliance and of the International Finance Facility for Immunisation. The 2022 Annual Financial Report was approved by the Board and published on the Gavi website in June 2023: www.gavi.org/funding/financial-reports. © The Gavi Alliance. All rights reserved. This publication may be freely reviewed, quoted, reproduced or translated, in part or in full, provided the source is acknowledged. The material in this publication does not express any opinion whatsoever on the part of Gavi, the Vaccine Alliance concerning the legal status of any country, territory, city or area or its authorities, or of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by Gavi, the Vaccine Alliance. \n\nCover photography: Afghanistan: Gavi/2023/Oriane Zerah; Bolivia: Gavi/2023/Sara Aliaga Ticona; \n\nCambodia: Gavi/2023/Erika Piñeros; Sudan: Gavi/2022 Learn more at  www.gavi.org  and VaccinesWork, our digital platform covering news, features and explainers from every corner of global health and immunisation. Inside this report \n\nVaccine equity means that girls in every country – regardless of income level – are protected from cervical cancer, which caused more than 179,000 deaths in lower-income countries in 2020. That’s why in December 2022 the Gavi Board approved the revitalisation of the human papillomavirus (HPV) vaccine programme. Together, we can meet our goal of reaching 86 million girls by 2025 with the HPV vaccine. This will protect women’s health and will support efforts to eliminate cervical cancer globally. \n\nSarah Goulding, Gavi Board Vice Chair September 2023 \n\n4 Introduction \n\n4 Foreword by Gavi Board Chair Prof José Manuel Barroso and Gavi CEO (ad int) David Marlow 6 Facts and figures \n\n8 Mission goals \n\n8 Gavi 5.0/5.1 mission and strategic goals 9 Mission indicators 12  Gavi-supported vaccine introductions and campaigns \n\n14  VaccinesWork in 2022 \n\n14  Ten of our most-read stories \n\n16  The vaccine goal \n\n17  Key highlights 18  Routine immunisation in 2022: from recovery to resilience 19  Results – vaccine goal strategy indicators 22  Progress – 2022 updates on Gavi-supported vaccine programmes \n\n28  The equity goal \n\n29  Key highlights 30  Results – equity goal strategy indicators 33  Progress – 2022 equity updates 34  2022 Gender Policy updates 35  COVAX: key learnings for future pandemic preparedness and response 36  Climate, health and immunisation \n\n38  The sustainability goal \n\n39  Key highlights 40  Results – sustainability goal strategy indicators 41  Progress – 2022 sustainability updates 42  How Gavi’s co-financing model works 43  Civil society’s crucial role in sustainability; public policy engagement \n\n44  The healthy markets goal \n\n45  Key highlights 46  Results – healthy markets goal strategy indicators 47  Progress – 2022 healthy markets updates \n\n48  Funding and finance \n\n49  Mobilising global support 50  Fighting the pandemic with financial innovation 51  African vaccine manufacturing; pandemic learnings 52  Private sector innovation \n\n53  Annexes \n\n54  Contributions to Gavi 57  Governance structure 58  Contributions pledged to Gavi 66  Commitments for country programmes 68  Board approvals for country programme expenditure 70  Commitments and Board approvals for investment cases 71  Donors 4Annual Progress Report \n\n> Foreword\n\n# On the road to recovery in 2022, a year of renewal in 2023 \n\n## Prof José Manuel Barroso, Chair of the Gavi Board, and Gavi CEO (ad int) David Marlow on achievements and challenges in 2022, and priorities and goals for 2023. \n\nJosé Manuel Barroso \n\nChair of the Gavi Board \n\n# José Manuel Barroso \n\nWelcome to Gavi’s 2022 Annual Progress Report – the second of Gavi’s 2021–2025 strategic period. Even as the COVID-19 pandemic raged on in 2022, this report will show that immunisation coverage in lower-income countries supported by the Alliance is recovering, with coverage of the third dose of diphtheria, pertussis and tetanus-containing vaccine (DTP3) rising by 3 percentage points in 2022. According to the 2022 WHO/UNICEF Estimates of National Immunization Coverage, nearly half of lower-income countries have recovered to or are above pre-pandemic DTP3 coverage levels. And Gavi implementing countries have reached roughly the same number of children as pre-pandemic – with coverage not fully returning to 2019 levels due to population growth, particularly in Africa. However, some countries saw slower progress. The number of zero-dose children has fallen from 12.4 to 10.2 million. This represents impressive progress, but the number of zero-dose children is still higher than the estimated 9 million in 2019, and a further 34% reduction is required to meet our 2025 target. As we reflect on the important progress and urgent challenges that remain, the Vaccine Alliance nonetheless acknowledges the tremendous effort countries have made to get routine immunisation back on track. The year 2022 was indeed complex and challenging for global health. More people were infected with COVID-19 than in 2020 and 2021 combined; and by end August, more than 1 million people had died from COVID-19 in 2022 alone. The pandemic’s negative impact on routine immunisation, resulting in the largest backslide in childhood vaccinations in three decades, continued to present challenges. Cases of polio and diphtheria were detected in some countries for the first time in decades; Uganda battled an outbreak of Sudan ebolavirus, which licensed vaccines don’t protect against; and mpox (formerly known as monkeypox) was declared a Public Health Emergency of International Concern (PHEIC). This is exactly why the Vaccine Alliance heralded 2023 as a Year of Renewal. In December 2022, the Gavi Board approved Gavi 5.1, an evolution of the current five-year programme strategy to renew focus on essential and COVID-19 vaccinations; reach zero-dose children; introduce new vaccines, including HPV and malaria; and strengthen our Alliance’s role in pandemic prevention, preparedness and response (PPPR). Alongside the growing threat of measles outbreaks, we witnessed a continuing risk of polio outbreaks – both wild poliovirus 1 (WPV1) and vaccine-derived poliovirus type 2 (VDPV2) – underscoring the urgency to boost routine immunisation coverage, reach zero-dose children and ensure they go on to receive the full complement of vaccines. Meanwhile, expanding girls’ access to the life-saving human papillomavirus (HPV) vaccine – among the most impactful of all Gavi-supported vaccines – is a core priority. To make up the ground we lost during the pandemic, in December 2022 the Gavi Board approved a more than US$ 600 million investment to protect 86 million girls by 2025. At 10%, HPV vaccine coverage in 2022 continued to surpass pre-pandemic levels (7%). With efforts underway to strengthen programme delivery and facilitate more introductions, and long-standing supply challenges easing thanks to increased vaccine production and a new one-dose recommendation, coverage is expected to further increase in the coming years. \n\nDavid Marlow \n\nGavi CEO (ad int) \n\n# David Marlow 5Annual Progress Report \n\n> Foreword\n\nOur fight against the COVID-19 pandemic continued with the same determination with which it began in 2020. By the end of 2022, COVAX had shipped more than 1.88 billion COVID-19 vaccine doses to 146 countries and territories; and complete primary series coverage across the 92 lower-income countries supported by the Gavi COVAX AMC stood at 53%, up from 31% in January. Across 69 AMC countries reporting, 82% of health care workers were vaccinated. As COVAX continued to plan for worst-case scenarios, the Board agreed, in principle, to explore integrating future COVID-19 vaccinations into Gavi’s core programming. As climate change, deforestation and migration increase the risk of infectious disease outbreaks, the number of cholera cases and cholera-associated deaths surged globally in 2022. This tragic turn follows years of decline. With the risk of another pandemic occurring with the same kind of impact as COVID-19 increasing by an estimated 2% each year, we are reminded of the importance of Gavi’s commitment to vaccine equity in PPPR planning, alongside the Pandemic Accord negotiations. Here, Gavi is working with our partners to apply learnings from COVID-19, COVAX and Ebola response to PPPR and to how we respond to new outbreaks. We have invested more than US$ 4.5 billion in PPPR-related activities between 2016–2022, another US$ 2 billion through the first half of 2022 and raised an additional US$ 12.5 billion for the Gavi COVAX AMC to fund COVID-19 vaccines, delivery and systems. As we learned the hard way during the COVID-19 pandemic, one of the biggest obstacles to vaccine equity is the dearth of vaccine manufacturing in some regions, particularly across Africa. As of 2022, less than 0.1% of the global supply of vaccines are produced in Africa. As the world’s largest purchaser of vaccines, and the main source to African nations, Gavi has a critical role to play in helping build healthier vaccine markets, and we will work closely with African countries and Africa CDC to support the African Union’s vision of sustainably expanding vaccine manufacturing capacity across Africa by 2040. Recognising the unique strengths of the Alliance, our Operational Excellence agenda launched in 2023 is focused on improving our ways of working to ensure we are as efficient and effective as possible to deliver on our mission. It will transform how Gavi supports countries and works with partners by creating a faster, more effective Gavi Secretariat that is able to react better to country needs, with a key focus on Alliance health and ways of working. Ensuring ethical behaviour, solid risk management, and compliance with laws and regulations remains critical to how we operate, sustain funding and innovate. In 2023, we established a dedicated Ethics, Risk & Compliance Office, headed by a newly appointed Chief Ethics, Risk & Compliance Officer. Our six core values guide our work at Gavi: teamwork, respect, openness, accountability, innovation and country-driven, which means that we put the Gavi-supported countries at the centre of everything we do. None of the Vaccine Alliance’s 2022 achievements would have been possible without the collective effort of our civil society, government and private sector partners, working in support of the health care workers who actually administer the vaccinations. We are truly grateful and proud to work alongside them to leave no one behind with immunisation. \n\nMilestone of more than 1 billion children vaccinated as Seth Berkley departs \n\nIn August 2023, soon after Gavi successfully completed the first half of its 5.0/5.1 strategic period “on track” to meet the majority of the key commitments made to donors, Dr Seth Berkley completed his 12-year tenure as CEO. Through Seth’s leadership, Gavi’s impact expanded dramatically in terms of protecting children and adults, and preventing deaths through routine and campaign-based vaccination – including outbreak response through emergency stockpiles. Also under his watch, Gavi-supported countries crossed the milestones of 1 billion unique children vaccinated; more than 1.8 billion vaccinations through preventive vaccination campaigns; and 1.96 billion COVID-19 vaccine doses shipped by COVAX to 146 countries and territories. During this time, Gavi has played an influential role in helping build sustainable health systems; robust and diverse vaccine markets (including new vaccines against Ebola, malaria and typhoid); and increasing commitment from countries to invest in their own immunisation programmes – more than US$ 1.5 billion since the co-financing policy was introduced in 2008. We commend Seth’s extraordinary contributions to global health over nearly four decades, and thank him for his unrelenting commitment to Gavi’s mission, the countries with which we work, our Alliance partners, and our incredible staff of employees, consultants and interns. \n\n> Dr Seth Berkley at the November 2022 commissioning of an ultra-modern National Medical Stores warehouse, constructed with support from the Government of Uganda, Gavi and the Global Fund. Read the report Credit: Gavi/2022\n\n## 6Facts and figures \n\n> Annual Progress Report\n\nAbout Gavi, the Vaccine Alliance \n\nGavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world’s children against some of the world’s deadliest diseases. The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organisations that fund Gavi’s work here. Since its inception in 2000, Gavi has helped to immunise a whole generation – over 1 billion children – and prevented more than 17.3 million future deaths, helping to halve child mortality in 78 lower-income countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningococcal and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation, above all the zero-dose children who have not received even a single vaccine shot. The Vaccine Alliance employs innovative finance and the latest technology – from drones to biometrics – to save lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at www.gavi.org and connect with us on Facebook and X (Twitter). \n\n# >1bn children vaccinated through routine programmes, 2000–2022 – more than 68 million in 2022 alone \n\n# >1.8bn vaccinations through preventive vaccination campaigns, 2000–2022 \n\n# >17.3m future deaths averted, 2000–2022. In addition, >2.7m deaths were averted by COVAX across participating low- and middle-income countries. \n\n# 56 %81 %$1.5bn by end 2022 \n\nBreadth of protection with vaccines in the Gavi portfolio is now higher in Gavi-supported countries (56%) than in the rest of the world (53%). In 2022, DTP3 coverage in Gavi-supported countries rebounded to 81% after two years of decline (compared to the 84% global average). In the face of fiscal challenges, climate change, conflict and instability, most Gavi-supported countries maintained or increased domestic resources for co-financing of Gavi-supported vaccines in 2022, bringing to US$ 1.5 billion their total contribution since the introduction of the co-financing policy in 2008. \n\nThe vaccine goal The equity goal The sustainability goal \n\n40 Gavi-supported vaccine introductions and preventive campaigns took place in 2022 – in addition to 40 outbreak response vaccination campaigns supported by Gavi. \n\n80 \n\n2.6 million more children received basic routine immunisations through Gavi-supported health systems in 2022 than in 2021. \n\n2.6m \n\nUS$ 162 million was contributed by countries towards the co-financing of Gavi-supported vaccines in 2022 – the highest amount yet and a testament to country ownership and the long-term financial sustainability of Gavi-supported vaccines. \n\n162m \n\n4 key SDG vaccines saw an increase in coverage among the 57 Gavi-supported countries since 2021. 4\n\n47 countries have installed more than 65,000 CCE units procured by UNICEF Supply Division through Gavi’s CCEOP – nearly 13,000 in 2022 alone. \n\n47 \n\n54 vaccine programmes originally introduced with Gavi funding are now self-financed by countries as of 2022, up from 40 in 2018. \n\n54 \n\n20 countries accessed emergency stockpiles for cholera, Ebola, meningococcal and yellow fever vaccines a total of 33 times in 2022. \n\n20 \n\n100% of countries fully met their 2022 co-financing obligation – except three waivers for humanitarian crises. \n\n100% \n\n25 Gavi-supported countries increased MCV1 coverage from 2021 to 2022, but measles immunity gaps remain a significant concern. \n\n25 7Annual Progress Report \n\n> Facts and figures\n\n# 603 1\n\nvaccine introductions and preventive vaccination campaigns, 2000–2022 \n\n1 Excluding COVID-19 vaccination. Routine introductions and preventive vaccination campaigns relate to Gavi-supported vaccines against 17 infectious diseases, as of 2022. In the Gavi 1.0 and 2.0 strategic period, introductions were completed for hepB mono and Tetra-DTP-hepB that are not counted here. \n\n# US$ 54 for US$ 1 spent \n\nA study covering 73 Gavi-supported countries shows that, for every US$ 1 spent on immunisation in the 2021–2030 period, US$ 21 are saved in health care costs, lost wages and lost productivity due to illness and death. When considering the value people place on lives saved by vaccines – which is likely to include the value of costs averted plus the broader societal value of lives saved and people living longer and healthier lives – the return on investment is estimated to be US$ 54 per US$ 1 spent. \n\nSim S.Y., Watts E., Constenla D., Brenzel L., Patenaude B.N. Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30. Health Affairs, 2020 \n\n# >US$ 220.5 bn in economic benefits generated in the countries we support, 2000–2022 \n\n# >US$ 1.5 bn in co-financing contributions from Gavi-supported countries since 2008 – and a high of US$ 162m in 2022 alone \n\n# 19 Through Gavi’s market shaping efforts, the number of manufacturers supplying prequalified Gavi-supported vaccines has grown from 5 in 2001 to 19 in 2022 (with more than half based in low- and middle-income countries) \n\nThe healthy markets goal \n\n10 markets for vaccines and immunisation products exhibited acceptable levels of healthy market dynamics in 2022, meeting the target for the year. \n\n10 \n\n9 innovative products were within the pipeline of commercial-scale manufacturers in 2022, meeting the Alliance target of 8 by 2025 well ahead of schedule. \n\n9\n\n2 new products with improved characteristics were newly offered to Gavi-supported countries in 2022: a new liquid rotavirus vaccine, improving ease of delivery for health care workers; and a new presentation for yellow fever vaccine, improving its cold chain footprint. \n\n2\n\n14.7 million children in Gavi-supported countries are under-immunised – they have not received all three doses of the essential childhood vaccine containing diphtheria, tetanus and pertussis (DTP). Of this group, 70% are “zero-dose” children – they have not received even a single dose of DTP-containing vaccine. In Gavi-supported countries in 2022, there were 10.2 million zero-dose children – down from 12.4 million in 2021. \n\n14.7m \n\n39% of children under 12 months in Gavi-supported countries in 2022 received the last recommended dose of each of the 11 antigens currently recommended by the World Health Organization (WHO) for all infants worldwide by their first birthday – an increase from 29% in 2021. \n\n39% \n\nGavi-supported countries continue to have higher coverage of vaccines against pneumococcus, rotavirus and Haemophilus influenza e type b (Hib) than the rest of the world. 8Annual Progress Report Gavi 5.0/5.1 mission and strategic goals \n\n# Gavi 5.0/5.1 mission and strategic goals \n\n## “Leaving no one behind with immunisation” is Gavi’s vision. \n\nThe Vaccine Alliance’s mission is: to save lives and protect people’s health by increasing equitable and sustainable use of vaccines. Six “mission indicators” reflect our overall progress against our aspirations for the 2021–2025 period. Summary: pages 9–11. This mission is also supported by the following four strategic goals, each with its own set of strategy indicators: \n\nGoal 01 \n\nIntroduce and scale up vaccines \n\nGoal 02 \n\nStrengthen health systems to increase equity in immunisation \n\nGoal 03 \n\nImprove sustainability of immunisation programmes \n\nGoal 04 \n\nEnsure healthy markets for vaccines and related products \n\nStrengthen countries’ \n\nprioritisation of vaccines \n\nappropriate to their context Support countries to introduce \n\nand scale up coverage of vaccines \n\nfor prevention of endemic, epidemic and pandemic diseases Enhance outbreak and pandemic response by ensuring equitable access to relevant vaccines including through stockpiles \n\nObjectives \n\nABC\n\nHelp countries extend immunisation services to regularly reach under-immunised and zero-dose children to build a stronger primary health care platform Support countries to ensure \n\nimmunisation services are \n\nresilient, well-managed, sustainable , harness \n\ninnovation and meet the needs of all caregivers Work with countries and communities to build resilient \n\ndemand , and to identify and address gender-related barriers \n\nto immunisation \n\nObjectives \n\nABC\n\nStrengthen national and subnational political and social commitment to immunisation Promote domestic public resources for immunisation and primary health care to improve allocative efficiency Prepare and engage self-financing countries to maintain or increase performance \n\nObjectives \n\nABC\n\nEnsure sustainable, healthy markets with diversified supply for vaccines and immunisation-related products at affordable prices Incentivise innovations for the development of suitable vaccines \n\nScale up innovative immunisation-related products \n\nObjectives \n\nABC9Annual Progress Report \n\n> Mission indicators\n\nThis indicator estimates the impact of Gavi-supported vaccinations in terms of averting future deaths from vaccine-preventable diseases – one of the ultimate impacts of Gavi support. \n\n2022 performance 1: By end 2022, more than 2.4 million future deaths had been averted by Gavi-supported vaccinations since the Gavi 5.0 strategic period began in 2021. The cumulative number of deaths averted from 2000 through 2022 is more than 17.3 million. 2\n\nData source: Vaccine Impact Modelling Consortium (VIMC), 2023 \n\n1 Baseline value reset to zero at the start of the strategy period. Targets for 2025 represent anticipated cumulative achievement over the duration of the strategy period. 2 This figure does not include more than 2.7 million deaths averted by COVAX across participating low-and middle-income countries by end 2022, according to Imperial College London estimates. \n\n# M.2 Future deaths averted with Gavi support \n\n# of future deaths averted as a result of vaccination with Gavi-supported vaccines in the countries we support. \n\n# Mission indicators \n\n## Amid the economic, political and social challenges of the COVID-19 pandemic in 2022, Vaccine Alliance partners and countries made significant progress towards achieving our six mission indicators for the 2021–2025 strategic period. \n\nBy increasing access to immunisation and enabling equal access to new and underused vaccines, Gavi support is contributing to the reduction in under-five deaths from vaccine-preventable diseases. \n\n2021 performance : The under-five mortality rate in the 57 lower-income countries supported by Gavi fell from 57.5 to 55.7 deaths per 1,000 live births between 2020 and 2021 – a 6% reduction from baseline. We are on track to reach our Mission target of a 10% reduction by 2025. Estimates for 2022 will be available in late 2023. \n\nData source: UN Inter-agency Group for Child Mortality Estimation (IGME), 2022 \n\nUnder-five mortality rate \n\nProbability of a child born in a specific year or period dying before they reach the age of five, if subject to age-specific mortality rates for that period; expressed as the number of deaths among children aged under five in a given year, per 1,000 live births. \n\n# M.1 \n\n2019 2020 2021 2022 2023 2024 2025 50 60 30 20 10 040 \n\n59.2 57.5 55.7 Baseline \n\nTarget: -10% \n\n2022 2023 2024 2025 0m 2m 4m 6m 8m 10m 2020 2021 \n\nNotes: Due to rounding, some figures may not add up precisely to the totals. Some figures from previous years have been updated due to revisions of historical data. \n\nTarget: 7–8m 1.2m 2.4m 10 Mission indicators \n\n> Annual Progress Report\n\nThe indicator serves as an equity measure, giving an indication of the reach of routine immunisation services to missed communities, with an emphasis on regularly reaching children who are being missed by routine immunisation. \n\n2022 performance : In 2022, there were 10.2 million zero-dose children in the 57 lower-income countries supported by Gavi, representing a 14% increase since 2019, and down from 12.4 million in 2021. Reaching the Gavi 5.0/5.1 target by 2025 will require a 34% reduction from 2022. \n\n> Data sources : Vaccine coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), 2023; population estimates: United Nations, Department of Economic and Social Affairs, Population Division, World Population Prospects 2022\n\nReduction in overall disease burden from vaccine-preventable diseases – one of the ultimate impacts of Gavi support. \n\n2022 performance 3: By end 2022, more than 121 million future DALYs had been averted by Gavi-supported vaccinations since the Gavi 5.0 strategic period began in 2021.   \n\n> Data source: VIMC, 2023\n> 3Baseline value reset to zero at the start of the strategy period. Targets for 2025 represent anticipated cumulative achievement over the duration of the strategy period.\n\nThis indicator tracks the number of children immunised with the last recommended dose of at least one vaccine delivered through routine systems with Gavi support. \n\n2022 performance 5: Countries immunised more than 68 million unique children with Gavi-supported routine vaccines in 2022 – an impressive effort, meaning we remain on track to reach our Mission target of immunising 300 million additional children during the 2021–2025 strategic period. By end 2022, Gavi-supported countries had immunised more than 1 billion unique children with Gavi support since 2000.    \n\n> Data sources: Vaccine coverage: WUENIC, 2023; population estimates: World Population Prospects 2022\n> 4To not double-count recipients of more than one vaccine, only the vaccine with the highest coverage level per country is taken into account.\n> 5Baseline value reset to zero at the start of the strategy period. Targets for 2025 represent anticipated cumulative achievement over the duration of the strategy period.\n\n# M.3 Future DALYs averted # of future disability-adjusted life years (DALYs) averted as a result of vaccination with Gavi-supported vaccines. DALYs measure the number of healthy life years lost due to disability or premature death. \n\n# M.4 Reduction in number of zero-dose children \n\n# of zero-dose children in Gavi-eligible countries relative to baseline. Zero-dose children are infants who have not received the first dose of diphtheria, tetanus and pertussis-containing vaccine (DTP1) by the end of their first year of life. \n\n# M.5 Unique children immunised through routine immunisation with Gavi support \n\n# of children immunised with the last recommended dose of at least one vaccine delivered through routine systems with Gavi support. 4 (People immunised through campaigns and supplementary immunisation activities are not included.) \n\n2022 2023 2024 2025 0m 100m 200m 300m 400m 2020 2021 2022 2023 2024 2025 0m 100m 200m 300m 400m 2020 2021 \n\n60m 121m \n\nTarget: \n\n320–380m \n\n2022 2023 2024 2025 0m 5m 10m 15m 2019 2020 2021 \n\n> Baseline\n\n9m 11.6m 12.4m 10.2m \n\nTarget: -25% 65m 133m \n\nTarget: 300m 11 Annual Progress Report \n\n> Mission indicators\n\nGavi-supported vaccines have impact beyond health benefits to include the direct and indirect economic benefits of averting illness, death and long-term disability. \n\n2022 performance 6,7 : More than US$ 35.8 billion in economic benefits in the countries we support have been generated through Gavi-supported immunisations since the Gavi 5.0 strategic period began in 2021. From 2000 through 2022, that figure is more than US$ 220.5 billion. \n\nData sources: The DOVE ROI model as outlined in Sim et al. 2019. Additionally, the DOVE-ROI models use health impact estimates from VIMC. \n\n6 Baseline value reset to zero at the start of the strategy period. Targets for 2025 represent anticipated cumulative achievement over the duration of the strategy period. 7 For Gavi 5.0, this indicator is calculated using a new method, which has resulted in a downward revision of historical estimates compared with figures reported in the Gavi 4.0 strategic period (2016–2020). \n\n# M.6 Economic benefits generated through Gavi-supported immunisations \n\nAmount in US dollars of the direct and indirect benefits of immunisation supported by Gavi, derived as the costs of illness averted through vaccination (including medical and associated costs); and productivity loss due to illness and death. \n\n2022 2023 2024 2025 0bn 20bn 40bn 60bn 100bn 80bn 2020 2021 \n\nUS$ \n\nDr Habou Abdoulrahamane, chief medical officer of the third district in Niamey, Niger. Read the article Credit: Gavi/2022/Isaac Griberg 18.1bn 35.8bn \n\nTarget: \n\nUS$ 80–100bn \n\n# It’s really a great relief and a great pleasure when we manage to find zero-dose children and to know that we may have managed to save a child from the risk of developing a disease that could compromise their life. 12 Annual Progress Report \n\n> Introductions & campaigns\n\n## 12 \n\nAfrican Region Vaccines launched in 2022 Vaccines launched 2000−2021 Per capita, US$ (2020) Transition status (2022) \n\nAngola 1,306,749 69 42% R R R RC C 2,230 \n\nBenin 460,723 84 76% Meningococcal A (R+C) R R R D R RC C RC 1,280 \n\nBurkina Faso 762,151 83 91% HPV (R) R R R D RC R 2C R2C C 790 \n\nBurundi 426,016 53 91% Measles-rubella (C) R R R D RC R C C 270 \n\nCameroon 923,258 70 68% R R R RD R R2C C RC 1,500 \n\nCentral African Republic 224,799 100 42% R R R C RC RC 510 \n\nChad 727,088 107 60% Measles (R) R R 3C R2C R 660 \n\nComoros 23,300 50 88% R RC RRC 5 1,450 \n\nCongo 174,567 43 78% Yellow fever (C) R R R R C R 1,830 \n\nCôte d'Ivoire 901,482 75 76% R R R RD RC RR2C 5 R2C C 2,280 \n\nDR Congo 3,965,786 79 65% Measles (R) R R R R 3C C RC 550 \n\nEritrea 102,355 38 95% HPV (R+C) R R R RC R RC RC low 6\n\nEthiopia 3,819,980 47 65% Measles (C) R R R RD R R3C C 890 \n\nGambia 86,361 48 79% Measles-rubella (C) R R R RCD R R C R2C 750 \n\nGhana 881,846 44 99% R R R D RC R 2C R2C RC 2,230 \n\nGuinea 446,098 99 47% Measles (R+C) Meningococcal A (C) R R RC RC 1,020 \n\nGuinea-Bissau 61,890 74 74% Measles (R) R R R R C C R 760 \n\nKenya 1,451,833 37 90% HPV (C) R R R RD R 2C C R 1,760 \n\nLesotho 56,474 73 87% HPV (R+C) Measles-rubella (C) R R R R C 1,100 \n\nLiberia 157,137 76 78% R R R RD RC RC RC RC 530 \n\nMadagascar 880,625 66 57% Measles (C) R R R D R R 460 \n\nMalawi 649,567 42 86% R R R RD RC R C 580 \n\nMali 892,365 97 77% R R R D R RC R2C RC 830 \n\nMauritania 150,443 40 76% R R R RC R RC C 1,640 \n\nMozambique 1,141,329 70 61% R R R RD R R RC 460 \n\nNiger 1,140,790 115 84% Measles (C) R R R D R C R2C R 540 \n\nNigeria 7,570,882 111 62% Rotavirus (R) R R R R5C R2C RC 2,000 \n\nRwanda 396,133 39 98% Inactivated polio (C) R R R R R R 2C 780 \n\nSao Tome and Principe 6,300 15 97% R R R RCD RC R C R 2,070 \n\nSenegal 545,212 39 88% R R R RD RC R 3C C C 1,430 \n\nSierra Leone 251,464 105 91% HPV (R) R R R D RC R RC RC 490 \n\nSouth Sudan 300,399 99 73% R R C C low 6\n\nTogo 268,452 63 82% Inactivated polio (C) Measles-rubella (C) R R R D R RRC 5 R2C RC 920 \n\nUganda 1,668,269 42 89% Yellow fever (R) Measles-rubella (R+C) 7 R R R R R RC C 800 \n\nUR Tanzania 2,282,224 47 88% R R R RD RC R 2C 1,080 \n\nZambia 661,373 58 82% R R R R RC R 2C 1,190 \n\nZimbabwe 475,650 50 90% Measles-rubella (C) R R R RCD RC R2C RC 1,090 \n\n# Gavi-supported vaccine introductions & campaigns \n\n> Pentavalent 1Rotavirus 2Pneumococcal Human papillomavirus Inactivated polio 3Japanese encephalitis Measles Measles-rubella Meningococcal A Typhoid Yellow fever\n\nCountry \n\n> R = routine C = campaign (preventive) D = demonstration project 1 – Initial self-financing 2 – Preparatory transition 3 – Accelerated transition 4 – Fully self-financing\n\nNotes: Any numeral before the letter C denotes the total number of campaigns that have taken place. Outbreak response vaccination campaigns supported through the International Coordinating Group (ICG) on Vaccine Provision stockpile mechanism for Ebola, meningococcal, oral cholera and yellow fever vaccines are not included in this table. The total number of launches may not correspond to the launches listed in this chart due primarily to the following reasons: some figures from previous years have been updated due to revisions of historical data; some country names do not appear in this chart, as they no longer receive Gavi support; and some countries have introduced vaccines into their routine immunisation programmes independently of Gavi support. \n\nSources: vaccine launches: Gavi, the Vaccine Alliance; surviving infants: United Nations, Department of Economic and Social Affairs, Population Division, World Population Prospects 2022; child mortality: United Nations Inter-agency Group for Child Mortality Estimation (UN IGME), 2022; immunisation coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), 2023; eligibility: World Bank, World Development Indicators \n\n> Gross national income 4Immunisation coverage (DTP3/pentavalent 3rd dose)  (2022)\n> Under-five mortality rate\n> deaths <5 years per 1,000 births (2021)\n> Surviving infants\n> surviving to 1 year (2022)\n\n## 13 Annual Progress Report \n\n> Introductions & campaigns\n\nRegion of the Americas Vaccines launched in 2022 Vaccines launched 2000−2021 Per capita, US$ (2020) Transition status (2022) \n\nBolivia (Plurinational State of) 258,219 25 69% R R R R 3,200 \n\nCuba 99,349 5 99% R upper 8\n\nGuyana 15,790 28 98% R R RC R 6,600 \n\nHaiti 258,823 59 51% R R R R C 1,250 \n\nHonduras 215,156 17 78% R R R R 2,200 \n\nNicaragua 137,669 13 92% R R R 1,850 \n\nEastern Mediterranean Region \n\nAfghanistan 1,397,103 56 69% Measles (C) R R R R 2C 500 \n\nDjibouti 23,785 54 59% R R R R 3,320 \n\nPakistan 6,155,881 63 85% Measles-rubella (R) R R R R 2C C RC 1,280 \n\nSomalia 720,510 112 42% Measles (C) R R RC 310 \n\nSudan 1,499,138 55 84% R R R RC C R2C R2C 9 650 \n\nSyria 440,207 22 46% Measles-rubella (C) low 6\n\nYemen 969,803 62 74% R R R R 2C low 6\n\nEuropean Region \n\nArmenia 32,329 11 93% R R R RD R 4,220 \n\nAzerbaijan 121,879 19 83% R R R 4,450 \n\nGeorgia 48,759 9 85% R R R RD 4,290 \n\nKyrgyzstan 152,979 17 90% HPV (R+C) R R R RC 1,160 \n\nRepublic of Moldova 36,541 14 88% R R R RD RC 4,570 \n\nTajikistan 253,849 31 97% Pneumococcal (R) R R RC 1,060 \n\nUzbekistan 768,382 14 99% Measles-rubella (C) R R R RC RC 1,670 \n\nSouth-East Asia Region \n\nBangladesh 2,940,527 27 98% R R D RC R 2C 2,010 \n\nBhutan 9,469 27 98% R R12 RC 2,860 \n\nDPR Korea 336,352 15 0% 13 R R R RC low 6\n\nIndia 22,519,905 31 93% R R R R C 1,900 \n\nIndonesia 4,392,068 22 85% R R 12,14 D RC 15 RC 16 C 3,870 \n\nMyanmar 886,467 42 71% R R R R R RC 16 R 2C 1,260 \n\nNepal 605,385 27 90% Typhoid (R+C) R R R D R RC R C 1,190 \n\nSri Lanka 299,963 7 98% R R R 3,720 \n\nTimor-Leste 32,187 51 86% R R R 1,830 \n\nWestern Pacific Region \n\nCambodia 312,448 25 85% R R D R RC 16 R 2C 1,490 \n\nKiribati 3,400 48 91% R R R 3,010 \n\nLao PDR 157,386 43 80% R R RCD R RC 16 R 2,480 \n\nMongolia 68,948 15 95% R R12 RC 3,670 \n\nPapua New Guinea 247,322 43 36% R R R R2C 2,660 \n\nSolomon Islands 20,960 19 89% R R R RCD R R2C 2,300 \n\nViet Nam 17 1,423,035 21 91% R RC R 2C 2,660 \n\nTotal launches 2000–2021 67 52 61 65 96 10 51 74 47 6 34 Total launches 2000–2022 67 53 62 74 98 10 61 84 50 8 36 \n\nCountry \n\n1 All 73 countries have introduced pentavalent vaccine. Six of the 73 countries introduced pentavalent vaccine independently of Gavi support. 2 Kiribati introduced rotavirus vaccine independently of Gavi support. 3 All 73 countries have introduced inactivated polio vaccine (IPV), while 34 countries have also switched to using a second dose of inactivated polio vaccine (IPV2). Two of the 73 countries introduced IPV1 independently of Gavi support. 4 Gross national income (GNI) per capita for 2020 in US$, Atlas method, as updated by the World Bank on 1 July 2021. 5 Comoros, Côte d’Ivoire and Togo have introduced the second dose of measles-containing vaccine (MCV2) and rubella-containing vaccine (RCV) into the routine immunisation programme. This is represented by “RR”. 6 Estimated to be low-income (GNI per capita US$ 1,045 or less). 7 Uganda launched a second dose of measles-rubella vaccine (MCV2) through a follow-up campaign. 8 Estimated to be upper middle-income (GNI per capita US$ 4,096 to US$ 12,695). 9 In 2020, an exceptional catch-up campaign in Sudan was approved and commenced, continuing into 2021. 10 Excludes Abkhazia and South Ossetia. 11 Excludes Transnistria. 12 Bhutan, Indonesia and Mongolia are fully self-financing and accessed the Pneumococcal Advance Market Commitment (AMC) price for pneumococcal vaccines. 13 The Democratic People’s Republic of Korea (DPRK) reported 0% coverage of the third dose of diphtheria, tetanus and pertussis-containing vaccine (DTP3) in 2022 due to country-wide stock-outs. 14 In 2021, Indonesia piloted introduction of pneumococcal conjugate vaccine (PCV) in four provinces. The national PCV immunisation programme launched in September 2022. 15 As of 1 January 2017, Indonesia had transitioned to fully self-financing. However, currently IPV is supported by Gavi irrespective of a country’s transition status. 16 Prior to the Board decision in 2016, countries supported by Gavi for routine introduction of Japanese encephalitis vaccine received a Vaccine Introduction Grant (VIG), not co-financing for vaccine doses. 17 Viet Nam transitioned to fully self-financing at the end of 2019. However, currently IPV is supported by Gavi irrespective of a country’s transition status. \n\nVisit the gavi.org: country hub 10 11 \n\n> Pentavalent 1Rotavirus 2Pneumococcal Human papillomavirus Inactivated polio 3Japanese encephalitis Measles Measles-rubella Meningococcal A Typhoid Yellow fever R = routine C = campaign (preventive) D = demonstration project 1 – Initial self-financing 2 – Preparatory transition 3 – Accelerated transition 4 – Fully self-financing Gross national income 4Immunisation coverage (DTP3/pentavalent 3rd dose)  (2022)\n> Under-five mortality rate\n> deaths <5 years per 1,000 births (2021)\n> Surviving infants\n> surviving to 1 year (2022)\n\n## 14 Annual Progress Report \n\n> VaccinesWork in 2022\n\n# VaccinesWork in 2022: Ten of our most-read stories \n\n## Features from VaccinesWork’s team of writers across the world, telling the stories behind the headlines. VaccinesWork is an award-winning digital platform hosted by Gavi, the Vaccine Alliance covering news, features and explainers from every corner of global health and immunisation. Launched in 2020, the VaccinesWork writers network now encompasses more than 70 independent journalists contributing news and features from over 40 countries. With 12 million page views across VaccinesWork in 2022, here are ten of the year’s most-read feature stories from the community. \n\n> Health workers who have been trained to detect suspected cases of yellow fever. Credit: Mike Mwaniki\n\nKenya rolls out yellow fever vaccine to fight first outbreak in a decade \n\nGavi and WHO to help deploy yellow fever vaccine to reduce the risk from the latest outbreak. \n\nKenya saw its first yellow fever outbreak in more than a decade. On 4 March 2022, the country’s Ministry of Health (MoH) issued a yellow fever outbreak alert following the death of three people in Isiolo County, according to the World Health Organization (WHO). The first case was recorded on 12 January. Following the outbreak, WHO has assessed the public health risk as high at the national and regional levels. Read the full article by Mike Mwaniki \n\n> Mothers bring their children for vaccination. Credit: Huma Khawar\n\nThe female bridge: How a new link in the health care chain helps vaccines reach kids in under-immunised Lakki Marwat \n\nIn a culturally conservative part of northwestern Pakistan, mothers were disconnected from a very male healthcare system until female community workers – like Nusrat Bibi – built a bridge. \n\nIn a village called Masha Mansoor, some 20 women have gathered in the drawing room of a community elder. The room, known locally as a hujra, is a space usually reserved for men and, though this meeting is an all-female, informal affair, some of the women have kept their burqas on – a visual reminder, to outsider eyes, that Lakki Marwat is perhaps the most conservative part of an especially conservative province. Read the full article by Huma Khawar \n\n> People waiting to vaccinate their children. Credit: Aayushi Shukla\n\nGetting routine immunisation back on track in India \n\nWith the pandemic under relative control, India is getting back on track with its nationwide routine immunisation programme through Mission Indradhanush 4.0. \n\nFrom waiting 30-plus years for a polio vaccine to developing multiple vaccines for COVID-19, India has come a long way on its immunisation journey, while showing the potential of its health system. However, with focus switching to vaccinating people against COVID-19, routine immunisation took a back seat. Read the full article by Aayushi Shukla 15 Annual Progress Report \n\n> VaccinesWork in 2022\n> Health worker Michelline Uwimana treks to reach remote communities in Uganda Credit: Gavi/2022/ Nes Motion Media\n\nA mountain to climb: often – too often – the “last mile” is a health worker’s extra mile \n\nMichelline Uwimana treks through the mountainous terrain of rural Uganda come rain or shine. The walk is gruelling, but the alternative – communities going without vital healthcare – would be worse. \n\nOne morning in late July, Michelline Uwimana of Kisoro, neat in a navy blue, skirted nurse’s uniform and good sturdy sneakers, carried the rudiments of a health clinic into the mountains. The sky above Mukungu was scumbled with dust, the vegetation anaemic from lack of rain, and the weather so blustery along the ridges that Uwimana cut a figure in italics, wedging forward into the wind. Had it been April instead of July, it would have been wet instead of windy, the paths gummed with mud, but the nurse, her backpack, her vaccine cooler box, and armful of soft cardboard patient files would have been here just the same. Read the full article by Maya Prabhu and George Stanley Nsamba Le site internet francophone de Gavi (gavi.org/fr) héberge VaccinesWork en français. Découvrez trois des récits de la communauté les plus lus en 2022. A Madagascar, le défi de l’accès aux médicaments dans les régions reculées Pour endiguer la rougeole, le Cameroun vaccine les enfants zéro-dose On a parlé vaccins avec ... Jean-Pierre Mouanda, chef de quartier à Pointe-Noire au Congo \n\nPakistan’s drive to end tuberculosis \n\nTB, the single biggest killer among the world’s infectious diseases, is a major concern in Pakistan. But a concerted government strategy to find and treat hidden patients all over the country is paying off. Read the full article by Rahul Basharat \n\n> Credit: Rahul Basharat\n\nPakistan reignites polio vaccination drive \n\nCivil society, media, local influencers, celebrities, religious scholars and frontline workers are all reinforcing the Pakistan government’s fight against poliomyelitis. Read the full article by Saadeqa Khan \n\n> Credit: Saadeqa Khan\n\nCelebrating Nepal’s typhoid conjugate vaccine introduction \n\nThe introduction of typhoid conjugate vaccine in Nepal is a great step forward in keeping children healthy and protected from typhoid. Read the full article by Sagar Dahal \n\n> Credit: PATH/Rocky Prajapati\n\nTackling stigma and misinformation to beat back hepatitis B in Uganda \n\nEmma Lutamaguzi was diagnosed with hepatitis B in 2016. Now he’s raising awareness to boost vaccine uptake and help vanquish the life-threatening liver infection. Read the full article by Evelyn Lirri \n\n> Credit: Hepatitis Aid Organization\n\nTwelve million vaccinations in three days: how Bangladesh used a pandemic lull to shore up its defences \n\nBangladesh’s COVID-19 fatality rates are at an all-time low – but that hasn’t stopped the country’s vaccination programme from flooring the gas pedal. Read the full article by Maya Prabhu \n\n> Credit: Gavi/2022/Saydul Fateheen Murad\n\nHow involving men is boosting routine immunisation in Nigeria \n\nEducating men in Lagos about the importance of immunisations in protecting their children’s health is improving vaccine coverage. Read the full article by Adesewa Adelaja \n\n> Credit: Adesewa Adelaja The vaccine goal\n\n## 16 Annual Progress Report \n\n# The vaccine goal \n\n# 01 \n\n# Introduce and scale up vaccines \n\n“Vaccines protect our children’s health and are a true testament to how far we humans have come.” \n\nZagdbazar, speaking about his daughter, Enkhgerel, 16, a high school student who wants to become a doctor. Read the full article Erdene, Mongolia Credit: Gavi/2023/Khasar Sandag The vaccine goal 17 Annual Progress Report \n\n# Key highlights \n\n## Including routine, preventive campaign 1 and COVID-19 vaccinations, the 57 Gavi-supported countries administered nearly three times as many vaccine doses in 2022 as in 2020. \n\n# 56 %\n\n## Breadth of protection with vaccines in the Gavi portfolio is now higher in Gavi-supported countries (56%) than in the rest of the world (53%), and is up 5 percentage points from 2021. \n\n20 countries accessed emergency stockpiles for cholera, Ebola, meningococcal and yellow fever vaccines a total of 33 times in 2022. \n\n4 key SDG vaccines saw an increase in coverage among the 57 Gavi-supported countries since 2021. \n\n40 Gavi-supported vaccine introductions and preventive campaigns took place in 2022 – in addition to 40 outbreak response vaccination campaigns \n\nsupported by Gavi. \n\n1 Excluding polio vaccination campaigns. The vaccine goal 18 Annual Progress Report \n\n2001–2005 \n\nGavi 1.0 \n\n2006–2010 \n\nGavi 2.0 \n\n2011–2015 \n\nGavi 3.0 \n\n2016–2020 \n\nGavi 4.0 \n\n2021–2025 \n\nGavi 5.0/5.1 4\n\nOutbreak response Measles (2nd dose) Rotavirus Meningococcal A Multivalent meningococcal 3Oral polio vaccine (OPV) 3Pneumococcal conjugate vaccine (PCV) Human papillomavirus (HPV) Inactivated polio vaccine (IPV) Oral cholera vaccine (OCV) 2Japanese encephalitis Typhoid conjugate vaccine (TCV) Ebola 3COVID-19 Malaria OCV (preventive) Measles-rubella 611 15 17 19 Pentavalent 1Hepatitis B \n\nHaemophilus influenzae \n\ntype b (Hib) Yellow fever 2\n\nAs anticipated, the WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) released in July 2023 confirmed that Gavi, the Vaccine Alliance has helped countries reach over 1 billion unique children with routine immunisation since 2000. In 2022, Gavi-supported countries completed a total of 16 routine introductions against a target of 15, bringing to 29 the total introductions in 2021–2022. And coverage of the third dose of diphtheria, tetanus and pertussis-containing vaccine (DTP3) in the 57 lower-income countries supported by Gavi increased by 3 percentage points in 2022 – only 2 percentage points below 2019 levels. Breadth of protection increased by 5 percentage points in 2022 and now stands at 56%, remaining on track for the Gavi 5.0/5.1 target. Breadth of protection with vaccines in the Gavi portfolio is now higher in Gavi-supported countries (56%) than in the rest of the world (53%), meaning that children in Gavi-supported countries are better protected than children in other countries. Increases in coverage of the second dose of inactivated polio vaccine (IPV2), third dose of pneumococcal conjugate vaccine (PCV3), second dose of measles-containing vaccine (MCV2), first dose of rubella-containing vaccine (RCV1), last dose in the schedule for rotavirus vaccine (RotaC) and last dose in the schedule for human papillomavirus vaccine (HPVC) are driving the increase in breadth of protection. Among Gavi-supported countries, HPV vaccine coverage increased during the pandemic, from 7% in 2019 to 10% in 2022 for HPVC. This was largely driven by countries introducing the vaccine into their national immunisation programmes, with five additional Gavi-supported countries introducing HPV vaccine in 2022. Coverage is expected to further increase in the coming years, with HPV vaccine programme revitalisation efforts strengthening programme delivery and ensuring quality routine introductions. \n\n# Routine immunisation in 2022: from recovery to resilience Gavi’s vaccine portfolio has grown significantly over time \n\nGavi supports vaccines against 19 infectious diseases \n\nthrough 46 product presentations           \n\n> 1Diphtheria, tetanus, pertussis (DTP), hepatitis B, Haemophilus influenzae type b (Hib). 2Gavi supports both preventive vaccination and emergency stockpiles. 3Emergency stockpiles. 4The Vaccine Investment Strategy (VIS) 2018 vaccine programmes that were unpaused in 2023 will be available as follows: The funding window for hexavalent vaccine and DTP boosters will open in October 2023, with first country introductions forecasted for the first quarter of 2025. The funding window for hepatitis B birth dose and rabies post-exposure prophylaxis (PEP) vaccines will open in the second quarter of 2024, with first country introductions forecasted in the third quarter of 2025. A funding window for preventive multivalent meningococcal conjugate vaccine (MMCV) will open pending a Board decision. Respiratory syncytial virus (RSV) vaccine will be available in the Gavi 6.0 strategic period, beginning in 2026, pending availability of product.\n\n2001–2005 \n\nGavi 1.0 \n\n2006–2010 \n\nGavi 2.0 \n\n2011–2015 \n\nGavi 3.0 \n\n2016–2020 \n\nGavi 4.0 \n\n2021–2025 \n\nGavi 5.0/5.1 4\n\nOutbreak response Measles (2nd dose) Rotavirus Meningococcal A Multivalent meningococcal 3Oral polio vaccine (OPV) 3Pneumococcal conjugate vaccine (PCV) Human papillomavirus (HPV) Inactivated polio vaccine (IPV) Oral cholera vaccine (OCV) 2Japanese encephalitis Typhoid conjugate vaccine (TCV) Ebola 3COVID-19 Malaria OCV (preventive) Measles-rubella 611 15 17 19 Pentavalent 1Hepatitis B \n\nHaemophilus influenzae \n\ntype b (Hib) Yellow fever 2The vaccine goal 19 Annual Progress Report \n\n# Results – vaccine goal strategy indicators \n\n## Four in five children in Gavi-supported countries receive routine immunisation. Summary measure of prioritised vaccine introductions, rate of scale-up of newly introduced vaccines and vaccine coverage. \n\n2022 progress : The 57 Gavi-supported countries increased breadth of protection by 5 percentage points in 2022 to 56%. For the first time, breadth of protection in Gavi-supported countries was higher than in the rest of the world. \n\nData sources: Vaccine coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), WHO Joint Reporting Forum (JRF), 2023; population estimates: United Nations, Department of Economic and Social Affairs, Population Division, World Population Prospects 2022 \n\n1 Gavi’s 2021–2025 strategic period (Gavi 5.0/5.1) uses an updated definition of breadth of protection (BOP), which now includes coverage of human papillomavirus (HPV) vaccine and the second dose of inactivated polio vaccine (IPV2). Adding these new vaccines leads to lower BOP values overall, compared to BOP reported during Gavi’s 2016–2020 strategic period (Gavi 4.0). Note that IPV2 was not reported in WUENIC and was instead calculated from reported on IPV2 in JRF and IPV1 in WUENIC. The Gavi 5.0/5.1 definition of BOP includes the following vaccines: third dose of pentavalent vaccine, IPV2, third dose of pneumococcal conjugate vaccine (PCV3), first dose of rubella-containing vaccine (RCV1), rotavirusC (last dose in schedule), second dose of measles-containing vaccine (MCV2), yellow fever, meningococcal A, Japanese encephalitis, human papillomavirus (HPVC; last dose in schedule). \n\n2022 progress: on track \n\n# S1.1 Breadth of protection 1\n\nAverage vaccination coverage across key Gavi-supported vaccines in Gavi-supported countries. \n\nCoverage of DTP-containing vaccine (third dose): % of surviving infants who received three doses of diphtheria, tetanus and pertussis-containing vaccine in a given year. \n\n2022 progress: DTP3 coverage in Gavi57 countries increased by 3 percentage points in 2022 and now sits 2 percentage points below 2019 levels. \n\n2022 progress: moderate delays/challenges \n\n2020 2021 2022 2023 2024 2025 100% 60% 40% 20% 0% 80% \n\n# S1.2 Vaccine coverage \n\nMeasures access to the four vaccines included in the Sustainable Development Goal (SDG) indicator 3.b.1 across the life course, including newly available or underutilised vaccines, at the national level. \n\n2022 progress : Across the four vaccines, the third dose of pneumococcal conjugate vaccine (PCV3) and the last dose in the schedule of human papillomavirus vaccine (HPVC) were trending slightly higher in 2022 than originally projected when Gavi 5.0 targets were set, whereas coverage of the third dose of diphtheria, tetanus and pertussis-containing vaccine (DTP3) and the second dose of measles-containing vaccine (MCV2) were off track but improving. \n\nData sources: Vaccine coverage: WUENIC, 2023; population estimates: United Nations, Department of Economic and Social Affairs, Population Division, World Population Prospects 2022 \n\nNote: In the above and below graphs, the dotted lines represent the projected annual trajectory forecasted when 2025 targets were set with the Gavi Board. Traditionally, Gavi has shown annual targets as “linear” (e.g. DTP3 coverage is expected to increase by 1 percentage point each year). However, given disruptions caused by the COVID-19 pandemic, these target trajectories reflect assumptions made with the Gavi Board in May 2021. \n\n2020 2021 2022 2023 2024 2025 100% 60% 40% 20% 0% 80% \n\n48% 50% 51% 56% \n\nTarget: +16 percentage points \n\n2019 \n\nBaseline \n\n2019 \n\nBaseline \n\n2022 progress: on track \n\n2020 2021 2022 2023 2024 2025 100% 60% 40% 20% 0% 80% Coverage of pneumococcal conjugate vaccine (last dose in the schedule): \n\n% of surviving infants who received the nationally recommended doses of pneumococcal conjugate vaccine (PCV) in a given year. \n\n2022 progress : Among Gavi57 countries, PCV3 coverage was flat at 56% in 2019–2021 and has increased to 70% in 2022, slightly ahead of original projections. \n\n2019 \n\nBaseline \n\nTarget: +4 percentage points 83% 79% 78% 81% \n\nTarget: +23 percentage points 56% 56% 56% 70% The vaccine goal 20 Annual Progress Report \n\n2022 progress: on track \n\n2020 2021 2022 2023 2024 2025 100% 60% 40% 20% 0% 80% Third dose of pneumococcal conjugate vaccine (PCV3) Second dose of measles-containing vaccine (MCV2) 2022 progress: on track \n\nRotavirusC (last dose in schedule) Yellow fever 2022 progress: on track \n\n2022 progress: significant delays/challenges 2022 progress: significant delays/challenges \n\n# S1.3 Rate of scale-up of new vaccines \n\nCoverage of routine vaccines PCV3, rotavirusC (last dose in schedule), MCV2 and yellow fever relative to benchmark vaccines (i.e. DTP3 for PCV3 and rotaC; MCV1 for MCV2 and yellow fever), within reference time frame for new introductions. \n\n2019 \n\n> Baseline\n\n2020 2021 2022 2023 2024 2025 100% 60% 40% 20% 0% 80% 2020 2021 2022 2023 2024 2025 2019 \n\n> Baseline\n\n2020 2021 2022 2023 2024 2025 100% 60% 40% 20% 0% 80% 2019 \n\n> Baseline\n\n2020 2021 2022 2023 2024 2025 2019 \n\n> Baseline\n\nTarget: +17 percentage points 7% 8% 9% 10% 86% 88% 86% 89% 98% 98% 98% 99% Target: 90% \n\nTarget: 90% \n\nCoverage of human papillomavirus vaccine (HPVC; last dose in the schedule): % of girls aged 15 years who received the recommended doses of HPV vaccine in a given year. \n\n2022 progress : At the portfolio level, HPVC coverage has increased modestly among Gavi57 countries, from 7% in 2019 to 9% in 2021 and 10% in 2022, slightly ahead of original projections. \n\n2019 \n\n> Baseline\n\n2022 progress : Coverage of MCV2 and yellow fever vaccine were both under the target of 90% relative coverage, with a decline in 2022. PCV3 and rotaC both exceed the benchmark, although rotaC declined in 2022, due to supply disruptions.  \n\n> Data sources: Vaccine coverage: WUENIC, 2023; population estimates: United Nations, Department of Economic and Social Affairs, Population Division, World Population Prospects 2022; vaccine introductions: Gavi, the Vaccine Alliance, 2023\n\n100% 60% 40% 20% 0% 80% 97% 97% 90% 100% \n\nTarget: 90% \n\n100% 60% 40% 20% 0% 80% 88% 89% 91% 89% Target: 90% \n\nCoverage of measles-containing vaccine (second dose): % of children aged 12–23 months who received two doses of measles-containing vaccine according to the nationally recommended schedule through routine immunisation services in a given year. \n\n2022 progress : MCV2 coverage among Gavi57 increased slightly from 2019 to 2021, from 58% to 60% respectively, before further improving to 64% in 2022, slightly behind original projections. \n\n100% 60% 40% 20% 0% 80% 2022 progress: moderate delays/challenges \n\n2020 2021 2022 2023 2024 2025 Target: +13 percentage points 58% 60% 60% 64% \n\n2019 \n\n> Baseline The vaccine goal\n\n## 21 Annual Progress Report \n\n# S1.5 Country prioritisation of vaccines \n\nExtent to which countries use robust evidence to inform prioritisation of their vaccine programmes. Indicator has been in abeyance given the pause in rolling out the Vaccine Investment Strategy (VIS) 2018 vaccines during the COVID-19 pandemic; it will be reported in the 2024 Annual Progress Report. \n\n2024 2025 Target: 50% increase \n\n2022 progress: significant delays/challenges \n\n2022 2023 100% 60% 40% 20% 0% 80% 2019 \n\nBaseline \n\n2021 \n\n# S1.7 Timely detection of and response to outbreaks \n\n% of cholera, Ebola, measles, meningitis and yellow fever outbreaks (i.e. diseases for which there are established outbreak global response mechanisms) detected and responded to in a timely manner. \n\n2022 progress : In 2022, the proportion of globally supported outbreak responses which met the timely detection and response criteria was 18%, a significant decline from 28% in 2021. This decrease was driven by cholera and measles, which accounted for more than 70% of all internationally supported outbreak response vaccination campaigns. \n\nData sources: Routine reports from the International Coordinating Group (ICG) on Vaccine Provision, Measles & Rubella Partnership, Global Polio Eradication Initiative (GPEI), World Health Organization (WHO), national immunisation and disease surveillance programmes, 2023 \n\n18% 25% 28% Target: 50% increase \n\n2022 progress 3 : on track \n\n2021 2022 2023 2024 2025 2025 100% 60% 40% 20% 0% 80% \n\n# S1.6 Measles campaign reach \n\n% of children aged under 5 previously unvaccinated against measles who received a dose of measles-containing vaccine (MCV) in a Gavi-supported preventive campaign. This indicator measures the reach and quality of Gavi-supported MCV campaigns. \n\n2022 progress : In 2022, 70.2% of children aged under five previously unvaccinated against measles received an MCV dose among countries conducting a Gavi-supported preventive MCV campaign, an increase from 37.3% in 2021. \n\nData sources: World Health Organization MCV post-campaign coverage survey reports, 2023 \n\n3 This indicator is based only on the campaigns with post-campaign coverage surveys (PCCS) which were appropriately carried out and which provide robust estimates on measles zero-dose children reached. \n\n37.3% \n\nTarget: 50% 70.2% \n\n# S1.4 Vaccine introductions \n\n# of introductions of Gavi-supported vaccines into routine immunisation in a given year, to monitor incremental change in numbers of countries introducing under-used vaccines into the routine immunisation schedule, with Gavi support. 2\n\n2022 progress: on track \n\n2021 2022 2023 2024 2025 100 60 40 20 080 \n\n2022 progress: In 2022, 16 new routine introductions took place against a target of 15. The cumulative total for introductions in 2021–2022 is 29, which is on track against the target of 82 by 2025. \n\nData source: Gavi, the Vaccine Alliance, 2023 \n\n2 Excludes COVID-19 vaccination and the second dose of inactivated polio vaccine (IPV2). 29 13 Target: 82 The vaccine goal 22 Annual Progress Report \n\nPentavalent vaccine coverage in the 57 Gavi-supported countries increased from 0% in 2000 to 81% in 2022. While there were setbacks in coverage during the COVID-19 pandemic, coverage rates for the first and third doses of pentavalent vaccine are almost back to pre-pandemic levels. Efforts by Vaccine Alliance core and expanded partners to operationalise the zero-dose agenda have facilitated these improvements. By end 2022, more than 705 million children had been immunised with three doses of Gavi-funded pentavalent vaccine. \n\nPentavalent vaccine \n\nProtects against five major diseases in one vaccine: diphtheria, tetanus, pertussis (whooping cough), hepatitis B and Haemophilus influenzae type b (Hib). \n\nType of support offered by Gavi Routine immunisation Introductions & campaigns in 2022 0\n\nTotal introductions & campaigns to end 2022 67 1\n\nTotal reached to end 2022 >705m  \n\n> 1All 73 Gavi-eligible countries have introduced pentavalent vaccine. Six of the 73 countries introduced pentavalent vaccine independently of Gavi support.\n\nIn September 2022, Indonesia, which is fully self-financing and accessed the Pneumococcal Advance Market Commitment (AMC) price for pneumococcal vaccines, commenced a phased nationwide introduction of pneumococcal conjugate vaccine (PCV), having piloted introduction of PCV in four provinces in 2021. In November 2022, Tajikistan introduced PCV into the routine immunisation system. Several advocacy events supported by the Global Forum on Childhood Pneumonia have profiled the opportunity, challenges and support needed by some countries identified by Gavi as fragile and conflict-affected that have yet to introduce PCV – including Chad, Somalia and South Sudan – successfully mobilising political interest to introduce pneumococcal vaccines. \n\nPneumococcal conjugate vaccine (PCV) \n\nHelps prevent the primary cause of bacterial pneumonia, a leading cause of vaccine-preventable deaths among children aged under five. \n\nType of support offered by Gavi Routine immunisation 2Introductions & campaigns in 2022 1\n\nTotal introductions & campaigns to end 2022 62 3,4 \n\nTotal reached to end 2022 >372m      \n\n> 2Routine immunisation with or without catch-up. 3In 2021, Indonesia piloted introduction of PCV in four provinces. The national PCV immunisation programme launched in September 2022. 4Bhutan, Indonesia and Mongolia were fully self-financing at the time of pneumococcal conjugate vaccine (PCV) introduction and accessed the Pneumococcal Advance Market Commitment (AMC) price.\n\n# Progress – 2022 updates on Gavi-supported vaccine programmes \n\nDespite supply disruptions that affected all three Gavi-supported rotavirus vaccines, rotavirus vaccine coverage across the 57 Gavi-supported countries increased by an aggregate 2 percentage points in 2022, reaching 65%. Nigeria introduced the vaccine with a phased approach in August, reaching more than 900,000 children by year end; significant uptick in coverage is expected for 2023. Working with manufacturers, Gavi helped seven countries 5 switch to an alternative rotavirus vaccine to mitigate a significant disruption in supply of the most widely used product; however, coverage levels were impacted, with reductions ranging between 4 percentage points (Cameroon) and 68 percentage points (Kenya). Efforts are underway to catch up missed children (aged up to 24 months). \n\nRotavirus vaccine \n\nProtects against a leading cause of severe diarrhoea, which kills hundreds of thousands of children each year. \n\nType of support offered by Gavi Routine immunisation Introductions & campaigns in 2022 1\n\nTotal introductions & campaigns to end 2022 53 6\n\nTotal reached to end 2022 >291m   \n\n> 5Cameroon, Kenya, Senegal, Sudan, UR Tanzania, Zambia, Zimbabwe.\n> 6Kiribati introduced rotavirus vaccine independently of Gavi support. The vaccine goal\n\n## 23 Annual Progress Report \n\nIn 2022, 5 more countries successfully launched their HPV vaccine national programme with Gavi support, bringing the total to 32 countries – fully immunising more than 16.3 million girls since 2014. Twelve of these countries introduced and implemented multi-age cohort (MAC) vaccination, including 4 countries in 2022. In April 2022, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended a one-or two-dose schedule for HPV vaccine; subsequently, the WHO position paper was released in December 2022. In response to this potential gamechanger for Gavi’s HPV vaccine programme – and to overcome the challenges and impact of the COVID-19 pandemic on HPV vaccine delivery – in December 2022, the Gavi Board approved the revitalisation of Gavi’s HPV vaccine programme. This revitalisation, closely developed with Alliance partners, committed to reach 86 million adolescent girls with HPV vaccine by 2025 through reinforced support to countries for HPV vaccine introductions, including: delayed MAC catch-up campaigns; Targeted Country Assistance (TCA; approximately US$ 33 million); and health system strengthening (HSS) support (US$ 40 million). In addition, US$ 15 million was approved for a learning agenda to generate evidence on feasible, effective integrated approaches to reach adolescents  with HPV vaccine. \n\nHuman papillomavirus (HPV) vaccine \n\nProtects against the main causes of cervical cancer, from which about 179,000 women died in 2020 in lower-income countries.        \n\n> 7Countries can apply for support for: routine introduction; or routine introduction with multi-age cohort (MAC). 8A multi-age cohort (MAC) is a one-time immunisation of individuals of different ages (e.g. 9–14 years), followed by an annual routine immunisation of a single cohort (e.g. 9 years); this is intended to achieve wider protection and stronger herd immunity effects.\n> 9In addition to five routine introductions in 2022, this figure has been updated to include routine introductions in Armenia, Georgia and Republic of Moldova that commenced with a Gavi-supported demonstration programme. 10 Bhutan introduced HPV vaccine independently of Gavi support.\n> 11 From available reported country data. The method for calculating the fully vaccinated person (FVP) is based on the WHO programme coverage method.\n\nType of support offered by Gavi Demonstration programme National programme 7Routine MAC 8Introductions & campaigns \n\nin 2022 0 5 4\n\nTotal introductions & campaigns \n\nto end 2022 30 32 9,10 12 \n\nTotal reached \n\nto end 2022 >14.5m girls >1.7m girls 11 \n\nInactivated polio vaccine (IPV) \n\nProtects against a highly contagious viral infection, mainly affecting children aged under five, which can lead to paralysis or even death.       \n\n> 12 IPV catch-up vaccination targets children missed due to the global supply constraints in the period from 2016–2019, and related programme delays and disruptions. 13 All 73 countries have introduced inactivated polio vaccine (IPV), while 34 countries have also switched to using a second dose of inactivated polio vaccine (IPV2). Two of the 73 countries introduced IPV1 independently of Gavi support. 14 IPV is supported by Gavi irrespective of a country’s transition status. Indonesia and Viet Nam were fully self-financing at the time of their Gavi-supported IPV introduction.\n> 15 Results are only available for a portion of countries that have completed IPV catch-up to date and will require further analysis.\n\nType of support offered by Gavi Routine immunisation Catch-up vaccination 12 Introductions & campaigns in 2022 0 2\n\nTotal introductions & campaigns to end 2022 71 13,14 27 \n\nTotal reached to end 2022 >393m >17m 15 \n\nBy 2018, all Gavi-supported countries had introduced the first dose of inactivated polio vaccine (IPV1) into their routine immunisation schedules – reaching a coverage rate of 81% in 2022. All but six countries have implemented catch-up vaccination activities for birth cohorts missed during the period of global supply constraints (2016–2019). The switch from a one-dose schedule to a two-dose schedule (IPV2) is progressing since Gavi’s support window for IPV2 opened in 2021: by end 2022, 34 out of 63 eligible countries had switched to a two-dose schedule. The impact of the COVID-19 pandemic, capacity gaps and multiple competing priorities have resulted in delayed introduction for countries already approved to switch to IPV2 – and fewer new applications for IPV2 and IPV catch-up support. Twenty-three countries have not yet applied for IPV2. In 2022, Bangladesh applied for Japanese encephalitis vaccine support (subnational campaign and routine introduction in three divisions). The application was endorsed by the Independent Review Committee (IRC) in 2023, a re-review of a 2022 submission. Among the five countries that introduced the vaccine with Gavi support, Bangladesh is only the second country to access co-financing of Japanese encephalitis vaccine since it was approved by the Board in 2016. Partnership engagement is crucial to support countries not only to develop a sound application, but also to plan and implement immunisation activities. It is important to consider other immunisation activities in the country (e.g. TCV campaigns) to apply lessons learned and integrate when possible. \n\nJapanese encephalitis vaccine \n\nPrevents the main cause of viral encephalitis, especially in Asia. Case fatality rates can be as high as 30%, while up to 50% of survivors suffer permanent disability.    \n\n> 16 For children aged 9 months to 14 years, on the condition that countries subsequently co-finance introduction of the vaccine into the routine immunisation programme. 17 Prior to the Gavi Board decision in 2016, countries supported by Gavi for routine introduction of Japanese encephalitis vaccine received a Vaccine Introduction Grant (VIG), not co-financing for vaccine doses.\n\nType of support offered by Gavi Routine immunisation Catch-up campaigns 16 Introductions & campaigns in 2022 0 0\n\nTotal introductions & campaigns to end 2022 517 5\n\nTotal reached to end 2022 >7m >17.7m The vaccine goal 24 Annual Progress Report \n\nMeasles and rubella vaccines \n\nMeasles vaccine helps protect against measles infection and associated complications, which claimed 128,000 lives in 2021. Rubella vaccine protects against congenital rubella syndrome. Every year, 100,000 children are born with malformations and disabilities caused by the disease – the vast majority in Gavi-supported countries. \n\nType of support offered by Gavi Routine immunisation Campaigns Outbreak response fund \n\nMeasles or measles-rubella (MR) first and/ or second dose Measles follow-up 18 MR catch-up 19 and follow-up Managed by the Measles & Rubella Partnership \n\nIntroductions & campaigns 2022 6 6 8 Reached in 2022 : ~11.3m \n\nIntroductions & campaigns to end 2022 49 20 32 64 \n\nTotal reached to end 2022 >172m >366m >863m 21 ~823.3m        \n\n> 18 Follow-up campaigns generally target children aged 9–59 months based on epidemiological needs. 19 One-off, nationwide catch-up campaigns target all children aged 9 months to 14 years.\n> 20 Chad, Democratic Republic of the Congo, Guinea, Guinea-Bissau, Pakistan and Uganda introduced the second dose of measles-containing vaccine (MCV2) and rubella-containing vaccine (RCV) into the routine immunisation programme. 21 This figure now includes more than 300 million people reached through measles-rubella catch-up campaigns in India from 2017–2019, which was previously unreported.\n> 22 Afghanistan, Cameroon, Democratic Republic of the Congo, Ethiopia, Liberia, Niger, Syrian Arab Republic, Tajikistan, Yemen, Zambia.\n\nIn 2022, 14 countries launched measles or measles-rubella follow-up campaigns, including four countries facing challenges of conflict and fragility – for example, Niger, which achieved an impressive 93% coverage. Also in 2022, five countries successfully introduced the second dose of measles-containing vaccine (MCV2) into their routine immunisation programmes; only three countries remain to launch MCV2. Pakistan introduced two doses of rubella-containing vaccine into the routine immunisation programme (which already included MCV2). Among Gavi57 countries, there has been a gradual increase in routine coverage from 2021 to 2022: MCV1 increased from 77% to 79%; and MCV2 improved from 60% to 64%. The impact of the COVID-19 pandemic on routine immunisation coverage – as well as delayed, low-coverage preventive campaigns – have led to large measles outbreaks in Gavi-supported countries. The Outbreak Response Fund, managed by the Measles & Rubella Partnership and funded by Gavi, supported ten countries 22 with US$ 16 million to respond to large and disruptive outbreaks in 2022. Competing priorities and unforeseen events negatively impacted the planning, implementation and measurement of campaigns. \n\nMeningococcal A vaccine \n\nSuccessfully protects against seasonal epidemics of meningococcal meningitis A in Africa’s meningitis belt, but continued vaccination and vigilance is required. \n\nBenin introduced meningococcal A vaccine into the routine immunisation programme in early 2022, followed by a catch-up campaign targeting children aged one to nine years, achieving 89% coverage. No new applications were received in 2022, meaning that eight countries conducted a preventive mass vaccination campaign more than five years ago but have not yet introduced the vaccine into the routine immunisation programme. \n\nType of support offered by Gavi Routine immunisation Campaigns Mass Catch-up Introductions & campaigns in 2022 1 0 2\n\nTotal introductions & campaigns to end 2022 14 24 10 \n\nTotal reached to end 2022 >51m >344m The vaccine goal 25 Annual Progress Report \n\nThe multivalent meningococcal conjugate vaccine (MMCV) was licensed in India in 2022 – a critical step to include this new vaccine in the meningitis outbreak response stockpile – as it is cheaper and can be produced on a larger scale than the other conjugated vaccines available in the market. Niger has reported Neisseria meningitidis C outbreaks in Zinder region in 2021 and 2022. Globally, 502,182 meningococcal vaccine doses were approved for outbreak response in 2022 – all for Niger. This demonstrates the need to develop robust preventive and reactive vaccination strategies for outbreak response in countries at risk of meningitis outbreaks, in view of the MMCV licensure and upcoming prequalification. \n\nMeningococcal vaccines stockpile \n\nProtects against a variety of meningococcal meningitis strains (A, C, W and Y) that continue to cause outbreaks across parts of Africa and elsewhere in the world. \n\nType of support offered by Gavi Stockpile Campaigns in 2022 Doses accessed for outbreak response 2x by 1 country Repurposed doses from the stockpile for preventive campaigns accessed 1x by 1 country       \n\n> Total campaigns to end 2022 Accessed 57x by 16 countries\n> Total doses shipped to end 2022 >26m 23\n> 23 Historical review of data and indicators is in progress.\n\nIn 2022, cholera outbreaks were reported across the globe, with 30 countries reporting cholera transmission. Overall, 32.7 million doses of oral cholera vaccine (OCV) were shipped to vaccinate 28.1 million people in areas at high risk of cholera transmission or experiencing outbreaks. The large majority of OCV doses available in 2022 were used for outbreak response vaccination in Bangladesh, Cameroon, Ethiopia, Haiti, Malawi, Nepal, Niger, Pakistan, Somalia and Syrian Arab Republic. In view of the limited global availability of OCV and surge in demand, the International Coordinating Group (ICG) on Vaccine Provision, following Strategic Advisory Group of Experts on Immunization (SAGE) guidance, recommended the use of a single-dose strategy for outbreak response. Five countries (Democratic Republic of the Congo, Nigeria, South Sudan, Yemen and Zambia) conducted targeted preventive cholera vaccination, while other planned preventive vaccination campaigns were put on hold to allow OCV doses to be prioritised for emergency response needs. In 2023, the focus will be on supporting countries to detect and respond in a timely manner to outbreaks; and to develop and implement cholera prevention and control plans – including supporting countries to apply to Gavi for multi-year support for preventive vaccination campaigns and the procurement of rapid diagnostic tests to improve cholera surveillance. \n\nOral cholera vaccine (OCV) \n\nPrevents cholera, an acute intestinal infection caused by contaminated food or water. It can lead to severe dehydration and, in its extreme form, can be fatal. \n\nType of support offered by Gavi Stockpile 24 Campaigns in 2022 Accessed 23x by 13 countries      \n\n> Total campaigns to end 2022 Accessed 125x by 24 countries\n> Total doses shipped to end 2022 ~130m\n> 24 The Global OCV Stockpile comprises an emergency component managed by the International Coordinating Group (ICG) on Vaccine Provision – the same mechanism used for emergency Ebola, meningococcal and yellow fever vaccine stockpiles – and a non-emergency reserve, which is used to vaccinate preventively in cholera hotspots.\n> Oral cholera vaccines douse a swelling outbreak in populous Dhaka\n> After researchers spotted an uptick in patients hospitalised with cholera in the capital city, Bangladesh launched a two-part vaccination campaign to bring the disease to heel. Read the full article Credit: icddr,b The vaccine goal\n\n## 26 Annual Progress Report \n\nTwo Ebola virus disease (EVD) outbreaks were reported in 2022, in Équateur and North Kivu provinces of the Democratic Republic of the Congo (DRC). Both outbreaks of Zaire ebolavirus were rapidly contained, with only six cases reported overall. Outbreak response activities included the vaccination of 2,654 people. In addition, 12,000 Ebola vaccine doses with close expiry date were repurposed for preventive use in Uganda – made possible by the rapid control of EVD in 2021 and 2022 and, therefore, the limited use of the global Ebola vaccine stockpile. In 2021, Gavi helped launch and continues to support a global stockpile to respond to EVD outbreaks. However, currently there are no licensed vaccines against other viral haemorrhagic fevers, such as Sudan ebolavirus and Marburg virus disease. In September 2022, an outbreak of Sudan ebolavirus was notified in Uganda; during the outbreak, a total of 164 cases (142 confirmed; 22 probable) and 77 deaths (55 confirmed cases; 22 probable cases) were reported. Despite the rapid response and country commitment to test available candidate vaccines, vaccine trials were not conducted, because the first doses of candidate vaccine did not arrive in Uganda until just before the outbreak concluded – demonstrating the need for a mechanism that ensures timely shipment and use of candidate vaccines for diseases with high epidemic potential. \n\nCOVID-19 vaccine \n\nProvides strong protection against severe illness and death from COVID-19, the disease caused by the SARS-CoV-2 coronavirus. \n\nEbola virus disease (EVD) vaccine \n\nHelps prevent Zaire ebolavirus, a severe, often fatal illness affecting humans and other primates. \n\nType of support offered by Gavi Stockpile Campaigns in 2022 Accessed 2x by 1 country Repurposed doses from the stockpile for preventive vaccination of frontline workers accessed 1x by 1 country     \n\n> Total campaigns to end 2022 Accessed 4x by 2 countries\n> Total doses shipped to end 2022 18.6k\n\nCOVAX reached the milestone of 1 billion doses shipped to 144 countries and territories in January 2022, just one year after the first COVAX-supplied vaccine was administered in a lower-income country. By December 2022, nearly 1.9 billion doses had been shipped, 90% to Gavi COVAX AMC lower-income countries. Supported by the COVID-19 Vaccine Delivery Partnership (CoVDP) – a collaboration across Alliance partners – the number of AMC countries with less than 10% coverage reduced from 34 in January to just 7 by December. Lower income countries made significant progress, covering 53% of their population with complete primary series (i.e. two doses), compared to 64% globally; and protecting high-risk populations: 82% of health care workers and 67% of older adults (compared to high-income countries at 87% and 92%, respectively). By end 2022, as COVAX supplies continued to ramp up and more people were reached, Imperial College London estimates that 2.7 million deaths were averted across AMC countries by COVAX vaccines, with the total proportion of deaths averted attributable to COVAX rising to 34% across AMC countries (excluding India). Meanwhile, nearly 50% of doses used by governments in humanitarian settings were supplied by COVAX. Around US$ 1 billion in COVID-19 vaccine Delivery Support (CDS) was disbursed to 87 countries to help reach their vaccination goals. The impact of these investments – upscaling ultra-cold chain (UCC) units, strengthening routine immunisation and digitising health systems – will be felt for decades to come. The COVID-19 vaccine supply landscape saw a shift in 2022, and COVAX was able to meet 100% of countries’ requested supply. \n\nType of support offered by Gavi COVAX support Countries & territories reached to end 2022 146   \n\n> Total doses shipped to end 2022 ~1.88bn\n> Which lower-income countries saw the biggest COVID-19 vaccination coverage gains in 2022?\n> Throughout 2022 COVAX helped lower-income governments to roll out jabs and launched an initiative to help those furthest behind improve. So which countries made the biggest strides in coverage? The answer may be surprising. Read the full article Credit: UNICEF/2021 The vaccine goal\n\n## 27 Annual Progress Report \n\nIn April 2022, Nepal introduced typhoid conjugate vaccine (TCV) into the national immunisation schedule, with a successful catch-up campaign for children and adolescents aged 15 months up to 15 years. Vaccine cards included information on all routine immunisations – and safe water, sanitation and hygiene (WASH) behaviours – and were used by vaccinators to identify children missing other routine vaccines (e.g. measles). In late 2022, Pakistan completed the national TCV introduction, including implementing the third and final phase of the catch-up campaign in extremely difficult conditions following nationwide flooding and displacement. Administrative coverage was 104% and included some displaced communities who had moved into urban areas that were targeted for the campaign. Survey coverage was 91%. Globally, meetings were organised in the South-East Asian, African and Eastern Mediterranean regions to share experience, new evidence and learning between global partners, academic institutions and country representatives; and advance the roll-out of TCV among Gavi-supported countries. Key discussions related to gathering evidence needed for TCV introduction decision-making; and sharing learning from countries that had recently introduced the vaccine. One key challenge that countries face is to accurately diagnose typhoid infection with currently available diagnostic tools; and the resulting lack of reliable burden data continues to impede national decision-making around the use of TCV in routine immunisation programmes. In response, the Gavi Board approved funding to catalyse bringing to market validated, accurate typhoid diagnostic tests; and to procure these tests for countries that require additional evidence on typhoid burden for vaccine decision-making. Academic article published by Gavi staff: Progress in the Typhoid Conjugate Vaccine Program Rollout Supported by Gavi During the COVID-19 Pandemic and the Path Forward \n\nTyphoid conjugate vaccine \n\nProtects against life-threatening typhoid fever, mainly transmitted through contaminated food or water by the bacterium Salmonella Typhi. Antimicrobial resistance (AMR) is increasingly complicating case management, increasing the risk of complications and death and the cost to families and health systems.  \n\n> 25 One-time catch-up campaigns target children aged 9 months up to 15 years with the aim of boosting immunity and increasing the impact of TCV introduction, and are conducted just before or during vaccine introduction into the routine immunisation schedule.\n\nType of support offered by Gavi Routine immunisation Catch-up campaigns 25 Outbreak response campaigns Introductions & campaigns \n\nin 2022 1 1 0\n\nTotal introductions & campaigns \n\nto end 2022 4 4 1\n\nTotal reached \n\nto end 2022 >10.5m ~44.2m >325k \n\nIn October 2022, Uganda introduced yellow fever vaccine into the routine immunisation system during Integrated Child Health Days (ICHD). This marks a significant milestone in yellow fever prevention, as now there are only two countries at high risk of yellow fever that are pending routine introduction: Ethiopia and South Sudan. However, routine coverage remains suboptimal in most countries in the WHO African Region at high risk of yellow fever, with some lagging behind measles vaccine coverage. The Republic of the Congo implemented a preventive mass vaccination campaign (PMVC) targeting more than 4 million people (aged 9 months to 60 years), integrated in some areas with measles vaccination and vitamin A. Nigeria and the Democratic Republic of the Congo (DRC) continued roll-out of multi-year phased campaigns. DRC launched a campaign in three provinces (South Kivu, Maniema, Sankuru), while Nigeria implemented an integrated campaign with measles and meningococcal A vaccines in additional states. Several countries suffered yellow fever outbreaks in 2022, including several where yellow fever vaccines are included in the routine immunisation schedule and that had previously conducted PMVCs. Overall, this resulted in six outbreak response requests approved in 2022 to vaccinate 4.2 million people in five countries. This illustrates the need to sustain disease surveillance efforts; develop strategies to catch up individuals who have missed vaccination; and improve outbreak response readiness, especially in urban settings where the risk of amplification of transmission is high. \n\nYellow fever vaccine \n\nHelps prevent a deadly viral disease spread by mosquitoes. Death rates can be as high as 50% among those severely affected.     \n\n> 26 In 2020, an exceptional catch-up campaign in Sudan was approved and commenced, continuing into 2021. 27 Historical review of data and indicators is in progress.\n> Notes: The total numbers reached have been updated, which has resulted in a downward revision for certain vaccines. This is due primarily to revisions of: historical data; and Gavi support. Due to rounding, some figures may not add up precisely to the totals. As reported in Gavi’s 2021 Annual Progress Report, the Gavi Board made history in December 2021 by approving funding to support the roll-out of the world’s first malaria vaccine – nearly 35 years in development – in sub-Saharan Africa in 2022–2025. According to WHO, the vaccine is estimated to save 1 life for every 200 children vaccinated. Gavi’s new malaria vaccination programme will protect children against a disease that kills hundreds of thousands in Africa every year. The first 18 million malaria vaccine doses were allocated to 12 countries in July 2023; their roll-out will be reported in Gavi’s 2023 Annual Progress Report.\n\nType of support offered by Gavi Routine immunisation Mass Campaigns Stockpile Introductions & campaigns \n\nin 2022 1 1Accessed 6x by 5 countries \n\nTotal introductions & campaigns \n\nto end 2022 19 17 26 Accessed 73x by 21 countries \n\nTotal reached \n\nto end 2022 >157m >232m >78m 27 doses shipped The equity goal 28 Annual Progress Report \n\n# The equity goal \n\n# 02 \n\n# Strengthen health systems to increase equity in immunisation \n\n“I got vaccinated against HPV when I was 10. There are so many rumours around the vaccine. Certification that the vaccines are genuine, and not fake, would help people to trust it.” \n\nNakate, 16, who wants to become a TV presenter. Read the full article Kampala, Uganda Credit: Gavi/2023/Esther Ruth Mbabazi The equity goal 29 Annual Progress Report \n\n# Key highlights \n\n## In Gavi 5.0/5.1, health system strengthening (HSS) support prioritises equity in immunisation delivery, to reduce the number of zero-dose and under-immunised children. \n\n# 81 %\n\n## In 2022, DTP3 coverage in Gavi-supported countries rebounded to 81% after two years of decline (compared to the 84% global average). \n\n2.6 million more children received basic routine immunisations through Gavi-supported health systems in 2022 than in 2021. \n\n47 countries have installed more than 65,000 CCE units procured by UNICEF Supply Division through Gavi’s CCEOP – nearly 13,000 in 2022 alone. \n\n17.2 million immunisation sessions were reported in Gavi-supported countries in 2022. \n\n25 Gavi-supported countries \n\nincreased MCV1 coverage from 2021 to 2022, but measles immunity gaps remain a significant concern. The equity goal 30 Annual Progress Report \n\n2020 2021 2022 2023 2024 2025 100% 60% 40% 20% 0% 80% 2019 \n\nBaseline \n\n# Results – equity goal strategy indicators \n\n## Gavi 5.0/5.1 indicators are designed to better measure the impact of health system strengthening activities. \n\n2022 progress: significant delays/challenges \n\n2020 2021 2022 2023 2024 2025 100% 60% 40% 20% 0% 80% 2019 \n\nBaseline \n\nTarget: +7 percentage points 67% \n\nThis indicator measures how well Gavi-supported countries are able to increase coverage in areas with limited access to immunisation services. \n\n2022 progress: Geographic equity of DTP3 coverage remained at 62% in 2022, down from 67% in 2019, demonstrating that the most vulnerable districts had not yet recovered from the impact of the COVID-19 pandemic. There is additional uncertainty around coverage levels and trends in low-coverage districts, because subnational data is frequently observed to have data quality issues (e.g. inaccurate estimates of population size and movement; incomplete reporting). \n\nData source: WHO/UNICEF Joint Reporting Form, 2023 \n\nThis indicator aims to measure access to the first dose of measles-containing vaccines through routine immunisation. \n\n2022 progress: MCV1 coverage patterns in 2022 were similar to those of DTP3. MCV1 coverage in Gavi57 countries decreased by 4 percentage points between 2019 and 2021, falling from 81% to 77%, before increasing by 2 percentage points to 79% in 2022. \n\nData source: Vaccine coverage: WUENIC, 2023; population estimates: United Nations, Department of Economic and Social Affairs, Population Division, World Population Prospects 2022 \n\n2022 progress: DTP drop-out increased overall in Gavi57 countries, from 6% in 2019 to 7% in 2021, before declining back to 6% in 2022. In 2022, countries recovered to 2019 levels; this progress must be maintained to reach the target of a 1 percentage point reduction by 2025. \n\nData source: Vaccine coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), 2023; population estimates: United Nations, Department of Economic and Social Affairs, Population Division, World Population Prospects 2022 \n\n# S2.1 Geographic equity of DTP3 coverage \n\nAverage unweighted coverage of third dose of diphtheria, pertussis and tetanus-containing vaccine (DTP3) in 20% of districts with lowest coverage in each country. \n\n# S2.2 DTP drop-out % drop-out rate between first and third doses of DTP-containing vaccine. \n\n# S2.3 MCV1 coverage \n\nCoverage of first dose of measles-containing vaccine (MCV1) in Gavi-supported countries through routine immunisation, as a measure of access. 66% 62% 62% \n\n2022 progress: moderate delays/challenges \n\n2020 2021 2022 2023 2024 2025 10% 6% 4% 2% 0% 8% 2019 \n\nBaseline \n\n7% \n\nTarget: -1 percentage point \n\n2022 progress: moderate delays/challenges \n\nTarget: +4 percentage points 81% 79% 79% 77% 6% 6% 6% The equity goal 31 Annual Progress Report    \n\n> 20m 10m 5m 0m 15m 2022 progress: New strategy indicator for Gavi 5.0/5.1; no baseline; no target set.\n> Fixed site Outreach\n> 2022 progress: New strategy indicator for Gavi 5.0/5.1; no target set.\n\nThis indicator measures the capacity of countries to reliably forecast and distribute vaccines to health facilities, ensuring they are always available whenever a child comes for vaccination. \n\n2022 progress: In 2021, the reported average full stock availability of DTP-containing and measles-containing vaccines across the 57 Gavi-supported countries was 71.6%. However, in 2022, this data was not collected through eJRF, as some WHO regions were concerned about the lack of reliable country systems to capture this indicator. Instead, the eJRF collected information from countries to ascertain presence of a system to measure vaccine availability at the service delivery level, which will be used to help determine if the eJRF will include this question for a subset of countries or regions in future cycles. In parallel, UNICEF has led Alliance efforts to continue to scale up the Thrive360 platform to strengthen stock visibility and monitoring. The composite Effective Vaccine Management (cEVM) score reflects the efforts of the Gavi Secretariat and Alliance partners to support countries to improve the performance of their immunisation supply chains, and ensure that equity and efficiency goals are met. In 2022, the cEVM score for Gavi-supported countries was 73.3%, a slight increase from 72.5% in 2021. \n\n2022 progress: In 2022, Gavi-supported countries reported 17.2 million immunisation sessions were conducted, with 9.6 million taking place in fixed site facilities and 7.6 million in outreach facilities. Twenty-eight Gavi-supported countries reported data on this indicator in 2022, up from 26 in 2021. This is a new indicator that was recently added to the WHO/UNICEF electronic Joint Reporting Form (eJRF); therefore, time trends likely reflect changes in reporting completeness.  \n\n> Data source: WHO/UNICEF Joint Reporting Form, 2023\n\n# S2.5 Stock availability at facility level \n\n# S2.4 Immunisation sessions conducted # of immunisation sessions conducted in Gavi-supported countries, a key desired output of HSS investments and an intermediate result in the causal pathway to increasing vaccine coverage.         \n\n> 2021 2022 2023 2024 2025 5m 1.4m 9.6m 7.6m 2022 2023 2024 2025 100% 60% 40% 20% 0% 80% 2021\n> 71.6%\n> Teodoro and Celia, of Santiago de Okola, Bolivia, with their children, Nohemi and Teo. Both children are fully vaccinated. Credit: Gavi/2023/Sara Aliaga Ticona The equity goal\n\n## 32 Annual Progress Report \n\nDemand-related barriers can include social and behavioural determinants; and environmental or practical factors that prevent individuals from seeking and supporting vaccination. Vaccine demand can be particularly challenging in high-risk communities (i.e. vulnerable to un-/under-immunisation; falling below coverage targets; high drop-out rates; high numbers of never vaccinated). Methods for measuring progress on demand are still evolving. \n\n2022 progress: Among the 48 Gavi57 countries reporting in 2022, 33 (69%) implemented one or more strategies to address under-vaccination; 15 countries did not implement any strategies; and 9 countries did not report on this indicator. 1 The most common strategies: behaviourally informed interventions, health care worker training and interventions to improve the service experience. Among nine countries that recently completed surveys on the behavioural and social drivers (BeSD) of vaccine uptake, a key barrier to demand was the cost to caregivers of taking children to be vaccinated (e.g. transportation, lost wages). In partnership with the Bill & Melinda Gates Foundation, Gavi plans to support countries in scaling up BeSD surveys and tracking key demand indicators, to enable more robust monitoring and measurement of demand trends and interventions in the future.   \n\n> Data source: WHO/UNICEF Joint Reporting Form (JRF), 2023\n> 1In 2021, 49 Gavi57 countries reported having implemented behavioural or social strategies to address under-vaccination. This indicator has been significantly changed since 2021, so these values are not comparable.\n\n# S2.7 Implementation of tailored plans to overcome demand-related barriers 2022 progress: New strategy indicator for Gavi 5.0/5.1; no target set. \n\nOf the nine health system strengthening (HSS) and/or Equity Accelerator Fund (EAF) applications that were reviewed and approved by the Independent Review Committee (IRC) in 2022, six applications (67%) included interventions to address gender-related barriers to immunisation. The Full Portfolio Planning (FPP) process identified various gender-related barriers experienced by caregivers and health workers, including: long, and in some cases unsafe, distances to health facilities; discomfort with interactions with men vaccinators; and lack of time to bring children for immunisation services. Quality of planned programming remained variable; therefore, the Alliance is scaling up technical assistance to support countries in developing and implementing robust gender programming.  \n\n> Data sources: Gavi health system strengthening (HSS) and Equity Accelerator Fund (EAF) applications, 2022\n\n# S2.8 Addressing gender-related barriers to immunisation 2022 progress: New strategy indicator for Gavi 5.0/5.1; no target set. \n\n> 42103\n\nStrengthened institutional capacity for programme management and monitoring is on the critical pathway to programmatic and financial sustainability, and a strategic enabler of Gavi’s 2021–2025 strategy. \n\n2022 progress: Following an external review of the Alliance approach to build country EPI management capacity, the refinement of leadership, management and coordination (LMC) strategy was paused due to COVID-19 pandemic-related reprioritisation, to avoid burdening country EPI teams. (This indicator had increased significantly in Gavi’s 2016–2020 strategic period, before the impact of the COVID-19 pandemic.) Ongoing LMC support continued, with additional surge management support if requested. Testing and piloting new approaches was initially paused but has resumed in 2023. Reporting for this indicator to resume in 2024.  \n\n> Data source: Gavi institutional capacity assessment tool, 2022\n\n# S2.6 Expanded Programme on Immunization (EPI) management capacity 2020 2021 2022 2023 2024 2025 2019  \n\n> Baseline\n> 2022 progress:\n\nNew strategy indicator for Gavi 5.0/5.1; no target set.   \n\n> 2.73 2.70 2.51\n\nNiger is one of the youngest countries in the world, with children representing more than half its population. The country’s new “Operation Koutouho” is helping ensure none of them miss out on life-saving vaccines. Read the full article Credit: Gavi/2022/Isaac Griberg The equity goal 33 Annual Progress Report \n\n# Progress – 2022 equity updates Achievements and progress \n\nIn 2022, the 57 lower-income countries supported by Gavi reached roughly the same number of children with routine vaccines as in 2019, with coverage not fully returning to 2019 levels due to population growth, particularly in Africa. This is a testament to the hard work of countries and the Alliance to recover quickly from the COVID-19 pandemic and shows the resilience of immunisation programmes in Gavi-supported countries. With nine million more children born each year in Gavi-supported countries today than in 2000, health systems need to protect growing birth cohorts from infectious diseases, while also being extended to reach communities with large numbers of zero-dose children. In 2022, Gavi supported health systems to deliver basic routine immunisations to 2.6 million more children than in 2021. Routine coverage rebounded in Gavi-supported countries in 2022 after two years of decline, with coverage for the third dose of diphtheria, tetanus and pertussis-containing vaccine (DTP3) in the 57 Gavi-supported countries increasing by 3 percentage points (pp) from 2021, reaching 81% in 2022. Recovery in India, Myanmar, United Republic of Tanzania and Pakistan in particular drove the overall rebound in routine coverage, although many Gavi-supported countries (23) increased routine coverage in 2022. The increase in DTP3 coverage was concentrated in lower middle-income countries, with many low-income countries not yet increasing coverage – indicating the work remaining to help the most vulnerable health systems recover. Coverage for the first dose of measles-containing vaccine (MCV1) increased from 77% in 2021 to 79% in 2022, following a 4 percentage point decline from 2019 to 2021. While 25 Gavi-supported countries increased MCV1 coverage from 2021 to 2022, measles immunity gaps remain a significant concern given the high transmissibility of the virus and risk for serious outbreaks. \n\nLaser focus on zero-dose agenda, equity in immunisation \n\nThe number of zero-dose children in Gavi-supported countries has decreased to 10.2 million in 2022, down 17% from 12.4 million in 2021. This represents impressive progress in recovering routine immunisation coverage, but the number of zero-dose children is still higher than the estimated value of 9 million in 2019; and a further 34% reduction will be required to meet the Gavi 5.0/5.1 2025 target. Zero-dose children account for 70% of under-immunised children in Gavi-supported countries and often belong to households that suffer from multiple deprivations, face gender-related barriers to immunisation and are not reached by any health services. These zero-dose children are also at the highest risk of disease outbreaks and deaths. Reaching zero-dose children with life-saving immunisation is the foundation of Gavi’s equity goal. In 2022, Gavi launched the Zero-Dose Immunization Programme (ZIP), a new partnership between Gavi, the International Rescue Committee and World Vision dedicating up to US$ 100 million to reach zero-dose children living in displaced communities, and fragile and conflict settings, across 11 countries in the Horn of Africa and the Sahel. \n\nAccelerating new programming \n\nIn 2022, Gavi 5.0 programming progressed as five countries were fully approved for Full Portfolio Planning (FPP). A further two countries were approved for standalone Equity Accelerator Fund (EAF) funding to extend health systems to reach zero-dose children and missed communities. All five fully approved FPP countries adhered to the Board decision requiring all Gavi-supported countries to allocate at least 10% of their combined HSS, EAF and Targeted Country Assistance (TCA) ceilings for activities undertaken by civil society organisation (CSO) partners. Based on the approved funding applications, a combined 29%, or US$ 95.7 million, has been allocated to CSOs. Of this amount, US$ 24.7 million has been allocated to local CSOs. Countries are increasing investment and strengthening diagnostics on demand, and on gender-related barriers to immunisation; but the quality of proposed programming remains variable and could be further tailored. The Alliance is scaling up technical assistance in these critical areas to help countries measure, understand and address the social and behavioural drivers of immunisation. \n\nContinued scaling of innovations \n\nForty-seven Gavi-supported countries have installed more than 65,000 CCE units procured by UNICEF Supply Division through Gavi’s Cold Chain Equipment Optimisation Platform (CCEOP) – nearly 13,000 of which were installed in 2022 alone. Approximately 40 countries are now using DHIS2, the world’s largest health management information system, for immunisation – with most rapidly adding modules for COVID-19 vaccines. In June 2022, the Gavi Board approved top-up funding for catalytic investments in select proven innovations on an as-needed basis, particularly for countries with insufficient HSS/Ops funding to scale up; the first applications were received, and disbursements made, in 2023. In 2022, health systems reached 68 million unique children with Gavi-supported routine vaccines, administering 9% more routine vaccine doses than in 2019. The equity goal 34 Annual Progress Report \n\n> Anila, a Lady Health Worker (LHW), administers typhoid conjugate vaccine (TCV) at a government girls’ middle school in Dera Allah Yar, Pakistan. Read the full article Credit: Gavi/2022/Asad Zaidi\n\nFirst approved by the Gavi Board in June 2008, updated in November 2013 and revised effective July 2020, the goal of Gavi’s Gender Policy is to identify and overcome gender-related barriers to reach zero-dose and under-immunised children, individuals and communities with the full range of vaccines. This encompasses: identifying and addressing underlying gender-related barriers faced by caregivers, adolescents and health workers; in the specific pockets where they exist, overcoming differences in children’s immunisation coverage among genders; and encouraging and advocating for women’s and girls’ full and equal participation in decision-making related to health programmes and well-being. Due to gender norms, it is often women’s responsibility to bring children for vaccination; yet women in lower-income countries often face gender-related barriers to doing so, including: time constraints due to high workload; limited funds for transport; and lack of access to information on disease prevention. In many countries, vaccinators are predominantly women, and they may face barriers in delivering vaccine services due to gender norms, sexual harassment and assault, unsafe working conditions, poor or irregular pay, and heavy workload. At country level, implementation of Gavi’s Gender Policy is a work in progress. While countries’ HSS grant applications demonstrate increasing understanding of and focus on addressing gender-related barriers, countries don’t have the support and expertise they need: there are few or no gender experts from government, core partners or expanded partners involved in the design of countries’ National Immunisation Strategy (NIS) or Gavi grant applications; and despite women’s significant role as vaccinators, their representation in decision-making positions in the immunisation sector are limited. Therefore, the quality of proposed programming remains variable. Below are examples from three countries that are elevating the role of women in health care and immunisation services, and addressing gender-related barriers to immunisation. \n\nAchievements and progress \n\nIn Pakistan , to address women’s avoidance of health care provision by men, Gavi is funding the hiring and training of Lady Health Workers (LHW). Partnering with women influencers and normalising the role of women health workers can potentially shift gender norms and increase women’s decision-making power. Also, Gavi has worked with government leaders to include women managers in mid-level managerial trainings, to enable women in leading roles to benefit from formal capacity building opportunities. In South Sudan , a 2022 situation analysis conducted as part of the Full Portfolio Planning (FPP) process revealed a lack of men’s involvement in immunisation despite their formal decision-making role; and that services were not available at appropriate times for women caregivers. In response, Gavi’s health system strengthening (HSS) funds will specifically target men to ensure they understand and are supportive of vaccination services; and improve joint decision-making among guardians to bring children for health services. To ensure families receive multiple services at one time, immunisation services will be integrated with water, sanitation and hygiene (WASH) services. In Cambodia , two main barriers faced by women caregivers were identified as low literacy rates and lack of autonomy to take decisions about their child’s health. To address this, locally influential Commune Committee for Women and Children will meet with women and men caregivers to improve understanding of the benefits of immunisation and support joint decision-making for their child’s health. To increase trust in health workers and use of health services among urban poor families, migrant workers, ethnic minorities and remote rural poor families, targeted outreach will include routine immunisations for children; COVID-19 vaccination for adults; and multiple health services that meet the needs of all family members. COVAX also delivered on immunisation for women, who comprise a significant proportion of the health workforce: by end 2022, 81% of health care workers had been fully protected in Gavi COVAX AMC lower-income countries. \n\n# 2022 Gender Policy updates \n\n## Applying a gender lens to identify and overcome barriers faced by health workers, caregivers and adolescents. The equity goal 35 Annual Progress Report \n\nCOVAX was launched in April 2020 to ensure that people in all corners of the world get equitable access to COVID-19 vaccines. Through pooled demand, advance agreements with manufacturers, self-financing participant and donor funding, COVAX was able to make large-scale investments and build a diverse portfolio of 11 vaccine candidates across four technology platforms (of which 10 received regulatory approval) – the largest portfolio in the world. With its first deliveries commencing in January 2021, COVAX delivered nearly 1.9 billion doses of vaccine to people in 146 economies by end 2022. Approximately 90% of these doses have gone to lower-income economies (see page 26 for more), representing the fastest and most complex global deployment of vaccines ever. In terms of achieving equitable access during this pandemic, the COVID-19 pandemic demonstrated the clear need for the world to be better prepared for the next public health emergency of this scale. Drawing on its unique experience enabling an unprecedented global roll-out at scale during a pandemic, COVAX – co-convened by Gavi, CEPI, WHO and UNICEF – published a white paper in September 2022 outlining the key challenges the mechanism faced in seeking to ensure equitable access to COVID-19 vaccines, the actions it took in response and recommendations for future pandemic prevention, preparedness and response. \n\n1.  Equitable access requires an end-to-end solution that centres on public health, and the needs of the most vulnerable, at every step \n\nPrioritise strengthening end-to-end capabilities during non-pandemic periods, thereby ensuring that a resilient ecosystem is already in place when an emergency strikes. Build access for the most vulnerable into the pandemic architecture. An end-to-end solution focused on equity must account for the disproportionate impact of such an emergency on hard-to-reach populations in fragile, conflict and humanitarian settings. Map out existing global health mechanisms, networks, expertise, policies, frameworks and tools – and retain, incorporate and evolve these as needed. Sufficient resources, with rapid disbursement mechanisms, should be available for all aspects of the vaccine and ancillary product value chain from R&D, procurement and in-country delivery – in parallel. Establish clear standards, processes and expectations for rapid and agile end-to-end governance, decision-making, communication, transparency and risk sharing. Set up processes and expectations – in advance – for the systematic consultation and updating of all relevant stakeholders. Processes and expectations for transparency should be carefully considered in advance. \n\n2.  Hoarding, export restrictions and nationalism should be expected \n\nEnsure volumes supplied to high income countries (HICs) are accompanied in parallel (not sequentially) by proportionate doses for lower-income countries. Increase and geographically diversify vaccine manufacturing. Strengthen multinational trade-facilitation measures to ensure the free flow of vaccines, manufacturing supplies and other life-saving equipment during health emergencies. \n\n3.  A successful global pandemic response involves taking risks \n\nEnsure that response mechanisms are flexible and agile, with appropriate funding and risk tolerance they need to successfully operationalise a response. Outline a clear, shared understanding of risk thresholds and risk sharing. Make available, in advance, contingent at-risk funding for global health agencies and mechanisms that is immediately deployable when needed. Sustain and leverage existing financing mechanisms. \n\n> COVAX: KEY LEARNINGS FOR FUTURE PANDEMIC PREPAREDNESS AND RESPONSE  7\n\nKEY LEARNINGS THE CHALLENGE \n\nDuring a global crisis, and when there is great uncertainty about which medical interventions will become available, governments will always seek to protect their own citizens first. Both during the 2009 H1N1 pandemic and with COVID-19, this led to the wealthiest governments leveraging their resources to hedge against unknowns – ordering large volumes of doses, and leaving the majority of the world at the back of the queue. Similarly, during both these pandemics other forms of nationalism had negative impacts on global supply, including export restrictions imposed by governments around the world. This not only affected the free flow of vaccines, but also vital components and materials needed to make them. However, this systemic hurdle is not easy to overcome. Players within the pandemic ecosystem (including countries, private sector actors and global organizations) will always respond to their incentives. These incentives – protecting domestic populations first, prioritizing the fastest and highest bidder to help de-risk investments and focusing on entrenched priorities, processes and stakeholder requirements – are rooted in a clear rationale and cannot be disrupted overnight, nor guaranteed by agreements established during \"peace-time\". Efforts in climate change and peace negotiations have faced similar hurdles for decades. \n\nTHE RESPONSE \n\nAnticipating this, COVAX’s solution was to pool demand, not just for lower-income economies, but also from wealthier nations that had resources but still lacked the power to secure bilateral deals in a supply-constrained environment. This included, for example, upper-middle income countries that had also missed out on doses during the 2009 H1N1 pandemic. COVAX’s goal was to leverage the fair allocation mechanism to ensure doses were available to cover 20% – or high-risk groups – in all countries, as a public health imperative. Alongside fully-funded doses supplied through the COVAX AMC to lower-income countries, COVAX created a self-financing model that gave these countries access to the same insurance mechanism in the face of uncertainties around R&D successes and failures. This combined approach, developed in consultation with countries, resulted in more than 160 countries joining COVAX within months, eventually reaching more than 191 participants in total – an unprecedented show of global solidarity in an environment where political buy-in was critical to success. This pooled demand, as well as self-financing participant and donor funding, gave COVAX the ability to make large-scale investments and build a diverse portfolio. In the end, COVAX was able to secure agreements for access to 11 vaccine candidates across four technology platforms, of which ten received regulatory approval, and more than 4 billion doses in total – the largest portfolio in the world. However, despite rapid global solidarity, designing, consulting, implementing and raising funds for COVAX still took several crucial months during which the race to secure early access to vaccines was on. The lack of advance and early at-risk funding meant that COVAX still came to the table later than countries with resources readily at hand at the start of the global emergency, putting COVAX several months behind in building a broad portfolio. This meant that, with a limited set of approved products in the early stages of global rollout, COVAX was disproportionately impacted by manufacturers prioritizing earlier bilateral customers for early supply – as well as by export restrictions that further impacted supply of the majority of the volumes expected to be available to COVAX in the first half of 2021. \n\n2. HOARDING, EXPORT RESTRICTIONS AND NATIONALISM SHOULD BE EXPECTED \n\n# COVAX: key learnings for future pandemic preparedness and response \n\n> COVAX: KEY LEARNINGS FOR FUTURE PANDEMIC PREPAREDNESS AND RESPONSE  1\n\nCOVAX: KEY LEARNINGS FOR FUTURE PANDEMIC PREPAREDNESS AND RESPONSE SEPTEMBER 2022 \n\nRead the full report here: https://www.gavi.org/news-resources/ knowledge-products/covax-key-learnings-future-pandemic-preparedness-and-response \n\nKey learnings and summary of recommendations: 36 Annual Progress Report \n\n> Climate, health and immunisation\n\n# Climate, health and immunisation \n\n## Gavi’s role in response and prevention The climate crisis is a fundamental factor in the spread of vaccine-preventable diseases globally – through climate-sensitive diseases, including vectors expanding into new regions; and a surge in extreme weather events. Lower-income countries are disproportionately affected when disaster strikes: clean water and sanitation may be interrupted, access to and delivery of essential health services disrupted, and people temporarily or permanently displaced. Gavi’s programmes are adapting to sustain routine immunisation, and respond to and prevent outbreaks, to prevent further loss of life. Gavi-supported vaccines against climate-sensitive diseases: \n\nCholera – food-/water-borne: \n\noral cholera vaccine (OCV) – emergency stockpile; preventive use. Total stockpile doses shipped to end 2022: ~130m \n\nJapanese encephalitis – vector-borne: \n\nJapanese encephalitis vaccine – routine; catch-up campaigns. Total reached with Gavi-supported vaccines to end 2022: >24.7m \n\nMalaria – vector-borne: \n\nRTS,S/AS01 – funding window opened in 2022; first allocations in 2023 \n\nMeningitis – respiratory: \n\nmeningococcal A conjugate vaccine (MenACV) – routine; outbreak response campaigns. Total reached with Gavi-supported vaccines to end 2022: 395m. Multivalent meningococcal conjugate vaccine (MMCV) – emergency stockpile. Total stockpile doses shipped to end 2022: >26m \n\nTyphoid – food-/water-borne: \n\ntyphoid conjugate vaccine – routine; catch-up campaigns; outbreak response campaigns. Total reached with Gavi-supported vaccines to end 2022: >55m \n\nYellow fever – vector-borne: \n\nyellow fever vaccine – routine; outbreak response campaigns; emergency stockpile; diagnostics. Total reached with Gavi-supported vaccines by end 2022: >389m; total stockpile doses shipped to end 2022: >78m \n\nDisease outbreaks increasing \n\nAlong with droughts and floods, deforestation, earthquakes and extreme temperatures, climate-sensitive disease outbreaks continue to rise. Mass migration, urbanisation, deforestation and continued encroachment by humans into animal habitats means that diseases can spread quickly across borders and around the globe. Climate change has pushed mosquitoes that spread malaria into higher elevations, spelling trouble for the spread of infectious diseases such as malaria, yellow fever, chikungunya and dengue. Climate disasters are increasing the risk of waterborne diseases, including diarrhoea caused by cholera and typhoid. Also, climate change exacerbates antimicrobial resistance (AMR), which could result in 10 million annual deaths globally by 2050. \n\nVaccine Alliance steps up response \n\nMarginalised communities in fragile and conflict settings are often disproportionately affected by the impacts of climate change. In 2022, Gavi launched the Zero-Dose Immunization Programme (ZIP) across 11 countries in the Horn of Africa and the Sahel to reach children in displaced communities, and fragile and conflict settings, with routine immunisation and integrated health services to help build their health resilience – including against the impacts of climate change. Also, Gavi has collaborated with the International Rescue Committee (IRC) to conduct risk assessment on the impacts of climate change on health infrastructure in ZIP countries. Meanwhile, in Pakistan, in response to the devastating 2022 floods, Gavi’s Fragility, Emergency and Displaced Populations (FED) Policy was mobilised to provide surge support, including both additional district-level surveillance, as well as equipped rapid outbreak response teams – enabling provinces and partners to target responses quickly based on real-time information. In 2022, political momentum on the climate change and global health agendas have gained more traction across policy forums. Gavi engaged in relevant dialogues, including the Intergovernmental Negotiating Body (INB) on pandemic prevention, preparedness and response, G20, UN General Assembly, Group of Friends of Human Security and UN-Energy, to promote alignment on health equity and reaching zero-dose children and missed, marginalised communities with routine immunisation. This is key to building resilience and preparedness against health emergencies, including those related to climate change.  \n\n> “It’s difficult, but we’ll find a way”: a new vaccine against typhoid rolls out in a flood-devastated province of Pakistan. Read the full article Watch the video Credit: Gavi/2022/Asad Zaidi\n\n## 37 Annual Progress Report \n\n> Climate, health and immunisation\n\nEnvironmental protection: a cornerstone of resilient health systems \n\nAccording to the World Health Organization (WHO), the direct damage costs to health from climate change are estimated to be between US$ 2–4 billion per year by 2030. Both budget cuts and climate disasters can lead to disruption of access to electricity and essential health services. Gavi’s Health Systems and Immunisation Strengthening (HSIS) programmes are helping to “green” vaccine storage, reduce the carbon footprint of immunisation programmes and enable health facilities to be more resilient when disasters strike (e.g. gap in health care services due to lack of energy). \n\nPandemic prevention, preparedness and response (PPPR) \n\nThe world’s ability to respond to outbreaks is a bellwether of its ability to respond to future pandemics. A key outcome of Gavi’s COVAX learnings is a global health security flywheel of innovation, training and preparedness. To learn more, we invite you to explore our collection of original research reports on the Gavi website: www.gavi.org/news-resources/document-library/white-papers \n\n## In my country – where climate-change and displacement are making it harder, not easier, to deliver health services – vaccines are an essential way to manage outbreaks and save lives. \n\n> Dr Abdelmadjid Abderahim, Minister of Public Health and Prevention, Chad Read the news release\n\nVaccinesWork \n\nGavi’s VaccinesWork platform has become a leading resource on climate, health and immunisation. Click here for the latest news and information: www.gavi.org/vaccineswork/tag/climate-change \n\nCold chain equipment \n\nHistorically, much of the off-grid vaccine cold chain in Gavi-supported countries has been gas- or kerosene-powered – unreliable, expensive and carbon-intensive. Launched in 2015, Gavi’s Cold Chain Equipment Optimisation Platform (CCEOP) pools technology demands from countries and procurement through UNICEF Supply Division, negotiating with manufacturers for better pricing and effective deployment. Climate-friendly solar-powered refrigeration technologies account for 60% of the more than 65,000 CCE units installed to date across 47 Gavi-supported countries. \n\nSolarisation \n\nWithout stable, reliable electricity, energy-reliant medical equipment is unable to serve its purpose. Since 2021, Gavi has been working with Orange in Sierra Leone to support health facility solar electrification (HFSE) to improve immunisation and climate sustainability (see page 52 for more). And in 2022, Gavi began planning to accelerate HFSE at scale – building on CCEOP – to expand off-grid solar solutions in health facilities. \n\nHealth care waste management \n\nHealth care waste management (HCWM) is a growing concern across all health areas, including immunisation. Most countries have adopted WHO standards and international agreements for HCWM at the national policy level. Yet often policies are not strictly followed at sub-national level. Health care waste (e.g. incineration of medical waste) has had a significant impact on climate change. To help reduce immunisation waste and promote environmentally sustainable practices, Gavi is supporting priority countries with improved technology; training; and partnerships – including with Africa CDC and the Global Fund to Fight AIDS, Tuberculosis and Malaria. \n\nWhen it rains: how the global climate crisis is already threatening public health on the shores of Lake Victoria \n\nFaced with the many disease threats posed by repeated, calamitous floods, Nyando in western Kenya needs its health services more than ever. But longer-term resiliency will require more than just a shot in the arm. Read the full article \n\n> Credit: Justin Motaro\n\nStormy weather: boat-borne vaccines ferry a dose of hope to the Sundarbans \n\nIn an ecosystem threatened by climate change, cyclones and COVID-19 have battered human health and livelihoods. Mobile health care is finding a way to navigate these intersecting crises. Read the full article \n\n> Credit: Gavi/2022/Benedikt v.Loebell The sustainability goal\n\n## 38 Annual Progress Report \n\n# The sustainability goal \n\n# 03 \n\n# Improve sustainability of immunisation programmes \n\n“Vaccines prevent us from getting sick. They are free, and that is good because we are very poor.” \n\nShahwali, 53, with his daughters, Zahra and Zainab. Read the full article Kabul, Afghanistan Credit: Gavi/2023/Oriane Zerah The sustainability goal 39 Annual Progress Report \n\n# Key highlights \n\n## The year 2022 confirmed the robustness of the Vaccine Alliance’s co-financing approach and the steady financial commitment of countries despite rising debt levels and the war in Ukraine. \n\n# $1.5 bn In the face of fiscal challenges, climate change, conflict and instability, most Gavi-supported maintained or increased domestic resources for co-financing of Gavi-supported vaccines in 2022, bringing to US$ 1.5 billion their total contribution since the introduction of the co-financing policy in 2008. \n\nUS$ 162 million was contributed by countries towards the co-financing of Gavi-supported vaccines in 2022 – the highest amount yet and a testament to country ownership and the long-term financial sustainability of Gavi-supported vaccines. \n\n54 vaccine programmes originally introduced with Gavi funding are now self-financed by countries as of 2022, up from 40 in 2018. \n\n100% of countries fully met their 2022 co-financing obligation – except three waivers for humanitarian crises. The sustainability goal 40 Annual Progress Report \n\n# Results – sustainability goal strategy indicators \n\n## Despite the ongoing COVID-19 pandemic, countries met their co-financing obligation. \n\n2022 progress: on track \n\n# S3.2 Preventing backsliding in Gavi-transitioned countries \n\nThis indicator assesses the sustainability of immunisation systems in former Gavi-eligible countries, as demonstrated through the capacity to maintain or increase DTP3 coverage following transition from Gavi support – reflecting Gavi’s Middle-Income Countries (MICs) Approach. For the most recent two-year period, this indicator captures countries in which coverage was held constant or increased in at least one year compared to coverage in 2019. \n\n2022 progress: Of the 17 former Gavi-eligible countries eligible for support under the Middle-Income Countries (MICs) Approach when this indicator was approved by the Gavi Board in December 2020, eight former-Gavi MICs-eligible countries maintained or increased DTP3 coverage in 2021 or 2022 compared to 2019, while nine countries did not maintain or increase DTP3 coverage.  \n\n> Data source: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC), 2023\n\n2021 \n\n> Baseline\n\n10 864202022 2023 2024 2025 8 8Target: no decline \n\n2022 progress: on track \n\n# S3.1 Co-financing fulfilment \n\nPercentage of countries with a co-financing obligation to Gavi that meet their co-financing commitment, which is a measure of country commitment to financing vaccines. Co-financing serves as a mechanism to support countries on a path toward greater sustainability. \n\n2022 progress: Most Gavi-eligible countries have been able to maintain or increase domestic resources for co-financing of Gavi-supported vaccines. Excluding countries whose co-financing obligation was exceptionally waived, 100% of countries fully met their 2022 co-financing obligation.  \n\n> Data source: Gavi Secretariat estimates, based on UNICEF Supply Division reports, 2023\n\n100% 60% 40% 20% 0% 80% 2021 2022 2023 2024 2025 2020  \n\n> Baseline\n> Target: 100%\n\n# S3.3 Vaccine introductions in Gavi-transitioned countries and never Gavi-eligible countries \n\nNew vaccine introductions are a core driver of Gavi’s achievement through the MICs Approach. This indicator measures the number of introductions of pneumococcal conjugate, rotavirus and HPV vaccines in former and never Gavi-eligible countries currently eligible for support under the MICs Approach. \n\n2022 progress: The MICs Approach was approved by the Gavi Board in June 2022; no introductions occurred in former and never Gavi-eligible MICs in 2022. As such, this indicator will be reported in the 2024 Annual Progress Report. \n\nMore than 150,000 girls in Sierra Leone will have access to the HPV vaccine after the government introduced it into the routine immunisation programme. Read the news release Credit: Gavi/2022/Joshua Kamara The sustainability goal 41 Annual Progress Report \n\n# Progress – 2022 sustainability updates \n\n> Countries’ co-financing contributions in 2022 were the highest amount yet at US$ 162 million.\n\n# $162m In the face of fiscal challenges, conflict and instability, Gavi implementing countries’ co-financing contributions in 2022 were the highest amount yet at US$ 162 million, provided to Gavi in a more timely manner and were mostly (97%) generated from domestic resources. Despite grappling with global shocks and uncertainty, only three countries (down from six in 2021) required the granting of a co-financing waiver – specifically due to humanitarian crises. And for the first time, South Sudan contributed to co-financing of Gavi-supported vaccines. Yet challenges remain: countries that are the closest to transitioning out of Gavi support are struggling to ramp up their co-financing requirements. Concerted efforts are necessary to make immunisation sustainable, both financially and programmatically, so that countries can independently maintain high immunisation coverage and ensure equal access to life-saving vaccines. \n\nAchievements and progress \n\nThe year 2022 was another challenging one, and particularly so for the most vulnerable economies in the world. Conflict, the impacts of climate change and economic distress hindered countries’ ability to invest in their health systems. However, despite rising debt levels and the worsening impact of the war in Ukraine, most Gavi-supported countries maintained or increased domestic resources for co-financing of Gavi-supported vaccines in 2022. Not only did co-financing increase, but also it was provided on a more timely basis: a clear demonstration of resilience and commitment. In addition, while navigating an uncertain global environment, for the second year in a row, countries remarkably reached an all-time high in co-financing contributions: countries contributed US$ 162 million in 2022 (US$ 1 million more than 2021), bringing to US$ 1.5 billion the total co-financing contributions since the introduction of the co-financing policy in 2008. More than 90% of country co-financing in 2021 and 2022 came from domestic budgetary resources. Most of the remainder came from borrowing from Gavi founding partner the World Bank. To prevent backsliding and protect immunisation progress, the Gavi Board in June 2022 granted the Secretariat the authority to implement an approach to apply co-financing flexibilities for countries facing severe fiscal distress and/or humanitarian crises. (Board paper and decision available on the Gavi website.) Three countries grappling with fragility and conflict (Somalia, South Sudan and Syrian Arab Republic) were granted a co-financing waiver for humanitarian crises in 2022, down from six waivers granted for COVID-19 in 2021 – meaning Gavi absorbed a cost of US$ 2 million in 2022. The co-financing waiver for South Sudan was only partial: for the first time, South Sudan contributed to co-financing of Gavi-supported vaccines, meeting 42% of their co-financing obligation – a noteworthy achievement in the country’s 12-year history with Gavi. Moreover, the reduction in waivers from 2022 to 2021 reflects countries’ continued commitment to immunisation financing, despite a challenging context – as well as the Alliance’s joint advocacy efforts and technical support in health budget planning. Former Gavi-eligible countries that are eligible for Gavi support under the Middle-Income Countries (MICs) Approach showed signs of recovery in 2022, driven by improvements in large countries. As of 2022, eight former Gavi-supported MICs maintained or increased DTP3 coverage in 2022 and 2021 compared to 2019, on track for the Gavi 5.0/5.1 target, while nine countries did not maintain or increase DTP3 coverage. 1 The MICs Approach will be critical in supporting these countries to prevent and mitigate further backsliding of routine immunisation coverage. \n\nChallenges and lessons learned \n\nIncreasing debt levels, associated with government response to the economic impact of the COVID-19 pandemic, are hampering the capacity of countries in the “accelerated transition” phase of country co-financing to ramp up their co-financing requirements on the path to fully self-financing. To reduce the risk of unsuccessful transition associated with these fiscal challenges, in December 2022 the Gavi Board approved two changes to the accelerated transition phase: (1) extension from five to eight years; and (2) minimum threshold of 35% co-financing, in addition to attainment of the gross national income (GNI) per capita eligibility threshold. While these Board decisions are expected to facilitate countries in their trajectory towards the fully self-financing phase, an intensification of transition preparedness activities, at both programmatic and financing levels, is required to ensure success.  \n\n> 1Based on indicator S3.2 “Preventing backsliding in Gavi-transitioned countries”. The sustainability goal\n\n## 42 Annual Progress Report \n\nSao Tome and Principe Lao PDR Papua New Guinea Solomon Islands Bangladesh Nigeria Djibouti Kenya Ghana Côte d'Ivoire Nicaragua Honduras Cuba Angola Republic of Moldova Armenia Sri Lanka Bhutan Mongolia Indonesia Viet Nam Timor-Leste Kiribati Georgia Azerbaijan Uzbekistan India Bolivia Guyana \n\n# How Gavi’s co-financing model works Countries fully self-financing and in accelerated transition \n\n## To bring countries on a trajectory towards financial sustainability, and to empower them to take ownership of their vaccination programmes, Gavi has pioneered an approach to co-financing and transition. Countries share the costs of the vaccine programmes by directly co-procuring a portion of the vaccines and safe injection devices from a supplier or procurement agency to fulfil their co-financing requirements. As a country’s gross national income (GNI) per capita increases, so the level of its co-financing payments also rises. Countries are grouped under different categories according to their level of GNI per capita as a proxy of their ability to pay. \n\n19 countries fully self-financing 210 countries in accelerated transition \n\n2 As of July 2022, four former-Gavi eligible countries have been selected to apply for targeted support to help mitigate backsliding in vaccine coverage: Angola, Bolivia, Honduras, Indonesia. \n\nVariable duration Low-income country threshold: \n\nUS$ 1,045 GNI per capita \n\nGavi MICs Approach support threshold: \n\nLower middle-income countries (≤ US$ 4,095 GNI per capita) and/or IDA-eligible \n\nEligibility threshold: \n\nUS$ 1,660 GNI per capita \n\nVariable duration Through 2025 8 years Initial self-financing \n\nVaccine price \n\nPreparatory transition Former Gavi-eligible countries Never Gavi-eligible countries Co-financing model, 2022 Accelerated transition \n\nPer Board-approved Middle-Income \n\nCountries (MICs) Approach The sustainability goal 43 Annual Progress Report \n\n# Civil society’s crucial role in sustainability, advancing Gavi 5.0/5.1 \n\n## Civil society organisations strengthen national and subnational political and social commitment to immunisation, toward Gavi’s strategic goal of improving sustainability of immunisation programmes. Building on the momentum created by a Gavi Board-approved initiative to support and empower civil society organisations (CSOs) and communities to identify and reach under-served and missed communities, in 2022 Gavi launched a Civil Society and Community Engagement (CSCE) approach. Co-developed with Gavi’s civil society partners, the new approach aims to catalyse strategic partnerships between governments, CSOs and communities to accelerate progress on reaching every child and adult with life-saving vaccines. As part of this process, Gavi shifted its operational model; streamlined its grant process; and added a new funding requirement for CSO engagement (see page 33 for more). In April 2022, Gavi appointed Amref Health Africa as host of the Gavi CSO Constituency – the first organisation located in a lower middle-income country to host this platform comprising more than 300 member organisations. In the first year of this new hosting arrangement, Amref Health Africa and members of the Gavi CSO Constituency extended the base of civil society partners working on equitable access to vaccines in lower-income countries.From April to May 2022, the Gavi CSO Constituency, in collaboration with RESULTS UK, UNICEF, Save the Children, USAID’s Momentum Country and Global Leadership, the Geneva Learning Foundation and Gavi, hosted a three-part webinar series on the need for equitable access to COVID-19 vaccines and best practices to address the backsliding in routine immunisation during the pandemic (read the briefing here). As part of Gavi’s efforts to facilitate meaningful participation of civil society in its various areas of work, the Alliance has organised regular dialogues in collaboration with the Gavi CSO Constituency, including five COVAX CSO dialogues, with a focus on integrating COVID-19 vaccination into routine immunisation; and in November 2022 launched a series of live talks with CSOs and partners on successes and challenges in vaccine equity, and the roles of civil society and local partners. The Gavi Secretariat further facilitated the engagement of the CSO Constituency in Gavi Board and Programme and Policy Committee meetings. \n\nPublic policy engagement: 2022 highlights \n\nTo deliver on the Gavi 5.0/5.1 strategy and COVAX, Gavi deepened its regional policy engagement in 2022 through advocacy, roundtable discussions and workshops, and resources such as Gavi impact in Africa. Some notable successes: \n\n– Routine immunisation and zero-dose agenda included in key regional and national policy frameworks – such as the African Union Campaign on Accelerated Reduction of Maternal Mortality in Africa (CARMMA PLUS) and draft Nigeria Governors’ Forum (NGF) comprehensive health advocacy, communication strategy and implementation plan \n\n– 18 First Ladies from the Organization of African First Ladies for Development (OAFLAD) joined Gavi in calling on governments and stakeholders to recommit to routine immunisation – recognising women’s roles in sustainable access to immunisation \n\n– Gavi and Amref Health Africa facilitated consultations in ten African countries – with highest numbers of zero-dose children \n\n– High-level political advocacy and technical discussions on COVID-19 pandemic response with the African Union (AU), Africa Centres for Disease Control and Prevention (Africa CDC) and Partnerships for African Vaccine Manufacturing (PAVM) – in November 2022, Gavi published a ten-point plan outlining key priorities to achieve the AU vision of sustainably expanding vaccine manufacturing capacity across Africa by 2040 \n\n– Health equity, immunisation and lessons learned from COVAX included in discussions on the Pandemic Accord and initial preparations for the Political Declarations on Pandemic Prevention, Preparedness and Response (PPPR) and Universal Health Coverage (UHC) – adopted in the 78th session of the United Nations General Assembly in September 2023 \n\n– Continued collaboration with the other 12 signatory agencies of the Global Action Plan for Healthy Lives and Well-being for All (SDG3 GAP) platform – for a more integrated impact 44 The healthy markets goal \n\n> Annual Progress Report\n\n# The healthy markets goal \n\n# 04 \n\n# Ensure healthy markets for vaccines and related products \n\n“My son recently got vaccinated against measles and polio. I am happy that he is safe now.” \n\nAlamgir, father to two-year-old Fazain. Read the full article Peshawar, Pakistan Credit: Gavi/2023/Asad Zaidi 45 Annual Progress Report \n\n> The healthy markets goal\n\n# Key highlights \n\n## Gavi’s market shaping efforts make life-saving vaccines and other immunisation products more accessible and affordable for lower-income countries. \n\n# 19 Through Gavi’s market shaping efforts, the number of manufacturers supplying prequalified Gavi-supported vaccines has grown from 5 in 2001 to 19 in 2022 (with more than half based in low-and middle-income countries). \n\n10 markets for vaccines and immunisation products exhibited acceptable levels of healthy market dynamics in 2022, meeting the target for the year. \n\n9 innovative products were within the pipeline of commercial-scale manufacturers in 2022, meeting the Alliance target of 8 by 2025 well ahead of schedule. \n\n2 new products with improved characteristics were newly offered to Gavi-supported countries in 2022: a new liquid rotavirus vaccine, improving ease of delivery for health care workers; and a new presentation for yellow fever vaccine, improving its cold chain footprint. 46 The healthy markets goal \n\n> Annual Progress Report\n\n# Results – healthy markets goal strategy indicators \n\n## Gavi’s 2021–2025 Market Shaping Strategy aims to shape market dynamics in more depth and breadth, with longer-term effects. \n\n2022 progress: on track \n\n2022 progress: on track \n\n2022 progress: on track \n\n# S4.1 S4.2 S4.3 \n\nHealthy market dynamics Incentivise innovations Scale up innovations \n\nHealthy market dynamics are assessed via analysis of fundamental market attributes: demand side dynamics, supply side dynamics and innovation. This holistic view of markets aligns market shaping activities and objectives with Gavi’s strategic goals to: introduce and scale up vaccines; and improve sustainability of immunisation programmes. \n\n2022 progress: Gavi’s ongoing market shaping efforts and collaborations with manufacturers helped ensure that 10 vaccine markets exhibited acceptable levels of healthy market dynamics, compared with a record 11 markets in 2021. Each market’s status for 2022 has been formally assessed with partners. This outcome is in line with Gavi’s target, despite a regression in the rotavirus vaccine market in 2022. \n\nData source: vaccine procurement data: UNICEF SD Memorandum of Understanding (MoU) reports; market intelligence data: Gavi MS roadshows, Alliance partner industry engagements, 2023 \n\nNumber of innovative products within the pipeline of commercial-scale manufacturers. \n\n2022 progress: The Vaccine Innovation Prioritisation Strategy (VIPS) sees continued progress. In 2022, five microarray patch (MAP) pipeline candidates have advanced through development; and two products have received approval for controlled temperature chain (CTC) labelling. The 2022 progress has brought the overall achievement to nine, meeting the Alliance target for 2025 well ahead of schedule. \n\nData source: Market intelligence data – Gavi Market Shaping roadshows, Vaccine Alliance partner industry engagements, 2023; Vaccine Innovation Prioritisation Strategy (VIPS) industry engagement \n\nNumber of vaccines and immunisation-related products with improved characteristics procured by Gavi, which gives an indication of the incremental benefits we are able to bring to countries’ immunisation programmes. \n\n2022 progress: Two new products with improved characteristics are newly offered. A liquid rotavirus vaccine was procured, improving ease of delivery for health care workers. A new presentation for a yellow fever vaccine was also procured, changing from ampoule to vial containers, improving its cold chain footprint. \n\nData source: Gavi-UNICEF SD MoU reports and key performance indicators, 2023 \n\n12 10 10 666444222000810 882022 2023 2024 2025 2021 2022 2022 2023 2023 2024 2024 2025 2025 2021 2021 Target: 10 \n\nTarget: 8\n\n11 10 209Target: 9\n\n247 Annual Progress Report \n\n> The healthy markets goal\n\n## Reflections on Year 2 of Gavi 5.0, Year 3 of COVID-19 pandemic \n\n# Progress – 2022 healthy market updates Achievements, progress and market challenges addressed \n\nCold chain equipment (CCE): The market for ice-lined refrigerators/ freezers (ILR) and solar direct drive (SDD) refrigerators/freezers has shown continued achievement of several market shaping goals. The ILR/SDD market supports seven suppliers and is seeing more balanced demand for different brands against the backdrop of a historical duopoly. Savings were achieved in 2022 against 2021 baseline pricing, largely through accessing volume-based discounts and shifts to cheaper products. Interventions are being developed and deployed to address the issue of monitoring unit performance, specifically country access to, and use of, CCE temperature data. \n\nVaccine Innovation Prioritisation Strategy (VIPS): Good progress continued on all three fronts of the VIPS initiative: microarray patches (MAPs), heat-stability and barcoding. Several phase 1 and 2 trials have been initiated for measles-rubella (MR), COVID-19 and influenza vaccines. Developers have started either to build or to design their manufacturing facilities, gearing up for late-stage clinical trials. VIPS partners are collaborating on Full Value of Vaccine Assessments (FVVA) for two MAPs: MR, which has been finalised; and typhoid conjugate vaccine (TCV), which is ongoing – establishing a new framework to assess their broad public health and socio-economic value. Two new vaccines received new or improved controlled temperature chain (CTC) qualification: TCV and an extension in the number of days that human papillomavirus (HPV) vaccine can remain in CTC without loss of potency/stability. Based on Gavi and UNICEF’s mandatory requirement, GS1 barcodes are now available on secondary packaging for most Gavi-funded vaccines; and serialisation is available for COVID-19 vaccines. \n\nCOVID-19 vaccine: In October 2022, Gavi published the COVID-19 vaccine market shaping roadmap, paving the way for a core Gavi vaccine programme. The strategy was developed in the context of an anticipated epidemiological and programmatic transition from the acute phase of the COVID-19 pandemic to an endemic phase of the disease. \n\nMalaria vaccine: The year 2022 saw WHO prequalification of the world’s first malaria vaccine (GSK’s RTS,S/AS01) and a contract for supply of GSK’s entire capacity of 18 million doses of this vaccine was rapidly concluded by UNICEF Supply Division on behalf of the Alliance. These 18 million doses of RTS,S, available in 2023–2025, will likely fall short of demand, such that when market health for malaria vaccine was assessed for the first time in 2022, it was designated “unacceptable requiring further intervention”. Hence Gavi is working to accelerate access to additional supply, expected to come with improved pricing – both through a second vaccine (R21/MatrixM) that is currently undergoing WHO policy and prequalification review, and via product transfer of RTS,S to a lower-cost manufacturer. Malaria vaccine market shaping roadmap is available on the Gavi website. \n\nHPV vaccine: The overall picture improved dramatically in 2022, with an imminent increase in global supply that will exceed demand – including via a fourth (quadrivalent) HPV vaccine in late-stage development, and the Strategic Advisory Group of Experts on Immunization (SAGE)’s April 2022 recommendation of a one-dose or two-dose schedule. There are three market dynamics requiring ongoing vigilance from Alliance teams: (1) imbalance in demand across the product menu, with no uptake of a new bivalent product available since 2021 – meaning continued overall inability to meet accumulated multi-age cohort (MAC) and routine vaccination demand; (2) uncertainties surrounding country adoption of the SAGE recommendation and, hence, overall Gavi market volumes in the long term; and (3) some delayed implementation as a result of the COVID-19 pandemic. However, with the SAGE one-dose recommendation currently applying only to two incumbent vaccines, challenges could persist for the uptake of newer vaccines to which the recommendation does not yet apply. HPV vaccine market shaping roadmap available on the Gavi website (to be updated in 2023). \n\nOral cholera vaccine (OCV): The supplier base produced reliably at full capacity, shipping a record 34 million doses in 2022 despite a historically challenging demand signal. Furthermore, in 2022 EuBiologics (in close alignment with Alliance partners) made investments in new equipment and production sites to increase capacity that will be available in 2024 and 2025. The surge in cholera outbreaks experienced in 2022 (see page 25 for more) was manageable within available supply, with 93% of global supply being used for outbreak response and aided by the adoption of a temporary one-dose outbreak-response schedule. However, this left 2.3 million doses available for preventive campaigns against 20 million doses approved by the Gavi Board. Long-term market health will benefit from Gavi’s imminent programmatic shift to high-quality preventive campaigns that will underpin stable, predictable demand. \n\nRotavirus vaccine: Unforeseen issues impacting all three rotavirus vaccine suppliers in 2021–2022 led to limitations in country access to preferred product presentations, and Gavi moved quickly to help seven countries switch to an alternative rotavirus vaccine to mitigate a significant disruption in supply of the most widely used product. The Alliance continues to closely monitor suppliers’ production planning to understand and further mitigate ongoing risks, and is improving tools to support countries in assessing different product presentations and optimising their vaccine portfolio. Rotavirus market shaping roadmap available on the Gavi website. Funding and finance 48 Annual Progress Report \n\n# Funding and finance \n\n# 05 \n\n# Partnering with governments and business to change immunisation for good \n\n“I have seen firsthand the devastation that preventable diseases can cause. That is why I am committed to promoting vaccination and making a difference in my community.” \n\nBauma, 24, a laboratory technician who is passionate about medicine Goma, Democratic Republic of the Congo Credit: Gavi/2023/Wise Kubuya Bebukya Funding and finance 49 Annual Progress Report \n\nBreak COVID Now Summit \n\nAt the April 2022 Break COVID Now Summit, world leaders committed additional resources to COVAX, affirming the international community’s solidarity in fighting the COVID-19 pandemic. Co-hosted by Gavi, alongside the leaders of Germany (G7 Presidency), Indonesia (G20 Presidency), Senegal (African Union Chair) and Ghana, the gathering resulted in US$ 4.8 billion in new commitments, including US$ 1.7 billion in sovereign donor pledges. As noted by H.E. Nana Addo Dankwa Akufo-Addo, President of the Republic of Ghana, “[M]any people still remain unvaccinated and unprotected; and in the event of another wave of infections or a mutation of the virus, these people will be at great risk. We therefore need to renew our commitment to support lower-income countries and support national COVID-19 vaccine objectives.” By end 2022, working closely with donors and partners, Gavi was able to raise US$ 12.5 billion for COVID-19 vaccine procurement and delivery. This was complemented by an ambitious dose donation programme, which secured more than 900 million doses. Thanks to these joint efforts, by December 2022 COVAX had shipped more than 1.88 billion COVID-19 vaccine doses to 146 countries and territories; and the 92 lower-income countries supported by the Gavi COVAX AMC had reached complete primary series coverage of 53%. \n\nSurge financing for equitable access \n\nThe COVID-19 pandemic made clear that upfront financing was needed to lock in doses early in order to deliver doses fast. In response, Gavi used its innovative financial expertise to swiftly develop new mechanisms. The Pandemic Vaccine Pool (PVP) enabled lower-income countries to maintain access to COVID-19 vaccines, including in response to new emergencies. New facilities were developed with the European Investment Bank (EIB) and U.S. International Development Finance Corporation (DFC) to access funds more rapidly than ever. The year 2022 was also a landmark in bolstering the International Finance Facility for Immunisation (IFFIm), and launching new mechanisms to mitigate risks and expand access to vaccines. Moving forward, Gavi will go further by bringing these innovative financing tools together into an overarching Day Zero Financing Facility that will accelerate equitable access to vaccines in the next pandemic. \n\n# Mobilising global support; scaling up innovation, private sector partnerships \n\n## The year 2022 was pivotal for Gavi, as we continued to fight the COVID-19 pandemic and launched new innovations that will help shape the future of global health security, while simultaneously redoubling our efforts on Gavi’s core programmes. It is more evident than ever that broad, equitable access to routine immunisation is the bedrock of global health security. Funding and finance 50 Annual Progress Report \n\nFighting the pandemic with unique financial innovation expertise \n\nU.S. International Development Finance Corporation (DFC) COVAX Rapid Financing Facility is a liquidity frontloading facility of up to US$ 1 billion to monetise pledges soon after donors make them, enabling Gavi to purchase vaccines faster. The partnership was announced in May 2022 at the second Global COVID-19 Summit, co-hosted by the United States of America, Belize, Germany, Indonesia and Senegal. \n\nEuropean Investment Bank (EIB) Frontloading Facility is designed to frontload grants to Gavi to boost routine and pandemic vaccination, bringing forward signed donor grants and immediately converting them to available funds. Beyond EIB’s earlier pandemic facilities, a new tranche of €500 million was signed in December 2022 to support Gavi’s broader agenda. The Facility goes beyond providing immediate liquidity from traditional grants by accepting contingent pledges for which the contingency has been met. \n\nPandemic Vaccine Pool (PVP) was created in 2022 as a fund with immediate liquidity to respond to the uncertainties of the pandemic. In addition to supporting COVID-19 vaccination efforts – including the purchase of variant-containing vaccines and boosters – the PVP enables Gavi to respond to unanticipated demand, including potential variants that may spike demand (or evade the protection provided by current vaccines), avoiding delays in delivering vaccines which would otherwise lead to a vicious cycle of more disease. \n\nInternational Finance Facility for Immunisation (IFFIm) has proven its versatility and value in ways that could not have been foreseen at its creation in 2006, providing a foundation for market shaping and surge production of vaccines. In 2022, the United Kingdom and Spain added new pledges to IFFIm totalling US$ 680 million; and IFFIm provided more than US$ 2 billion to Gavi, including US$ 1 billion for COVAX – the highest IFFIm funding to Gavi in a single year. Since inception, IFFIm has attracted more than US$ 9.6 billion. It was one of the earliest pandemic-response funding sources available to the Gavi COVAX AMC and CEPI. \n\nIFFIm Contingent Financing Mechanism (CFM) is currently being developed to provide rapid, at-risk financing for future pandemic response. It draws on lessons from the pandemic to allow donors to preposition funding via contingent grants, to be activated if needed during a future pandemic. The IFFIm CFM capitalises on IFFIm’s 17 years of experience frontloading funding through the issuance of bonds in capital markets, as well as IFFIm’s stress-tested role as a surge funding vehicle for the Gavi COVAX AMC. The IFFIm CFM is expected to contribute significantly to Gavi’s pandemic response financing capabilities in the future. \n\nCOVAX Cost-Sharing Mechanism was designed to allow countries to access incremental COVID-19 doses through a streamlined procurement process while leveraging domestic resources. Launched as a partnership between Gavi, the World Bank and the Asian Development Bank, and later supported by the European Investment Bank, MedAccess and the Soros Economic Development Fund, this mechanism was available throughout the pandemic to support countries in reaching their COVID-19 immunisation ambitions. \n\nSovereign donors and the European Union in 2022 \n\n> 2021–2037\n> US$ 23.4bn COVAX US$ 12.5bn\n> 2000–2010\n> US$ 4.2bn\n> 2011–2015\n> US$ 7.4bn\n> 2016–2020\n> US$ 9.2bn US$ 20.8bn 2000–2020\n> US$ 10.9bn\n\nDonor commitments by end 2022 to Gavi, 2000–2037, US$  \n\n> Gavi core COVAX Funding and finance\n\n## 51 Annual Progress Report \n\nAdvance Market Commitment for African vaccine manufacturing \n\nThe COVID-19 crisis underlined the strong need for diversified manufacturing of vaccines – both pandemic and routine – especially to serve the African continent. In response, Gavi launched a process in 2022 that delivered a white paper in June, a ten-point plan for the AU and G7 in November, and a Gavi Board paper in December. The Board approved this comprehensive strategy that rests on four pillars: (1) support for strategic antigen selection by manufacturers/ countries; (2) market shaping; (3) demand creation; and (4) an Advance Market Commitment (AMC) for African vaccine manufacturing. The Board requested detailed proposals for the AMC, with a full concept to be presented to the Board in late 2023. \n\nSharing Gavi’s pandemic learnings across multilateral forums \n\nThroughout 2022, Gavi took a leading role in various multilateral negotiations, including G7 and G20, as well as in forums shaping the future architecture of global health. Under Germany’s leadership of the G7, Gavi played a significant role in global health deliberations; and with the Indonesian G20 Presidency, as part of the Health and Finance-Health tracks, Gavi provided insights and lessons from COVAX – along with recommendations for the vaccines pillar of the ecosystem of equitable access to medical countermeasures for future pandemic preparedness. In particular, Gavi deepened engagement with international financial institutions (IFIs) on practical solutions to provide fast-triggered surge financing mechanisms in the future; and to support Gavi’s foundational pandemic prevention, preparedness and response (PPPR) work to strengthen primary health care systems. In addition, Gavi is one of 13 implementing entities for the World Bank-hosted Pandemic Fund and is engaged closely as an observing Board member of the Fund as it takes shape. Gavi laid the groundwork with other implementing entities and countries to develop a future proposal, likely in 2023. \n\nGavi’s June 2023 Mid-Term Review event \n\nThe June 2023 Global Vaccine Impact Conference in Madrid convened global leaders to evaluate the Vaccine Alliance’s progress midway through its five-year strategy and reinforce efforts to extend the power of immunisation. The Conference, convened by Spain’s Minister for Foreign Affairs, European Union and Cooperation José Manuel Albares, saw health ministers from 17 Gavi implementing countries, and ministers and officials from 23 donor countries, renew their commitment to work together; build on the successes of the past two years; tackle ongoing challenges; and harness innovation and collaboration. This event launched Gavi’s Mid-Term Review (MTR) report, Raising Generation ImmUnity, which looked at data from the first two years of the Alliance’s 2021–2025 strategic period. The report charted progress against the 2019 Investment Opportunity and showed that the Vaccine Alliance is on track to meet the majority of the key commitments made to donors. The Alliance’s success in providing an agile response to the COVID-19 pandemic through the largest vaccine roll-out in history, and in sustaining progress in immunisation, are testaments to its power and resilience. At the Conference, the Republic of Korea pledged US$ 70 million to allow Gavi to continue its efforts to fight against COVID-19; this funding could also support wider efforts by Gavi to make sure the world is better prepared for the next pandemic. The Conference also saw Gavi and the European Investment Bank (EIB) extend its partnership to immediately convert signed donor grants to available funds. The €1 billion financing facility will boost routine and outbreak vaccination programmes, and will accept contingent grants once those conditions have been met. The Conference also saw many other critical commitments to Gavi’s immunisation programmes from governments, civil society organisations and the private sector. \n\nPhilanthropic partners: supporting vaccine equity \n\nPhilanthropic partners have a critical role to play in providing flexible capital to catalyse innovation and new approaches to immunisation delivery. The Rockefeller Foundation partnered with Gavi to accelerate the availability and adoption of innovations that could strengthen the critical role that frontline health workers play in delivering immunisation services in Gavi-supported countries. The Foundation supported the rapid implementation of innovative solutions, leveraged new partners, and generated insights through evaluations and landscape analyses. In 2022, Gavi worked with partners to transform health workers’ learning and performance management (including through digital technologies), which is now being applied at country level to improve health worker performance, strengthen programmes and increase immunisation coverage. \n\n> Gavi, Orange, Power Africa and RESOLVE are providing sustainable electricity to remote off-grid health facilities in Sierra Leone (see page 52 for more). Read the full article Credit: Power Africa, Tolu Jethro Bade, Envizage Concepts Annexes\n\n## 52 Annual Progress Report \n\nBuilding on the lessons of the Wellness Pass pilot project in \n\nMauritania , which digitally tracks the routine immunisation status of 30,000 children, the partnership between Gavi and Mastercard expanded to Ethiopia in June 2022. Now leveraging the DHIS2 tracker’s Electronic Immunisation Register (EIR) digital platform, the Wellness Pass solution will enable 2 million Ethiopians to carry their vaccination data digitally, allowing for quick identification and monitoring, regardless of location. With strong project objectives, a robust structure and the Ethiopia Ministry of Health’s enthusiastic support, the USAID-funded Ethiopia Digital Health Activity has joined the partnership as a technical lead, with additional funding of US$ 2.5 million – aiming to double the project’s impact. Since 2021, Gavi has been working closely with Orange, Power Africa and RESOLVE in Sierra Leone to provide off-grid renewable electricity generation, storage systems and internet connectivity to rural health facilities, in order to increase their operational capacity and their community’s immunisation uptake. In 2022, the project equipped 16 health facilities with solar panels. The project received high-level visibility; and in April 2022, USAID’s Power Africa announced the creation of a five-year Global Development Alliance (GDA), investing US$ 47 million to catalyse an additional US$ 150 million dollars from partners to expand the model to 10,000 health facilities in sub-Saharan Africa through the Health Electrification and Telecommunication Alliance (HETA). Also in partnership with Orange, Gavi’s initiative with Côte d’Ivoire’s \n\nMinistry of Health, Public Hygiene and Universal Health Coverage is a mobile phone app, M-Vaccin, that creates electronic vaccination schedules and sends caregivers text and voice reminders in seven vernacular languages. Launched in December 2019, implementation accelerated in 2022, with a total of 1,000 health agents trained and 20,000 mother/child pairs registered on an upgraded M-Vaccin app that integrates epidemiological surveillance forms; tracks registered caregivers across health facilities; and automatically identifies zero-dose children and those who have missed immunisations. A June 2022 impact assessment revealed that M-Vaccin reduced health workers’ administrative workload by 96%, so they can devote more time and attention to essential vaccination tasks and caregivers. The Ministry of Health aims to expand M-Vaccin nationally. \n\nPrivate sector spotlight Private sector and innovation partners: key roles in Gavi’s mission \n\nThe private sector has provided unprecedented funding, expertise, advocacy and innovative solutions that are transforming the way lower-income countries deliver immunisation. The pandemic brought a new focus on the power of immunisation from the private sector. Underpinned by innovative mechanisms such as the Gavi Matching Fund and INFUSE, more than 80 private sector partners across industry sectors and geographies have provided support to Gavi’s programmes as of 2022. And at the Break COVID Now Summit, new private sector donor commitments exceeded US$ 123 million. Showcasing the power of country-driven solutions and innovation, Gavi and Girl Effect joined forces once more in 2022 with a four-year, US$ 8 million programme in Ethiopia and United Republic of Tanzania to increase uptake of HPV and other routine vaccines. Working in collaboration with the Ministries of Health, Gavi and Girl Effect will develop youth-centred behaviour change communication to create demand for vaccination among young people and address the gender-related barriers that limit vaccine uptake. \n\nPioneering tomorrow’s health technology today \n\nIn 2022, Gavi continued to fuel the scale-up of groundbreaking solutions – including INFUSE Pacesetters – by connecting high-impact, proven innovations where countries need them most. 2017 INFUSE Pacesetter Parsyl – a data-powered insurance and risk management solution for essential supply chains – scaled up in Senegal, Burkina Faso and Côte d’Ivoire, monitoring temperature in transport devices and collecting valuable data for maintenance. Through a 2019 pilot in Bangladesh with Gavi and NEC, 2018 INFUSE Pacesetter Simprints – a biometric solution to verify “last mile” vaccine delivery – demonstrated in that biometrics can be used to confirm the identity of children as young as nine months. This partnership was expanded to Ghana and is gearing up to support malaria vaccination. To reach zero-dose and under immunised children in India’s urban slums, 2019 INFUSE Pacesetter ZMQ leverages the power of transgender people to help map communities and build health-seeking behaviours through traditional storytelling artforms. Adding to existing operations in Rwanda, Ghana and Kenya, Zipline’s drone delivery service opened its first distribution centre in 2022 in Kaduna State, Nigeria – with support from Gavi and the UPS Foundation – becoming the, supplier to 293 health facilities, of which 108 are exclusively served by Zipline. \n\n> Wellness Pass Ethiopia project launch, June 2022 Read the full article Credit: JSI Ethiopia/2022 Annexes\n\n## 53 Annual Progress Report \n\n# Annexes \n\nPage 54 1.  Contributions to Gavi \n\nCash received by Gavi Gavi COVAX AMC contributions Country co-financing commitments Innovative finance mechanisms: AMC and IFFIm Page 57 2.  Governance structure \n\nThe Gavi Board Other Gavi-related governance structures Page 58 3.  Contributions pledged to Gavi \n\nPage 66 4.  Commitments for country programmes \n\n## 2000–2026 \n\nPage 68 5.  Board approvals for country programme \n\n## expenditure 2000–2028 \n\nPage 70 6.  Commitments and Board approvals for \n\n## investment cases \n\nCommitments for investment cases 2000–2028 Board approvals for investment case expenditure 2000–2028 \n\nDue to rounding, numbers presented throughout these annexes may not add up precisely to the totals, and percentages may not reflect the absolute figures. 54 Annexes  \n\n> Annual Progress Report\n\nSweden 36 642 665 \n\nSwitzerland 14 171 \n\nTownship Zug <1 <1 \n\nUganda <1 <1 <1 \n\nUnited Kingdom 1 3,281 63 3,404 \n\nUnited States of America 580 3,360 6,860 \n\nViet Nam 1 1\n\nDonor governments and the European Union total: 1,114 13,918 1,489 22,410 AerCap Ireland Limited <1 \n\nAl Ansari Exchange 1 1\n\nAlight Solutions <1 \n\nAlwaleed Philanthropies 4 4\n\nAnalog Devices Foundation 1\n\nArm Limited <1 1 1\n\nAsia Philanthropy Circle 2\n\nBill & Melinda Gates Foundation 341 4,602 4,808 \n\nBlackBerry <1 \n\nCentene Charitable Foundation <1 \n\nCharities Trust 1\n\nCisco 5\n\nThe Coca-Cola Foundation 1\n\nCODE (RED) <1 <1 \n\nCollins Aerospace (Goodrich Corporation) <1 \n\nCroda Foundation <1 <1 \n\nDolby Laboratories Charitable Fund <1 \n\nELMA Vaccines and Immunization Foundation \n\n4 4\n\nEpiroc AB <1 \n\nEtsy <1 \n\nFrank McHugh O'Donovan Foundation, Inc. <1 \n\nGamers Without Borders (GWB) 1 2\n\nGates Philanthropy Partners 18 \n\nGoogle.org <1 <1 <1 8\n\nDonors 2022 Total 2000–2022 Gavi COVAX AMC (2022) GRAND TOTAL (inc. Gavi COVAX AMC) Australia 1 449 56 538 \n\nAustria 9\n\nBahrain 3\n\nBelgium 5 9\n\nBhutan <1 \n\nBrazil 1 23 23 \n\nBurkina Faso 1 1\n\nCanada 73 828 37 1,239 \n\nChina 1 4 13 100 113 \n\nColombia 1\n\nCroatia 1\n\nDenmark 3 65 11 91 \n\nEstonia <1 <1 \n\nEuropean Union (EU) 1 16 333 69 944 \n\nFinland 3 19 22 \n\nFrance 55 363 563 \n\nGermany 138 1,181 2,129 \n\nGreece 2\n\nIceland 1 1 2 9\n\nIndia 3 18 18 \n\nIreland 3 69 1 78 \n\nItaly 25 145 105 692 \n\nJapan 1 30 218 800 1,218 \n\nKuwait 1 10 51 \n\nLiechtenstein <1 1\n\nLuxembourg 1 19 2 24 \n\nMalaysia <1 \n\nMalta <1 <1 \n\nMauritius <1 \n\nMexico <1 \n\nMonaco <1 2 2\n\nNetherlands 12 610 32 729 \n\nNew Zealand 19 \n\nNiger 1 1\n\nNorway 1 123 2,160 2,248 \n\nOman 3 4\n\nPalau 1 <1 <1 \n\nPhilippines 1\n\nPoland 1\n\nPortugal <1 <1 1\n\nQatar 12 22 \n\nRepublic of Korea 1 10 40 100 250 \n\nRepublic of Moldova <1 \n\nRussian Federation 10 10 \n\nSaudi Arabia 25 50 175 \n\nSingapore 5\n\nSlovenia <1 1\n\nSpain 2 54 5 60 \n\n## 1. Contributions to Gavi as of 31 December 2022 (US$ millions) \n\nCash received by Gavi Donors 2022 Total 2000– 2022 Gavi COVAX AMC (2022) GRAND TOTAL (inc. Gavi COVAX AMC) Donors 2022 Total 2000– 2022 Gavi COVAX AMC (2022) GRAND TOTAL (inc. Gavi COVAX AMC) 55 Annual Progress Report \n\n> Annexes\n\nHis Highness Sheikh Mohamed bin Zayed Al Nahyan 38 38 \n\nInternational Federation of Pharmaceutical Wholesalers (IFPW) 2 2\n\nKerk in Actie <1 <1 \n\nKing Baudouin Foundation <1 \n\nKing Salman Humanitarian Aid & Relief Centre (KSrelief) 5 5\n\n”la Caixa” Foundation 4 50 50 \n\nMastercard 3 10 10 26 \n\nOPEC Fund for International Development (OFID) 1 1\n\nPagerDuty <1 \n\nPortuguese private sector 2\n\nPratt & Whitney <1 \n\nProcter & Gamble 5\n\nReed Hastings and Patty Quillin 30 \n\nThe Rockefeller Foundation 2 5 5\n\nRussell Reynolds Associates <1 \n\nSalesforce <1 1\n\nShell International B.V. 10 \n\nSMBC Aviation Capital Limited <1 \n\nSovereign Order of Malta <1 \n\nSpotify 1\n\nStanley Black & Decker 1\n\nSymAsia Foundation <1 \n\nThistledown Foundation 4\n\nTikTok 5 10 \n\nToyota Tsusho 4 1\n\nTwilio 5 10 \n\nUBS Optimus Foundation 2\n\nUnilever 5 1 7 7\n\nUPS 1 2 2\n\nVaccine Forward <1 2\n\nVisa Foundation 5\n\nWellcome Trust <1 <1 <1 \n\nWHO Foundation - Go Give One campaign 7 7\n\nWise <1 \n\nWorkday Foundation <1 <1 \n\nOther donors 6 1 145 68 259 \n\nVaccine delivery and/or logistics to Gavi COVAX AMC COVAX dose sharing – ancillary costs Gavi COVAX AMC Donor 2022 Total Belgium 3 3\n\nCanada 32 32 \n\nDenmark 2\n\nEuropean Union (EU) 43 43 \n\nIreland 1 2\n\nNew Zealand 3 4\n\nUnited Kingdom 2\n\nTotal: 82 89 Foundations, institutions, organisations and corporations total: 360 4,876 88 5,342 Subtotal: 1,474 18,793 1,577 27,751 IFFIm proceeds 7,8 634 4,416 195 5,391 \n\nPneumococcal AMC proceeds 9 1,313 1,313 \n\nTotal contributions: 2,108 24,522 1,772 34,455 Gavi COVAX AMC Donor 2022 Total Belgium 1 1\n\nCanada 87 143 \n\nEuropean Union (EU) 355 355 \n\nFrance 23 \n\nGermany 417 630 \n\nIreland 4 4\n\nNew Zealand 6\n\nUnited States of America 500 \n\nBill & Melinda Gates Foundation 30 \n\nTotal: 864 1,691 COVAX Humanitarian Buffe r\n\nGavi COVAX AMC Donor 2022 Total France 6\n\nGermany (47) 10 11 \n\nTotal: (47) 10 16 \n\nNotes: 1 Contribution amounts include cash donations to the COVAX Facility from funds remaining from Self-Financing Participant (SFP) commitments and/or dose sharing activities. \n\n2 Includes contributions from the Basque Agency for Development Cooperation and the Catalan Agency for Development Cooperation. \n\n3 Mastercard has contributed: (i) US$15 million to support the Gavi COVAX AMC with a US$ 15 million grant for the purchase of COVID-19 vaccines, US$ 10 million of which was matched by the Bill & Melinda Gates Foundation (US$ 2 million) and Gates Philanthropy Partners (US$ 8 million); and (ii) a US$ 10 million cash contribution to support the implementation of digital solutions to Gavi core programmes (no match). In addition, Mastercard conducted a consumer-based fundraising campaign through its donation platform that raised a total of US$ 2.5 million. \n\n4 Toyota Tsusho contributed 100,000,000 Japanese yen to the Gavi COVAX AMC. In addition, Toyota Tsusho has donated five Vaccine Land Cruisers to Gavi which are specifically designed for last-mile vaccine delivery and which have been prequalified by WHO. \n\n5 Unilever provides resources to Gavi on a leveraged partnership project. \n\n6 Includes contributions from other private sector corporations, foundations, individuals, institutions and organisations. \n\n7 IFFIm proceeds: cash disbursements from the World Bank to the GAVI Fund Affiliate (GFA) (2006–2012) and to Gavi (2013–2022). \n\n8 In 2018, the Gavi Alliance Board approved Gavi supporting research and development of new vaccines by the Coalition for Epidemic Preparedness Innovations (CEPI) through an IFFIm transaction of 600 million Norwegian kroner (US$ 66 million) to frontload an equivalent Norway grant for this purpose. Subsequently in 2020, the Gavi Alliance Board approved Gavi supporting research and development of new COVID-19 vaccines by CEPI, through a similar IFFIm arrangement. To date, IFFIm has raised US$ 206 million for this initiative supported by additional grants from Norway and Italy. \n\n9 Pneumococcal AMC proceeds: cash transfers from the World Bank to Gavi. \n\n10 The “(47)” pertains to the remainder of funds that were returned to the donor after completion of the project, as per terms of the donor agreement. Contributions presented in the tables on pages 54 and 55 may not add up precisely to the grand totals due to rounding; and because contributions to the Gavi COVAX AMC in 2020 and/or 2021 are not shown in separate columns. \n\nDonors 2022 Total 2000– 2022 Gavi COVAX AMC (2022) GRAND TOTAL (inc. Gavi COVAX AMC) 56 Annexes \n\n> Annual Progress Report\n\nRe-directed funds: Gavi COVAX AMC (177.5) \n\nGavi core programmes (10) \n\nNet total applied to Pneumococcal AMC: 1,312.5 1. Contributions to Gavi as of 31 December 2022 (US$ millions) \n\nAMC commitments Total 2009–2020 US$ equivalent (in millions) 2Bill & Melinda Gates Foundation 50 \n\nCanada 200 \n\nItaly 635 \n\nNorway 50 \n\nRussian Federation 80 \n\nUnited Kingdom 485 \n\nTotal contributed: 1,500 \n\nCash received by Gavi \n\nin support of Gavi for its role in supporting the Polio Eradication and Endgame Strategic Plan (2013–2020) \n\nInnovative finance mechanisms: Pneumococcal AMC 3Period of commitment (years) Amount committed (millions) Donor Currency of pledge (in millions) US$ equivalent (in millions) 2Australia 2011–2030 AUD 284 284 \n\nBrazil 2018–2037 US$ 20 20 \n\nFrance 2007–2026 EUR 1,390 1,884 \n\nItaly 2006–2030 EUR 649 815 \n\nNetherlands 2009; 2012–2030 EUR 330 US$ 67 487 \n\nNorway 2006–2020; 2022–2030 NOK 5,500 US$ 27 686 \n\nSouth Africa 2007–2026 US$ 20 20 \n\nSpain 2006–2035 EUR 290 345 \n\nSweden 2007–2031 SEK 526 66 \n\nUnited Kingdom 2007–2029 GBP 2,091 3,558 \n\nTotal: 8,165 IFFIm grants for CEPI (signed as of 31 December 2022) Donor Period of commitment (years) Currency pledged (in millions) US$ equivalent (in millions) 2Italy 2020 EUR 5 6\n\nNorway 2021–2030 NOK 2,600 266 \n\nTotal: 272 IFFIm grants for Gavi COVAX AMC (signed as of 31 December 2022) Donor Period of commitment (years) Currency pledged (in millions) US$ equivalent (in millions) 2Australia 2022–2030 AUD 86 62 \n\nNorway 2021–2030 NOK 1,000 116 \n\nSweden 2021–2030 SEK 2,250 259 \n\nUnited Kingdom 2022–2029 GBP 500 672 \n\nTotal: 1,109 IFFIm grants announced but unsigned by 31 December 2022 Donor Period of commitment (years) Currency pledged (in millions) US$ equivalent (in millions) 2Canada (Gavi Core) 2023–2030 CAD 125 92 \n\nSpain (CEPI) TBD EUR 75 TBD \n\nAustralia (CEPI) TBD AUD 50 TBD \n\nInnovative finance mechanisms: IFFIm commitments \n\nIFFIm grants for Gavi core programmes (signed as of 31 December 2022) \n\nNotes: 1 This includes the three countries with fiscal year alignment for which obligations were due by June 2022: Ethiopia, Kenya and Pakistan. It excludes the United Republic of Tanzania, for which Gavi aligned co-financing obligations to its fiscal year (with obligations due by June 2023 instead of December 2022). \n\n2 Local currency pledge values converted to US$ at rates prevailing at the time of signing of the respective donor grant agreements. \n\n3 A total of US$ 187.5 million of Pneumococcal Advance Market Commitment (AMC) funds remained unutilised at the close of the Pneumococcal AMC on 31 December 2020, of which US$ 177.5 million was redirected for use in the Gavi COVAX AMC and US$ 10 million was redirected for use in Gavi core programmes, as agreed with Pneumococcal AMC donors. \n\nDonors 2022 Total Norway 147 \n\nUnited Kingdom 40 \n\nGovernments total: 187 Bill & Melinda Gates Foundation 241 \n\nPrivate contributions total: 0 241 Total: 0 428 2022 2000–2021 Co-financing 162.7 million 1 1.33 billion \n\nCountry co-financing commitments (in US$) Annexes 57 Annual Progress Report  \n\n> Source: Gavi, the Vaccine Alliance\n\nOrganisations WHO \n\nZsuzsanna Jakab \n\nUNICEF \n\nOmar Abdi \n\nThe World Bank \n\nJuan Pablo Uribe \n\nBill & Melinda Gates Foundation \n\nViolaine Mitchell \n\nIndependent members \n\nJosé Manuel Barroso, Chair \n\nMargaret (Peggy) Hamburg Teresa Ressel Yibing Wu Afsaneh Beschloss Awa Marie Coll Seck Naguib Kheraj Anne Schuchat Deena Shiff \n\nIndependent individuals (x9) Implementing country governments (x5) WHO UNICEF The World Bank Donor country governments (x5) Gavi CEO (non-voting) Research and technical health institutes Bill & Melinda Gates Foundation Civil society organisations Industrialised country vaccine industry Developing country vaccine industry 28 seats on the Gavi Board \n\nThe Gavi Board Constituencies Implementing country government representatives \n\nConstituency 1: Ethiopia & Ghana \n\nKwaku Agyeman-Manu (Ghana) \n\nConstituency 2: India & Lao People’s Democratic Republic \n\nMansukh Mandaviya (India) \n\nConstituency 3: Pakistan & Somalia \n\nAamer Ikram (Pakistan) \n\nConstituency 4: Armenia & Honduras \n\nAnahit Avanesyan (Armenia) \n\nConstituency 5: Burkina Faso & Angola \n\nRobert Lucien Kargougou (Burkina Faso) \n\nDonor government representatives \n\nUSA/Australia/Republic of Korea \n\nSarah Goulding (Australia), Vice Chair \n\nUnited Kingdom/Canada/Qatar \n\nBeth Arthy (United Kingdom) \n\nJapan/Italy/New Zealand/Spain \n\nTakeshi Akahori (Japan) \n\nGermany/France/Luxembourg/European Union/Ireland \n\nGabriella Fésüs (European Union) \n\nNorway/Finland/Netherlands/Sweden/ Switzerland \n\nJohn Arne Røttingen (Norway) \n\nIndustrialised country vaccine industry \n\nRoger Connor (GSK) \n\nDeveloping country vaccine industry \n\nMahima Datla (Biological E. Limited, India) \n\nCivil society organisations \n\nRafael Vilasanjuan (ISGlobal) \n\nResearch and technical health institutes \n\nMarta Nunes (Vaccine Preventable Diseases/Respiratory and Meningeal Pathogens Research Unit, South Africa) \n\nNon-voting member \n\nSeth Berkley (CEO, Gavi) \n\nOther Gavi-related governance structures The International Finance Facility for Immunisation (IFFIm) Company \n\nKenneth G. Lay, Chair \n\nSenior Managing Director, The Rock Creek Group \n\nBertrand de Mazières, Audit Committee Chair \n\nDirector General for Finance, European Investment Bank \n\nDoris Herrera-Pol \n\nFormer Global Head of Capital Markets, the World Bank \n\nHelge Weiner-Trapness \n\nFounding Partner, Quintus Partners \n\nJessica Pulay \n\nCo-Head of Policy and Markets, UK Debt Management Office \n\nHassatou Diop N’Sele \n\nVice-President for Finance and Chief Financial Officer (CFO), African Development Bank Group \n\nMonique Barbut \n\nPresident, WWF France \n\nIngrid van Wees \n\nVice-President for Finance and Risk Management, Asian Development Bank \n\n## 2. Governance structure as of 31 December 2022 58 Annexes  \n\n> Annual Progress Report\n\nDonor governments and the European Union \n\n> Direct contributions Pneumococcal AMC IFFIm  2Total As % of grand total  3Direct contributions Matching Fund Pneumococcal AMC IFFIm  2Total As % of grand total  3Direct contributions Matching Fund Pneumococcal AMC IFFIm  4Gavi COVAX AMC Gavi COVAX AMC (Matching Fund) Total As % of grand total  3\n\nAustralia 7 29 29 1% 242 28 270 4% 157 77 234 3% \n\nAustria \n\nBahrain \n\nBelgium 8\n\nBhutan \n\nBrazil 7 3 3 <1% \n\nBurkina Faso \n\nCameroon \n\nCanada 9 152 125 277 7% 120 50 169 2% 404 404 4% \n\nChina 7 5 5 <1% \n\nColombia \n\nCroatia \n\nDenmark 10 32 32 1% 13 13 <1% 11 11 <1% \n\nEstonia \n\nEuropean Union (EU) 7 58 58 1% 35 35 <1% 240 240 3% \n\nFinland 3 3 <1% \n\nFrance 11, 12 19 192 211 5% 127 306 433 6% 109 347 456 5% \n\nGermany 13 22 22 1% 186 186 3% 668 668 7% \n\nGreece \n\nIceland 7 1 1 <1% \n\nIndia 3 3 <1% 9 9 <1% \n\nIreland 14 30 30 1% 15 15 <1% 17 17 <1% \n\nItaly 158 107 265 6% 266 152 418 6% 115 131 130 376 4% \n\nJapan 7 54 54 1% 95 95 1% \n\nKuwait 1 1 <1% \n\nLiechtenstein \n\nLuxembourg 6 6 <1% 5 5 <1% 5 5 <1% \n\nMalaysia \n\nMalta \n\nMauritius \n\nMexico \n\nMonaco 1 1 <1% \n\nNetherlands 216 14 230 5% 149 72 220 3% 211 11 82 304 3% \n\nNew Zealand 15 \n\nNiger \n\nNorway 7 526 2 41 569 14% 612 42 94 748 10% 770 96 866 9% \n\nOman 3 3 <1% \n\nPalau 7Philippines \n\nPoland \n\nPortugal \n\nQatar 10 10 <1% \n\nRepublic of Korea 7 <1 <1 <1% 7 7 <1% 22 22 <1% \n\nRepublic of Moldova \n\nRussian Federation 8 8 <1% 40 40 1% 22 22 <1% \n\nSaudi Arabia 23 23 <1% \n\nSingapore \n\n## 3. Contributions pledged to Gavi 1 includes pledges as of 31 December 2022 (US$ millions) \n\n2000–2010 2011–2015 2016–2020 59 Annual Progress Report \n\n> Annexes\n\n219 62 95 25 400 2% 74 37 112 5% 9 9 <1% 3 3 <1% 3 16 20 <1% <1 <1 <1% 5 109 114 1% 12 12 1% 1 1 <1% 1 1 <1% 460 586 1,046 5% 20 100 120 1% 1 1 <1% 1 1 <1% 7 29 36 <1% <1 <1 <1% 321 1,009 1,331 6% 19 19 <1% 268 579 336 1,182 6% 156 156 7% 716 1,589 2,305 11% 2 2 <1% 8 8 <1% 15 15 <1% 20 15 35 <1% 112 153 548 813 4% 180 180 8% 140 1,500 1,640 8% 50 50 <1% 1 1 <1% 6 6 11 <1% <1 <1 <1% <1 <1 <1% <1 <1 <1% <1 <1 <1% 1 <1 1 <1% 56 28 153 119 355 2% 153 153 7% 29 29 <1% 1 1 <1% 650 151 88 58 947 4% 271 58 329 15% 1 1 <1% <1 <1 <1% 1 1 <1% 1 1 <1% <1 1 1 <1% 10 10 20 <1% 30 210 240 1% <1 <1 <1% 10 10 <1% 3 150 153 1% 5 5 <1% \n\n> Direct contributions Matching Fund  5IFFIm  6Gavi COVAX AMC Gavi COVAX AMC (Matching Fund) Gavi COVAX AMC (IFFIm)  6Total As % of grand total  3IFFIm  6Gavi COVAX AMC (IFFIm)  6Total As % of grand total  3\n\n2021–2025 2026–2037 Donors Australia 7Austria Bahrain Belgium 8Bhutan Brazil 7Burkina Faso Cameroon Canada 9China 7Colombia Croatia Denmark 10 Estonia European Union (EU) 7Finland France 11, 12 Germany 13 Greece Iceland 7India Ireland 14 Italy Japan 7Kuwait Liechtenstein Luxembourg Malaysia Malta Mauritius Mexico Monaco Netherlands New Zealand 15 Niger Norway 7Oman Palau 7Philippines Poland Portugal Qatar Republic of Korea 7Republic of Moldova Russian Federation Saudi Arabia Singapore 60 Annexes \n\n> Annual Progress Report\n\n2000–2010 2011–2015 2016–2020 Donors \n\n> Direct contributions Pneumococcal AMC IFFIm  2Total As % of grand total  3Direct contributions Matching Fund Pneumococcal AMC IFFIm  2Total As % of grand total  3Direct contributions Matching Fund Pneumococcal AMC IFFIm  4Gavi COVAX AMC Gavi COVAX AMC (Matching Fund) Total As % of grand total  3\n\nSlovenia \n\nSouth Africa 4 4 <1% 4 4 <1% 3 3 <1% \n\nSpain 16 43 58 101 2% 51 51 1% 43 43 <1% \n\nSweden 123 10 132 3% 255 11 266 4% 189 9 198 2% \n\nSwitzerland 14 14 <1% \n\nTownship Zug \n\nUganda \n\nUnited Kingdom 7, 17 137 22 153 313 7% 1,424 61 317 475 2,277 31% 1,378 85 696 2,159 23% \n\nUnited States of America 18, 19 647 647 15% 733 733 10% 1,400 1,400 15% \n\nViet Nam \n\nDonor governments and the European Union total: 2,039 316 578 2,933 70% 3,980 61 715 1,192 5,947 80% 5,860 11 238 1,487 7,597 82% \n\nNotes: 1 Some contributions may be received by Gavi in years different to those for which the pledges were made. \n\n2 A number of the “US$ equivalent values” of actual International Finance Facility for Immunisation (IFFIm) donor contributions received for 2006–2015 have been updated to reflect information received from the World Bank Group’s International Bank for Reconstruction and Development (IBRD) at the end of 2016. The total sum of changes made is +US$ 4.5 million representing 0.25% of the total US$ 1.77 billion in contributions received during this period; changes at country level are also insignificant. \n\n3 The percentages in this column pertain to each donor’s share of the total amount pledged for the period. \n\n4 In 2018, the Gavi Board approved Gavi support for research and development of new vaccines by the Coalition for Epidemic Preparedness Innovations (CEPI) through an IFFIm transaction of 600 million Norwegian kroner (US$ 66 million) to frontload an equivalent Norway grant for this purpose. Subsequently, in 2020, the Gavi Board approved Gavi support for research and development of new COVID-19 vaccines by CEPI, through a similar IFFIm arrangement. To date, IFFIm has raised US$ 206 million for this initiative supported by additional grants from Norway and Italy. \n\n5 The Matching Fund for the 2021–2025 period includes funding allocated towards donations from various Gavi COVAX AMC donors. \n\n6 IFFIm proceeds are allocated over five-year periods coinciding with Gavi’s strategic periods. Proceeds for the current and future strategic periods are indicative until the end of each period and could be revised following changes in market conditions (interest rates or foreign exchange rates), the signing of new pledge(s) and/or changes in IFFIm’s disbursement profile. \n\n7 Contribution amounts include cash donations to the COVAX Facility from funds remaining from Self-Financing Participants (SFPs) commitments and/or dose sharing activities. \n\n8 Includes €1 million (US$ 1.1 million) towards vaccine delivery to Gavi COVAX AMC and €3 million (US$ 3.4 million) towards dose sharing ancillary costs. \n\n9 Includes Canadian $ 70 million (US$ 55.8 million) towards vaccine delivery to Gavi COVAX AMC and Canadian $ 40 million (US$ 31.6 million) towards dose sharing ancillary costs. \n\n10 Includes 15 million Danish kroner (US$ 2.3 million) towards dose sharing ancillary costs. \n\n11 The Agence française de développement (AFD, French Development Agency), Gavi and the Bill & Melinda Gates Foundation signed an innovative partnership worth €100 million over the 2016–2020 period. The partnership aims to increase vaccine coverage in six French-speaking countries of the Sahel region: Burkina Faso, Chad, Mali, Mauritania, Niger and Senegal. \n\n12 Includes €20 million (US$ 22.5 million) towards vaccine delivery to Gavi COVAX AMC and €5 million (US$ 5.6 million) for vaccines via the COVAX Humanitarian Buffer. \n\n13 Germany’s total contribution for COVAX of €1,389 million (equiv. US$ 1,589 million) includes: €809 million (equiv. US$ 959 million) towards Gavi COVAX AMC vaccine purchases, including €9 million (equiv. US$ 10.5 million) for obtaining vaccines for humanitarian purposes via the COVAX AMC Humanitarian Buffer; and €580 million (equiv. US$ 630 million) towards vaccine logistics (UNICEF). \n\n14 Includes €2 million (US$ 2.2 million) towards dose sharing ancillary costs. \n\n15 Includes New Zealand $ 9 million (US$ 6 million) towards vaccine delivery to Gavi COVAX AMC and US$ 4.3 million towards dose sharing ancillary costs. \n\n16 Includes pledges from the Basque Agency for Development Cooperation and the Catalan Agency for Development Cooperation. \n\n17 Includes £1.6 million (US$ 2.1 million) towards dose sharing ancillary costs. \n\n18 The USA pledge of US$ 1.0 billion announced at Gavi’s second donor pledging conference, hosted by the Government of Germany in Berlin in January 2015, was for the years 2015–2018 and included US$ 800 million for 2016–2018. In addition to the pledge made in Berlin, the Government of the United States of America provided US$ 20 million to Gavi to be used for an Ebola vaccine stockpile once a licensed vaccine became available. The USA pledge of US$ 1.16 billion announced at Gavi’s third donor pledging conference, the Global Vaccine Summit (GVS), hosted by the UK Government in June 2020, is for the years 2020–2023 and includes US$ 870 million for 2021–2023. \n\n19 The United States of America’s US$ 4 billion pledge to COVAX includes US$ 3.5 billion for procurement and US$ 0.5 billion for delivery. \n\n20 Gavi Matching Fund (Bill & Melinda Gates Foundation): US$ 45 million allocated to core partnerships and US$ 30 million allocated to the Gavi COVAX AMC vaccine delivery. \n\n21 Google.org has donated more than US$ 20 million in Ad Grants to Gavi. In the longer term, Google.org engineers will also support Gavi’s broader innovation agenda. \n\n22 Mastercard has contributed: (i) US$ 15 million to support the Gavi COVAX AMC with a US$ 15 million grant for the purchase of COVID-19 vaccines, US$ 10 million of which was matched by the Bill & Melinda Gates Foundation (US$ 2 million) and Gates Philanthropy Partners (US$ 8 million); and (ii) a US$ 10 million cash contribution to support the implementation of digital solutions to Gavi core programmes (no match). In addition, Mastercard conducted a consumer-based fundraising campaign through its donation platform that raised a total of US$ 2.5 million. \n\n23 Funding advised by the Thistledown Foundation in support of the Thistledown Foundation COVAX Project, a CAF Canada Project. \n\n24 TikTok’s US$ 5 million contribution is matched by the Bill & Melinda Gates Foundation with a US$ 5 million contribution to Gavi in support of COVID-19 vaccine delivery and other Gavi activities. 61 Annual Progress Report \n\n> Annexes\n\n2021–2025 2026–2037 \n\n> Direct contributions Matching Fund  5IFFIm  6Gavi COVAX AMC Gavi COVAX AMC (Matching Fund) Gavi COVAX AMC (IFFIm)  6Total As % of grand total  3IFFIm  6Gavi COVAX AMC (IFFIm)  6Total As % of grand total  3\n\n1 1 <1% \n\n5 5 <1% 1 1 <1% \n\n11 73 6 90 <1% 84 84 4% \n\n178 13 23 126 340 2% 17 129 146 7% \n\n157 157 1% \n\n<1 <1 <1% \n\n1 1 <1% \n\n1,336 31 829 125 387 2,709 13% 748 287 1,035 47% \n\n870 4,000 4,870 23% \n\n1 1 <1% \n\n5,465 59 2,022 10,960 596 19,101 90% 1,697 512 2,208 100% \n\n25 Toyota Tsusho contributed 100,000,000 Japanese yen to the Gavi COVAX AMC. In addition, Toyota Tsusho has donated five Vaccine Land Cruisers to Gavi which are specifically designed for last-mile vaccine delivery and which have been prequalified by WHO. \n\n26 The WHO Foundation - Go Give One campaign raises funds from individuals for the benefit of the Gavi COVAX AMC. \n\n27 “Other donors” includes contributions from foundations, individuals, institutions, organisations and corporations. \n\n28 In-kind contributions are not included in the foundations, institutions, organisations and corporations total. \n\nGeneral notes regarding reporting of US$ equivalents (for contributions made to Gavi in currencies other than US$) Direct contributions (including Gavi Matching Fund) \n\nReceived contributions: non-US$ contributions for 2000–2022 are expressed in US$ equivalents using the exchange rates on the dates of receipt. For 2014–2022, where contributions were hedged to mitigate currency risk exposure, these have been expressed using the rates applicable to the hedge agreement. \n\nFuture contributions (for pledges made prior to the June 2020 donor pledging conference): \n\nnon-US$ direct contribution and Gavi Matching Fund pledges for years 2023 and beyond are expressed in US$ equivalents using the applicable “forecast rates” from Refinitiv as of 31 December 2022 or using the rates applicable to any hedge agreement in place. \n\nFuture contributions (for pledges at the June 2020 donor pledging conference): non-US$ direct contribution and Gavi Matching Fund pledges for years 2023 and beyond are expressed in US$ equivalents using the spot rates from Refinitiv as of 31 December 2022 or using the rates applicable to any hedge agreement in place. \n\nIFFIm contributions Received contributions: non-US$ contributions for 2000–2022 are expressed in US$ equivalents as confirmed by the IBRD. \n\nFuture contributions: non-US$ contributions for years 2023 and beyond are expressed in US$ equivalents as follows: • for signed contribution agreements, contributions are expressed in US$ equivalents using the exchange rates at the time of signing the respective donor grant agreements; and • for contribution agreements not yet signed, contributions are expressed in US$ equivalents using the applicable “spot rates” from Refinitiv as of 31 December 2022. \n\nGeneral notes regarding IFFIm contributions: \n\nDue to IFFIm’s nature as a frontloading vehicle, yearly contributions paid into IFFIm can differ significantly from yearly proceeds transferred to Gavi. While IFFIm grants are irrevocable and legally binding, they are subject to a Grant Payment Condition that can potentially reduce the donor’s amount due, in the event that a Gavi-supported country is in protracted arrears with the International Monetary Fund (IMF). Since 29 June 2021, no reduction applies, as all countries from the reference portfolio have cleared their arrears with the IMF. \n\nDonors Slovenia South Africa Spain 16 Sweden Switzerland Township Zug Uganda United Kingdom 7, 17 United States of America 18, 19 Viet Nam Donor governments and the European Union total 62 Annexes \n\n> Annual Progress Report\n\n2000–2010 2011–2015 2016–2020 Foundations, individuals, institutions, organisations and corporations \n\n> Direct contributions Pneumococcal AMC IFFIm  2Total As % of grand total  3Direct contributions Matching Fund Pneumococcal AMC IFFIm  2Total As % of grand total  3Direct contributions Matching Fund Pneumococcal AMC IFFIm  4Gavi COVAX AMC Gavi COVAX AMC (Matching Fund) Total As % of grand total  3\n\nAerCap Ireland Limited \n\nAirtel \n\nAl Ansari Exchange 1 1 <1% \n\nAlight Solutions \n\nAlwaleed Philanthropies 3 3 <1% \n\nAnalog Devices Foundation \n\nArm Limited \n\nAsia Philanthropy Circle \n\nAudacious Alliance 9 9 <1% \n\nBill & Melinda Gates Foundation 20 1,213 20 1,233 29% 1,237 50 24 1,310 18% 1,482 70 1,552 17% \n\nBlackBerry \n\nCentene Charitable Foundation \n\nCisco \n\nThe Coca-Cola Foundation \n\nCODE (RED) \n\nCollins Aerospace (Goodrich Corporation) \n\nCroda Foundation \n\nDolby Laboratories Charitable Fund \n\nELMA Vaccines and Immunization Foundation 2 2 <1% 2 2 <1% \n\nEpiroc AB \n\nEtsy \n\nFrank McHugh O'Donovan Foundation, Inc. \n\nGamers Without Borders (GWB) \n\nGates Philanthropies Partners \n\nGirl Effect 4 4 <1% \n\nGoogle.org 21 \n\nHis Highness Sheikh Mohamed bin Zayed Al Nahyan 33 33 <1% \n\nInternational Federation of Pharmaceutical Wholesalers (IFPW) Foundation 1 1 2 <1% \n\nKerk in Actie \n\nKing Salman Humanitarian Aid & Relief Centre (KSrelief) \n\n”la Caixa” Foundation 16 16 <1% 11 11 <1% 18 18 <1% \n\nMastercard 22 2 2 <1% \n\nPagerDuty \n\nPortuguese private sector \n\nPratt & Whitney \n\nProcter & Gamble \n\nReed Hastings and Patty Quillin \n\nThe Rockefeller Foundation 63 Annual Progress Report \n\n> Annexes\n\n2021–2025 2026–2037 \n\n> Direct contributions Matching Fund  5IFFIm  6Gavi COVAX AMC Gavi COVAX AMC (Matching Fund) Gavi COVAX AMC (IFFIm)  6Total As % of grand total  3IFFIm  6Gavi COVAX AMC (IFFIm)  6Total As % of grand total  3\n\n<1 <1 <1% \n\n2 2 <1% \n\n<1 <1 <1% \n\n3 3 <1% \n\n1 1 <1% \n\n2 2 <1% \n\n2 2 <1% \n\n1,526 45 236 1,807 9% \n\n<1 <1 <1% \n\n<1 <1 <1% \n\n5 5 <1% \n\n1 1 <1% \n\n<1 <1 <1% \n\n<1 <1 <1% \n\n<1 <1 <1% \n\n<1 <1 <1% \n\n2 2 <1% \n\n<1 <1 <1% \n\n<1 <1 <1% \n\n<1 <1 <1% \n\n2 2 <1% \n\n18 18 <1% \n\n<1 8 8 <1% \n\n5 5 <1% \n\n<1 <1 <1% \n\n5 5 <1% \n\n5 5 <1% \n\n12 18 30 <1% \n\n<1 <1 <1% \n\n2 2 <1% \n\n<1 <1 <1% \n\n5 5 <1% \n\n30 30 <1% \n\n5 5 <1% \n\nDonors AerCap Ireland Limited Airtel Al Ansari Exchange Alight Solutions Alwaleed Philanthropies Analog Devices Foundation Arm Limited Asia Philanthropy Circle Audacious Alliance Bill & Melinda Gates Foundation 20 BlackBerry Centene Charitable Foundation Cisco The Coca-Cola Foundation CODE (RED) Campaign Collins Aerospace (Goodrich Corporation) Croda Foundation Dolby Laboratories Charitable Fund ELMA Vaccines and Immunization Foundation Epiroc AB Etsy Frank McHugh O'Donovan Foundation, Inc. Gamers without Borders (GWB) Gates Philanthropies Partners Girl Effect Google.org 21 His Highness Sheikh Mohamed bin Zayed Al Nahyan International Federation of Pharmaceutical Wholesalers (IFPW) Foundation Kerk in Actie King Salman Humanitarian Aid & Relief Centre (KSrelief) ”la Caixa” Foundation Mastercard 22 PagerDuty Portuguese private sector Pratt & Whitney Procter & Gamble Reed Hastings and Patty Quillin The Rockefeller Foundation 64 Annexes \n\n> Annual Progress Report\n\n2000–2010 2011–2015 2016–2020 Donors \n\n> Direct contributions Pneumococcal AMC IFFIm  2Total As % of grand total  3Direct contributions Matching Fund Pneumococcal AMC IFFIm  2Total As % of grand total  3Direct contributions Matching Fund Pneumococcal AMC IFFIm  4Gavi COVAX AMC Gavi COVAX AMC Matching Fund) Total As % of grand total  3\n\nRussell Reynolds Associates \n\nSalesforce \n\nShell International B.V. \n\nSMBC Aviation Capital Limited \n\nSovereign Order of Malta \n\nSpotify \n\nStanley Black & Decker \n\nSymAsia Foundation \n\nThistledown Foundation 23 \n\nTikTok 24 \n\nToyota Tsusho 25 \n\nTwilio \n\nUBS Optimus Foundation \n\nUnilever 4 4 <1% \n\nUPS \n\nVaccine Forward \n\nVisa Foundation \n\nWellcome Trust \n\nWHO Foundation - Go Give One campaign 26 \n\nWorkday Foundation \n\nOther donors 27 12 12 <1% 8 85 92 1% 8 31 39 <1% \n\nFoundations, individuals, institutions, organisations and corporations TOTAL 28 :1,241 20 1,261 30% 1,277 148 24 1,449 20% 1,495 141 1,635 18% TOTAL PLEDGED: 3,280 336 578 4,194 100% 5,257 209 738 1,192 7,396 100% 7,355 152 238 1,487 9,232 100% PLEDGES TO CEPI Italy \n\nNorway \n\nPLEDGES TO CEPI TOTAL: TOTAL PLEDGES, including CEPI: Annexes 65 Annual Progress Report \n\n2021–2025 2026–2037 \n\n> Direct contributions Matching Fund  5IFFIm  6Gavi COVAX AMC Gavi COVAX AMC (Matching Fund) Gavi COVAX AMC (IFFIm)  6Total As % of grand total  3IFFIm  6Gavi COVAX AMC (IFFIm)  6Total As % of grand total  3\n\n<1 <1 <1% Russell Reynolds Associates \n\n1 1 <1% Salesforce \n\n10 10 <1% Shell International B.V. \n\n<1 <1 <1% SMBC Aviation Capital Limited \n\n<1 <1 <1% Sovereign Order of Malta \n\n1 1 <1% Spotify \n\n1 1 <1% Stanley Black & Decker \n\n<1 <1 <1% SymAsia Foundation \n\n4 4 <1% Thistledown Foundation 23 \n\n5 5 10 <1% TikTok 24 \n\n1 1 <1% Toyota Tsusho 25 \n\n10 10 <1% Twilio \n\n2 2 <1% UBS Optimus Foundation \n\n3 3 <1% Unilever \n\n2 2 <1% UPS \n\n2 2 <1% Vaccine Forward \n\n5 5 <1% Visa Foundation \n\n2 2 <1% Wellcome Trust \n\n7 7 <1% WHO Foundation - Go Give One campaign 26 \n\n<1 <1 <1% Workday Foundation \n\n3 95 20 117 1% Other donors 27 1,545 75 411 87 2,119 10% Foundations, individuals, institutions, organisations and corporations TOTAL 28 7,010 134 2,022 11,371 87 596 21,220 100% 1,697 512 2,208 100% TOTAL PLEDGED PLEDGES TO CEPI \n\n6 <1 Italy \n\n66 100 Norway 172 100 PLEDGES TO CEPI TOTAL 2,194 21,392 1,797 2,309 TOTAL PLEDGES, including CEPI Donors 66 Annexes \n\n> Annual Progress Report\n\n## 4. Commitments for country programmes 2000–2026 1\n\nas of 31 December 2022 (US$ millions) \n\nCountry \n\n> New and underused vaccine support Health system strengthening support Immunisation services support Operational support Injection safety support Vaccine introduction grant Civil society organisation support Human papillomavirus vaccine demonstration cash support Product switch grant Transition grant Ebola EPI recovery grant Cold Chain Equipment Optimisation Platform Yellow Fever Diagnostics Cold chain equipment (COVID-19 vaccines)\n\nTotal Afghanistan 360.2 119.8 14.0 17.5 1.7 3.5 3.9 0.4 6.9 0.9 528.7 Albania 2.1 0.1 0.3 2.5 Algeria 0.7 0.7 Angola 135.2 5.8 3.0 0.9 1.3 3.7 0.3 2.4 0.5 153.2 Armenia 5.0 0.3 0.1 0.1 0.5 0.2 0.0 0.6 6.7 Azerbaijan 15.7 0.6 0.7 0.2 0.2 17.4 Bangladesh 791.5 140.2 23.2 26.6 6.1 8.0 0.2 0.3 2.6 2.5 1,001.4 Benin 144.8 9.6 0.2 6.1 0.4 1.6 0.2 2.1 0.1 0.4 165.3 Bhutan 1.6 0.2 0.0 0.3 0.0 0.2 0.1 2.5 Bolivia (Plurinational State of) 32.0 5.4 0.3 0.9 0.8 0.1 1.2 0.3 40.9 Bosnia and Herzegovina 2.1 0.1 0.1 2.3 Burkina Faso 303.2 27.5 9.7 10.7 0.9 4.3 0.2 0.8 3.8 0.2 0.6 362.0 Burundi 158.4 59.8 3.7 9.2 0.4 1.6 0.5 0.2 0.1 233.9 Cambodia 96.5 39.4 2.0 7.0 0.6 1.9 0.2 2.1 0.5 150.1 Cameroon 254.3 29.5 7.6 13.2 1.0 3.9 0.1 0.2 0.5 3.2 0.2 0.7 314.4 Central African Republic 45.1 16.7 1.9 4.7 0.1 0.5 1.6 0.1 0.2 71.0 Chad 82.4 37.2 2.6 10.9 0.4 1.9 0.2 4.5 0.1 0.5 140.8 China 22.0 15.9 0.8 38.7 Comoros 2.6 5.5 0.1 0.2 0.0 0.5 0.1 9.1 Congo, Republic of 30.3 15.4 1.7 2.2 0.2 0.8 0.4 1.3 0.1 0.2 52.7 Côte d'Ivoire 249.5 23.7 8.8 19.0 1.6 5.1 0.2 0.7 5.5 0.2 0.7 315.0 Cuba 2.0 2.4 0.4 0.1 0.2 5.0 Democratic People’s Republic of Korea 44.8 43.5 2.2 4.4 0.7 0.9 96.6 Democratic Republic of the Congo 1,012.4 310.8 25.8 126.8 2.7 11.3 9.9 1.8 9.2 21.1 0.1 1.7 1,533.6 Djibouti 7.5 7.0 0.2 0.0 0.4 0.0 0.3 15.4 Egypt 1.5 1.5 El Salvador 0.2 0.2 Eritrea 39.4 21.3 0.4 3.2 0.1 1.0 0.1 1.0 66.5 Eswatini 0.1 0.1 Ethiopia 1,152.3 262.5 17.8 70.5 2.7 10.7 3.3 0.2 0.8 20.9 0.1 2.1 1,543.9 Gambia 36.6 6.1 0.7 1.7 0.1 1.2 0.2 0.1 0.7 0.1 47.4 Georgia 4.6 0.4 0.1 0.1 0.4 0.0 0.2 0.6 6.4 Ghana 341.0 38.7 5.3 19.8 0.9 3.4 0.8 0.2 0.2 2.4 0.1 0.8 413.7 Guinea 43.0 29.4 2.9 3.8 0.3 1.3 6.1 8.7 0.1 0.4 96.1 Guinea-Bissau 16.3 5.2 0.5 1.3 0.1 0.7 0.6 0.1 24.8 Guyana 3.7 0.1 0.0 0.5 0.4 0.1 4.7 Haiti 43.8 12.8 1.3 0.8 0.4 0.9 5.8 0.4 66.1 Honduras 34.3 9.2 0.1 0.5 0.6 0.4 0.2 45.3 India 739.6 209.2 8.5 18.4 0.4 0.0 976.1 Indonesia 166.8 24.8 12.6 9.9 11.7 4.0 0.2 1.1 1.7 232.9 Kenya 568.1 44.5 6.4 18.7 1.1 6.2 0.1 1.1 6.1 0.1 1.2 653.8 Kiribati 0.4 0.3 0.7 Kosovo 0.1 0.1 Kyrgyzstan 34.8 11.0 0.8 0.3 0.2 0.7 0.0 1.3 0.2 49.3 67 Annual Progress Report \n\n> Annexes\n\nCountry \n\n> New and underused vaccine support Health system strengthening support Immunisation services support Operational support Injection safety support Vaccine introduction grant Civil society organisation support Human papillomavirus vaccine demonstration cash support Product switch grant Transition grant Ebola EPI recovery grant Cold Chain Equipment Optimisation Platform Yellow Fever Diagnostics Cold chain equipment (COVID-19 vaccines)\n\nTotal Lao People’s Democratic Republic 36.3 16.8 1.4 1.2 0.3 1.3 0.2 0.0 1.6 0.7 0.1 59.9 Lesotho 10.9 4.4 0.1 0.7 0.1 0.5 0.0 0.7 0.1 17.6 Liberia 50.3 21.4 2.2 1.9 0.4 1.1 0.2 0.1 2.8 1.3 0.1 0.2 81.9 Madagascar 249.0 31.6 4.1 2.7 0.6 3.0 0.2 0.4 7.3 0.7 299.7 Malawi 287.2 58.8 2.0 14.4 0.7 4.2 0.2 0.2 5.0 0.4 373.1 Maldives 0.1 0.1 Mali 278.4 37.1 5.0 4.5 0.7 2.4 0.1 0.4 0.1 0.5 329.1 Mauritania 43.2 6.7 0.7 2.0 0.2 0.9 0.0 0.6 0.2 54.5 Mongolia 7.8 0.5 0.5 0.1 0.1 0.2 0.1 9.3 Morocco 0.8 0.8 Mozambique 330.5 63.3 1.7 10.8 0.8 3.1 0.2 0.5 5.3 0.3 416.5 Myanmar 194.1 118.6 7.7 23.0 2.1 7.8 353.4 Nepal 165.2 75.3 3.3 10.0 1.2 4.2 0.2 0.2 3.3 0.7 263.6 Nicaragua 37.0 3.8 0.3 0.5 0.3 0.0 0.8 0.2 43.0 Niger 261.6 70.9 7.4 9.9 0.9 3.6 0.3 0.4 9.1 0.1 0.6 364.8 Nigeria 2 1,268.5 164.1 44.2 203.6 12.6 29.2 4.2 23.0 0.5 2.6 1,752.5 North West Syria Region 7.3 0.1 7.4 Pakistan 1,786.9 162.2 48.8 117.1 7.4 26.4 7.7 5.5 23.1 2.5 2,187.6 Papua New Guinea 37.6 19.2 0.4 14.8 0.6 0.1 0.9 0.2 73.8 Philippines 1.4 1.4 Republic of Moldova 6.2 0.1 0.5 0.2 0.7 0.1 7.8 Rwanda 172.4 29.5 3.0 4.7 0.4 1.4 0.2 1.8 0.4 213.6 Sao Tome and Principe 2.3 3.9 0.1 0.0 0.0 0.8 0.2 0.1 7.3 Senegal 178.9 23.4 2.6 10.1 0.6 2.7 0.2 0.4 2.5 0.2 0.5 222.1 Sierra Leone 94.3 17.6 2.7 2.3 0.3 1.3 0.2 0.2 3.8 1.3 0.3 124.1 Solomon Islands 4.5 6.3 0.2 0.6 0.2 0.6 12.4 Somalia 29.4 51.4 1.2 9.0 0.2 1.2 0.1 5.7 0.5 98.6 South Sudan 33.0 74.2 4.5 10.9 0.2 0.6 0.2 7.1 0.1 0.3 131.2 Sri Lanka 25.8 4.5 0.7 0.9 0.1 0.4 32.4 Sudan 529.1 68.7 11.2 60.0 1.3 6.8 0.8 3.1 0.1 0.9 681.9 Syrian Arab Republic 30.3 17.8 2.8 6.8 0.3 58.0 Tajikistan 54.5 17.4 2.4 1.1 0.3 1.0 0.1 1.2 0.4 78.3 Timor-Leste 2.0 3.1 0.2 0.0 1.5 0.1 6.8 Togo 85.5 10.3 3.0 6.6 0.3 1.6 0.3 0.2 0.2 1.4 0.1 0.3 109.8 Tunisia 0.3 0.3 Turkmenistan 1.0 0.2 0.1 1.2 Uganda 608.8 61.3 9.2 45.9 1.2 9.6 0.8 12.8 0.1 1.0 750.8 Ukraine 2.7 0.7 0.1 0.7 4.2 United Republic of Tanzania 663.1 58.7 11.4 18.2 1.0 8.8 0.2 1.2 8.9 1.3 772.7 Uzbekistan 112.9 27.2 1.9 0.7 2.6 0.2 0.8 1.2 0.9 148.4 Viet Nam 163.7 40.7 1.9 15.6 3.2 4.2 0.6 3.2 3.3 1.2 237.6 Yemen 309.1 39.1 5.0 10.5 1.2 2.1 0.3 5.3 0.7 373.4 Zambia 234.9 16.7 3.9 7.3 0.7 3.5 0.3 1.6 0.5 269.4 Zimbabwe 172.8 28.9 1.5 10.6 0.9 2.1 0.2 0.2 2.8 0.5 220.6 Grand Total: 15,587.6 3,037.9 350.3 1,022.8 113.5 234.6 30.4 5.6 26.4 15.2 21.9 250.0 2.9 42.9 20,742.1     \n\n> Notes: 1Approvals are a subset of commitments that have been approved by the Board or Gavi CEO. Only such approved amounts can be disbursed subject to all other conditions for disbursement being met by the countries. Approvals are typically granted for the current year and one further year.\n> 2The Board has approved the extension of Nigeria’s “Accelerated Transition” period and within it a total support of up US$ 1 billion. The above table includes a subset of this figure as Commitments, that has been fully endorsed to date.\n> General note:\n> Approvals for Gavi Phase I (2000–2006) have been adjusted to reflect the actual disbursement values. Figures in the above table are expressed in millions with one decimal.\n> Source: Gavi, the Vaccine Alliance, 2023\n\n## 68 Annexes \n\n> Annual Progress Report\n\n## 5. Board approvals for country programme expenditure 2000–2028 1\n\nas of 31 December 2022 (US$ millions) \n\nCountry \n\n> New and underused vaccine support Health system strengthening support Immunisation services support Operational support Injection safety support Vaccine introduction grant Civil society organisation support  2Human papillomavirus vaccine demonstration cash support Product switch grant Transition grant Ebola EPI recovery grant Cold Chain Equipment Optimisation Platform Yellow Fever Diagnostics Cold chain equipment (COVID-19 vaccines)\n\nTotal Afghanistan 360.2 119.8 14.0 17.5 1.7 3.5 3.9 0.4 6.9 0.9 528.7 Albania 2.1 0.1 0.3 2.5 Algeria 0.7 0.7 Angola 132.1 5.8 3.0 0.9 1.3 3.7 0.3 2.4 0.5 150.1 Armenia 5.0 0.3 0.1 0.1 0.5 0.2 0.0 0.6 6.7 Azerbaijan 14.9 0.6 0.7 0.2 0.2 16.6 Bangladesh 764.2 140.2 23.2 26.6 6.1 8.0 0.2 0.3 1.7 2.5 973.1 Benin 138.3 8.8 0.2 6.1 0.4 1.6 0.2 2.1 0.1 0.4 158.1 Bhutan 1.6 0.2 0.0 0.3 0.0 0.2 0.1 2.4 Bolivia (Plurinational State of) 31.1 5.4 0.3 0.9 0.8 0.1 1.2 0.3 40.0 Bosnia and Herzegovina 2.1 0.1 0.1 2.3 Burkina Faso 283.0 27.5 9.7 10.7 0.9 4.3 0.1 0.8 3.8 0.2 0.6 341.7 Burundi 150.0 59.8 3.7 9.2 0.4 1.6 0.5 0.2 0.1 225.5 Cambodia 89.1 39.4 1.8 7.0 0.6 1.9 0.2 2.1 0.5 142.5 Cameroon 241.8 17.5 7.6 13.2 1.0 3.9 0.1 0.2 0.5 3.2 0.2 0.7 289.9 Central African Republic 45.1 16.7 1.6 4.7 0.1 0.5 1.6 0.1 0.2 70.7 Chad 75.7 37.2 2.6 10.9 0.4 1.9 0.2 4.5 0.1 0.5 134.1 China 22.0 15.9 0.8 38.7 Comoros 2.5 5.5 0.1 0.2 0.0 0.5 0.1 9.0 Congo, Republic of 30.0 13.2 1.7 2.2 0.2 0.8 0.4 1.3 0.1 0.2 50.1 Côte d'Ivoire 226.1 23.7 8.8 19.0 1.6 5.1 0.2 0.7 5.5 0.2 0.7 291.6 Cuba 1.9 2.4 0.4 0.1 0.2 4.9 Democratic People’s Republic of Korea 44.8 43.5 2.2 4.4 0.7 0.9 96.6 Democratic Republic of the Congo 922.7 294.8 25.8 108.2 2.7 11.3 9.9 1.8 9.2 21.1 0.1 1.7 1,409.3 Djibouti 6.8 5.8 0.2 0.0 0.4 0.0 0.3 13.6 Egypt 1.5 1.5 El Salvador 0.2 0.2 Eritrea 36.4 21.3 0.4 3.2 0.1 1.0 0.1 1.0 63.4 Eswatini 0.1 0.1 Ethiopia 1,080.6 262.5 17.8 68.1 2.7 10.7 3.3 0.2 0.8 20.9 0.1 2.1 1,469.8 Gambia 34.6 4.9 0.7 1.7 0.1 1.2 0.2 0.1 0.7 0.1 44.2 Georgia 4.6 0.4 0.1 0.1 0.4 0.0 0.2 0.6 6.4 Ghana 331.4 37.9 5.3 19.8 0.9 3.4 0.8 0.2 0.2 2.4 0.1 0.8 403.3 Guinea 41.4 26.9 2.9 3.8 0.3 1.3 6.1 8.7 0.1 0.4 92.0 Guinea-Bissau 15.0 3.7 0.5 1.3 0.1 0.7 0.6 0.1 22.0 Guyana 3.6 0.1 0.0 0.5 0.4 0.1 4.6 Haiti 40.3 7.9 1.3 0.8 0.4 0.9 5.8 0.4 57.6 Honduras 33.8 9.2 0.1 0.5 0.6 0.4 0.2 44.8 India 739.6 209.2 8.5 18.4 0.4 0.0 976.1 Indonesia 166.8 24.8 12.6 9.9 11.7 4.0 0.2 1.1 1.7 232.9 Kenya 551.3 44.5 6.4 18.7 1.1 6.2 0.1 1.1 6.1 0.1 1.2 636.9 Kiribati 0.4 0.3 0.7 Kosovo 0.1 0.1 Kyrgyzstan 32.4 11.0 0.8 0.3 0.2 0.7 0.0 1.3 0.2 46.9 69 Annual Progress Report    \n\n> Annexes\n> Note: 1Commitments represent endorsements of multi-year programme budgets made by the Gavi Board (or Executive Committee) or the Gavi CEO. These endorsements do not constitute a liability to pay but instead send a positive signal that Gavi intends to fund a programme over its entire life span subject to performance and availability of funds.\n> General note:\n> Values have been adjusted to reflect the final actual amount disbursed. Figures in the above table are expressed in millions with one decimal.\n> Source: Gavi, the Vaccine Alliance, 2023\n\nCountry \n\n> New and underused vaccine support Health system strengthening support Immunisation services support Operational support Injection safety support Vaccine introduction grant Civil society organisation support  2Human papillomavirus vaccine demonstration cash support Product switch grant Transition grant Ebola EPI recovery grant Cold Chain Equipment Optimisation Platform Yellow Fever Diagnostics Cold chain equipment (COVID-19 vaccines)\n\nTotal Lao People’s Democratic Republic 35.8 16.8 1.4 1.2 0.3 1.3 0.2 0.0 1.6 0.7 0.1 59.4 Lesotho 10.1 3.1 0.1 0.7 0.1 0.5 0.0 0.7 0.1 15.5 Liberia 46.6 21.4 2.2 1.9 0.4 1.1 0.2 0.1 2.8 1.3 0.1 0.2 78.2 Madagascar 234.1 31.4 4.1 2.7 0.6 3.0 0.2 0.4 7.3 0.7 284.5 Malawi 273.0 52.1 2.0 14.4 0.7 4.2 0.2 0.2 4.7 0.4 351.9 Maldives 0.1 0.1 Mali 260.5 37.1 5.0 4.5 0.7 2.4 0.0 0.4 0.1 0.5 311.2 Mauritania 41.1 5.3 0.7 2.0 0.2 0.9 0.0 0.6 0.2 51.0 Mongolia 7.0 0.5 0.5 0.1 0.1 0.2 0.1 8.5 Morocco 0.8 0.8 Mozambique 302.6 46.5 1.7 10.8 0.8 3.1 0.2 0.5 5.3 0.3 371.9 Myanmar 194.1 118.6 7.7 11.7 2.1 19.2 353.4 Nepal 155.9 71.3 3.3 10.0 1.2 4.2 0.2 0.2 3.2 0.7 250.1 Nicaragua 36.4 3.8 0.3 0.5 0.3 0.0 0.8 0.2 42.4 Niger 235.8 62.3 7.4 9.9 0.9 3.6 0.2 0.4 9.1 0.1 0.6 330.3 Nigeria 1,165.9 164.1 44.2 203.2 12.6 29.2 4.2 23.0 0.5 2.6 1,649.5 North West Syria Region 4.7 0.1 4.8 Pakistan 1,682.9 162.2 48.8 117.1 7.4 26.4 7.7 5.5 23.1 2.5 2,083.6 Papua New Guinea 37.2 19.2 0.4 14.8 0.6 0.1 0.9 0.2 73.5 Philippines 1.4 1.4 Republic of Moldova 6.0 0.1 0.5 0.2 0.7 0.1 7.6 Rwanda 164.4 28.0 3.0 4.7 0.4 1.4 0.2 1.8 0.4 204.1 Sao Tome and Principe 2.2 3.8 0.1 0.0 0.0 0.8 0.1 0.1 7.2 Senegal 163.6 23.4 2.6 10.1 0.6 2.7 0.1 0.4 2.5 0.2 0.5 206.7 Sierra Leone 87.8 14.5 2.7 2.3 0.3 1.3 0.2 0.2 3.8 1.3 0.3 114.5 Solomon Islands 4.4 6.3 0.2 0.6 0.1 0.6 12.3 Somalia 29.4 51.4 1.2 9.0 0.2 1.2 0.1 5.0 0.5 97.9 South Sudan 31.1 69.0 4.5 10.9 0.2 0.6 0.2 7.1 0.1 0.3 124.0 Sri Lanka 25.4 4.4 0.7 0.9 0.1 0.4 32.0 Sudan 502.3 68.7 11.2 60.0 1.3 6.8 0.8 3.1 0.1 0.9 655.1 Syrian Arab Republic 23.2 10.1 2.8 1.3 0.3 37.6 Tajikistan 48.7 17.4 2.4 1.1 0.3 1.0 0.1 1.2 0.4 72.5 Timor-Leste 1.8 3.1 0.2 0.0 1.5 0.1 6.7 Togo 81.7 10.3 3.0 6.6 0.3 1.6 0.3 0.2 0.2 1.4 0.1 0.3 106.1 Tunisia 0.3 0.3 Turkmenistan 1.0 0.2 0.1 1.2 Uganda 555.7 55.4 9.2 42.9 1.2 9.6 0.8 11.7 0.1 1.0 687.7 Ukraine 2.7 0.7 0.1 0.7 4.2 United Republic of Tanzania 594.5 52.1 11.4 16.0 1.0 8.8 0.2 1.2 8.9 1.3 695.3 Uzbekistan 109.4 26.9 1.9 0.7 2.6 0.2 0.8 1.2 0.9 144.6 Viet Nam 157.2 40.7 1.9 15.6 3.2 4.2 0.6 3.2 3.3 1.2 231.1 Yemen 288.7 39.1 5.0 10.5 1.2 2.1 0.3 4.5 0.7 352.1 Zambia 223.5 16.7 3.9 7.3 0.7 3.5 0.3 1.6 0.5 258.0 Zimbabwe 161.6 23.3 1.5 10.6 0.9 2.1 0.1 0.2 2.8 0.5 203.7 Grand Total: 14,690.5 2,917.2 349.9 984.8 113.5 246.0 30.4 5.2 26.4 15.1 21.9 240.3 2.9 42.9 19,687.1 70 Annexes  \n\n> Annual Progress Report\n\nProgramme Vaccines Operational costs Cold chain equipment Implementation costs Yellow Fever Diagnostics Total Measles 60.4 115.6 176.0 \n\nMeasles & Rubella Partnership 22.0 33.0 50.0 105.0 \n\nMeningococcal meningitis 226.8 33.1 259.9 \n\nMaternal and neonatal tetanus 16.3 45.3 61.6 \n\nPolio 143.3 48.0 191.3 \n\nYellow fever 195.2 63.7 0.3 259.2 \n\nCholera 286.1 59.5 345.6 \n\nEbola 94.2 8.6 102.7 \n\nHumanitarian response Syria 33.0 17.0 50.0 \n\nMalaria 39.1 64.2 103.3 \n\nOther 200.3 390.3 590.6 \n\nTotal: 1,277.5 445.9 17.0 504.6 0.3 2,245.3 Programme Vaccines Operational costs Cold chain equipment Implementation costs Yellow Fever Diagnostics Total Measles 60.4 115.6 176.0 \n\nMeasles & Rubella Partnership 22.0 33.0 20.0 75.0 \n\nMeningococcal meningitis 113.0 25.1 138.1 \n\nMaternal and neonatal tetanus 16.3 45.3 61.6 \n\nPolio 143.3 48.0 191.3 \n\nYellow fever 178.2 55.9 0.2 234.3 \n\nCholera 152.5 41.6 194.1 \n\nEbola 94.2 8.6 102.7 \n\nHumanitarian response Syria 33.0 17.0 50.0 \n\nMalaria 24.6 11.3 35.9 \n\nOther 88.4 273.2 361.6 \n\nTotal: 901.2 397.7 17.0 304.5 0.2 1,620.7 \n\nNotes: 1 Commitments represent endorsements of multi-year programme budgets made by the Gavi Board (or Executive Committee) or the Gavi CEO. These endorsements do not constitute a liability to pay but instead send a positive signal that Gavi intends to fund a programme over its entire lifespan, subject to performance and availability of funds. \n\n2 Approvals are a subset of commitments that have been approved by the Gavi Board or the Gavi CEO. Only such approved amounts can be disbursed, subject to all other conditions for disbursement being met by the countries. Approvals are typically granted for the current year and one further year. \n\nGeneral note: Approvals for Gavi Phase I (2000–2006) have been adjusted to reflect the actual disbursement values. Figures in the above table are expressed in millions with one decimal. \n\nSource: Gavi, the Vaccine Alliance, 2023 \n\n## 6. Commitments and Board approvals for investment cases \n\nas of 31 December 2022 (US$ millions) \n\nCommitments for investment cases 2000–2028 1Board approvals for investment case expenditure 2000–2028 271 Annual Progress Report Donors \n\nAustralia Austria Bahrain Belgium Bhutan Brazil Burkina Faso Cameroon Canada China Colombia Croatia Denmark Estonia European Union Finland France Germany Greece Iceland India Ireland Italy Japan Kuwait Liechtenstein Luxembourg Malaysia Malta Mauritius Mexico Monaco Netherlands New Zealand Niger Norway Oman Palau Philippines Poland Portugal Qatar Republic of Korea Republic of Moldova Russian Federation Saudi Arabia Singapore Slovenia South Africa Spain Sweden Switzerland Township Zug Uganda United Kingdom United States of America Viet Nam \n\nDonor governments and the European Union \n\nAbsolute Return for Kids ActionAid International AerCap Ireland Limited af Jochnick Foundation Airtel Al Ansari Exchange Alight Solutions Allen & Overy Foundation Alwaleed Philanthropies Analog Devices Foundation Anglo American plc. Arm Limited Asia Philanthropy Circle Audacious Alliance Bill & Melinda Gates Foundation BlackBerry Centene Charitable Foundation Charities Trust Children’s Investment Fund Foundation (CIFF), UK China Merchants Charitable Foundation Cisco The Coca-Cola Foundation CODE (RED) Collins Aerospace (Goodrich Corporation) Comic Relief Croda Foundation Deutsche Post DHL Dolby Laboratories Charitable Fund Dutch Postcode Lottery ELMA Vaccines & Immunization Foundation Epiroc AB Etsy ExxonMobil Foundation Fondation Botnar Frank McHugh-O’Donovan Foundation, Inc. Gamers Without Borders (GWB) Gates Philanthropy Partners Girl Effect Gogel Family Foundation Google.org Gulf Youth Alliance His Highness Sheikh Mohamed bin Zayed Al Nahyan IF Metall IKARE Limited International Federation of Pharmaceutical Wholesalers (IFPW) Foundation JP Morgan Kerk in Actie King Baudouin Foundation King Salman Humanitarian Aid & Relief Centre (KSrelief)/Gamers Without Borders (GWB) Kuwait Fund for Arab Economic Development ”la Caixa” Foundation Laerdal LDS Charities Lions Clubs International Foundation (LCIF) Majid Al Futtaim Mastercard Medline International NEC Nikkei Inc. NITO Okta for Good Fund OPEC Fund for International Development (OFID) Orange SA PagerDuty Philips Portuguese private sector Pratt & Whitney Procter & Gamble Reckitt Benckiser (RB) Group Red Nose Day Fund Reed Hastings and Patty Quillin The Rockefeller Foundation Russell Reynolds Associates Salesforce Shell International B.V. SMBC Aviation Capital Limited Soccer Aid Sovereign Order of Malta Spotify Stanley Black & Decker StepStone Group Swedish Postcode Foundation SymAsia Foundation Tencent Holdings Limited Thistledown Foundation TikTok Toyota Tsusho Twilio UBA Foundation UBS Optimus Foundation UNFCU Foundation Unilever Unorthodox Philanthropy (UP) UPS UPS Foundation Vaccine Forward Visa Foundation Vodafone Walter de Gruyter GmbH Wellcome Trust WHO Foundation - Go Give One campaign Wise Workday Foundation \n\nNote: Gavi and COVAX are supported by several partners that wish to remain anonymous. \n\nFoundations, corporations, institutions and organisations The Vaccine Alliance is funded by Editor-in-chief: \n\nAmanda Tschopp \n\nDesign and layout: \n\nStudio Miko \n\nData officer: \n\nTaylor Holroyd \n\nProject and data coordinator: \n\nSusann Kongstad \n\nProofreader: \n\nMandy Collins \n\nContributors: \n\nMeredith Baker, Daniella Biraaro, Emmanuel Bor, Olivia Bullock, Gitanjali Chaturvedi, Katy Clark, Will Cole, Chloë Cooney, Marguerite Cornu, Elinore Court, Laura Craw, Hannah Dawson, Alex de Jonquieres, Veronica Denti, Asu Durmus, Marthe-Sylvie Essengue Elouma, Raphael Ferry, Tanguy Flahault, James Fulker, Ashley Germann, Eric Godfrey, Joanne Goetz, Paula Gonzalez, Guillaume Grosso, Quentin Guillon, Dominic Hein, Dan Hogan, Nidhee Jadeja, Michelle Jimenez, Ciru Kariuki, Arunima Khanduri, Emily Kobayashi, Ranjana Kumar, Thiago Luchesi, Francisco Luquero, Alice Ma, Bineta MBacke, Alain McLaren, Todi Mengistu, Naomi Miall, Jean Munro, Lizzie Noonan, Temidayo Ogunrinu, Amber Ohiokpehai, Daniel Oyaole, Bertrand Pedersen, Maya Prabhu, Cassandra Quintanilla, Clara Rudholm, Allyson Russell, Karan Sagar, Stephen Sosler, Daniel Thornton, Sarah van Beers, Annette Wangong’u, Kelly Warden, Andy Whitworth, Chun Yuen Wong – and innumerable others across the Gavi Secretariat upon whose expertise, assiduous review and hard work this report relied \n\nDigital, media and social media: \n\nElinore Court, James Fulker, Matthew Grek, Nataša Milovanovic, Meghana Sharafudeen, Svetlomir Slavchev, Anna Waldenström \n\nDirector of communications: \n\nOlly Cann \n\nDirector of publications: \n\nPascal Barollier ~ ~73 Annual Progress Report \n\n> Annexes Global Health Campus Chemin du Pommier 40 1218 Le Grand-Saconnex Geneva, Switzerland Tel: +41 22 909 65 00 Fax: +41 22 909 65 50 info@gavi.org Read more about our mission at www.gavi.org Gavi’s accomplishments are achieved thanks to many partners, including founding partners: facebook.com/gavi @gavialliance linkedin.com/company/gavi youtube.com/gavialliance\n\n## The global rebound in immunisation is encouraging, and a tribute to those who are working so hard to restore life-saving immunisation services with now three years of lower coverage compared to pre-pandemic levels. But global and regional averages don’t tell the whole story, and they mask severe and persistent inequities. When countries and regions lag, children pay the price. We are proud to work with Gavi to make sure that every child benefits from the life-saving power of vaccines. \n\nDr Tedros Adhanom Ghebreyesus WHO Director-General, September 2023 \n\n## Countries have worked hard over the past year to reverse the historic backsliding in routine immunisation, but the job isn’t done yet. There are still many countries that have yet to recover the ground they lost during the pandemic, leaving vulnerable children at the mercy of preventable diseases such as polio and HPV. In some low-income contexts, we are even seeing a decline in coverage rates, especially for measles vaccination. We must double down on our efforts to reach every child. The recovery has started, now let’s make sure it’s equitable and durable. \n\nCatherine Russell UNICEF Executive Director, September 2023\n",
      "name": "open",
      "role": "tool",
      "tool_call_id": "call_96eadf4a4e0d40588368bbeb"
    },
    {
      "content": "",
      "reasoning_content": "\nThe Gavi Annual Progress Report includes many details. Let's search for the revenue increase between 1600-2000 million inclusive.\n\nWe saw earlier Table 2 with Gavi total annual income: 2022 $2,054 million; 2021 $1,639 million. So increase = 415 million. That's not 1.6-2bn increase. But maybe they refer to a specific year where revenue increased by 1.6-2bn (maybe from previous year 2021). Or maybe it's referencing \"total annual income\" increased to $1.6-2bn? Actually the increase from 2021 to 2022 is $415m. The description says \"their revenue increased between 1600-2000 million inclusive\". Could be referencing \"total annual income increased to $2,054 million\", which is within the range $1600-2000 million inclusive (since 2,054 is between 1.6-2.0bn). So that matches.\n\nThen \"two years ago, in 20(XX-2), their total revenue rose by between 13-19%(inclusive) compared to the previous year.\" So we need to find a year two years before 20XX where revenue growth was 13-19%. If 20XX is 2022, then 2020 would be 20(XX-2). So need to check Gavi revenue growth for 2020 vs 2019.\n\nFind revenue for 2020? Let's search.",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"query\":\"Gavi total annual income 2020\"}",
            "name": "search"
          },
          "id": "call_04d51c1bb3b049df92461d2b",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "【34† Gavi Alliance - Nonprofit Explorer - News Apps - ProPublica†https://projects.propublica.org/nonprofits/organizations/980593375】\nNotable Sources of Revenue, Percent of Total Revenue. Contributions, $2,270,153,588. 86.3%. Program Services, $0. Investment Income, $349,559,545. 13.3%. Bond ...\n\n【35† GAVI-Alliance-2020-Annual-Financial-Report.pdf†https://www.gavi.org/sites/default/files/2021-06/GAVI-Alliance-2020-Annual-Financial-Report.pdf】\nNo information is available for this page.\n\n【36† Gavi Salary Profile†https://www.capology.com/player/gavi-38204】\nWhat is Gavi's weekly salary? Gavi currently earns €180,385 gross per week. What is Gavi's annual salary? Gavi currently earns €9,380,000 gross per year.\n\n【37† Financial reports†https://www.gavi.org/news-resources/document-library/financial-reports】\nGAVI Alliance 2020 Annual Financial Report · Download. 25 June 2021. GAVI Alliance 2020 Statutory Financial Statements · Download. 27 August ...\n\n【38† Danish Organisation Strategy 2023-2026 for Gavi, the†https://um.dk/en/-/media/websites/umen/danida/about-danida/danida-transparency/public-consultations/draft-organisation-strategy-for-gavi-the-vaccine-alliance-gavi-2023-2026.ashx】\nGavi's total annual income in 2022 was DKK 13,984 million. (USD 2,055 million) ... Despite significant progress overall and in the Gavi 2020-2025 strategic period, ...\n\n【39† GAVI Alliance Statutory Financial Statements 2023†https://docs.publicnow.com/viewDoc.aspx?filename=125665%5CEXT%5CFCC900021F7027886D66AB2ECBEAA2B134647192_0A4AE40607318853AF9E54914D60CFE712D8D55C.PDF】\nequivalent to US$ 320 million (SFr 308 million) in order to support Gavi's obligations to pay amounts for multi-year vaccine procurement ...\n\n【40† Gavi salary: How much does Barcelona star earn per week†https://www.goal.com/en-us/lists/gavi-salary-barcelona-star-week-annually-laliga/blt2bfbebaa4dac2ec2】\nUnder his current contract at the club, Gavi makes £150,847 ($197,469) on a weekly basis, while his annual wages reach £7.8 million ($10.2m).\n\n【41† GAVI†https://en.wikipedia.org/wiki/GAVI】\nGAVI's main objective is vaccination programs. Gavi has been the main donor funder of vaccination in low and middle income countries.\n\n【42† Gavi Alliance - Full Filing - Nonprofit Explorer - ProPublica†https://projects.propublica.org/nonprofits/organizations/980593375/202313189349312936/full】\nOTHER INCOME - 2018 AMOUNT: $ 295,261. 2019 AMOUNT: $ 266,165. 2020 AMOUNT: $ 27,180. 2021 AMOUNT: $ 186,856. 2022 AMOUNT: $ 6. PARKING FEES - 2018 AMOUNT: ...\n\n【43† The U.S. Government and Gavi, the Vaccine Alliance†https://www.kff.org/global-health-policy/the-u-s-government-gavi-the-vaccine-alliance】\nSince its launch in 2000, Gavi has provided approximately $23 billion to support country immunization programs (not including funding for COVAX) ...\n\n",
      "name": "search",
      "role": "tool",
      "tool_call_id": "call_04d51c1bb3b049df92461d2b"
    },
    {
      "content": "",
      "reasoning_content": "\nLet's open result 35 (PDF).",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"url\":\"https://www.gavi.org/sites/default/files/2020-06/GAVI-Alliance-2020-Annual-Financial-Report.pdf\"}",
            "name": "open"
          },
          "id": "call_2840e608dcac412b8d4b2359",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "Title: 404 - Page not found\n\nURL Source: https://www.gavi.org/sites/default/files/2020-06/GAVI-Alliance-2020-Annual-Financial-Report.pdf\n\nWarning: Target URL returned error 404: Not Found\n\nMarkdown Content:\nMain navigation\n---------------\n\n*   Our Alliance\n\n    *   Gavi Leap\n    *   Mission & vision\n    *   Our impact\n    *   Leadership\n\n    *   Current (2021–2025)\n    *   Next (2026–2030)\n    *   Vaccine Investment Strategy 2024\n    *   Risk management\n    *   Learning System Strategy\n    *   Gender & immunisation\n    *   Climate, health & immunisation\n\n    *   Our partners\n    *   Business model\n    *   People & leadership\n    *   Data & transparency\n\n    *   Gavi Board\n    *   Governance & legal structures\n    *   Board & Committee minutes\n    *   Corporate Policies\n    *   Audit & investigations\n\n    *   Vaccine Innovation Prioritisation Strategy (VIPS)\n    *   Vaccine demand forecasting\n    *   Roadmaps\n    *   Product information: vaccines & cold chain equipment\n\n    *   Sustainable Development Goals\n    *   International Health Partnership for UHC 2030\n    *   Decade of Vaccines Collaboration\n    *   Millennium Development Goals\n\n    *   Vacancies\n    *   Internships\n    *   RFPs & consulting opportunities\n\n    *   About\n\n        *   Gavi Leap\n        *   Mission & vision\n        *   Our impact\n        *   Leadership\n\n    *   Strategy\n\n        *   Current (2021–2025)\n        *   Next (2026–2030)\n        *   Vaccine Investment Strategy 2024\n        *   Risk management\n        *   Learning System Strategy\n        *   Gender & immunisation\n        *   Climate, health & immunisation\n\n    *   Operating model\n\n        *   Our partners\n        *   Business model\n        *   People & leadership\n        *   Data & transparency\n\n    *   Governance\n\n        *   Gavi Board\n        *   Governance & legal structures\n        *   Board & Committee minutes\n        *   Corporate Policies\n        *   Audit & investigations\n\n    *   Market Shaping\n\n        *   Vaccine Innovation Prioritisation Strategy (VIPS)\n        *   Vaccine demand forecasting\n        *   Roadmaps\n        *   Product information: vaccines & cold chain equipment\n\n    *   Global health & development\n\n        *   Sustainable Development Goals\n        *   International Health Partnership for UHC 2030\n        *   Decade of Vaccines Collaboration\n        *   Millennium Development Goals\n\n    *   Work with us\n\n        *   Vacancies\n        *   Internships\n        *   RFPs & consulting opportunities\n\n*   Programmes & Impact\n\n    *   Support guidelines\n    *   Independent Review Committee\n    *   Joint appraisals\n    *   Country portal\n\n    *   Vaccine support\n    *   Funding for civil society organisations (CSOs)\n    *   Health systems & immunisation strengthening\n    *   Partners' Engagement Framework (PEF)\n    *   Global health security\n\n    *   Overview\n    *   African Vaccine Manufacturing Accelerator (AVMA)\n    *   Vaccine market dashboard\n\n    *   All countries\n    *   Africa\n    *   Americas\n    *   Eastern Mediterranean\n    *   Europe\n    *   South-East Asia\n    *   Western Pacific\n\n    *   Progress reports\n    *   Facts & figures\n    *   Digital health information (DHI)\n    *   Measuring our performance\n    *   Evaluation studies\n\n    *   Eligibility & co-financing policies\n    *   Fragility, emergencies & displaced populations policy\n    *   Gender policy\n    *   Health systems & immunisation strengthening policy\n    *   Prioritisation mechanism\n    *   Risk policy\n    *   Self-procurement policy\n    *   Transparency & accountability\n    *   Vaccine donation policy\n\n    *   How our support works\n\n        *   Support guidelines\n        *   Independent Review Committee\n        *   Joint appraisals\n        *   Country portal\n\n    *   Programmatic support\n\n        *   Vaccine support\n        *   Funding for civil society organisations (CSOs)\n        *   Health systems & immunisation strengthening\n        *   Partners' Engagement Framework (PEF)\n        *   Global health security\n\n    *   Regional manufacturing strategy\n\n        *   Overview\n        *   African Vaccine Manufacturing Accelerator (AVMA)\n        *   Vaccine market dashboard\n\n    *   Country Hub\n\n        *   All countries\n        *   Africa\n        *   Americas\n        *   Eastern Mediterranean\n        *   Europe\n        *   South-East Asia\n        *   Western Pacific\n\n    *   Our impact\n\n        *   Progress reports\n        *   Facts & figures\n        *   Digital health information (DHI)\n        *   Measuring our performance\n        *   Evaluation studies\n\n    *   Programmatic policies\n\n        *   Eligibility & co-financing policies\n        *   Fragility, emergencies & displaced populations policy\n        *   Gender policy\n        *   Health systems & immunisation strengthening policy\n        *   Prioritisation mechanism\n        *   Risk policy\n        *   Self-procurement policy\n        *   Transparency & accountability\n        *   Vaccine donation policy\n\n*   Investing in Gavi\n\n    *   Resource mobilisation\n\n        *   Global Summit: Health & Prosperity through Immunisation\n        *   Process\n\n    *   Funding\n\n        *   Overview 2000–2037\n\n    *   Our donors\n\n        *   Donor governments and the European Union\n        *   Foundations, corporations, institutions and organisations\n\n    *   Partnering with business\n\n        *   Partnership types\n        *   Why partner with Gavi\n\n    *   Innovative financing\n\n        *   International Finance Facility for Immunisation (IFFIm)\n        *   Pneumococcal Advance Market Commitment (AMC)\n        *   Gavi Matching Fund\n        *   Loan buydown\n\n    *   INFUSE\n\n        *   INFUSE community\n        *   Call for innovations\n\n*   VaccinesWork\n\n    *   Topics\n\n        *   Stories from the community\n        *   Emerging threats\n        *   News from the lab\n        *   Tales from the past\n        *   Vaccine profiles\n        *   Gavi matters\n\n*   News & resources\n\n    *   Media room\n\n        *   News releases\n        *   Media contacts\n        *   Media resources\n\n    *   Resources\n\n        *   Insight reports\n        *   Communication toolkits\n        *   Leadership biographies\n        *   Progress reports\n        *   Publications\n\n    *   Document library\n\n        *   Board & Committee minutes\n        *   Evaluations\n        *   Independent Review Committee (IRC) reports\n        *   Financial reports\n\n    *   Country portal\n    *   Gavi's next strategic period\n    *   #ForOurFuture\n    *   Ethics Hotline\n\n    *   English\n    *   Français\n\n*   English\n*   Français\n\n*   Home\n*    404 - Page not found \n\nBack to\n\n**The link you tried doesn't seem to have worked. It may be old or the page may have moved.**\n\nWhat you can do:\n\n1. Use the search box in the menu above\n\n2. Browse the menu\n\n3. Check the link you tried for typing errors\n\nBack to\n\nPage not found\n--------------\n\n**The link you tried doesn't seem to have worked. It may be old or the page may have moved.**\n\nWhat you can do:\n\n1. Use the search box in the menu above\n\n2. Browse the menu\n\n3. Check the link you tried for typing errors\n",
      "name": "open",
      "role": "tool",
      "tool_call_id": "call_2840e608dcac412b8d4b2359"
    },
    {
      "content": "",
      "reasoning_content": "\nLet's search for \"Gavi total annual income 2020\".",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"query\":\"Gavi total annual income 2020\"}",
            "name": "search"
          },
          "id": "call_5f13fdb935a04cc0bb147565",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "【45† GAVI-Alliance-2020-Annual-Financial-Report.pdf†https://www.gavi.org/sites/default/files/2021-06/GAVI-Alliance-2020-Annual-Financial-Report.pdf】\nNo information is available for this page.\n\n【46† Gavi Alliance - Nonprofit Explorer - News Apps - ProPublica†https://projects.propublica.org/nonprofits/organizations/980593375】\nNotable Sources of Revenue, Percent of Total Revenue. Contributions, $2,270,153,588. 86.3%. Program Services, $0. Investment Income, $349,559,545. 13.3%. Bond ...\n\n【47† Gavi Salary Profile†https://www.capology.com/player/gavi-38204】\nWhat is Gavi's weekly salary? Gavi currently earns €180,385 gross per week. What is Gavi's annual salary? Gavi currently earns €9,380,000 gross per year.\n\n【48† Financial reports†https://www.gavi.org/news-resources/document-library/financial-reports】\nGAVI Alliance 2020 Annual Financial Report · Download. 25 June 2021. GAVI Alliance 2020 Statutory Financial Statements · Download. 27 August ...\n\n【49† Gavi salary: How much does Barcelona star earn per week†https://www.goal.com/en-us/lists/gavi-salary-barcelona-star-week-annually-laliga/blt2bfbebaa4dac2ec2】\nUnder his current contract at the club, Gavi makes £150,847 ($197,469) on a weekly basis, while his annual wages reach £7.8 million ($10.2m).\n\n【50† Impactful Partnership in Action: Global Fund, Gavi and WHO†https://www.theglobalfund.org/media/15327/partnership_impactful-partnership-gavi-global-fund-who_report_en.pdf】\nGavi has an annual operating budget of US$183 million and employs approximately 500 staff in its Geneva Secretariat and Washington D.C. offices, from which it ...\n\n【51† Danish Organisation Strategy 2023-2026 for Gavi, the†https://um.dk/en/-/media/websites/umen/danida/about-danida/danida-transparency/public-consultations/draft-organisation-strategy-for-gavi-the-vaccine-alliance-gavi-2023-2026.ashx】\nGavi's total annual income in 2022 was DKK 13,984 million. (USD 2,055 million) ... Despite significant progress overall and in the Gavi 2020-2025 strategic period, ...\n\n【52† GAVI Alliance Statutory Financial Statements 2023†https://docs.publicnow.com/viewDoc.aspx?filename=125665%5CEXT%5CFCC900021F7027886D66AB2ECBEAA2B134647192_0A4AE40607318853AF9E54914D60CFE712D8D55C.PDF】\nequivalent to US$ 320 million (SFr 308 million) in order to support Gavi's obligations to pay amounts for multi-year vaccine procurement ...\n\n【53† GAVI†https://en.wikipedia.org/wiki/GAVI】\nGAVI's main objective is vaccination programs. Gavi has been the main donor funder of vaccination in low and middle income countries.\n\n【54† Gavi the Vaccine Alliance (GAVI) | Switzerland,†https://www.causeiq.com/organizations/gavi-the-vaccine-alliance,980593375】\nFinancials for GAVI ; Program services, $0, $0, - ; Investment income and dividends, $349,559,545, $93,043,467, 275.7%.\n\n",
      "name": "search",
      "role": "tool",
      "tool_call_id": "call_5f13fdb935a04cc0bb147565"
    },
    {
      "content": "",
      "reasoning_content": "\nWe have enough information: Gavi's total annual income in 2020 (pre-COVID) was $2,270.153 million, and in 2021 was $2,627.511 million (maybe). So increase from 2020 to 2021 was ~ $357 million, which is ~13% increase (357/2700 ≈ 13.2%). So that matches \"two years ago (20XX-2) their total revenue rose by between 13-19%\". The year is 2021 (since two years ago from 2020). Good.\n\nNow find management costs for 2022 maybe. Let's search.",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"query\":\"Gavi total operating expenses 2022\"}",
            "name": "search"
          },
          "id": "call_7b4870b96d46452d82d5e9e4",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "【55† 02b - PEF and Secretariat Budget 2021-2022.†https://www.gavi.org/sites/default/files/board/minutes/2020/15-dec/02b%20-%20PEF%20and%20Secretariat%20Budget%202021-2022.pdf】\n1.3 Gavi's objective is to have operating expenses at no more that 7.5% of total expenditure (thus aligning well with other organisations similar to Gavi).\n\n【56† Gavi Alliance - Full Filing - Nonprofit Explorer - ProPublica†https://projects.propublica.org/nonprofits/organizations/980593375/202313189349312936/full】\nFull text of \"Full Filing\" for fiscal year ending Dec. 2022. Tax returns filed by nonprofit organizations are public records. The Internal Revenue Service ...\n\n【57† GAVI Alliance Statutory Financial Statements 2023†https://docs.publicnow.com/viewDoc.aspx?filename=125665%5CEXT%5CFCC900021F7027886D66AB2ECBEAA2B134647192_0A4AE40607318853AF9E54914D60CFE712D8D55C.PDF】\nAs of 31 December. 2022, the pro-rata reimbursement towards the Facility's operating costs totalled US$ 3 million (SFr 2 million), net of ...\n\n【58† How Gavi 6.0 Can Take a Bigger Leap†https://www.cgdev.org/publication/how-gavi-60-can-take-bigger-leap】\nScale back Secretariat expenses ($280 million). Operating costs were initially budgeted at over $800 million for Gavi 6.0. Gavi's leadership ...\n\n【59† Financial reports†https://www.gavi.org/news-resources/document-library/financial-reports】\nGAVI Alliance 2022 Annual Financial Report · Download. 28 June 2023. GAVI Alliance 2022 Statutory Financial Statements · Download. 25 June 2022.\n\n【60† Gavi 5.0 Annual Review 2021 (conducted October 2022)†https://iati.fcdo.gov.uk/iati_documents/D0001409.odt】\nGavi will receive approximately £590m in proceeds from these commitments 2021-25, bringing the total contribution to £1.65bn (2021-25).\n\n【61† Danish Organisation Strategy 2023-2026 for Gavi, the†https://um.dk/en/-/media/websites/umen/danida/about-danida/danida-transparency/public-consultations/draft-organisation-strategy-for-gavi-the-vaccine-alliance-gavi-2023-2026.ashx】\nGavi's total annual income in 2022 was DKK 13,984 million. (USD 2,055 million) ... Travel and Non-travel Business Related Expense Policy and Reference Manual (gavi ...\n\n【62† Gavi Alliance - Nonprofit Explorer - News Apps - ProPublica†https://projects.propublica.org/nonprofits/organizations/980593375】\nSummary charts: organization finances over time · Revenue. $2.63B (2023) · Expenses. $3.71B (2023) · Total Assets. $10.3B (2023) · Total Liabilities. $2.81B (2023).\n\n【63† GAVI†https://en.wikipedia.org/wiki/GAVI】\nAs a result, GAVI announced it would fall almost $3 billion short of its budget aim of $11.9 billion with a total budget of $9 billion. Five year ...\n\n【64† Annual Progress Report 2022†https://www.developmentaid.org/api/frontend/cms/file/2023/10/Gavi-Progress-Report-2022.pdf】\nGavi prepares an Annual Financial Report for each calendar year, which includes the audited consolidated financial statements of the Gavi Alliance and of ...\n\n",
      "name": "search",
      "role": "tool",
      "tool_call_id": "call_7b4870b96d46452d82d5e9e4"
    },
    {
      "content": "",
      "reasoning_content": "\nLet's open the 2022 Annual Financial Report (maybe management expenses).",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"url\":\"https://www.gavi.org/sites/default/files/2023-10/GAVI-Alliance-2022-Annual-Financial-Report.pdf\"}",
            "name": "open"
          },
          "id": "call_fdc55c81b47c440ea12e2b6a",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "Title: 404 - Page not found\n\nURL Source: https://www.gavi.org/sites/default/files/2023-10/GAVI-Alliance-2022-Annual-Financial-Report.pdf\n\nWarning: Target URL returned error 404: Not Found\n\nMarkdown Content:\nMain navigation\n---------------\n\n*   Our Alliance\n\n    *   Gavi Leap\n    *   Mission & vision\n    *   Our impact\n    *   Leadership\n\n    *   Current (2021–2025)\n    *   Next (2026–2030)\n    *   Vaccine Investment Strategy 2024\n    *   Risk management\n    *   Learning System Strategy\n    *   Gender & immunisation\n    *   Climate, health & immunisation\n\n    *   Our partners\n    *   Business model\n    *   People & leadership\n    *   Data & transparency\n\n    *   Gavi Board\n    *   Governance & legal structures\n    *   Board & Committee minutes\n    *   Corporate Policies\n    *   Audit & investigations\n\n    *   Vaccine Innovation Prioritisation Strategy (VIPS)\n    *   Vaccine demand forecasting\n    *   Roadmaps\n    *   Product information: vaccines & cold chain equipment\n\n    *   Sustainable Development Goals\n    *   International Health Partnership for UHC 2030\n    *   Decade of Vaccines Collaboration\n    *   Millennium Development Goals\n\n    *   Vacancies\n    *   Internships\n    *   RFPs & consulting opportunities\n\n    *   About\n\n        *   Gavi Leap\n        *   Mission & vision\n        *   Our impact\n        *   Leadership\n\n    *   Strategy\n\n        *   Current (2021–2025)\n        *   Next (2026–2030)\n        *   Vaccine Investment Strategy 2024\n        *   Risk management\n        *   Learning System Strategy\n        *   Gender & immunisation\n        *   Climate, health & immunisation\n\n    *   Operating model\n\n        *   Our partners\n        *   Business model\n        *   People & leadership\n        *   Data & transparency\n\n    *   Governance\n\n        *   Gavi Board\n        *   Governance & legal structures\n        *   Board & Committee minutes\n        *   Corporate Policies\n        *   Audit & investigations\n\n    *   Market Shaping\n\n        *   Vaccine Innovation Prioritisation Strategy (VIPS)\n        *   Vaccine demand forecasting\n        *   Roadmaps\n        *   Product information: vaccines & cold chain equipment\n\n    *   Global health & development\n\n        *   Sustainable Development Goals\n        *   International Health Partnership for UHC 2030\n        *   Decade of Vaccines Collaboration\n        *   Millennium Development Goals\n\n    *   Work with us\n\n        *   Vacancies\n        *   Internships\n        *   RFPs & consulting opportunities\n\n*   Programmes & Impact\n\n    *   Support guidelines\n    *   Independent Review Committee\n    *   Joint appraisals\n    *   Country portal\n\n    *   Vaccine support\n    *   Funding for civil society organisations (CSOs)\n    *   Health systems & immunisation strengthening\n    *   Partners' Engagement Framework (PEF)\n    *   Global health security\n\n    *   Overview\n    *   African Vaccine Manufacturing Accelerator (AVMA)\n    *   Vaccine market dashboard\n\n    *   All countries\n    *   Africa\n    *   Americas\n    *   Eastern Mediterranean\n    *   Europe\n    *   South-East Asia\n    *   Western Pacific\n\n    *   Progress reports\n    *   Facts & figures\n    *   Digital health information (DHI)\n    *   Measuring our performance\n    *   Evaluation studies\n\n    *   Eligibility & co-financing policies\n    *   Fragility, emergencies & displaced populations policy\n    *   Gender policy\n    *   Health systems & immunisation strengthening policy\n    *   Prioritisation mechanism\n    *   Risk policy\n    *   Self-procurement policy\n    *   Transparency & accountability\n    *   Vaccine donation policy\n\n    *   How our support works\n\n        *   Support guidelines\n        *   Independent Review Committee\n        *   Joint appraisals\n        *   Country portal\n\n    *   Programmatic support\n\n        *   Vaccine support\n        *   Funding for civil society organisations (CSOs)\n        *   Health systems & immunisation strengthening\n        *   Partners' Engagement Framework (PEF)\n        *   Global health security\n\n    *   Regional manufacturing strategy\n\n        *   Overview\n        *   African Vaccine Manufacturing Accelerator (AVMA)\n        *   Vaccine market dashboard\n\n    *   Country Hub\n\n        *   All countries\n        *   Africa\n        *   Americas\n        *   Eastern Mediterranean\n        *   Europe\n        *   South-East Asia\n        *   Western Pacific\n\n    *   Our impact\n\n        *   Progress reports\n        *   Facts & figures\n        *   Digital health information (DHI)\n        *   Measuring our performance\n        *   Evaluation studies\n\n    *   Programmatic policies\n\n        *   Eligibility & co-financing policies\n        *   Fragility, emergencies & displaced populations policy\n        *   Gender policy\n        *   Health systems & immunisation strengthening policy\n        *   Prioritisation mechanism\n        *   Risk policy\n        *   Self-procurement policy\n        *   Transparency & accountability\n        *   Vaccine donation policy\n\n*   Investing in Gavi\n\n    *   Resource mobilisation\n\n        *   Global Summit: Health & Prosperity through Immunisation\n        *   Process\n\n    *   Funding\n\n        *   Overview 2000–2037\n\n    *   Our donors\n\n        *   Donor governments and the European Union\n        *   Foundations, corporations, institutions and organisations\n\n    *   Partnering with business\n\n        *   Partnership types\n        *   Why partner with Gavi\n\n    *   Innovative financing\n\n        *   International Finance Facility for Immunisation (IFFIm)\n        *   Pneumococcal Advance Market Commitment (AMC)\n        *   Gavi Matching Fund\n        *   Loan buydown\n\n    *   INFUSE\n\n        *   INFUSE community\n        *   Call for innovations\n\n*   VaccinesWork\n\n    *   Topics\n\n        *   Stories from the community\n        *   Emerging threats\n        *   News from the lab\n        *   Tales from the past\n        *   Vaccine profiles\n        *   Gavi matters\n\n*   News & resources\n\n    *   Media room\n\n        *   News releases\n        *   Media contacts\n        *   Media resources\n\n    *   Resources\n\n        *   Insight reports\n        *   Communication toolkits\n        *   Leadership biographies\n        *   Progress reports\n        *   Publications\n\n    *   Document library\n\n        *   Board & Committee minutes\n        *   Evaluations\n        *   Independent Review Committee (IRC) reports\n        *   Financial reports\n\n    *   Country portal\n    *   Gavi's next strategic period\n    *   #ForOurFuture\n    *   Ethics Hotline\n\n    *   English\n    *   Français\n\n*   English\n*   Français\n\n*   Home\n*    404 - Page not found \n\nBack to\n\n**The link you tried doesn't seem to have worked. It may be old or the page may have moved.**\n\nWhat you can do:\n\n1. Use the search box in the menu above\n\n2. Browse the menu\n\n3. Check the link you tried for typing errors\n\nBack to\n\nPage not found\n--------------\n\n**The link you tried doesn't seem to have worked. It may be old or the page may have moved.**\n\nWhat you can do:\n\n1. Use the search box in the menu above\n\n2. Browse the menu\n\n3. Check the link you tried for typing errors\n",
      "name": "open",
      "role": "tool",
      "tool_call_id": "call_fdc55c81b47c440ea12e2b6a"
    },
    {
      "content": "",
      "reasoning_content": "\nThe PDF didn't load; maybe it's a scanning issue. Let's search for \"Gavi total operating expenses 2022 USD\".",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"query\":\"Gavi total operating expenses 2022 USD\"}",
            "name": "search"
          },
          "id": "call_033c44b2509c4780b91fb2a0",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "【66† 02b - PEF and Secretariat Budget 2021-2022.†https://www.gavi.org/sites/default/files/board/minutes/2020/15-dec/02b%20-%20PEF%20and%20Secretariat%20Budget%202021-2022.pdf】\nPEF: total budgeted amount for Gavi 5.0 stands at US$ 1,231 million, a 14% increase compared to Gavi 4.0 budgeted expenditure. (When excluding Post. Transition ...\n\n【67† Gavi Alliance - Full Filing - Nonprofit Explorer - ProPublica†https://projects.propublica.org/nonprofits/organizations/980593375/202313189349312936/full】\nFull text of \"Full Filing\" for fiscal year ending Dec. 2022. Tax returns filed by nonprofit organizations are public records. The Internal Revenue Service ...\n\n【68† How Gavi 6.0 Can Take a Bigger Leap†https://www.cgdev.org/publication/how-gavi-60-can-take-bigger-leap】\nOperating costs were initially budgeted at over $800 million for Gavi 6.0. Gavi's leadership has already committed to “radical simplification of ...\n\n【69† Annual Progress Report 2022†https://www.developmentaid.org/api/frontend/cms/file/2023/10/Gavi-Progress-Report-2022.pdf】\nGavi prepares an Annual Financial Report for each calendar year, which includes the audited consolidated financial statements of the Gavi Alliance and of ...\n\n【70† Gavi Presentation Template†https://lacaixafoundation.org/documents/386490/1630860/child-vaccination-audited-project-2022.pdf/6b4d9ddb-642d-c78d-624c-970e05b6487a?version=1.1&t=1744638736509】\nMatching funds. • In 2022, this partnership has channeled USD 3.22 M to Gavi, duplicated to USD 6.44 by BMGF. These funds have contributed funds to.\n\n【71† Gavi 5.0 Annual Review 2021 (conducted October 2022)†https://iati.fcdo.gov.uk/iati_documents/D0001409.odt】\nGavi will receive approximately £590m in proceeds from these commitments 2021-25, bringing the total contribution to £1.65bn (2021-25).\n\n【72† GAVI†https://en.wikipedia.org/wiki/GAVI】\nAs a result, GAVI announced it would fall almost $3 billion short of its budget aim of $11.9 billion with a total budget of $9 billion. Five year ...\n\n【73† GAVI, THE VACCINE ALLIANCE†https://docs.publicnow.com/viewDoc.aspx?filename=125665%5CEXT%5C24F3DB2A4E4D74841E017EF142E1E873A9779E2B_9C771451465E9C4EF9182A105DC7F67F61BE5379.PDF】\nGavi – Core's percentage operating expenses decreased slightly from 7.61% in 2022 to 6.83% in 2023. ... Total operating expenses percentage. 6.83%.\n\n【74† Danish Organisation Strategy 2023-2026 for Gavi, the†https://um.dk/en/-/media/websites/umen/danida/about-danida/danida-transparency/public-consultations/draft-organisation-strategy-for-gavi-the-vaccine-alliance-gavi-2023-2026.ashx】\nGavi's total annual income in 2022 was DKK 13,984 million. (USD 2,055 million) ... This only includes core Gavi programmes and not COVAX. TABLE 2: GAVI INCOME BY ...\n\n【75† Financial reports†https://www.gavi.org/news-resources/document-library/financial-reports】\nGavi, the Vaccine Alliance's audited consolidated financial statements are posted on this website once they are approved by Gavi's Board.\n\n",
      "name": "search",
      "role": "tool",
      "tool_call_id": "call_033c44b2509c4780b91fb2a0"
    },
    {
      "content": "",
      "reasoning_content": "\nWe have data from result 73: \"Gavi – Core's percentage operating expenses decreased slightly from 7.61% in 2022 to 6.83% in 2023.\" This suggests management/operating expenses were around 7.6% of total expenditure in 2022. But we need absolute numbers.\n\nLet's search for \"Gavi operating expenses 2022 million\".",
      "role": "assistant",
      "tool_calls": [
        {
          "function": {
            "arguments": "{\"query\":\"Gavi operating expenses 2022 million\"}",
            "name": "search"
          },
          "id": "call_35aba5d7ff274e77a1cf2fdc",
          "index": 0,
          "type": "function"
        }
      ]
    },
    {
      "content": "【76† Annual Progress Report 2022 - gavi.org†https://www.gavi.org/progress-report-2022】\nWelcome to Gavi’s 2022 Annual Progress Report, the second of the 2021–2025 strategic period.\n\n【77† New data highlights rebound in routine immunisation†https://www.developmentaid.org/news-stream/post/168221/gavis-2022-annual-progress-report】\nIn 2022, lower-income countries collectively contributed US$ 162 million to co-finance Gavi-supported vaccines, the highest amount in Gavi’s history. This brings the total amount contributed by lower-income countries since 2008 – when country co-financing began – to US$ 1.5 billion. Despite having to contend with rising debt levels as well as the impact of climate change, the war in Ukraine and other global shocks, in 2022 Gavi countries continued to demonstrate strong commitment to sustainability and country ownership of vaccination programmes. Goal 1: Introduce and scale up vaccines – With the addition of COVID-19 and malaria vaccines during the current strategic period, the Gavi portfolio now offers countries vaccines against 19 infectious diseases.\n\n【78† Gavi’s Annual Progress Report highlights rebound in routine†https://iffim.org/news/gavis-annual-progress-report-highlights-rebound-routine-immunisation-underpinned-record】\nIn its latest Annual Progress Report, Gavi reveals that basic childhood immunisation rebounded in 2022 as lower-income countries collectively contributed US$ 162 million to co-finance Gavi-supported vaccines, the highest amount in their 23-year history.\n\n【79† GAVI, THE VACCINE ALLIANCE - docs.publicnow.com†https://docs.publicnow.com/viewDoc?filename=125665%5CEXT%5C24F3DB2A4E4D74841E017EF142E1E873A9779E2B_9C771451465E9C4EF9182A105DC7F67F61BE5379.PDF】\nGavi – Core’s percentage operating expenses decreased slightly from 7.61 % in 2022 to 6.83% in 2023. This decrease in the Gavi – Core’s percentage overhead expenses and operating expenses was driven primarily by an increase in Gavi – Core programme expenses from 2022 to 2023.\n\n【80† Gavi Annual Progress Report 2022: A Path to Recovery†https://clh-immunisation-bd.org/e-library/gavi-annual-progress-report-2022-a-path-to-recovery-challenges-ahead】\nThey collectively contributed an impressive $162 million to co-finance Gavi-supported vaccines in 2022, the highest amount in Gavi’s history. This brings the total contribution by these nations since 2008 to an astounding $1.5 billion.\n\n【81† Gavi’s 2022 progress report: rebounds and challenges†https://vaccinenation.org/global-health/gavis-2022-progress-report-rebounds-and-challenges】\n“To make up the ground we lost during the pandemic, in December 2022 the Gavi Board approved a more than $600 million investment to protect 86 million girls [with HPV vaccines] by 2025.” With “climate change, deforestation, and migration” come increased risks of infectious disease outbreaks.\n\n【82† Financial reports - GAVI†https://www.gavi.org/news-resources/document-library/financial-reports】\nGavi, the Vaccine Alliance’s audited consolidated financial statements are posted on this website once they are approved by Gavi’s Board.\n\n【83† Footballer Gavi's Age, Parents, Girlfriend, Height, Salary, Net Worth†https://playerswiki.com/gavi】\nGavi's annual salary is €100,000 ($107,000). According to Forbes, he is the lowest-paid regular first-squad player after breaking into the senior fold at the beginning of last season.\n\n【84† India-made vaccine to help control typhoid in Pakistan - The Hindu†https://www.thehindubusinessline.com/news/science/india-made-vaccine-to-help-control-typhoid-in-pakistan/article30005153.ece】\nThe company announced a price of $1.50 per dose for procurement by GAVI-supported countries. This enabled the procurement and supply to UNICEF, GAVI, and Pan American Health Organisation (PAHO).\n\n【85† 02b - PEF and Secretariat Budget 2021-2022.†https://www.gavi.org/sites/default/files/board/minutes/2020/15-dec/02b%20-%20PEF%20and%20Secretariat%20Budget%202021-2022.pdf】\n1.3 Gavi's objective is to have operating expenses at no more that 7.5% of total ... US$ 132.7 million in 2022, compared to US$ 110.3 million for 2020. The.\n\n",
      "name": "search",
      "role": "tool",
      "tool_call_id": "call_35aba5d7ff274e77a1cf2fdc"
    }
  ],
  "gold_score": 0,
  "gold_judge": [],
  "other": ""
}